US20030129601A1

US20030129601A1 - Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses

Info

Publication number: US20030129601A1
Application number: US10/080,170
Authority: US
Inventors: Stewart Cole
Original assignee: Individual
Current assignee: Individual
Priority date: 2001-02-22
Filing date: 2002-02-22
Publication date: 2003-07-10
Also published as: US20040197896A1; EP1401866A2; WO2002074903A3; WO2002074903A2; US7538206B2; US20040121322A9; CA2438279A1; CN1599751A; AU2002302919A1; CN1277843C

Abstract

The present invention is directed to a method of selection of purified nucleotidic sequences or polynucleotides encoding proteins or part of proteins carrying at least an essential function for the survival or the virulence of mycobacterium species by a comparative genomic analysis of the sequence of the genome of M. tuberculosis aligned on the genome sequence of M. leprae and M. tuberculosis and M. leprae marker polypeptides of nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is based on and claims the benefit of U.S. Provisional application Ser. No. 60/270,123, filed Feb. 22, 2001 (attorney docket no. 03495.6061) The entire disclosure of this application is relied upon and incorporated by reference herein.[0001]

BACKGROUND OF THE INVENTION

The present invention is directed to a method of selection of purified nucleotidic sequences or polynucleotides encoding proteins or part of proteins carrying at least an essential function for the survival or the virulence of mycobacterium species by a comparative genomic analysis of the sequence of the genome of M. tuberculosis aligned on the genome sequence of M. leprae. The selection by the method of the invention of these nucleotidic or peptidic sequences of interest which are encoding said essential functions of mycobacterium leads to identify and characterize specific antigens or regulator sequences, said antigens being chosen as potential candidates for an immunogenic or vaccine composition, but also useful to determine novel potential drug targets for the pharmaceutical industry. The molecules having essential functions encoded by these genes or corresponding to regulatory elements represent also new highly specific targets for chemotherapy. The sequence of the polynucleotides according to the invention have the particularity to be maintained during the evolution of the mycobacterium and therefore have been highly conserved in pathogenic mycobacterium species. The invention is directed to purified nucleic acid selected by the method of the invention as well as the purified polypeptides with essential functions for the survival or the virulence of mycobacterium species encoded by these sequences. In a preferred embodiment, the invention is directed to genes that code for essential proteins for which the functions have been attributed. The invention is also directed to a process for the production of recombinant polypeptides and chimeric polypeptides comprising them, antibodies generated against these polypeptides, immunogenic or vaccine compositions comprising at least one polypeptide useful as protective antigens or capable to induce a protective response in vivo or in vitro against mycobacterium infections, immunotherapeutic compositions comprising at least such a polypeptide according to the invention, and the use of such nucleic acids and polypeptides in diagnostic methods, vaccines, kits, or antimicrobial therapy.

To illustrate the new approach of comparative mycobacterial genomics for identifying essential molecules as regulator nucleotidic sequences and proteins for the survival or the virulence of mycobacterium species, the inventors made several examples which will not limit the scope of the present invention. A comparative genomic analysis, which permitted the inventors to select the sequences encoding essential molecules as regulatory nucleotidic sequences and proteins for the survival or the virulence of mycobacterium species, has been made by analysis of the complete genome sequence of both Mycobacterium tuberculosis and Mycobacterium leprae. The whole genome comparisons led also to the identification of genes that are present in both M. tuberculosis and M. leprae but have no counterparts elsewhere. The polypeptides having essential functions for the survival or the virulence mycobacterium species are characterized by at least 40% identity at the protein level and at least 70% identity at the gene level between both genomic sequences. The amino acid sequences have been compared using the program GAP, “GCG” (Genetic Computer Group) from Program Manual (UNIX), Wisconsin Sequence Analysis Package™, Algorithm of Needleman and Wunsch. (J.Mol.Biol.48:443, 1970) The parameters are chosen as follows:

For amino acid comparisons:

Gap penalty: 5

Gap extension penalty: 0.30

Length: the sequence to be compared are the following XXX SED ID NO:XXX and having XXX amino acids.

For nucleotide comparisons:

Gap penalty: 50

Gap extension penalty: 3

Also the parameters could be adapted case by case.

Other techniques are known by the man of the art for the comparison of sequences. We can refer to the algorithm of Smith and Wateman (Ad. App. Math. 2: 482, 1982), the method of search of similarities of Pearson and Lipman (Proc. NatI. Acad. Sci. USA 85: 2444, 1988), Zhang et al. “a greedy algorithm for aligning DNA sequences” (J. Comp. Biol. 2000, Feb-Apr. 7 (1-2) p203-214), these algorithms are used by the way of informatic tools (GAP, BLASTP, BLASTN, BLASTX, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Sciences Dr., Madison Wis.).

The recombinant clones carrying DNA from Mycobacterium tuberculosis and Mycobacterium leprae strains containing genomic sequences of said bacteria, have been deposited at the Collection Nationale de Cultures de Microoganismes (C.N.C.M.), of Institut Pasteur, 28, rue du Docteur Roux, F-75724 Paris cedex 15, France, and are designated as following.

HRV37 genomic library, deposited on Nov. 19, 1997 . . . under the accession number I-1945;

A recombinant BAC containing a fragment of M. tuberculosis genome deposited at the C.N.C.M. under the accession number I-2625.

A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001, at the C.N.C.M. under the accession number I-2626.

A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001, at the C.N.C.M. under the accession number I-2627.

A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001, at the C.N.C.M. under the accession number I-2628.

A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001, at the C.N.C.M. under the accession number I-2629.

A recombinant cosmid containing a fragment of M. leprae genome deposited on Feb. 21, 2001, at the C.N.C.M. under the accession number I-2632.

A recombinant cosmid containing a fragment of M. leprae genome deposited on Feb. 21, 2001, at the C.N.C.M. under the accession number I-2633.

Leprosy, one of the oldest recorded diseases, remains a major public health problem. Although prevalence has been reduced extensively by WHO multidrug therapy and vaccination with BCG1,2, the incidence of the disease remains worrying with more than 690,000 new cases annually3 in the world. Leprosy was common in Europe in the middle ages but gradually disappeared.

In 1873, in the first convincing association of a microorganism with a human disease, Armauer Hansen4 discovered the leprosy bacillus in skin biopsies but failed to culture Mycobacterium leprae. A century later, the nine-banded armadillo5 was used as a surrogate host, enabling large quantities of the bacillus to be isolated for biochemical and physiological studies. Subsequent efforts to demonstrate multiplication in synthetic media have been equally fruitless altough metabolic activity can be detected6. The exceptionally slow growth of the bacillus, which has a doubling time of ˜14 days 7, may contribute to these failures.

The means of transmission of leprosy is uncertain but, like tuberculosis, it is believed to be spread by the respiratory route since lepromatous patients harbour bacilli in their nasal passages. The bacterium accumulates principally in the extremities of the body where it resides with macrophages and infects the Schwann cells of the peripheral nervous system. Lack of myelin production by infected Schwann cells, and their desctruction by host-mediated immune reactions, leads to nerve damage, sensory loss and the disfiguration that, sadly, are hallmarks of leprosy.

There is no data or technical information in the prior art which permit to select specifically potential new targets and protective antigens for new drugs and vaccine compositions to treat and prevent mycobacterial diseases, particularly tuberculosis and leprosy. Furthermore, there is a need for the development of new tools for the selection of genes which are encoding for essential proteins or regulatory nucleotidic sequences in the survival or infection of mycobacterium species and useful for the design of antituberculosis drugs and vaccines based on the knowledge of comparative mycobactertial genomics.

SUMMARY OF THE INVENTION

The invention aids in fulfilling these needs in the art. The method according to the invention has the advantage to reduce drastically the number of potential new targets and protective antigens by giving for the first time an exhaustive description of conserved proteins in the tuberculosis and leprae bacilli. The isolated polynucleotides and proteins described in the present invention, which are highly conserved in both genomic sequences of M. tuberculosis and M. leprae, are by this characteristic essential for the survival or the virulence of these mycobacteria in the host. The identification of antigens and potentially therapeutic targets has been made on an evolutionary basis by a method of comparative genomic analysis.

This invention provides a method for the identification and the selection of essential genes for the survival or the virulence of mycobacterium species which comprises:

a. Aligning the genomic sequence of a first mycobacterium species on a genomic sequence of the genomic sequence of a second mycobacterium species,

b. Selecting a polypolynucleotide sequence highly conserved in both genomes with no counterparts in other bacterial genomic sequences and which corresponds to an essential gene for the survival or the virulence of mycobacterium species, and

c. Optionaly, testing the polypolynucleotide selected in step b) for its capacity of virulence or involved in the survival of a mycobacterium species, said testing being based on the activation or inactivation of said polyucleotide in a bacterial host or said testing being based on the activity of the product of expression of said polynucleotide in vivo or in vitro.

This invention provides also a method for the identification and the selection in silico of essential genes for the survival or the virulence of mycobacterium species which comprises the following steps:

a. Aligning the genomic sequence of a first mycobacterium specie on a genomic sequence of the genomic sequence of a second mycobacterium specie, and

b. Selecting a polynucleotide sequence highly conserved in both genomes with no counterparts in other bacterial genomic sequences and which corresponds to an essential gene for the survival or the virulence of mycobacterium species.

Optionally, testing the polypolynucleotide selected in step b) for its capacity of virulence or involved in the survival of a mycobacterium species can be carried out, said testing being based on the activation or inactivation of said polynucleotide in a bacterial host or said testing being based on the activity of the product of expression of said polynucleotide in vivo or in vitro.

The method according to the invention permits also to determine the polynucleotidic sequences, which encode for polypeptides and regulatory sequences essential for the virulence and/or the survival of mycobacterium which are, in one hand, specific to Mycobacterium tuberculosis and, in the other hand, specific to Mycobacterium leprae, that is to say, said polynucleotidic sequences are not found in publicly accessible banks of non-Mycobacterium tuberculosis and non-Mycobacterium leprae genome.

A gene according to the invention is a defined nucleotidic sequence, which contains an open reading frame with base composition, codon usage, GC skew and other features typical of a microorganism, preferably a mycobacterium. The definition of gene according to the invention comprises nucleotidic sequences, which encode an antigen or a fragment thereof, or nucleotidic sequences, which encode for essential polypeptide with essential function in the host, or nucleotidic sequence, which encodes polypeptide with regulation function in the bacteria, by example, in the DNA expression or in the transcription. An essential function for a polypeptide in bacteria according to the invention comprises functions implicated in the survival or in the virulence of the bacteria.

In a preferred embodiment the first genomic sequence of mycobacterium belongs to Mycobacterium tuberculosis. The Mycobacterium microti is a Mycobacterium which infect the vole. It has a genome sequence close to the sequence of Mycobacterium tuberculosis (Cole et al. (1998, Nature, 393, 537-544)) and therefore in a second preferred embodiment, the first genomic sequence of Mycobacterium microti belongs to Mycobacterium genus.

In another preferred embodiment the second genomic sequence of mycobacterium belongs to Mycobacterium leprae.

In a preferred embodiment, the method according to the invention comprises the complete genomic sequence of said mycobacterium species which is analysed. This invention provides purified polypolynucleotide molecule obtained by the method according to the invention.

Further, this invention provides a purified polynucleotide molecule according to the invention which encodes essential proteins or fragments of proteins of Mycobacterium species.

The invention also encompasses a purified polynucleotide molecule of a formula selected from the group consisting of polynucleotidic sequences, which encode for polypeptides and regulatory sequences essential for the virulence and/or the survival of mycobacterium which are, in one hand, specific to Mycobacterium tuberculosis and, in the other hand, specific to Mycobacterium leprae, that is to say, said polynucleotidic sequences are not found in publicly accessible banks of non-Mycobacterium tuberculosis and non-Mycobacterium leprae genome. In a preferred embodiment, this purified polynucleotide is obtained by the method according to the invention.

The invention emcompasses a purified polypolynucleotide molecule that hybridizes to either stand of a denatured, double-stranded DNA comprising the purified polynucleotide sequence according to the invention under conditions of moderate stringency in 50% formamide and 6× SSC at 42° C. with washing conditions of 60° C., 0.5×SSC, 0.1% SDS.

This invention provides a purified polypeptide of a formula selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 644.

This invention also provides a purified nucleic acid molecule encoding a polypeptide of a formula selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:644.

The nucleic acid molecules of the invention, which include DNA and RNA, are referred to herein as “ M. tuberculosis and M. leprae marker nucleic acids” or “M. tuberculosis and M. leprae marker DNA”. The polypeptides encoded by these molecules, which are referred to herein as “M. tuberculosis and M. Ieprae marker polypeptides,” have formulas selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:644.

Further, this invention provides a purified nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid molecule encoding the polypeptide of a formula selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:644 under conditions of moderate stringency in 50% formamide and 6× SSC, at 42° C. with washing conditions of 60° C., 0.5×SSC, 0.1% SDS. This nucleic acid molecule that hybridizes under the stated conditions can be derived by in vitro mutagenesis of a M. tuberculosis and M. leprae marker nucleic acid of the invention.

The invention also encompasses purified nucleic acid molecules degenerate from M. tuberculosis and M. leprae marker nucleic acids as a result of the genetic code, purified nucleic acid molecules that are allelic variants of M. tuberculosis and M. leprae marker nucleic acids, and a species homolog of M. tuberculosis and M. leprae marker nucleic acids. The invention also encompasses recombinant vectors that direct the expression of these nucleic acid molecules and host cells transformed or transfected with these vectors.

The invention further encompasses methods for the production of M. tuberculosis and M. leprae marker polypeptides, including culturing a host cell under conditions promoting expression, and recovering the polypeptide from the culture medium. Especially, the expression of M. tuberculosis and M. leprae marker polypeptides in bacteria, yeast, plant, and animal cells is encompassed by the invention.

This invention also provides labeled M. tuberculosis and M. leprae marker polypeptides. Preferably, the labeled polypeptides are in purified form. It is also preferred that the unlabeled or labeled polypeptide is capable of being immunologically recognized by human body fluid containing antibodies to a mycobacterium. The polypeptides can be labeled, for example, with an immunoassay label selected from the group consisting of radioactive, enzymatic, fluorescent, chemiluminescent labels, and chromophores.

Immunological complexes between the M. tuberculosis and M. leprae marker polypeptides of the invention and antibodies recognizing the polypeptides are also provided. The immunological complexes can be labeled with an immunoassay label selected from the group consisting of radioactive, enzymatic, fluorescent, chemiluminescent labels, and chromophores.

Furthermore, this invention provides a method for detecting infection by mycobacteria. The method comprises providing a composition comprising a biological material suspected of being infected with a mycobacteria, and assaying for the presence of M. tuberculosis and M. leprae marker polypeptide of the mycobacteria. The polypeptides are typically assayed by electrophoresis or by immunoassay with antibodies that are immunologically reactive with M. tuberculosis and M. leprae marker polypeptides of the invention.

This invention also provides an in vitro diagnostic method for the detection of the presence or absence of antibodies, which bind to an antigen comprising a M. tuberculosis and M. leprae marker polypeptide of the invention or mixtures of the polypeptides. The method comprises contacting the antigen with a biological fluid for a time and under conditions sufficient for the antigen and antibodies in the biological fluid to form an antigen-antibody complex, and then detecting the formation of the complex. The detection step can further comprise measuring the formation of the antigen-antibody complex. The formation of the antigen-antibody complex is preferably measured by immunoassay based on Western blot technique, ELISA (enzyme linked immunosorbent assay), indirect immunofluorescent assay, or immunoprecipitation assay.

The polypeptides of this invention are thus useful as a portion of a diagnostic composition for detecting the presence of antibodies to antigenic proteins associated with mycobacteria. Thus, a diagnostic kit for the detection of the presence or absence of antibodies, which bind to the M. tuberculosis and M. leprae marker polypeptide of the invention or mixtures of the polypeptides, contains antigen comprising the M. tuberculosis and M. leprae marker polypeptide, or mixtures thereof, and means for detecting the formation of immune complex between the antigen and antibodies. The antigens and the means are present in an amount sufficient to perform the detection.

This invention also provides an immunogenic composition comprising a M. tuberculosis and M. leprae marker polypeptide of the invention or a mixture thereof in an amount sufficient to induce an immunogenic or protective response in vivo, in association with a pharmaceutically acceptable carrier therefor. A vaccine composition of the invention comprises a neutralizing amount of the M. tuberculosis and M. leprae marker polypeptide and a pharmaceutically acceptable carrier therefor.

In addition, the M. tuberculosis and M. leprae marker polypeptides can be used to raise antibodies for detecting the presence of antigenic proteins associated with a mycobacterium. Purified polyclonal or monoclonal antibodies that bind to M. tuberculosis and M. leprae marker polypeptides are encompassed by the invention.

The polypeptides of the invention can be also employed to raise neutralizing antibodies that either inactivate the mycobacteria, reduce the viability of a mycobacterium in vivo, or inhibit or prevent bacterial replication. The ability to elicit mycobacteria-neutralizing antibodies is especially important when the proteins and polypeptides of the invention are used in immunizing or vaccinating compositions to activate the B-cell arm of the immune response or induce a cytotoxic T lymphocyte response (CTL) in the recipient host, or other T cell mediated response.

Further, this invention provides a method for detecting the presence or absence of a mycobacterium comprising:

(1) contacting a sample suspected of containing bacterial genetic material of a mycobacterium with at least one nucleotide probe, and

(2) detecting hybridization between the nucleotide probe and the bacterial genetic material in the sample,

wherein said nucleotide probe is complementary to the full-length sequence of a purified M. tuberculosis and M. leprae marker nucleic acid of the invention.

Also, this invention provides a method of comparing genetic complements of different types of organisms, wherein the method comprises:

(a) providing a database including sequence libraries for a plurality of types of organisms, said libraries having multiple genomic sequences;

(b) providing one or more probe sequences encoding a polypeptide of a formula selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:644;

(c) determining homologous matches between one or more of said probe sequences and one or more sequences of said sequences in said genomic libraries; and

(d) displaying the results of said determination.

The method can be carried out using a computer system comprising a database including sequence libraries for a plurality of types of organisms, wherein the libraries have multiple genomic sequences, and providing a database including the one or more probe sequences encoding a polypeptide of a formula selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:644. The computer system includes a user interface capable of receiving sequence information from the sequence libraries and the probe sequence information for comparison and displaying the results of the comparison.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee. This invention will be described with reference to the drawings in which: [0067]
FIG. 1 is a circular genome map. From the outside, circles [0068] 1, 2, clockwise and anticlockwise, genes on the − and + strands, respectively; circles 3 and 4, pseudogenes; 5 and 6, M. leprae specific genes; 7, repeat sequences; 8, G+C content; 9, G/C bias (G+C)/(G−C). See legend to FIG. 2 for colour code.
FIG. 2 is a comparison of the pros loci of [0069] M. leprae and M. tuberculosis . A. The M. Ieprae pros region is shown above that of M. tuberculosis. Genes or operons are depicted by arrows while crosses denote pseudogenes. Note the absence of ugpAEBC and dinF from M. leprae and the presence of pros at this site. B. Domain structures of prolyl-tRNA synthetases of bacterial (M. tuberculosis ) or eukaryotic (M. leprae ) types after¹⁹.
FIG. 3 shows distribution of genes by functional category. The number of complete (blue) and pseudogenes (red) within each category for [0070] M. leprae is shown. Data for M. tuberculosis (green) were taken from the published genome sequence⁸. Functional categories: 1. Small-molecule catabolism, 2. Energy Metabolism, 3. Central intermediary metabolism, 4. Amino acid biosynthesis, 5. Nucleosides and nucleotide biosynthesis and metabolism, 6. Biosynthesis of cofactors, prosthetic groups and carriers, 7. Lipid biosynthesis, 8. Polyketide and nonribosomal peptide synthesis, 9. Proteins performing regulatory functions, 10. Synthesis and modification of macromolecules, 11. Degradation of macromolecules, 12. Cell envelope constituents, 13. Transport/binding proteins, 14. Chaperones/Heat shock proteins, 15. Cell division proteins, 16. Protein and peptide secretion, 17. Adaptations and atypical conditions, 18. Detoxification, 19. Virulence determinants, 20. IS elements and phage derived proteins, 21. PE and PPE families, 22. Antibiotic production and resistance, 23. Cytochrome P450 enzymes, 24. Coenzyme F420-dependent enzymes, 25. Miscellaneous transferases, 26. Miscellaneous phosphatases, lyases and hydrolases, 27. Cyclases, and 28. Chelatases. Inset graph: The Y axis shows the number of genes within each functional category. The X axis shows the functional categories: 29. Conserved hypothetical proteins, 30. Hypothetical proteins which share no significant similarity with any protein currently in the databases.
FIG. 4: Polynucleotidic sequence of the [0071] Mycobacterium tuberculosis H37Rv BAC clone, BAC-Rv221, deposited at the C.N.C.M. under the accession number I-2625, which corresponds to pBelo BACII with HindIII partial digest fragment from the genome of M. tuberculosis H37 Rv that starts at position 2,115,612 and extends to position 2,198,604 according to Cole et al. (1998, Nature, 393, 537-544). All of the M. tuberculosis genes contained herein are of interest.
FIG. 5: Polynucleotidic sequence of the [0072] Mycobacterium tuberculosis H37Rv BAC clone, BAC-Rv230, deposited at the C.N.C.M. under the accession number I-2626, which corresponds to pBelo BACII with HindIII partial digest fragment from the genome of M. tuberculosis H37 Rv that starts at position 1,336,764 and extends to position 1,411,979 according to Cole et al. (1998, Nature, 393, 537-544). All of the M. tuberculosis genes contained herein are of interest.
FIG. 6: Polynucleotidic sequence of the [0073] Mycobacterium tuberculosis H37Rv BAC clone, BAC-Rv234, deposited at the C.N.C.M. under the accession number I-2627, which corresponds to pBelo BACII with HindIII partial digest fragment from the genome of M. tuberculosis H37 Rv that starts at position 2,847,864 and extends to position 2,928,420 according to Cole et al. (1998, Nature, 393, 537-544). All of the M. tuberculosis genes contained herein are of interest.
FIG. 7: Polynucleotidic sequence of the [0074] Mycobacterium tuberculosis H37Rv BAC clone, BAC-Rv265, deposited at the C.N.C.M. under the accession number I-2628, which corresponds to pBelo BACII with Hindlul partial digest fragment from the genome of M. tuberculosis H37 Rv that starts at position 514,402 and extends to position 599,515 according to Cole et al. (1998, Nature, 393, 537-544). All of the M. tuberculosis genes contained herein are of interest.
FIG. 8: Polynucleotidic sequence of the [0075] Mycobacterium tuberculosis H37Rv BAC clone, BAC-Rv267, deposited at the C.N.C.M. under the accession number I-2629, which corresponds to pBelo BACII with HindIII partial digest fragment from the genome of M. tuberculosis H37 Rv that starts at position 1,124,621 and extends to position 1,169,811 according to Cole et al. (1998, Nature, 393, 537-544). All of the M. tuberculosis genes contained herein are of interest.
FIG. 9: Polynucleotidic sequence of the [0076] Mycobacterium leprae cosmid which corresponds to pYUB18 with Sau3A partial digest fragment from the genome of M. leprae that starts at position 1,373,705 and extends to position 1,403,746. This sequence comprises the sequence of the Mycobacterium leprae cosmid MLCY 811 which corresponds to pYUB18 with Sau3A partial digest fragment of the genome of M. leprae deposited at the C.N.C.M. under the accession number I-2633 that starts at position 1,363,759 and extends to position 1,403,737 according to Cole et al. (2001, Nature, 409, 1007-1011).
FIG. 10: Polynucleotidic sequence of the [0077] Mycobacterium leprae cosmid which corresponds to pYUB18 with Sau3A partial digest fragment of the genome of M. leprae that starts at position 3,160,443 and extends to position 3,194,161. This sequence comprises the sequence of the Mycobacterium leprae cosmid MLCY 047 which corresponds to pYUB18 with Sau3A partial digest fragment of the genome of M. leprae deposited at the C.N.C.M. under the accession number I-2632 that starts at position 3,160,458 and extends to position 3,194,087 according to Cole et al. (2001, Nature, 409, 1007-1011).
FIG. 4 to [0078] 10 can be found in the APPENDIX hereto.

DETAILED DESCRIPTION OF THE INVENTION

Sequence Analysis of M. Ieprae

The complete genome sequence of [0079] M. leprae contains 3,268,203 bp, and has an average G+C content of 57.8%. These values are much lower than those reported for the M. tuberculosis genome, comprising ˜4,000 genes, 4,411,529 bp and 65.6% G+C⁸. On detailed pairwise comparisons of both genome and proteome sequences^{8, 9}, it was immediately apparent that only 49.5% of the genome was occupied by protein-coding genes, while 27% contained recognisable pseudogenes, inactive reading frames with functional counterparts in the tubercle bacillus. The remaining 23.5% of the genome did not appear to be coding, and probably contains gene remnants mutated beyond recognition. The distribution of the 1,114 pseudogenes was essentially random (FIG. 1) and, after their exclusion, 1604 potentially active genes remained, of which 1,439 were common to both pathogens. Among the remaining 165 genes, with no ortholog in M. tuberculosis , were 29 for which functions could be attributed. Many of the 136 residual CDS in M. leprae , showing no similarity to known genes, may also represent pseudogenes as they are shorter than average and occur in regions of low gene density (FIGS. 1).

Reductive evolution

Assuming that the genome of [0080] M. leprae was once topologically equivalent and similar in size to those of all other mycobacteria (˜4.4 Mb)^10-12, then extensive downsizing and rearrangement must have occurred during evolution. Loss of 1.1 Mb would eliminate ˜1100 CDS, and M. leprae would, therefore, be expected to produce 3000 proteins compared to the 4000 predicted in M. tuberculosis. On analysis of the proteome only 391 soluble protein species were detected¹³, compared to nearly 1800 in M. tuberculosis ⁴, consistent with there being many pseudogenes. In conclusion, since diverging from the last common mycobacterial ancestor, the leprosy bacillus may have lost >2000 genes.
Reductive evolution is documented in obligate intracellular parasites, such as Rickettsia and Chlamydia spp., and in some endosymbionts[0081] ¹⁵, as genes become inactivated once their functions are no longer required in highly specialised niches. This process may have naturally defined the minimal gene set for a pathogenic mycobacterium. The most extensive genome degradation reported previously was in Rickettsia prowazekii, the typhus agent, where only 76% of the potential coding capacity was used and 12 pseudogenes identified¹⁶. In comparison with M. leprae, the level of gene loss detected was modest, and it is striking that elimination of pseudogenes by deletion lags far behind gene inactivation in both pathogens. Intriguingly, the G+C content of M. leprae genes (60.1%) is higher than that of the pseudogenes (56.5%), and the remainder of the genome (54.5%). The high G+C content of M. leprae, and other mycobacteria, is apparently driven by the codon preference of active genes, while random mutation within non-coding regions results in drift towards a more neutral G+C content, closer to that of the host.

Mosaic Organisation and Horizontal Transfer

While the precise mechanism behind pseudogene formation in [0082] M. leprae is unclear, loss of dnaQ-mediated proof-reading activities of DNA polymerase III¹⁷may have contributed. By contrast, there is extensive evidence for large scale rearrangements and deletions arising from homologous recombination events. Comparison with M. tuberculosis delineated ˜65 segments that show synteny but differ in their relative order and distribution in the M. leprae genome. Breaks in synteny generally correspond to dispersed repeats, tRNA genes or gene-poor regions. Copies of all three repeats, RLEP, REPLEP, and LEPREP, occur at the junctions of discontinuity suggesting that the mosaic arrangement of the M. leprae genome reflects multiple recombination events between related repetitive sequences. In some cases, aberrant recombination may have occurred as truncated repeats exist.
While there is little sequence similarity indicating that they are insertion sequences, RLEP is clearly capable of transposition since it exists within sequences corresponding to known genes. Unlike [0083] M. tuberculosis H37Rv, which contains at least two prophages and 56 intact or truncated IS elements^{8, 18}, M. leprae has only three phage-like genes, all with M. tuberculosis orthologs, and 26 transposase gene fragments. However, some signs of horizontal transfer of genetic material were detected when the aminoacyl-tRNA synthetase genes were examined. With one exception, all of these are more closely related to M. tuberculosis enzymes than to those of any other organism. Surprisingly, prolyl-tRNA synthetase, encoded by proS, is more similar to the enzymes of Borrelia burgdorfieri and eukaryotes such as Drosophila, humans and yeast. It has been proposed that horizontal transfer of tRNA synthetase genes occurs frequently, and that the pathogen B. burgdorferi may have acquired proS from its host¹⁹. Comparison of the genetic context provides further support for this hypothesis as the M. leprae proS is both displaced and inverted with respect to the M. tuberculosis genome (FIG. 4), consistent with recent acquisition.

Multigene Families

Half of the genes (52%) present in M. tuberculosis arose from gene duplication events leading to extensive functional redundancy⁹. Many of these are involved in lipid metabolism or belong to the novel PE and PPE families, encoding unusual glycine-rich proteins of repetitive structure and unknown function. The latter are confined to certain mycobacterial species²⁰, and represent sources of genetic and, possibly antigenic, variation⁸. The corresponding 167 genes are exceptionally GC-rich and occupy >8% of the M. tuberculosis genome²¹. By contrast, only 9 intact PE and PPE genes were found in M. leprae although 30 pseudogenes were present. No intact members of the PE-PGRS subfamily were found. This reduction partly contributes to the smaller genome size and the lower GC content of M. leprae . Recently, some PE-PGRS proteins were shown to be upregulated in Mycobacterium marinum during granuloma formation in frogs²². However, this effect is probably not mediated directly by the PE-PGRS, as granulomas are a prominent cytological feature of all forms of leprosy. Essentially all of the gene families⁹have undergone extensive retraction in M. leprae and now encode “just-enough” activity to permit intracellular growth. Selected examples of this are given in Table 1, whereas the comprehensive comparison presented in FIG. 3 shows that all functional categories have shrunk.

TABLE 1


Selected examples of metabolic streamlining.

M.
tuberculosis	M. leprae	M. leprae	Function	Pathway

Gene	Gene	Pseudogene
gitA1, gltA2,	gltA2	citA	Citrate synthase	Krebs cycle
cit, 4
icd1, icd2	icd2	icd1	Isocitrate	Krebs cycle
			dehydrogenase
ic1, aceA	aceA	ic1	Isocitrate lyase	Glyoxy-
				latecycle
gnd1, gnd2	gnd1	qnd2	6-	Pentose
			phosphogluconated	phosphate
			ehydrogenase	pathway
pfkA, pjkB	pfkA	pfkB	Phospho-	Glycolysis
			fructokinase
aceE, lpdA,	aceE, lpd	lpdA, pdhA,	Pyruvate,	Energy
pdhA, pdhB,	(Rv0462)	pdhB, pdhC	dehydrogenase	metabolism
pdhC, lpd			complex
(Rv0462)
lldD1, lldD2	lldD2	lldD1	L-lactate	Respiration
			dehydrogenase
mmaA1, mmaA2,	mmaA1,	mmaA2,	Methyltransferase	Mycolic acid
mmaA3, mmaA4,	mmaA4,	nmaA3,		modification
cmaA1, cmaA2,	cmaA2, umaA2	cmaA1, umaA1
umaAl, umaA2
glnA1, glnA2,	glnA1, glnA2	glnA3, glnA4	Glutamine	Glutamine
glnA3, glnA4			synthase	biosynthesis
metA, metB,	met4, metB,	metC	Various	Methionine
metC, metE,	metE,			biosynthesis
metH, metK, metZ	metH, metK,
	metZ
bfrA, bfrB	bfrA	bfrB	Bacterioferritin	Iron storage
ligA, 11gB, ligC	ligA	1igB	DNA ligase	DNA metabolism

Metabolic clues

Successive generations of microbiologists have failed to grow [0085] M. leprae in axenic culture leading to the notion that the bacterium lacks certain biosynthetic pathways. Complete genome comparisons shed new light on this. Lipid metabolism is prominent in the biochemical repertoire of M. leprae but to a lesser extent than in the tubercle bacillus whose cell envelope has a greater diversity of lipids, glycolipids and carbohydrates²³.

Envelope Biogenesis

Mycolic acids, structural components of all mycobacteria, include the alpha mycolates, lacking oxygen functions, and the oxygenated keto- and methoxy- forms. Reappraisal of mycolic acid modification is now possible in the light of the reduced cmaA, mmaA and umaA gene-sets encoding the effector methyltransferases. [0086] M. Ieprae contains no methoxy-mycolates²³, probably due to the loss of the MmaA2 and MmaA3 enzymes that attach the methoxy group in M. tuberculosis ^{10, 24}. However, the mycolic acids do contain cyclopropane functions²⁵that in M. tuberculosis are introduced by MmaA2 and CmaAI. Since both the mmaA2 and cmaA1 genes have decayed in M. leprae , cyclopropanation must be encoded by one of the related umaA genes. Recently, both umaA2 and cmaA2 were shown to be essential for the cyclopropanation function in M. tuberculosis ²⁶, The same enzymes also catalyse cyclopropanation in M. leprae as their duplicate copies are both inactive (Table 1).
Foremost among the outer lipids of the leprosy bacillus is phenolic glycolipid 1 (PGL1), an envelope component not found in [0087] M. tuberculosis ²⁷. PGL1 is derived from phthiocerol-dimycocerosate (PDIM), an esterified compound lipid generated by mycocerosic acid synthase and a type I polyketide synthase (PKS), by addition of three o-methylated deoxy sugars²³. However, the genes for the glycosyltransferases, that modify PDIM to produce PGLI, could not be detected despite extensive comparisons. PDIM, a virulence factor in M. tuberculosis, requires the RND protein, MmpL7, for its transport across the cytoplasmic membrane^9,28,29. Of the 18 PKS systems identifiable in M. tuberculosis ⁸, only six were predicted in M. leprae and the number of mmpL genes (often linked to PKS genes) has decreased from 16 to five, presumably because they are no longer required for polyketide or lipid export. Deletion of such systems may be reflected in the lack of mycolipenic and hydroxylipenic acids, polyketides esterified to trehalose in M. tuberculosis. Further PKS missing from M. leprae include the mbt operon required for production of the salicylate-based mycobactin siderophores. Lipids, polyketides and aromatic compounds are often substrates, for cytochrome-P450 monooxygenases³⁰, enzymes that are exceptionally abundant in M. tuberculosis ⁸. Astonishingly, none of these is functional in M. leprae although a novel enzyme is predicted.

Lipolysis

Intracellular mycobacteria probably derive much of their energy from degradation of host-derived lipids[0088] ³¹, a process initiated by lipases. In remarkable contrast to the 22 lip genes of M. tuberculosis, M. Ieprae has only two lipase genes, of which, lipG, clusters with mmaA genes and could, therefore, effect fatty acid remodelling. This appears to leave just one lipase for scavenging fatty acids. The enzyme LipE (ML1190) or its counterpart in M. tuberculosis (Rv3775) could represent an attractive drug target. In addition to the multifunctional FadA and FadB enzymes, which catalyse β-oxidation, M. tuberculosis has numerous alternative systems for fatty acid degradation⁸. Once again, M. leprae has roughly one third as many potential enzymes; however, there are three-times more FadD acyl-CoA synthases than FadE acyl-CoA dehydrogenases, whereas these are expected in equal amounts in M. tuberculosis. This may be explained by the dual role of FadD in β-oxidative and anabolic processes while FadE only participates catabolically.
The acetyl-CoA produced by β-oxidation, or glycolysis, flows into the central pathways of carbon metabolism in [0089] M. leprae . However, the pattern of “just enough” genes for each step is firmly established, so that the redundancy seen in M. tuberculosis almost never occurs. For instance, there is only one isocitrate lyase (with low predicted activity) capable of participating in the glyoxylate shunt (Table 1)^{32, 33}, and one enzyme complex that oxidatively decarboxylates pyruvate to acetyl-CoA, compared to two such systems in M. tuberculosis. In the Krebs cycle, as in glycolysis, replicate genes for the same activity are deleted although differences in expression levels might compensate for some missing copies. Thus, while lack of pdh genes is reflected in a low rate of oxidative decarboxylation of pyruvate, isocitrate dehydrogenase activity is comparable in host-grown leprosy and tubercle bacilli³⁴even though a duplicate icd gene is inactivated in M. leprae.

Central and Energy Metabolism

Despite an active glyoxylate cycle, there appear to be fundamental differences elsewhere in anaplerotic pathways between [0090] M. leprae and M. tuberculosis. Here, phospho-enol-pyruvate (PEP) carboxylase replaces the pyruvate carboxylase of M. tuberculosis, and the malic enzyme, associated with fast growth in mycobacteria³⁵, is missing. The metabolic implications are that flux between C3 and C4 compounds and the balance between glycolysis and gluconeogenesis will be very different. Another missing link between by-products of lipid metabolism and the Krebs cycle is the production of succinyl-CoA by catabolic Acc carboxylases predicted for M. tuberculosis ⁸. Other carbon sources lost to M. leprae are acetate, as ackA, pta and acs are all inactive, and galactose, so the cell wall galactan can only be produced from glucose since the galK, T genes are missing. This might imply that M. leprae is limited to growth on very few carbon sources, or even a limited and rather specialised combination, on which it can maintain a balanced carbon metabolism. Though a similar range of potential substrates is available to both M. leprae and M. tuberculosis in the host, marked differences in their ability to exploit them are apparent on examination of the systems involved in carbon and nitrogen compound degradation: there are fewer oxidoreductases, oxygenases and short-chain alcohol dehydrogenases, and their probable regulatory genes, (FIG. 3). The inescapable conclusion is that catabolism in M. leprae is severely limited.
In the same vein, the leprosy bacillus has lost anaerobic and microacrophilic electron transfer systems, such as formate dehydrogenase, nitrate, and fumarate reductase together with the biosynthetic and transport systems required to produce the cognate prosthetic groups. Likewise, the aerobic respiratory chain of [0091] M. leprae is truncated as only the 3′-end of the NADH oxidase operon, nuoA-N, remains. The consequences of this event are far-reaching, for not only has the potential to produce ATP from the oxidation of NADH been lost, but also regeneration of NAD⁺ may be limited, relying heavily on ndh, which is involved only in recycling NAD⁺. Alternatively, M. leprae may regenerate NAD⁺ from NADH by (1) diverting pyruvate to acetate and CO₂using lactate dehydrogenase and lactate oxidase; (2) diverting PEP to malate or fumarate via oxaloacetate, using its PEP carboxylase (an enzyme not found in the tubercle bacillus) that only catalyses the reaction in this direction. Given the loss of genes reviewed above, the acids produced by (1) and (2) cannot be recycled and must be excreted.

Anabolism

In surprising contrast, all the anabolic pathways seem to be relatively intact. With few exceptions, complete enzyme systems are predicted for synthesis of amino acids, purines, pyrimidines, nucleosides, nucleotides, most vitamins and cofactors. This suggests that the availability of these metabolites in phagosomes is either highly limited or that [0092] M. leprae cannot transport them efficiently. It also sets the biology of the leprosy bacillus apart from that of the other obligate parasites for which genomes have been sequenced^{15, 16}. M., leprae may, however, be auxotrophic for methionine as metC, encoding cystathionine β-lyase, is a pseudogene, whereas the other counterparts of M. tuberculosis met genes are all intact. This requirement for methionine may be dictated by the inactivation of the sulphate transport operon, cysYWA, and in turn this implies that M. leprae depends upon an organic source of sulphur. A second auxotrophy that is predicted is for cobinamide, as examination of the cob genes shows selective deletion of those to make cobinamide, while the genes needed to produce vitamin B12 from cobinamide are retained.

Pathogenesis and Disease Control

Central to a successful pathogenic lifestyle is the ability to obtain iron. [0093] M. leprae has many genes for haem and iron-based proteins and employs the iron regulatory systems, ideR and furB, yet may be severely handicapped compared to M. tuberculosis as it appears to have lost the mbt operon, encoding the non-ribosomal peptide synthase required for production of the iron-scavenging siderophores, mycobactin/exochelin^{8, 36, 37}. However, part of the iron uptake system is functional in M. leprae, as it transports exochelinMN, from M. neoaurum but not those of M. smegmatis or M. tuberculosis ³⁸. The genes for exochelinMN are unknown and seem unlikely to occur in M. leprae.
As might be expected given the differences in their respective pathologies, [0094] M. leprae contains several enzymes that have no counterparts in the tubercle bacillus, including a eukaryotic-like uridine phosphorylase and adenylate cyclase. In addition, there are two transport systems that may play significant physiological roles: an ABC-transporter for sugars, and a second member of the Nrampl family, involved in divalent metal ion uptake. M. leprae may have acquired another Nrampl gene³⁹to ensure adequate intracellular iron concentrations resulting from its lack of mycobactin siderophores.
[0095] M. leprae, shows a marked tropism for myelin-producing Schwann cells, and a surface-exposed 21 kDa laminin-binding protein (LBP) may be an important virulence factor^40-42. Inspection of the genome sequence revealed a single LBP gene and this also occurs in M. tuberculosis . No further candidates for virulence genes were detected, and many of those present in M. tuberculosis have been inactivated or lost, including three of the Mce operons encoding putative invasins^{9, 43}. Although the leprosy and tubercle bacilli both survive within macrophages, M. leprae has no catalase-peroxidase⁴⁴, and fewer peroxidoxins and epoxide hydrolases to combat reactive oxygen species. It has retained both superoxide dismutases suggesting that these may contribute to its survival.

Comparative Mycobacterial Genomics

Comparative genomics is a powerful new tool for exploring micobial evolution and identifying those genes that might encode new drug targets or protective antigens. Coupled with knowledge derived from bioinformatic analysis of the proteome, and understanding of the underlying microbiology, it is possible to reduce the number of potential new targets within a pathogen to a more tangible level. [0096]
This invention includes discoveries resulting from the findings of a comparative analysis in which gene and protein sets of the leprosy and tubercle bacilli have been compared pairwise, and against the completed genome sequences of various prokaryotes and eukaryotes. [0097]
The genome of [0098] M. leprae , an exceptionally slow growing bacterium, is substantially smaller than that of M. tuberculosis and contains numerous pseudogenes. While the genome of M. tuberculosis comprises 4.41 Mb and contains around 4,000 genes, the genome of M. leprae is only 3.27 Mb and a mere 49.5% is occupied by protein-coding genes. About 27% of the M. leprae genome contains recognizable pseudogenes, inactive reading frames with functional counterparts in the tubercle bacillus. The remaining 23.5% of the genome does not appear to be coding, and probably contains gene remnants mutated beyond recognition. The distribution of the 1,114 pseudogenes was essentially random throughout the chromosome. 1,604 potentially active genes were identified, of which 1,439 were common to both pathogens. Among the remaining 165 genes, with no ortholog in M. tuberculosis, were 29 for which functions could be attributed. Many of the 136 residual CDS in M. leprae, showing no similarity to known genes, may also represent pseudogenes as they are shorter than average and occur in regions of low gene density. In summary, assuming that all mycobacteria are descendants of a common ancestor, M. leprae has probably lost around 2,000 genes during evolution and the minimal gene set required by a pathogenic mycobacterium has been naturally defined.
Whole genome comparisons led to the identification of genes that are present in both [0099] M. tuberculosis and M. leprae but have no counterparts elsewhere. Since these pathogenic mycobacteria occupy similar niches in the human body where they encounter the same physiological stresses and immune responses, it is conceivable that the products of some of these genes may conduct highly specialized functions that could be essential for intracellular growth of mycobacteria. If this were the case, the corresponding proteins or enzymes might represent novel drug targets. In addition to those proteins that are confined to the species or the genus, there is a second group of polypeptides that also occur in Streptomyces spp., related members of the Actinomycetales kingdom, but not in other prokaryotes. It is reasonable to assume that such proteins confer specific properties on actinomycetes.
Knowledge of the subcellular location of proteins is particularly valuable for the design of new tuberculosis vaccines since it is widely believed that surface-exposed or secreted proteins correspond to those antigenic components that are first encountered by the immune system during infection[0100] ⁵¹. Bioinformatics has also been used to identify proteins that localize to the cell envelope and these include transmembrane proteins with hydrophobic domains, and lipoproteins with N-terminal cysteine residues that are modified by addition of lipid groups. Proteins that are secreted via the general secretory pathway⁵²are readily identifiable by their characteristic signal peptides, whereas those metallo-enzymes that are secreted by the twin arginine transporter system, Tat, can be recognized by the presence at the N-terminus of the cognate motif, S/TRRXFLK preceeding the signal peptide⁵³, ⁵. This will be discussed further below.
Other proteins that lack signal peptides and are secreted from mycobacteria in a Sec-independent manner, include those belonging to the ESAT-6 family[0101] ⁶¹. ESAT-6 is a potent T-cell antigen that induces strong Th1-type responses⁵⁵and has been extensively studied as a potential diagnostic reagent for infection⁵⁶, since its gene is missing from BCG⁵⁷, ⁵⁸, ⁵⁹, and as a component of a subunit vaccine⁶⁰. The comparative genomic analysis identified several ESAT-6 proteins, and their potential secretion machinery, that were common to both M. tuberculosis and M. leprae (Table 2).
Several examples are given in Table 2 of proteins of limited distribution with potential drug targets, diagnostic antigens or subunit vaccine components. [0102]
Legend of Table 2: [0103]
The reading of the first example, by instance, [0104]
[0105] M. leprae
ML0048: Name of an identified ORF in the genome of [0106] M. leprae.
[0107] M. tub.:
Rv3876: Name of Equivalent ORF in the genome of [0108] M. tuberculosis published in 1998.
BLASTP: [0109]
Method of comparing protein sequences for establishing their degree of similarity or identity. [0110]
1,00[0111] ^E−79:
BLASTP score, which indicates how similar the protein sequences are. The analyses of the results are described in Cole et al. for the comparisons between the genome of [0112] M. tuberculosis and the genome of BCG (Analysis of the proteome of Mycobacterium tuberculosis in silico, tuber Lung. Dis. 1999; 79(6):329-42).
Description: [0113]
Description of the protein, identified from all publically accessible databases, with highest similarity for the [0114] M. leprae protein ML0048.
Sc3C3.03C: Nomenclature of the streptomyces protein. [0115]
EMB : AL031231: Accession number in EMBL databank for the sequence of the Streptomyces protein found to be most similar to ML0048. [0116]
1083: length of the sequence in the EMBL databank. [0117]
FASTA score: Different method, like BLAST, for comparing sequences for their similarity. [0118]
Score denotes the degree of similarity. [0119]

31.6%: Percentage of identity between C terminal part of the Streptomyces protein and the amino acid sequence of ML0048. This 31.6% identity is found in an overlapping region of 580 amino acids between the two sequences. The other examples should be read similarly.

TABLE 2


Proteins of limited distribution with potential as drug targets,
diagnostic antigens or subunit vaccine components

	M.
Group	leprae	M. tub.	BLASTP	Description

A	ML0048	Rv3876		1,00E-	C-terminal half of Streptomyces coelicolor SC3C3.03C,
			79	hypothetical protein, TR:O86637 (EMBL:AL031231) (1083
				aa); Fasta score E( ): 5.9e-27, 31.6% identity in 580
				aa overlap, which contains Pro-Gln repeats
A	ML0115	Rv3780		2,00E-	S. coelicolor SCGD3.23C, hypothetical protein,
			44	TR:Q9XA56 (EMBL:AL096822)
A	ML0124	Rv0164		2,00E-	S. coelicolor SC6CG0.02C, hypothetical protein,
			40	TR:Q9X7Y8 (EMBL:AL049497) (144 aa); Fasta score E( ):
				7e-05, 21.9% identity in 137 aa overlap.
A	ML0151	Rv0948c		2,00E-	S. coelicolor SC063.16C, hypothetical protein,
			25	TR:CAB82023 (EMBL:AL161755)
A	ML0169	Rv0966c		7,00E-	S. coelicolor SCE6.30C, hypothetical protein,
			66	TR:CAB88834 (EMBL:AL353832) (277 aa); Fasta score E( ):
				3.3e-20, 41.0% identity in 205 aa overlap.
A	ML0229	Rv3603c		2,00E-	N-terminal half of S. coelicolor SCE126.02C,
			60	hypothetical protein, TR:Q9X845 (ENBL:AL049630) (420
				aa); Fasta score E( ): 4.1e-24, 36.7% identity in 294
				aa overlap
A	lsr2	Rv3597c		1,00E-	S. coelicolor SCE94.26C, putative lsr2-like protein,
			27	TR:g9X8N1 (EMBL:AL049628) (111 aa); Fasta score E( ):
				7.3e-18, 56.3% identity in 112 aa overlap
A	ML0284	Rv0360c		3,00E-	S. coelicolor SCH10.25C, hypothetical protein,
			23	TR:Q9X8R4 (EMBL:AL049754)
A	whiB3	Rv3416		6,00E-	Transcriptional regulator
			38
A	lppS	Rv2518c	e-135	many predicted lipoproteins from S. coelicolor.
A	ML0451	Rv2609c		2,00E-	S. coelicolor e.g. SC2E1.17, hypothetical protein,
			85	TR:O69888 (EMBL:AL023797) (172 aa); Fasta score E( ):
				2e-13, 43.3% identity in 150 aa overlap.
A	ML0486	Rv2588c		2,00E-	S. coelicolor SCL2.07C, putative secreted protein,
			19	TR:CAB70919 (EMBL:AL137778) (169 aa); Fasta score E( )
				7.3e-08, 35.8% identity in 120 aa overlap
A	ML0542	Rv1390		6,00E-	S. coelicolor 5C9C5.02C, hypothetical protein,
			51	TR:CAB93358 (EMBL:AL357523) (90 aa); Fasta score E( ):
				2e-18, 71.3% identity in 80 aa overlap.
A	ML0561	Rv1417		3,00E-	Corynebacterium ammoniagenes ribX, hypothetical
			38	protein, TR:O24754 (EMBL:AB003693) (184 aa); Fasta
				score E( ): 2.1e-15, 34.5% identity in 148 aa overlap.
				Contains hydrophobic, possible membrane-spanning
				regions
A	ML0580	Rv1446c		2,00E-	hypothetical proteins from S. coelicolor e.g.
			64	SCC22.20, hypothetical protein, TR:Q9XAB8
				(EMBL:AL096839) (351 aa); Fasta score E( ): 7.1e-21,
				36.0% identity in 203 aa overlap, although these have
				a short N-terminal extension relative to this
				homologue.
A	ML0603	Rv2413c		3,00E-	S. coelicolor SCC123.02C, putative DNA-binding
			77	protein, TR:Q9RDM2 (EMBL:AL136518) (336 aa); Fasta
				score E( ): 0, 39.3% identity in 326 aa overlap.
A	ML0630	Rv2365c		2,00E-	S. coelicolor SCC77.05, hypothetical protein,
			15	TR:Q9RDF3 (Er4BL:AL136503) (132 aa); Fasta score E( ):
				3.3e-06, 39.4% identity in 99 aa overlap.
A	ML0642	Rv3195	e-143	S. coelicolor SCE9.14C, hypothetical protein,
				TR:Q9X8I7 (EMBL:AL049841) (375 aa) ; Fasta score E( )
				4.9e-12, 24.9% identity in 305 aa overlap.
A	whiB2	Rv3260c		9,00E-	Transcription factor
			31
A	ML0762	Rv3258c		4,00E-	S. coelicolor hypothetical 15.0 kDa protein 5CE34.11C
			41	TR:CAB88914 (EMBL:AL353862) fasta scores: E( ): 4.8e-
				16, 47.0% id in 151 aa.
A	lpqB	Rv3244c	0.0	S. coelicolor putative lipoprotein SCE33.13C
				TR:CAB90922 (EMBL:AL355774) fasta scores: E( ):
				0.00039, 24.4% id in 624 aa
A	whiB1	Rv3219	6,00E-	Transcription factor
			31
A	ML0814	Rv3208c	3,00E-	S. coelicolor hypothetical protein
			32	gp\|AL390975\|AL390975_32 (94 aa) E( ): 2.5e-09; 47.945%
				identity
A	ML0816	Rv3207c	e-101	S. coelicolor putative membrane protein SC2H12.28c
				(314 aa) TR:CAB94652 (EMBL:AL359215) fasta scores:
				E( ): 1e-13, 30.2% id in 331 aa
A	ML0857	Rv2219	2,00E-	S. coelicolor putative integral membrane protein
			59	SC3H12.04 TR:CAB90843 (EMBL:AL355740) (234 aa) fasta
				scores: E( ): 1.2e-26, 39.6% id in 230 aa
A	ML0869	Rv2206	4,00E-	S. coelicolor putative integral membrane protein
			40	SC5F7.32 TR:Q9S2R7 (EMBL:AL096872)
A	ML0876	Rv2199c	2,00E-	S. coelicolor hypothetical proteins e.g. putative
			43	integral membrane protein SC6G10.27C TR:Q9X812
				(EMBL:AL049497) (132 aa) fasta scores: E( ) : 6.2e-15,
				38.8% id in 139 aa
A	ML0920	Rv2147c	3,00E-	pir\|\|T34949 hypothetical protein SC4A10.12c -
			89	Streptomyces coelicolor
A	ML0921	Rv2146c	5,00E-	S. coelicolor TR:Q9S2X3 (EMBL:AL109663) (94 aa); Fasta
			32	score E( ): 2.9e-12, 40.7% identity in 86 aa overlap.
				Contains possible membrane spanning hydrophobic
				domains.
A	ML0986	Rv2738c		3,00E-	S. coelicolor TR:O50484 (EMBL:AL020958) (64 aa); Fasta
			21	score E( ) : 2.5e-08, 44.4% identity in 63 aa overlap
A	ML0994	Rv2728c		1,00E-	S. coelicolor TR:O69964 (EMBL:AL022268) (237 aa);
			56	Fasta score E( ): 1.3e-13, 32.9% identity in 243 aa
				overlap
A	ML1009	Rv2714	e-106	pir\|\|T35742 hypothetical protein SC7H2.11c S.
				coelicolor
A	ML1016	Rv2708c		1,00E-	emb\|CAB72193.1\| (AL138851) hypothetical protein
			25	SCE59.06c [S. coelicolor A3(2)] Length = 97
A	ML1026	Rv2699c		2,00E-	T34816 hypothetical protein SC2E9.05 SC2E9.05 - S.
			32	coelicolor 144 2e-34
A	ML1027	Rv2698		1,00E-	membrane protein, S. coelicolor TR:O54132
			33	(EMBL:AL021530) (154 aa); Fasta score E( ) : 1.1e-08,
				33.6% identity in 149 aa overlap.
A	ML1029	Rv2696c		7,00E-	pir\|\|T34821 hypothetical protein SC2E9.10 SC2E9.10 -
			69	S. coelicolor 86 4e-16
A	ML1041	Rv2680		2,00E-	pir\|\|T34710 hypothetical protein SC1C3.18c SC1C3.18c -
			62	S. coelicolor 158 5e-38
A	ML1067	Rv1211		9,00E-	emb\|CAC01346.1\| (AL390975) conserved hypothetical
			23	protein S. coelicolor 101 1e-21
A	ML1093	Rv1244		5,00E-	lipoprotein, pir\|\|T35857 probable secreted substrate-
			78	binding protein - S. coelicolor 67 3e-10
A	ML1105	Rv1259	e-115	S. coelicolor TR:Q9S2L3 (EMBL:AL109732) (237 aa);
				Fasta score E( ): 0, 54.5% identity in 231 aa overlap.
A	ML1117	Rv1276c		3,00E-	pir\|\|T36773 hypothetical protein SC128.03c - S.
			53	coelicolor 115 4e-25
A	ML1147	Rv1312		3,00E-	possible secreted protein, emb\|CAB94546.1\| (AL359152)
			42	putative secreted/membrane protein S. coelicolor 66
				2e-10
A	ML1166	Rv1332		7,00E-	S. coelicolor TR:Q9S2G6 (EMBL:AL096852) (202 aa);
			54	Fasta score E( ) 1.5e-05, 34.6% identity in 188 aa
				overlap.
A	ML1230	Rv1182	e-149	papA3, emb\|CAC08383.1\|(AL392176) hypothetical protein
				S.coelicolor 132 8e-30
A	ML1306	Rv2125		5,00E-	S. coelicolor TR:Q9S2K6 (EMBL:AL109732) (312 aa);
			87	Fasta score E( ) 1.6e-07, 23.4% identity in 278 aa
				overlap
A	ML1321	Rv2111c		3,00E-	upstream of bacterial proteasome beta subunits
			07	including: Mycobacterium smegmatis TR:O30517
				(EMBL:AF009645) (64 aa); Fasta score E( ): 6.2e-18,
				82.8% identity in 64 aa overlap, Rhodococcus
A	ML1338	Rv2673	e-150	conserved integral membrane protein, S. coelicolor
				TR:Q53873 (EMBL:AL031317) (411 aa); Fasta score E( )
				1.1e-12, 28.3% identity in 410 aa overlap
A	ML1439	Rv2050		4,00E-	emb\|CAB61670.1\| (AL133213) hypothetical protein
			31	SC6D7.18c. S. coelicolor 101 4e-21
A	ML1485	Rv2466c		2,00E-	S. coelicolor TR:CAB71809 (EMBL:AL138662) (216 aa);
			66	Fasta score E( ): 0, 52.3% identity in 214 aa overlap
A	ML1508	Rv1155		2,00E-	S. coelicolor TR:Q9XAG1 (EMBL:AL079356) (144 aa);
			48	Fasta score E( ): 5.6e-25, 54.3% identity in 140 aa
				overlap.
A	ML1525	Rv2771c		8,00E-	S. coelicolor TR:Q9RD46 (EMBL:AL133424) (151 aa);
			27	Fasta score E( ): 1.3e-28, 56.1% identity in 148 aa
				overlap
A	ML1548	Rv2795c	e-132	S. coelicolor TR:O88028 (EMBL:AL031107) (295 aa);
				Fasta score E( ): 0, 54.4% identity in 285 aa overlap
A	ML1557	Rv2840c		2,00E-	emb\|CAB91141.1\| (AL355913) hypothetical protein S.
			27	coelicolor 46 7e-05
A	ML1561	Rv2844		1,00E-	S. coelicolor TR:CAB91137 (ENBL:AL355913) (167 aa);
			39	Fasta score E( ): 1.4e-07, 35.8% identity in 137 aa
A	ML1624	Rv2917	0.0	S. coelicolor TR:Q9S3Y6 (EMBL:AF170560) (597 aa);
				Fasta score E( ): 0, 55.5% identity in 566 aa overlap
A	ML1644	Rv2235	e-113	N-terminal signal sequence plus membrane spanning
				hydrophobic domain; emb\|CAB59445.1\| (AL132644)
				putative membrane protein [Streptomyc . . . 109 4e-23
A	ML1649	Rv2239c		3,00E-	emb\|CAB92846.1\| (AL356892) hypothetical protein
			36	[Streptomyces Co . . . 137 6e-32
A	ML1652	Rv2242	0.0	S. coelicolor TR:Q9RDP8 (EMBL:AL133423) (401 aa);
				Fasta score E( ) : 4.3e-26, 42.0% identity
A	ML1666	Rv2968c		9,00E-	S. coelicolor putative integral membrane protein
			59	TR:CAB93387 (EMBL:AL357523) (240 aa); Fasta score E( ):
				3.6e-25, 36.1% identity in 191 aa overlap
A	ML1698	Rv3005c		4,00E-	conserved membrane protein, emb\|CAB61735.1\| (AL133220)
			54	putative membrane protein. S. coelicolor 99 5e-20
A	ML1706	Rv3015c		1,00E-	S. coelicolor TR:Q9Z586 (EMBL:AL035569) (331 aa);
			91	Fasta score E( ): 0, 38.6% identity in 337 aa overlap,
A	ML1781	Rv2256c		4,00E-	4pir\|\|T11215 hypothetical protein 5 - Streptomyces
			62	glaucescens >g . . . 153 1e-36
A	ML1782	Rv2257c	e-121	S. coelicolor SC4A7.08 TR:Q9RDQ4 (EMBL:AL133423) (273
				aa); Fasta score E( ): 0, 53.2% identity in 269 aa
				overlap
A	ML1791	Rv1976c		8,00E-	S. coelicolor hypothetical protein SC1C3.03C TR:O69845
			25	(EMBL:AL023702) (125 aa); Fasta score E( ): 4.3e-06,
				36.6% identity in 112 aa overlap.
A	ML1908	Rv0637		3,00E-	S. coelicolor SCD82.07 TR:CAB77410 (EMBL:AL160431)
			62	(150 aa); Fasta score E( ): 4.7e-11, 29.3% identity in
				150 aa overlap.
A	ML1910	Rv0635		9,00E-	emb\|CAB77410.1\| (AL160431) hypothetical protein
			49	SCD82.07 S. coelicolor 83 1e-15
A	ML1926	Rv0431		6,00E-	S. coelicolor hypothetical protein SCD95A.20
			24	TR:CAB93047 (EMBL:AL357432) (84 aa); Fasta score E( ):
				4.1e-11
A	ML1927	Rv0430		2,00E-	S. coelicolor hypothetical protein SCD95A.20
			25	TR:CAB93047 (EMBL:AL357432) (84 aa) ; Fasta score E( )
				4.1e-11, 52.8% identity in 72 aa overlap.
A	ML1997	Rv0970	7,00E-	S. coelicolor putative integral membrane protein
			39	SCM2.15C
A	ML2030	Rv1884c	1,00E-	Rpf, emb\|CAC09538.1\| (AL442120) putative secreted
			34	protein S. coelicolor 108 5e-23
A	ML2031	Rv1883c	1,00E-	Streptomyces actuosus NSH-OrfB TR:P72384 (EMBL:U75434)
			44	fasta scores: E( ): 2.5e-08, 34.4% in 125 aa
A	ML2048	Rv1871c	2,00E-	S. coelicolor hypothetical protein TR:CAE88434
			14	(EMBL:AL353815) fasta scores: E( ): 0.0092, 39.3% in 61
				aa; truncated at C-terminus; may represent a
				pseudogene
A	ML2063	Rv1846c	3,00E-	possible regulator, pir\|\|T36388 hypothetical protein
			35	SCE94.28c - S. coelicolor 64 6e-10
A	ML2064	Rv1845c	3,00E-	S. coelicolor putative integral membrane protein
			82	SC10A7.04 TR:Q9XAS1 (EMBL:AL078618) fasta scores: E( ):
				1.8e-19, 32.6% in 328 aa
A	ML2073	Rv1830	2,00E-	S. coelicolor hypothetical 19.1 kda protein
			74	TR:CAB88877 (ENBL:AL353861) fasta scores: E( ): 3.7e-
				30, 64.8% in 145 aa
A	ML2075	Rv1828	7,00E-	S. coelicolor hypothetical 26.5 kda protein
			71	TR:CAB88879 (EMBL:AL353861) fasta scores: E( ): 1.1e-
				14, 41.4% in 237 aa.
A	ML2114	Rv0909		7,00E-	S. coelicolor hypothetical 9.9 kda protein TR:O69965
			07	(EMBL:AL022268) fasta scores: E( ): 0.038, 41.3% in 46
				aa
A	ML2135	Rv0885	e-123	S. coelicolor putative membrane protein TR:Q9XAE8
				(EMBL:AL079356) fasta scores: E( ) : 1.5e-13, 27.1% in
				255 aa
A	ML2137	Rv0883c		1,00E-	S. coelicolor hypothetical 39.0 kda protein TR:O50529
			76	(EMBL:AL009204) fasta scores: E( ): 2.2e-19, 36.0% in
				247 aa
A	ML2142	Rv0877		8,00E-	S. coelicolor hypothetical 32.2 kda protein
			91	TR:CAB93404 (EMBL:AL357524) fasta scores: E( ): 2.5e-
				19, 43.3% in 270 aa.
A	ML2143	Rv0876c	e-172	S. coelicolor putative integral membrane protein
				TR:CAB93403 (EMBL:AL357524) fasta scores: E( ): 5.3e-
				16, 38.8% in 448 aa.
A	ML2151	Rv0867c		1,00E-	Probable resusicitation-promoting factors, exported
			35	protein
A	ML2156	Rv0862c	0.0	S. coelicolor hypothetical 90.4 kda protein
				TR:CAB93395 (EMBL:AL357524) fasta scores: E( ): 3.9e-
				27, 34.6% in 856 aa
A	ML2193	Rv0819		2,00E-	Acetyltransferase (GNAT) family, emb\|CAB88484.1\|
			87	(AL353816) putative acetyltransferase S. coelicolor
				216 3e-55
A	ML2199	Rv3118		1,00E-	Saccharopolyspora erythraea hypothetical 10.2 kda
			28	protein TR:Q54084 (EMBL:M29612) fasta scores: E( ):
				2.7e-16, 53.0% in 100 aa
A	ML2200	Rv0813c		3,00E-	S. coelicolor hypothetical 21.7 kda protein
			59	TR:CAB94083 (EMBL:AL358692) fasta scores: E( ): 4.4e-
				11, 30.5% in 167 aa
A	ML2204	Rv0810c		2,00E-	S. coelicolor hypothetical 9.3 kda protein SCD25.24C
			13	TR:Q9RKJ8 (EMBL:AL118514) fasta scores: E( ): 1.3e-06,
				46.8% id in 62 aa.
A	ML2207	Rv0807		8,00E-	S. coelicolor hypothetical protein SCD25.20 TR:Q9RKK0
			36	(EMBL:AL118514) (202 aa) fasta scores: E( ): 6.6e-16,
				52.5% id in 101 aa.
A	ML2219	ARv0787A		1,00E-	S. coelicolor hypothetical protein SCD25.13 (AL118514)
			33
A	ML2253	Rv2145c		1,00E-	antigen 84 homolog, also in S. coelicolor, etc.
			06
A	ML2261	Rv0546c		1,00E-	emb\|CAB95979.1\| (AL360034) conserved hypothetical
			43	protein S. coelicolor 119 1e-26
A	ML2289	Rv3662c		7,00E-	S. coelicolor putative oxidoreductase SCH5.22C
			64	TR:Q9X924 (EMBL:AL035636) (274 aa) fasta scores: E( )
				1e-11, 40.9% id in 269 aa
A	ML2295	Rv3668c		7,00E-	emb″CAB61552.1\| (AL133171) protease precursor S.
			67	coelicolor 53 2e-06
A	ML2296	Rv3669		2,00E-	Similar_to S. coelicolor putative integral membrane
			43	transport protein SCH5.28 TR:Q9X930 (EMBL:AL035636)
				(162 aa) fasta scores: E( ): 3.3e-10, 37.3% id
A	ML2306	Rv3680	e-110	S. coelicolor putative ion-transporting ATPase
				TR:Q9XA35 (EMBL:AL079353) (481 aa) fasta scores: E( ):
				0, 48.6% id in 432 aa
A	ML2307	Rv3681c		4,00E-	whiB4
			28
A	ML2330	Rv3716c		6,00E-	pir\|\|T35387 hypothetical protein SC66T3.30c - S.
			10	coelicolor 47 6e-05
A	ML2332	Rv3718c		1,00E-	S. coelicolor conserved hypothetical protein TR:Q9ZBJ2
			39	(EMBL:AL035161) (147 aa) fasta scores: E( ) : 1.4e-22,
				47.6% id in 147 aa.
A	ML2410	Rv0528	e-160	conserved membrane protein, emb\|CAC08381.1\| (AL392176)
				putative integral membrane protein S. coelicolor 221
				2e-56
A	ML2425	Rv0504c		7,00E-	emb\|CAB77410.1\| (AL160431) hypothetical protein
			52	SCD82.07 [Strept . . . 73 2e-12
A	ML2428	ARv0500B		6,00E-	Small, strongly basic, S. coelicolor SCE68.25c,
			17	gp\|AL079345\|AL079345_25 S. coelicolor (32 aa) E( ):
				1.7e-07; 93.103%
A	ML2432	Rv0498	e-101	S. coelicolor hypothetical protein TR:Q9X8H0
				(EMBL:AL049819) (285 aa) fasta scores: E( ): 3.2e-30,
				51.6% id in 273 aa
A	ML2435	Rv0495c		7,00E-	S. coelicolor hypothetical protein TR:Q9X8H2
			94	(EMBL:AL049819) (271 aa) fasta scores: E( ): 0, 48.4%
				id in 250 aa
A	ML2442	Rv0487		1,00E-	emb\|CAC04041.1\| (AL391406) conserved hypothetical
			47	protein S. coelicolor 142 2e-33
A	ML2446	Rv0483	e-137	possible lipoprotein, S. coelicolor putative
				lipoprotein TR:CAB76012 (EMBL:AL157916) fasta scores:
				E( ): 2.5e-24, 28.6% id in 405 aa.
A	ML2453	Rv0476	9,00E-	conserved membrane protein, emb\|CAC04036.1\| (AL391406)
			22	putative membrane protein S. coelicolor 57 3e-08
A	ML2522	Rv0309	5,00E-	S. coelicolor putative secreted protein SCL24.08
			65	TR:CAB76092 (EMBL:AL157956)
A	ML2529	Rv0290	e-116	S. coelicolor putative integral membrane protein
				SC3C3.21 TR:O86654 (EMBL:AL031231) fasta scores: E( ):
				1.9e-05, 23.8% id in 483 aa
A	ML2566	Rv0241c	e-125	S. coelicolor putative dehydratase TR:CAB77291
				(EMBL:AL160312)
A	ML2630	Rv0007	4,00E-	emb\|CAB92992.1\| (AL357152) putative integral membrane
			06	protein S. coelicolor 69 5e-11
A	ML2640	Rv0146	3,00E-	pir\|\|T35930 hypothetical protein 5C9E5.10 - S.
			93	coelicolor 141 1e-32
A	ML2664	Rv0116c	1,00E-	possible secreted protein, pir\|\|T35535 probable
			72	secreted protein - S. coelicolor 154 7e-37
A	ML2687	Rv0051	e-150	conserved membrane protein, pir\|\|T36589 probable
				transmembrane protein - S. coelicolor 185 1e-45
A	ML2699	Rv3909	0.0	putative secreted protein, pir\|\|T36582 hypothetical
				protein SCH24.17c - S. coelicolor 90 8e-17
M	ML0007	Rv0007	6,00E-	Putative membrane protein
			51
M	ML0012	Rv0010c	4,00E-	Contains hydrophobic, possible membrane-spanning
			30	regions.
M	ML0013	Rv0011c		3,00E-	Contains hydrophobic, possible membrane-spanning
			36	regions.
M	ML0022	Rv0020c	e-114	—
M	ML0030	Rv0039c		9,00E-	putative membrane protein
			06
M	ML0031	Rv0040c		3,00E-	Contains a probable N-terminal signal sequence
			48
M	ML0042	Rv3882c	e-138	putative membrane protein
M	ML0044	Rv3880c		2,00E-	—
			19
M	ML0047	Rv3877	e-146	putative membrane protein
M	ML0049	Rv3875		5,00E-	possible secreted protein, ESAT-6
			14
M	ML0050	Rv3874		4,00E-	possible secreted protein, ESAT-6
			12
M	ML0051	Rv3873		1,00E-	PPE-family protein
			30
M	ML0054	Rv3869	e-151	putative membrane protein
M	ML0056	Rv3867		2,00E-	—
			13
M	ML0068	Rv3850		8,00E-	—
			71
M	ML0069	Rv3849		4,00E-	—
			41
M	ML0071	Rv3847		2,00E-	—
			65
M	ML0073	Rv3843c		3,00E-	putative membrane protein
			51
M	ML0081	Rv3835	e-107	putative membrane protein, possible membrane-spanning
				region near the N-terminus.
M	ML0091	Rv3810		1,00E-	erp, pirG, exported repetitive protein precursor
			39
M	ML0093	Rv3808c	0.0	—
M	ML0094	Rv3807c		6,00E-	putative membrane protein
			30
M	ML0096	Rv3805c	0.0	putative membrane protein
M	ML0099	Rv3802c		8,00E-	—
			96
M	embB	Rv3795	0.0	arabinosyl transferase
M	embA	Rv3794	0.0	arabinosyl transferase
M	embC	Rv3793	0.0	arabinosyl transferase
M	ML0107	Rv3792	0.0	Nycobacterium smegmatis ORF3, hypothetical membrane
				protein
M	ML0116	Rv3779	e-179	putative membrane protein
M	ML0133	Rv2949c		3,00E-	Pfam match to entry PF01947 DUF98, Protein of unknown
			64	function
M	lppX	Rv2945c		6,00E-	putative lipoprotein
			60
M	ML0158	Rv0954		4,00E-	34 kDa antigen, membrane protein
			20
M	ML0159	Rv0955		2,00E-	putative membrane protein
			74
M	ML0185	Rv0996		2,00E-	possible membrane-spanning regions
			74
M	ML0187	Rv0998	e-124	Cyclic nucleotide-binding domain.
M	ML0199	Rv3647c	2,00E-	—
			52
M	ML0208	Rv3632	2,00E-	putative membrane protein
			38
M	ML0227	Rv3605c	3,00E-	putative membrane protein
			36
M	MML0228	Rv3604c	2,00E-	putative membrane protein
			51
M	lpqT	Rv1016c	1,00E-	putative lipoprotein
			52
M	ML0256	Rv1024	2,00E-	Contains hydrophobic, possible membrane-spanning
			42	region
M	ML0271	Rv0401	1,00E-	putative membrane protein
			23
M	ML0279	Rv0356c	9,00E-	—
			63
M	ML0281	Rv0358	2,00E-	—
			36
M	ML0285	Rv0361	1,00E-	putative membrane protein
			50
M	ML0298	Rv0416	5,00E-	possibly thiamine_biosynthesis
			10
M	lpqE	Rv3584	3,00E-	putative lipoprotein
			40
M	ML0370	Rv3438	2,00E-	Contains PS00107 Protein kinases ATP-binding region
			78	signature
M	NL0383	Rv3415c	5,00E-	—
			59
M	ML0386	Rv3412	4,00E-	—
			45
M	ML0405	Rv3616c	1,00E-	—
			71
M	ML0406	Rv3615c	2,00E-	—
			14
M	ML0407	Rv3614c	2,00E-	—
			45
M	ML0410	Rv2107	8,00E-	PE-family protein
			08
M	ML0411	Rv2108	1,00E-	PPE-family protein, serine-rich antigen
			22
M	ML0425	Rv2520c	2,00E-	putative membrane protein
			10
M	ML0431	Rv2507	1,00E-	putative membrane protein
			41
M	ML0520	Rv2536	1,00E-	putative membrane protein
			40
M	PE	Rv1386	1,00E-	PE protein family
			21
M	PPE.0	Rv1387	3,00E-	PPE protein family
			99
M	mihF	Rv1388	4,00E-	integration host factor
			24
M	lprG	Rv1411c	1,00E-	putative lipoprotein
			50
M	mtb12	Rv2376c	2,00E-	putative secreted protein
			28
M	ML0676	Rv3354	2,00E-	—
			15
M	ML0703	Rv3311	e-125	—
M	ML0730	Rv3281	1,00E-	Contains Ffam match to entry PF01039 Carboxyl_trans,
			20	Carboxyl transferase domain
M	ML0733	Rv3278c	4,00E-	putative membrane protein
			53
M	ML0734	Rv3277	2,00E-	putative membrane protein
			64
M	ML0748	Rv3269	1,00E-	irpA
			15
M	ML0761	Rv3259	2,00E-	Mycobacterium smegmatis hypothetical 6.0 kDa protein
			48	(partial CDS) TR:Q9S425 (EMBL:AE164439) fasta scores:
				E( ): 1e-10, 75.5% id in 53 aa
M	ML0764	Rv3256c	1,00E-	—
			79
M	ML0806	Rv3217c	5,00E-	putative membrane protein
			25
M	ML0810	Rv3212	e-104	putative membrane protein
M	ML0813	Rv3209	2,00E-	putative membrane protein
			24
M	ML0818	Rv3205c	e-102	—
M	ML0834	Rv2342	1,00E-	—
			21
M	ML0872	Rv2203	9,00E-	putative membrane protein
			43
M	mmpS3	Rv219Bc	3,00E-	putative membrane protein
			49
M	ML0878	Rv2197c	1,00E-	putative membrane protein
			55
M	ML0888	Rv2186c	8,00E-	—
			41
M	ML0889	Rv2185c	8,00E-	—
			41
M	ML0891	Rv2183c	2,00E-	—
			27
M	ML0895	Rv2179c	1,00E-	—
			60
M	ML0898	Rv2175c	1,00E-	putative DNA-binding protein
			41
M	MML0901	Rv2172c	e-102	—
M	ML0902	Rv2171	3,00E-	probable lipoprotein
			57
M	ML0903	Rv2170	9,00E-	—
			55
M	ML0904	Rv2169c	7,00E-	putative membrane protein
			32
M	ML0907	Rv2164c	2,00E-	putative conserved membrane protein
			50
M	ML0923	Rv2144c	3,00E-	possible membrane protein
			07
M	ML0984	Rv2740	3,00E-	—
			31
M	ML0990	Rv2732c	9,00E-	possible conserved membrane protein
			46
M	ML1001	Rv2722	7,00E-	—
			06
M	ML1004	Rv2719c	1,00E-	possible conserved membrane protein
			17
M	ML1015	Rv2709	7,00E-	possible conserved membrane protein
			26
M	ML1025	Rv2700	1,00E-	possible secreted protein
			62
M	ML1030	Rv2695	1,00E-	—
			47
M	ML1053	Rv2107	8,00E-	PE protein
			11
M	ML1055	Rv2347c	1,00E-	—, family
			19
M	ML1056	Rv3619c	6,00E-	—, family
			18
M	ML1065	Rv1209	6,00E-	membrane protein
			21
M	ML1077	Rv1222	3,00E-	Mycobacterium avium TR:O05736 (EMBL:U87308) (133 aa);
			34	Fasta score E( ): 0, 71.7% identity in 138 aa overlap
M	ML1079	Rv1224	2,00E-	possible secreted protein
			29
M	ML1096	Rv1249c	2,00E-	putative membrane protein
			48
M	ML1098	Rv1251c	0.0	some_similarity_to_GTP-binding_proteins
M	ML1099	Rv1252c	5,00E-	putative lipoprotein
			41
M	ML1115	Rv1274	3,00E-	lipoprotein, lprB
			58
M	ML1116	Rv1275	8,00E-	lipoprotein, lprC
			54
M	ML1120	Rv1278	0.0	Contains multiple possible coiled-coils. Contains
				PS00017 ATP/GTP-binding site motif A (P-loop)
M	ML1138	Rv1303	3,00E-	integral membrane protein
			20
M	ML1176	Rv1342c	3,00E-	possible conserved membrane protein
			34
M	ML1177	Rv1343c	5,00E-	possible lipoprotein, membrane protein
			43
M	ML1180	Rv3619c	6,00E-	ESAT-6 family
			18
M	ML1181	Rv2347c	1,00E-	QILSS family
			19
M	ML1182	Rv1361c	2,00E-	PPE family
			47
M	ML1183	Rv2107	8,00E-	PE family
			11
M	ML1190	Rv2525c	3,00E-	—, twin-Arginine secreted protein
			70
M	ML1221	Rv1590	2,00E-	—
			18
M	ML1222	Rv1591	1,00E-	membrane protein
			29
M	ML1232	Rv1184c	2,00E-	Possibly secreted PE protein, Contains PS00017
			77	ATP/GTP-binding site motif A (P-loop)
M	ML1233	Rv3821	9,00E-	conserved membrane protein
			33
M	ML1244	Rv2484c	e-130	conserved membrane protein
M	ML1255	Rv2468c	1,00E-	—
			41
M	ML1270	Rv1610	8,00E-	conserved membrane protein, Contains Pfam match to
			36	entry PF00218 IGPS,
M	ML1296	Rv2137c	1,00E-	—
			25
M	ML1299	Rv2134c	9,00E-	—
			60
M	ML1300	Rv2133c	4,00E-	—
			90
M	ML1315	Rv2116	1,00E-	lipoprotein, LppK
			35
M	ML1334	Rv2091c	6,00E-	conserved membrane protein, calcium-binding
			28
M	ML1357	Rv1693	7,00E-	—
			09
M	ML1361	Rv1697	e-114	conserved membrane protein
M	ML1362	Rv1698	6,00E-	conserved secreted protein
			58
M	ML1389	Rv1635c	e-144	conserved membrane protein
M	ML1446	Rv2061c	5,00E-	—
			35
M	ML1470	Rv2446c	2,00E-	conserved membrane protein
			16
M	ML1505	Rv1158c	7,00E-	conserved hypothetical Proline rich protein, possibly
			17	secreted
M	ML1506	Rv1157c	4,00E-	—
			62
M	ML1526	Rv2772c	2,00E-	conserved membrane protein
			43
M	ML1537	Rv1797	1,00E-	possible secreted protein
			98
M	ML1540	Rv1794	e-101	—
M	ML1544	Rv1782	e-155	conserved membrane protein
M	ML1560	Rv2843	8,00E-	—
			24
M	ML1584	Rv2876	3,00E-	conserved membrane protein
			25
M	ML1607	Rv2898c	2,00E-	Contains Pfam match to entry PF02021 UPF0102,
			17	Uncharacterised protein family UPF0102,
				sp\|O83883\|Y913_TREPA HYPOTHETICAL PROTEIN TP0913
				>gi\|7514634\|pir.
M	ML1610	Rv2901c		2,00E-	—
			39
M	ML1638	Rv2229c		2,00E-	—
			63
M	ML1677	Rv2980		3,00E-	possible secreted protein
			33
M	ML1704	Rv3013		6,00E-	—
			71
M	ML1720	Rv3035	e-107	—
M	ML1813	Rv1476		3,00E-	—
			39
M	PPE.1	Rv0256c	3,00E-	PPE-family protein
			93
M	ML1828A	Rv0257		1,00E-	Probably pseudogene as Rv0257 is longer
			15
M	ML1911A	Rv0634A		—, May be pseudogene as Rv0634A is predicted to be 13
				aa longer
M	ML1918	Rv3587c		5,00E-	conserved hypothetical membrane protein
			69
M	ML1937	Rv1111c		9,00E-	probable integral membrane protein
			39
M	MML1939	Rv1109c		9,00E-	—
			49
M	ML1945	Rv1100		6,00E-	possible membrane protein
			57
M	ML1991	Rv0096		4,00E-	PPE
			90
M	ML1988	Rv0093c		1,00E-	Contains possible membrane spanning hydrophobic
			52	domains. Note lacks the N-terminal 46 aa of the N.
				tuberculosis protein
M	ML1993	Rv0098		3,00E-	—
			50
M	ML1995	Rv0100		1,00E-	—
			18
M	ML2010	Rv1906c	4,00E-	putative lipoprotein (secreted in Mt)
			31
M	ML2022	Rv1893		2,00E-	—
			13
M	ML2023	Rv1891	2.00E-	Contains probable N-terminal signal sequence.
			46
M	ML2054	Rv1861	1,00E-	integral membrane protein
			07
M	ML2070	Rv1836c	e-171	—
M	ML2111	Rv0912	1,00E-	membrane protein
			35
M	ML2113	Rv0910	6,00E-	—
			49
M	ML2141	Rv0879c	9,00E-	—
			22
M	ML2144	Rv0875c	2,00E-	possible exported protein
			45
M	ML2155	Rv0863	2,00E-	—
			18
M	ML2195	Rv0817c	4,00E-	probable exported protein
			68
M	ML2228	Rv0779c	3,00E-	probable membrane protein
			50
M	ML2258	Rv0543c	2,00E-	—
			28
M	ML2259	Rv0544c	2,00E-	possible membrane protein
			16
M	ML2271	Rv0556	6,00E-	putative membrane protein
			46
M	ML2274	Rv0559c	9,00E-	putative secreted protein
			23
M	ML2320	Rv3705c	8,00E-	—
			64
M	ML2337	Rv3723	4,00E-	possible membrane spanning hydrophobic domains
			57
M	ML2377	Rv0451c	1,00E-	mmpS4, Mycobacterium avium TmtpA TR:Q9XCF4
			35	(ENBL:AF143772) (221 aa) fasta scores: E( ): 0, 58.9%
				id in 146 aa
M	ML2380	Rv0455c	2,00E-	possible secreted protein
			37
M	ML2388	Rv0463	9,00E-	possible membrane protein
			18
M	ML2390	Rv1083	1,00E-	possible secreted/membrane protein
			10
M	ML2392	Rv1081c	6,00E-	conserved membrane protein,
			34	hydrophobic_stretch_from_aa_26-48
M	ML2407	Rv0531	5,00E-	putative membrane protein
			06
M	ML2433	Rv0497	5,00E-	conserved membrane protein
			39
M	ML2450	Rv0479c	7,00E-	possible secreted protein, >gb\|AAF74996.1\|AF143402_1
			57	(AF143402) putative multicopper oxidase
				[Mycobacterium avium]
M	ML2452	Rv0477	2,00E-	—
			23
M	ML2454	Rv0475	6,00E-	possible hemagglutinin
			40
M	ML2465	Rv0464c	7,00E-	—
			53
M	ML2473	Rv3753c	2,00E-	—
			53
M	ML2489	Rv0383c	5,00E-	possible secreted protein, hydrophobic N-terminus and
			91	Pro-rich C-terminus
M	ML2491	Rv1754c	e-109	—
M	ML2518	Rv0313	1,00E-	—
			39
M	ML2527	Rv0292	2,00E-	conserved membrane protein,
			69
M	ML2530	Rv0289	2,00E-	—
			92
M	ML2531	Rv0288	5,00E-	ESAT-6 family, possible cell surface protein
			27
M	ML2532	Rv3020c	9,00E-	PE-family protein
			10
M	ML2534	Rv0285	9,00E-	PE-family protein
			13
M	ML2536	Rv0283	e-156	conserved membrane protein
M	ML2557	Rv0250c	2,00E-	—
			26
M	mce	Rv0169	e-107	Mce protein
M	ML2569A	Rv0236A	2,00E-	Small secreted protein with typical N-terminal signal
			24	peptide
M	ML2570	Rv0236c	0.0	possible integral membrane protein
M	ML2581	Rv0227c	e-116	putative integral membrane protein
M	ML2582	Rv0226c	e-132	conserved membrane protein
M	ML2595	Rv0175	2,00E-	possible membrane protein
			41
M	ML2596	Rv0176	1,00E-	conserved membrane protein
			73
M	ML2597	Rv0177	1,00E-	conserved membrane protein
			42
M	ML2598	Rv0178	2,00E-	conserved membrane protein
			43
M	ML2604	Rv0184	8,00E-	—
			64
M	ML2605	Rv0185	3,00E-	—
			47
M	ML2614	Rv0199	3,00E-	conserved membrane protein
			47
M	ML2615	Rv0200	5,00E-	probable membrane protein
			55
M	ML2616	Rv0201c	5,00E-	—
			36
M	ML2621	Rv0207c	2,00E-	—
			43
M	ML2627	Rv0216	e-103	—
M	ML2629	Rv0164	6,00E-	—
			44
M	ML2689	Rv0049	1,00E-	—
			45
X	ML0190	Rv1000	7,00E-	gp\|AL357613\|AL357613_12 S. coelicolor cosmid (210 aa)
			53	E( ): 2.4e-44; 55.122% identity in 205 aa overlap;
				AE003963\|AE003963_5 Xylella fastidiosa, E( ) 9.7e-
				14; 3 9.894% identity in 188 aa overlap. Weak
				similarity to proteins involved in DNA repair
X	ML0257	Rv1025		4,00E-	Also hypothetical proteins from Thermotoga maritima
			72	e.g. TN1078, hypothetical protein, TR:Q9X0G7
				(EMBL:AE001768) (170 aa)
X	ML0418	Rv3368c		2,00E-	weak similarity Thermus aquaticus nox, NADH
			76	dehydrogenase, SW:NOX_THETH (X60110) (205 aa); Fasta
				score E( ) 0.00023, 28.8% identity in 212 aa overlap.
X	ML0577	Rv1440		9,00E-	putative protein-export membrane protein, secG
			12
X	ML0776	Rv3242c		3,00E-	probable competence protein ComF - Deinococcus
			11	radio . . . 77 2e-13
X	ML1037	Rv2683		2,00E-	Contains 2 Pfam matches to entry PF00571 CBS, CBS
			42	domain.
X	ML1119	Rv1277	e-105	possibly phosphoesterase
X	ML1159	Rv1324	e-116	probable thioredoxin
X	ML1249	Rv2476c	0.0	Rickettsia prowazekii TR:Q9ZCI2 (ENBL:AJ235273) (1581
				aa); Fasta score E( ): 0, 32.9% identity in 1494 aa
				overlap
X	ML1399	Rv1647		1,00E-	weakly adenylate cyclases
			76
X	ML1444	Rv2054		3,00E-	Weakly several carboxymethylenebutenolidases (EC
			94	3.1.1.45) involved in 3-chlorocatechol degradation
				e.g. Pseudomonas putida SW:CLCD_PSEPU (P11453) (236
				aa)
X	ML1494	Rv1171		8,00E-	conserved membrane protein, pir\|\|PH0210 hypothetical
			19	protein 133 (fdxA 5′ region) - Saccharo . . . 74 5e-
				13
X	ML1503A	Rv1159A		9,00E-	S. coelicolor (SC5C7.25) gp\|AL03151
			33	5AL031515\|AL031515_25 (101 aa) E( ): 1.9e-06; 34.831%
				identity in 89 aa overlap; and archaebacteria.
X	ML1660	Rv2926c		2,00E-	—, pir\|\|E72412 conserved hypothetical protein -
			69	Thermotoga manitima . . . 66 4e-10
X	ML1723	Rv3038c	e-152	—, gb\|AAC01738.1\| (AF040571) methyltransferase
				[Amycolatopsis medit . . . 59 1e-07
X	ML1909	Rv0636		9,00E-	Contains Pfam match to entry PF01575 MaoC_dehydratas,
			72	MaoC like domain. ML2566
X	desA2	Rv1094		7,00E-	Gossypium hirsutum (Upland cotton) acyl-[acyl-carrier
			85	protein) desaturase precursor SW:STAD_GOSHI (X95988)
				(397 aa); Fasta score E( ): 5.6e-05, 23.9% identity in
				293 aa overlap.
X	ML1983	Rv1919c		8,00E-	weakly similar pollen allergen
			45
X	ML2366	Rv3760		1,00E-	Deinococcus radiodurans conserved hypothetical
			12	protein TR:Q9RU17
X	ML2463	Rv0466	e-102	weakly similar acyl-ACP thioesterase

TABLE 3


Possible twin arginine secreted proteins

M. tuberculosis	M. leprae	Gene	Predicted function

Rv0203	del	—	unknown
Rv0265c	NF	fecB2

iron_transport_protein_FeIII_dicitrate_transporter

Rv0846c	ML2171 pa	—	similar_to_several_L-ascorbate_oxidases
Rv1755c	del	plcD	phospholipase_C_precursor
Rv2349c	NF	plcC	phospholipase_C_precursor
Rv2350c	del	plcB	phospholipase_C_precursor
Rv2351c	NF	plcA	phospholipase_C_precursor
Rv2525c	ML1190	—	unknown
Rv2577	ML0497 ps	—	similarity_to_G755244_acid_phosphatase
Rv2833c	del	uqpB	sn-glycerol-3-phosphate transport
Rv3353c	del	—	unknown
NF	ML2649	—	unknown

The implications for this invention are widespread. [0122] M. tuberculosis and M. leprae marker polypeptides are disclosed in SEQ ID NO: 1 to SEQ ID NO:644. The discovery of the M. tuberculosis and M. Ieprae marker polypeptides and DNA encoding the polypeptides enables construction of expression vectors comprising nucleic acid sequences encoding M. tuberculosis and M. leprae marker polypeptides; host cells transfected or transformed with the expression vectors; biologically active M. tuberculosis and M. leprae marker polypeptides and M. tuberculosis and M. leprae marker polypeptides as isolated or purified peptides; and antibodies immunoreactive with M. tuberculosis and M. leprae marker polypeptides. In addition, understanding of the mechanism by which M. tuberculosis and M. leprae marker polypeptides function enables the design of assays to detect inhibitors of M. tuberculosis and M. leprae marker polypeptide activity.
As used herein, the term “[0123] M. tuberculosis and M. leprae marker polypeptides” refers to a genus of polypeptides that encompasses polypeptides of a formula selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:644, as well as those polypeptides having a high degree of similarity (at least 90% homology) with such amino acid sequences and which polypeptides are immunoreactive or biologically active.
The term “purified” as used herein, means that the [0124] M. tuberculosis and M. leprae marker polypeptides are essentially free of association with other proteins or polypeptides, for example, as a purification product of recombinant host cell culture or as a purified product from a non-recombinant source. The term “substantially purified” as used herein, refers to a mixture that contains M. tuberculosis and M. leprae marker polypeptides and is essentially free of association with other proteins or polypeptides, but for the presence of known proteins that can be removed using a specific antibody, and which substantially purified M. tuberculosis and M. leprae marker polypeptides can be used as antigens.
A [0125] M. tuberculosis and M. leprae marker polypeptide “variant” as referred to herein means a polypeptide substantially homologous to native M. tuberculosis and M. leprae marker polypeptides, but which has an amino acid sequence different from that of native M. tuberculosis and M. leprae marker polypeptides because of one or more deletions, insertions, or substitutions. The variant amino acid sequence preferably is at least 80% identical to a native M. tuberculosis and M. leprae marker polypeptide amino acid sequence, most preferably at least 90% identical. The percent identity can be determined, for example by comparing sequence information using the GAP computer program, version 6.0 described by Devereux et al. (Nucl. Acids Res. 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (J. Mol. Biol. 48:443, 1970), as revised by Smith and Waterman (Adv. Appl. Math 2:482, 1981). The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.
Variants can comprise conservatively substituted sequences, meaning that a given amino acid residue is replaced by a residue having similar physicochemical characteristics. Examples of conservative substitutions include substitution of one aliphatic residue for another, such as Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity characteristics, are well known. Naturally occurring [0126] M. tuberculosis and M. leprae marker polypeptide variants are also encompassed by the invention. Examples of such variants are proteins that result from alternate mRNA splicing events or from proteolytic cleavage of the M. tuberculosis and M. leprae marker polypeptides. Variations attributable to proteolysis include, for example, differences in the termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the M. tuberculosis and M. leprae marker polypeptides. Variations attributable to frameshifting include, for example, differences in the termini upon expression in different types of host cells due to different amino acids.
As stated above, the invention provides isolated and purified, or homogeneous, [0127] M. tuberculosis and M. leprae marker polypeptides, both recombinant and non-recombinant. Variants and derivatives of native M. tuberculosis and M. leprae marker polypeptides that can be used as antigens can be obtained by mutations of nucleotide sequences coding for native M. tuberculosis and M. leprae marker polypeptides. Alterations of the native amino acid sequence can be accomplished by any of a number of conventional methods. Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.
Alternatively, oligonucleotide directed, site specific mutagenesis procedures can be employed to provide an altered gene wherein predetermined codons can be altered by substitution, deletion, or insertion. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. ([0128] Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); Kunkel (Proc. Natl. Acad. Sci. USA 82:488, 1985); Kunkel et al. (Methods in Enzymol. 154:367, 1987); and U.S. Pat. Nos. 4,518,584 and 4,737,462, all of which are incorporated by reference.
Within an aspect of the invention, [0129] M. tuberculosis and M. leprae marker polypeptides can be utilized to prepare antibodies that specifically bind to M. tuberculosis and M. leprae marker polypeptides. The term “antibodies” is meant to include polyclonal antibodies, monoclonal antibodies, fragments thereof such as F(ab′)2 and Fab fragments, as well as any recombinantly produced binding partners. Antibodies are defined to be specifically binding if they bind M. tuberculosis and M. leprae marker polypeptides with a K_aof greater than or equal to about 10⁷M⁻¹. Affinities of binding partners or antibodies can be readily determined using conventional techniques, for example, those described by Scatchard et al., Ann. N. Y Acad. Sci., 51:660 (1949). Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats, using procedures that are well known in the art.
The invention further encompasses isolated fragments and oligonucleotides derived from the nucleotide sequences of the invention. The invention also encompasses polypeptides encoded by these fragments and oligonucleotides. [0130]
Nucleic acid sequences within the scope of the invention include isolated DNA and RNA sequences that hybridize to the native [0131] M. tuberculosis and M. leprae marker nucleic acids disclosed herein under conditions of moderate or severe stringency, and which encode M. tuberculosis and M. leprae marker polypeptides. As used herein, conditions of moderate stringency, as known to those having ordinary skill in the art, and as defined by Sambrook et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1, pp. 1.101-104, Cold Spring Harbor Laboratory Press, (1989), include use of a prewashing solution for the nitrocellulose filters 5× SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization conditions of 50% formamide, 6× SSC at 42° C. (or other similar hybridization solution, such as Stark's solution, in 50% formamide at 42° C.), and washing conditions of about 60° C., 0.5× SSC, 0.1% SDS. Conditions of high stringency are defined as hybridization conditions as above, and with washing at 68° C., 0.2× SSC, 0.1% SDS. The skilled artisan will recognize that the temperature and wash solution salt concentration can be adjusted as necessary according to factors such as the length of the probe.
Due to the known degeneracy of the genetic code, wherein more than one codon can encode the same amino acid, a DNA sequence can vary and still encode a [0132] M. tuberculosis and M. leprae marker polypeptide of a formula selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:644. Such variant DNA sequences can result from silent mutations (e.g., occurring during PCR amplification), or can be the product of deliberate mutagenesis of a native sequence.
The invention thus provides equivalent isolated DNA sequences, encoding [0133] M. tuberculosis and M. leprae marker polypeptides, selected from: (a) DNA derived from the coding region of a native M. tuberculosis and M. leprae marker nucleic acid; (b) cDNA comprising the nucleotide sequence of the invention; (c) DNA capable of hybridization to a DNA of (a) under conditions of moderate stringency and which encode M. tuberculosis and M. leprae marker polypeptides; and (d) DNA which is degenerate as a result of the genetic code to a DNA defined in (a), (b) or (c) and which encodes M. tuberculosis and M. leprae marker polypeptides. M. tuberculosis and M. leprae marker polypeptides encoded by such DNA equivalent sequences are encompassed by the invention.
DNA that is equivalent to the DNA sequence of the invention will hybridize under moderately stringent conditions to the double-stranded native DNA sequence that encodes polypeptides of a formula selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:644. Examples of [0134] M. tuberculosis and M. leprae marker polypeptides encoded by such DNA, include, but are not limited to, M. tuberculosis and M. leprae marker polypeptide fragments and M. tuberculosis and M. leprae marker polypeptides comprising inactivated N-glycosylation site(s), inactivated protease processing site(s), or conservative amino acid substitution(s), as described above. M. tuberculosis and M. leprae marker polypeptides encoded by DNA derived from other species, wherein the DNA will hybridize to the complement of the DNA of the invention are also encompassed.
Recombinant expression vectors containing a nucleic acid sequence encoding [0135] M. tuberculosis and M. leprae marker polypeptides can be prepared using well known methods. The expression vectors include a M. tuberculosis and M. leprae marker DNA sequence operably linked to suitable transcriptional or translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, an mRNA ribosomal binding site, and appropriate sequences which control transcription and translation initiation and termination. Nucleotide sequences are “operably linked” when the regulatory sequence functionally relates to the M. tuberculosis and M. leprae marker DNA sequence. Thus, a promoter nucleotide sequence is operably linked to a M. tuberculosis and M. leprae marker DNA sequence if the promoter nucleotide sequence controls the transcription of the M. tuberculosis and M. leprae marker DNA sequence. The ability to replicate in the desired host cells, usually conferred by an origin of replication, and a selection gene by which transformants are identified can additionally be incorporated into the expression vector.
In addition, sequences encoding appropriate signal peptides that are not naturally associated with [0136] M. tuberculosis and M. leprae marker polypeptides can be incorporated into expression vectors. For example, a DNA sequence for a signal peptide (secretory leader) can be fused in-frame to the M. tuberculosis and M. leprae marker nucleotide sequence so that the M. tuberculosis and M. leprae marker polypeptide is initially translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cells enhances extracellular secretion of the M. tuberculosis and M. leprae marker polypeptide. The signal peptide can be cleaved from the M. tuberculosis and M. leprae marker polypeptide upon secretion of the marker polypeptide from the cell.
Expression vectors fdr use in prokaryotic host cells generally comprise one or more phenotypic selectable marker genes. A phenotypic selectable marker gene is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement. Examples of useful expression vectors for prokaryotic host cells include those derived from commercially available plasmids. Commercially available vectors include those that are specifically designed for the expression of proteins. These include pMAL-p2 and pMAL-c2 vectors, which are used for the expression of proteins fused to maltose binding protein (New England Biolabs, Beverly, Mass., USA). [0137]
Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include β-lactamase (penicillinase), lactose promoter system (Chang et al., [0138] Nature 275:615, 1978; and Goeddel et al., Nature 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4057, 1980; and EP-A-36776), and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p. 412, 1982).
Suitable host cells for expression of [0139] M. tuberculosis and M. leprae marker polypeptides include prokaryotes, yeast or higher eukaryotic cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al. Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., (1985). Cell-free translation systems could also be employed to produce M. tuberculosis and M. leprae marker polypeptides using RNAs derived from DNA constructs disclosed herein.
It will be understood that the present invention is intended to encompass the previously described proteins in isolated or purified form, whether obtained using the techniques described herein or other methods. In a preferred embodiment of this invention, the [0140] M. tuberculosis and M. leprae marker polypeptides are substantially free of human tissue and human tissue components, nucleic acids, extraneous proteins and lipids, and adventitious microorganisms, such as bacteria and a mycoplasma. It will also be understood that the invention encompasses equivalent proteins having substantially the same biological and immunogenic properties. Thus, this invention is intended to cover serotypic variants of the proteins of the invention.
Depending on the use to be made of the [0141] M. tuberculosis and M. leprae marker polypeptides of the invention, it may be desirable to label them. Examples of suitable labels are radioactive labels, enzymatic labels, fluorescent labels, chemiluminescent labels, and chromophores. The methods for labeling proteins and glycoproteins of the invention do not differ in essence from those widely used for labeling immunoglobulin. The need to label may be avoided by using labeled antibody to the antigen of the invention or anti- immunoglobulin to the antibodies to the antigen as an indirect marker.
Once the [0142] M. tuberculosis and M. leprae marker polypeptides of the invention have been obtained, they can be used to produce polyctonal and monoclonal antibodies reactive therewith. Thus, a polypeptide of the invention can be used to immunize an animal host by techniques known in the art. Such techniques usually involve inoculation, but they may involve other modes of administration. A sufficient amount of the polypeptide is administered to create an immunogenic response in the animal host. Any host that produces antibodies to the antigen of the invention can be used. Once the animal has been immunized and sufficient time has passed for it to begin producing antibodies to the antigen, polyclonal antibodies can be recovered. The general method comprises removing blood from the animal and separating the serum from the blood. The serum, which contains antibodies to the antigen, can be used as an antiserum to the antigen. Alternatively, the antibodies can be recovered from the serum. Affinity purification is a preferred technique for recovering purified polyclonal antibodies to the antigen from the serum.
Monoclonal antibodies to the antigens of the invention can also be prepared. One method for producing monoclonal antibodies reactive with the antigens comprises the steps of immunizing a host with the antigen; recovering antibody producing cells from the spleen of the host; fusing the antibody producing cells with myeloma cells deficient in the enzyme hypoxanthine-guanine phosphoribosyl transferase to form hybridomas; select at least one of the hybridomas by growth in a medium comprising hypoxanthine, aminopterin, and thymidine; identifying at least one of the hybridomas that produces an antibody to the antigen, culturing the identified hybridoma to produce antibody in a recoverable quantity; and recovering the antibodies produced by the cultured hybridoma. [0143]
These polyclonal or monoclonal antibodies can be used in a variety of applications. Among these is the neutralization of corresponding proteins. They can also be used to detect viral antigens in biological preparations or in purifying corresponding proteins, glycoproteins, or mixtures thereof, for example, when used in a affinity chromatographic columns. [0144]
The [0145] M. tuberculosis and M. leprae marker polypeptides can be used as antigens to identify antibodies to a mycobacteria in materials and to determine the concentration of the antibodies in those materials. Thus, the antigens can be used for qualitative or quantitative determination of a mycobacteria in a material. Such materials of course include human tissue and human cells, as well as biological fluids, such as human body fluids, including human sera. When used as a reagent in an immunoassay for determining the presence or concentration of the antibodies to a mycobacteria, the antigens of the present invention provide an assay that is convenient, rapid, sensitive, and specific.
More particularly, the antigens of the invention can be employed for the detection of a mycobacterium by means of immunoassays that are well known for use in detecting or quantifying humoral components in fluids. Thus, antigen-antibody interactions can be directly observed or determined by secondary reactions, such as precipitation or agglutination. In addition, immunoelectrophoresis techniques can also be employed. For example, the classic combination of electrophoresis in agar followed by reaction with anti-serum can be utilized, as well as two-dimensional electrophoresis, rocket electrophoresis, and immunolabeling of polyacrylamide gel patterns (Western Blot or immunoblot). Other immunoassays in which the antigens of the present invention can be employed include, but are not limited to, radioimmunoassay, competitive immunoprecipitation assay, enzyme immunoassay, and immunofluorescence assay. It will be understood that turbidimetric, calorimetric, and nephelometric techniques can be employed. An immunoassay based on Western Blot technique is preferred. [0146]
Immunoassays can be carried out by immobilizing one of the immunoreagents, either an antigen of the invention or an antibody of the invention to the antigen, on a carrier surface while retaining immunoreactivity of the reagent. The reciprocal immunoreagent can be unlabeled or labeled in such a manner that immunoreactivity is also retained. These techniques are especially suitable for use in enzyme immunoassays, such as enzyme linked immunosorbent assay (ELISA) and competitive inhibition enzyme immunoassay (CIEIA). [0147]
When either the antigen of the invention or antibody to the antigen is attached to a solid support, the support is usually a glass or plastic material. Plastic materials molded in the form of plates, tubes, beads, or disks are preferred. Examples of suitable plastic materials are polystyrene and polyvinyl chloride. If the immunoreagent does not readily bind to the solid support, a carrier material can be interposed between the reagent and the support. Examples of suitable carrier materials are proteins, such as bovine serum albumin, or chemical reagents, such as gluteraldehyde or urea. Coating of the solid phase can be carried out using conventional techniques. [0148]
The invention provides immunogenic [0149] M. tuberculosis and M. leprae marker polypeptides, and more particularly, protective polypeptides for use in the preparation of vaccine compositions against a mycobacterium. These polypeptides can thus be employed as viral vaccines by administering the polypeptides to a mammal susceptible to a mycobacteria infection. Conventional modes of administration can be employed. For example, administration can be carried out by oral, respiratory, or parenteral routes. Intradermal, subcutaneous, and intramuscular routes of administration are preferred when the vaccine is administered parenterally.
The major purpose of the immune response in a mycobacteria-infected mammal is to inactivate the free mycobacteria and to eliminate mycobacteria infected cells that have the potential to release infectious mycobacteria. The B-cell arm of the immune response has some responsibility for inactivating free mycobacteria. The principal manner in which this is achieved is by neutralization of infectivity. Another major mechanism for destruction of the a mycobacteria-infected cells is provided by cytotoxic T lymphocytes (CTL) that recognize [0150] M. tuberculosis and M. leprae marker antigens expressed in combination with class I histocompatibility antigens at the cell surface. The CTLs recognize M. tuberculosis and M. leprae marker polypeptides processed within cells from a M. tuberculosis and M. leprae marker polypeptide that is produced, for example, by the infected cell or that is internalized by a phagocytic cell. Thus, this invention can be employed to stimulate a B-cell response to M. tuberculosis and M. leprae marker polypeptides, as well as immunity mediated by a CTL response following infection. The CTL response can play an important role in mediating recovery from primary mycobacterial infection and in accelerating recovery during subsequent infections.
The ability of the [0151] M. tuberculosis and M. leprae marker polypeptides and vaccines of the invention to induce protective levels of neutralizing antibody in a host can be enhanced by emulsification with an adjuvant, incorporating in a liposome, coupling to a suitable carrier, or by combinations of these techniques. For example, the M. tuberculosis and M. leprae marker polypeptides of the invention can be administered with a conventional adjuvant, such as aluminum phosphate and aluminum hydroxide gel, in an amount sufficient to potentiate humoral or cell-mediated immune responses in the host. Similarly, the M. tuberculosis and M. leprae marker polypeptides can be bound to lipid membranes or incorporated in lipid membranes to form liposomes. The use of nonpyrogenic lipids free of nucleic acids and other extraneous matter can be employed for this purpose.
The immunization schedule will depend upon several factors, such as the susceptibility of the host to infection and the age of the host. A single dose of the vaccine of the invention can be administered to the host or a primary course of immunization can be followed in which several doses at intervals of time are administered. Subsequent doses used as boosters can be administered as needed following the primary course. [0152]
The [0153] M. tuberculosis and M. leprae marker polypeptides and vaccines of the invention can be administered to the host in an amount sufficient to prevent or inhibit a mycobacteria infection or replication in vivo. In any event, the amount administered should be at least sufficient to protect the host against substantial immunosuppression, even though a mycobacterial infection may not be entirely prevented. An immunogenic response can be obtained by administering the polypeptides of the invention to the host in an amount of about 10 to about 500 micrograms antigen per kilogram of body weight, preferably about 50 to about 100 micrograms antigen per kilogram of body weight. The polypeptides and vaccines of the invention can be administered together with a physiologically acceptable carrier. For example, a diluent, such as water or a saline solution, can be employed.
Another aspect of the invention provides a method of DNA vaccination. The method also includes administering any combination of the nucleic acids encoding [0154] M. tuberculosis and M. leprae marker polypeptides, with or without carrier molecules, to an individual. In embodiments, the individual is an animal, and is preferably a mammal. More preferably, the mammal is selected from the group consisting of a human, a dog, a cat, a bovine, a pig, and a horse. In an especially preferred embodiment, the mammal is a human.
The methods of treating include administering immunogenic compositions comprising [0155] M. tuberculosis and M. leprae marker polypeptides, but compositions comprising nucleic acids encoding M. tuberculosis and M. leprae marker polypeptides as well. Those of skill in the art are cognizant of the concept, application, and effectiveness of nucleic acid vaccines (e.g., DNA vaccines) and nucleic acid vaccine technology as well as protein and polypeptide based technologies. The nucleic acid based technology allows the administration of nucleic acids encoding M. tuberculosis and M. leprae marker polypeptides, naked or encapsulated, directly to tissues and cells without the need for production of encoded proteins prior to administration. The technology is based on the ability of these nucleic acids to be taken up by cells of the recipient organism and expressed to produce an immunogenic determinant to which the recipient's immune system responds. Typically, the expressed antigens are displayed on the surface of cells that have taken up and expressed the nucleic acids, but expression and export of the encoded antigens into the circulatory system of the recipient individual is also within the scope of the present invention. Such nucleic acid vaccine technology includes, but is not limited to, delivery of naked DNA and RNA and delivery of expression vectors encoding M. tuberculosis and M. leprae marker polypeptides. Although the technology is termed “vaccine”, it is equally applicable to immunogenic compositions that do not result in a protective response. Such non-protection inducing compositions and methods are encompassed within the present invention.
Although it is within the present invention to deliver nucleic acids encoding [0156] M. tuberculosis and M. leprae marker polypeptides and carrier molecules as naked nucleic acid, the present invention also encompasses delivery of nucleic acids as part of larger or more complex compositions. Included among these delivery systems are mycobacterium, mycobacteria-like particles, or bacteria containing the nucleic acid encoding M. tuberculosis and M. leprae marker polypeptides. Also, complexes of the invention's nucleic acids and carrier molecules with cell permeabilizing compounds, such as liposomes, are included within the scope of the invention. Other compounds, such as molecular vectors (EP 696,191, Samain et al.) and delivery systems for nucleic acid vaccines are known to the skilled artisan and exemplified in, for example, WO 93 06223 and WO 90 11092, U.S. Pat. Nos. 5,580,859, and U.S. 5,589,466 (Vical's patents), which are incorporated by reference herein, and can be made and used without undue or excessive experimentation.
To further achieve the objective and in accordance with the purposes of the present invention, a kit capable of diagnosing mycobacteria infection is described. This kit, in one embodiment, contains the DNA sequences of this invention, which are capable of hybridizing to RNA or analogous DNA sequences to indicate the presence of a mycobacteria infection. Different diagnostic techniques can be used which include, but are not limited to: (I) Southern blot procedures to identify cellular DNA which may or may not be digested with restriction enzymes; (2) Northern blot techniques to identify RNA extracted from cells; and (3) dot blot techniques, i.e., direct filtration of the sample through an ad hoc membrane, such as nitrocellulose or nylon, without previous separation on agarose gel. Suitable material for dot blot technique could be obtained from body fluids including, but not limited to, serum and plasma, supernatants from culture cells, or cytoplasmic extracts obtained after cell lysis and removal of membranes and nuclei of the cells by centrifugation. [0157]
The invention also provides screening assays for identifying agents that modulate (e.g. augment or inhibit) the activity of [0158] M. tuberculosis and M. leprae marker polypeptides. Assays for detecting the ability of agents to inhibit or augment the activity of M. tuberculosis and M. leprae marker polypeptides provide for facile high-throughput screening of agent banks (e.g., compound libraries, peptide libraries, and the like) to identify antagonists or agonists of these marker polypeptides. Such M. tuberculosis and M. leprae marker polypeptide antagonists and agonists may modulate marker polypeptide activity and thereby modulate, inhibit, or even prevent infection of a host by M. tuberculosis and M. leprae
For example, yeast comprising (1) an expression cassette encoding a GAL4 DNA binding domain (or GAL4 activator domain) fused to a binding fragment of [0159] M. tuberculosis or M. leprae marker polypeptide, (2) an expression cassette encoding a GAL4 DNA activator domain (or GAL4 binding domain, respectively) fused to a binding fragment of a test polypeptide, and (3) a reporter gene (e.g., β-galactosidase) comprising a cis-linked GAL4 transcriptional response element can be used for agent screening. Such yeast are incubated, and expression of the reporter gene (e.g., β-galactosidase) is determined by the capacity of the agent to affect expression of the reporter gene and thereby identify the test polypeptide as a candidate modulatory agent for M. tuberculosis or M. leprae marker polypeptides.
Yeast two-hybrid systems can be used to screen a mammalian (typically human) cDNA expression library, wherein cDNA is fused to a GAL4 DNA binding domain or activator domain, and either a [0160] M. tuberculosis or M. leprae marker polypeptide sequence is fused to a GAL4 activator domain or DNA binding domain, respectively. Such a yeast two-hybrid system can screen for cDNAs that encode proteins that interact with M. tuberculosis or M. leprae marker polypeptides.
Polypeptides that interact with [0161] M. tuberculosis or M. leprae marker polypeptides can also be identified by immunoprecipitation of M. tuberculosis or M. leprae marker polypeptides with antibody, and identification of co-precipitating species. Further, polypeptides that interact with M. tuberculosis or M. leprae marker polypeptides can be identified by screening a peptide library (e.g., a bacteriophage peptide display library) with a M. tuberculosis or M. leprae marker polypeptide.
Additional embodiments of the invention are directed to methods that employ specific antisense polynucleotides complementary to all or part of [0162] M. tuberculosis or M. leprae marker nucleic acids. Such complementary antisense polynucleotides may include nucleotide substitutions, additions, deletions, or transpositions, so long as specific hybridization to the relevant target sequence corresponding to M. tuberculosis or M. leprae marker nucleic acids is retained as a functional property of the polynucleotide. Complementary antisense polynucleotides include soluble antisense RNA or DNA oligonucleotides that can hybridize specifically to M. tuberculosis and M. leprae marker nucleic acid species and prevent transcription of the mRNA species and/or translation of the encoded polypeptide. See (Ching et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:10006; Broder et al. (1990) Ann. Int. Med. 113:604; Loreau et al. (1990) FEBS Letters 274:53; Holcenberg et al., WO91/11535; U.S. Ser. No. 07/530,165; WO91/09865; WO91/04753; WO90/13641; and EP 386563). The antisense polynucleotides, therefore, inhibit production of M. tuberculosis or M. leprae marker polypeptides. Antisense polynucleotides that prevent transcription and/or translation of mRNA corresponding to M. tuberculosis or M. leprae marker polypeptides may inhibit or prevent infection by M. tuberculosis or M. leprae. Antisense polynucleotides of various lengths may be produced, although such antisense polynucleotides typically comprise a sequence of about at least 25 consecutive nucleotides, which are substantially identical to a naturally-occurring M. tuberculosis or M. leprae marker nucleic acids, and typically are identical to a M. tuberculosis or M. leprae marker nucleic acid. For general methods relating to antisense polynucleotides, see Antisense RNA and DNA, (1988) D.A. Melton, Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
Polypeptides with similar sequence should have similar function. Thus, the functions of [0163] M. tuberculosis and M. leprne marker polypeptides can be assessed by a database search. One method by which structural and functional domains can be identified is by comparison of the nucleotide and/or amino acid sequence data for M. tuberculosis and M. lepree marker polypeptides, or M. tuberculosis or M. leprae marker nucleic acids, to public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predict polypeptide conformation domains that occur in other polypeptides of known structure and/or function. For example, methods to identify protein sequences that fold into a known three-dimensional structure are known (Bowie et al. (1991) Science 253:164).
As other examples, but not for limitation, the programs GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, 575 Science Dr., Madison, Wis.) can be used to identify sequences in databases, such as GenBank/EMBL, that have regions of homology with [0164] M. tuberculosis or M. leprae marker polypeptides or M. tuberculosis or M. leprae marker nucleic acids. Such homologous regions are candidate structural or functional domains. Alternatively, other algorithms are provided for identifying such domains from sequence data. Further, network methods, whether implemented in hardware or software, can be used to: (1) identify related protein sequences and nucleotide sequences, and (2) define structural or functional domains in M. tuberculosis and M. leprae marker polypeptides.
Thus, those of skill in the art can recognize sequence motifs and structural conformations that may be used to define structural and functional domains in the [0165] M. tuberculosis and M. leprae marker nucleic acids of the invention. Hydrophobicity profiles can be generated and displayed graphically using the ProtScale utility at ExPASy (http://expasy.hcuge.ch/cqi-bin/protscale.pl). There are a number of different ways of predicting transmembrane helices in sequences, the simplest being merely to look for regions of the protein containing a run of 20 hydrophobic residues. However, there are also a number of more sophisticated, and accurate, algorithms which can be used not only to predict the location of transmembrane helices but also their orientation in the membrane.
Proteins can contain signals within their sequence which assist in their processing within the cell, for example leader sequences or signals which target proteins to specific compartments within cells. Web resources are available to help predict both these types of sites. Different regions of a polypeptide evolve at different rates; some parts of a polypeptide must retain a certain pattern of residues for the polypeptide to function. By identifying such conserved regions, it is possible to make predictions about the polypeptide function. Examples of conserved sequences can be found around the active sites of enzymes, sites of post-translational modification, binding sites for co-factors, protein sorting signals, etc. A number of bioinformatics resources have been developed both to build databases of conserved patterns and to search for instances of such patterns in sequences. One of the best known motif databases is PROSITE, which can be employed in this invention. [0166]
This invention will be described in greater detail in the following Examples. [0167]

EXAMPLE 1

The whole genome sequence was obtained from a combination of sequenced cosmids[0168] ⁴⁵and 54,000 end sequences (giving 7.1× coverage) from a pUC18 genomic shotgun library using dye terminator chemistry on ABI373 or 377 automated sequencers The sequences of 42 cosmids previously generated by multiplex sequencing46 were used for scaffolding purposes only. The sequence was assembled using Phrap (P. Green, unpublished), finished using GAP4⁴⁷then compared with sequences present in public databases using FASTA, BLASTN and BLASTX⁴⁸. Potential CDS were predicted, and gene and protein sequences analysed as described previously^{8, 49}, using Artemis⁵⁰to collate data and facilitate annotation. The genome and proteome sequences of M. leprae and M. tuberculosis H37Rv were compared pairwise to identify conserved genes using the Artemis Comparison Tool (ACT) (K. Rutherford; unpublished; http://www.sanger.ac.uk/Software/ACT/). Pseudogenes had one or more mutations that would ablate expression and were pinpointed by direct comparison with M. tuberculosis

EXAMPLE 2

Target Discovery

To illustrate the usefulness of comparative mycobacterial genomics for identifying potentially important proteins, a precise example will now be given. Preproteins transported by the TAT pathway generally bind redox cofactors and fold or oligomerize before crossing the membrane[0169] ^{54, 62}. After removal of the signal peptide, these proteins usually function in extracytoplasmic electron transfer chains. The specialized machinery that recognizes the twin-arginine motif, and translocates the preprotein across the membrane, is composed of several different Tat proteins. In Escherichia coli, TatA and TatE are 50% identical and share weak similarity with TatB. All three proteins are predicted to be anchored to the cytoplasmic membrane via an N-terminal hydrophobic alpha-helix, and to have cytoplasmic amphipathic helices followed by variable regions. The TatC protein is predicted to be an integral membrane protein with six transmembrane segments. M. tuberculosis and M. leprae both contain clearly identifiable tatA, tatB, tatC, and tatD genes and must, therefore, produce a functional Tat system.
On examination of the proteome of [0170] M. tuberculosis, eleven potential substrates for the Tat export system were recognized on the basis of their signal peptides containing potential twin arginine motifs (Table 3). During the extensive reductive evolution of the genome of M. leprae only one of the corresponding genes, ML1190, has escaped inactivation. It is orthologous to Rv2525c of M. tuberculosis but shows no similarity to proteins present in sequence databases. The 240 amino acid long precursor protein encoded by Rv2525c (or its counterpart ML1190 contains five histidines and one cysteine residue that may be important for coordinating divalent metal ions. The conservation of this coding sequence by M. leprae , in the face of massive gene loss, is a strong indication that it must play an important biological role. Given the many parallels with Tat systems elsewhere, it is likely to be in electron transport. These indirect arguments suggest on the one hand that, if this function were essential, the ML1190/Rv2525c gene product might represent a novel drug target or, on the other, since it is likely to be located extracellularly it may, therefore, be an important sentinel protein antigen.
The [0171] Mycobacterium tuberculosis strain HRV37 genomic library has been deposited at the Collection Nationale de Cultures de Microorganismes (C.N.C.M.), of Institut Pasteur, 28, rue du Docteur Roux, F-75724 Paris, Cedex 15, France, on Nov. 19, 1997, under the Accession Number I-1945. This genomic DNA library is disclosed in International patent application No. WO 9954487 (Institut Pasteur).
In summary, Leprosy, a chronic human neurological disease, results from infection with the obligate intracellular pathogen [0172] Mycobacterium leprae , a close relative of the tubercle bacillus. M. leprae has the longest doubling time of all known bacteria and has thwarted every effort at axenic culture. Comparison of the 3.27 Mb genome sequence of an armadillo-derived Indian isolate of the leprosy bacillus with that of Mycobacterium tuberculosis (4.41 Mb) provides clear explanations for these properties and reveals an extreme case of reductive evolution. Less than half of the genome contains functional genes while pseudogenes, with intact counterparts in M. tuberculosis, abound. Genome downsizing and the current mosaic arrangement appear to have resulted from extensive recombination events between dispersed repetitive sequences. Gene deletion and decay have eliminated many important metabolic activities including siderophore production, part of the oxidative, and all of the microaerophilic and anaerobic respiratory chains, together with numerous catabolic systems and their regulatory circuits.

REFERENCES

The entire disclosure of each of the following publications is relied upon and incorporated by reference herein. [0173]
1. Anon. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed [0174] Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 348, 17-24 (1996).
2. Nordeen, S. K. & Hombach, J. M. in [0175] Tropical disease resarch: Progress 1991-1992: eleventh programme report of the UNDP/Warld Bank/WHO Special Programme for Research and Training in Tropical Diseases. (eds. Walgate, R. & Simpson, K.) 47-55 (World Health Organisation, Geneva, 1993).
3. Anon. WHO [0176] Weekly Epidemiological Record 73, 40 (1998).
4. Hansen, G. H. A. Undersogelser angaende spedalskhedens aasager. [0177] Norsk Magazin for Laegervidenskaben (supplement) 4, 1-88 (1874).
5. Kirchheimer, W. K. &. Storrs, E. E. Attempts to establish the armadillo ([0178] Dasypus novemcinctus Linn.) as a model for the study of leprosy. 1. Report of lepromatoid leprosy in an experimentally infected armadillo. Int J Lep 39,693-702 (197 1).
6. Franzblau, S. Drug susceptibility testing of [0179] Mycobacterium leprae in the BACTEC 460 system. Antimicrobial Agents and Chemotherapy 33, 2115-2117 (1989).
7. Shephard, C. C. in [0180] Leprosy (eds. Hastings, R. C.) 269-286 (Churchill Livingstone, Edinburgh, 1985).
8. Cole, S. T., et al. Deciphering the biology of [0181] Mycobacterium tuberculosis from the complete genome sequence. Nature 393,537-544 (1998).
9. Tekaia, F., et al. Analysis of the proteome of [0182] Mycobacterium. tuberculosis in silico. Tubercle Lung Disease 79,329-342 (1999).
10. Brosch, R., Gordon, S. V., Eigimeier, K., Gamier, T. & Cole, S. T. Comparative genomics of the leprosy and tubercle bacilli. [0183] Res. Microbiol. 151, 135-142 (2000).
11. Philipp, W., Schwartz, D. C., Telenti, A. & Cole, S. T. Mycobacterial genome structure. [0184] Electrophoresis 19, 573-576(1998).
12. Stinear, T. P., Jenkin, G. A., Johnson, P. D. R. & Davies, J. K. Comparative genetic analysis of [0185] Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J. Bacteriol. 182, 6322-6330 (2000).
13. Marques, M. A. M., Chitale, S., Brennan, P. J. & Pessolani, M. C. V. Mapping and identification of the major cell-wall associated components of [0186] Mycobacterium leprae. Infection Immunity 66, 2625-2631 (1998).
14. Jungblut, P. R., et al. Comparative proteome analysis of [0187] Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol 33, 1103-1117 (1999).
15. Andersson, J. O. & Andersson, S. G. E. Insights into the evolutionary process of genome degradation. [0188] Curr. Opin. Genetics & Development 9, 664-671 (1999).
16. Anderssen, S. G. E., et al. The complete genome sequence of the obligate intracellular parasite [0189] Rickettsia prowazekii. Nature 396,133-140(1998).
17. Mizrahi, V., Dawes, S. S. & Rubin, H, in [0190] Molecular genetics of mycobacteria (eds. Haffull, G. F. & Jacobs, W. R., Jr.) 159-172(ASM Press, Washington, D.C., 2000).
18. Gordon, S. V., Heym, B., Parkhill, J., Barrell, B. & Cole, S. T. New insertion sequences and a novel repeated sequence in the genome of [0191] Mycobacterium tuberculosis H37Rv. Microbiology 145, 881-892 (1999).
19. Wolf, Y. I., Aravind, L., Grishin, N. V. & Koonin, E. V. Evolution of amino-acyl-tRNA synthetases —analysis of unique domain architectures and phylogenetic trees reveals a complex history of horizontal gene transfer events. [0192] Genome Research 9, 689-710. (1999).
20. Poulet, S. & Cole, S. T. Repeated DNA sequences in mycobacteria. [0193] Arch. Microbiol. 163, 79-86 (1995).
21. Cole, S. T. Learning from the genome sequence of [0194] Mycobacterium tuberculosis H37Rv. FEBS Letters 452, 7-10(1999).
22. Ramakrishnan, L., Federspiel, N. A. & Falkow, S. Granuloma-specific expression of mycobacteriurm virulence proteins from the glycine-rich PE-PGRS family. [0195] Science 288, 1436-1439 (2000).
23. Daffe, M. & Draper, P. The envelope layers of mycobacteria with reference to their pathogenicity. [0196] Advances in Microbial Physiology 39, 131-203 (1998).
24. Yuan, Y. & Barry, C. E., 3rd. A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in [0197] Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America 93, 12828-33 (1996).
25. Draper, P., Dobson, G., Minnikin, D. E. & Minnikin, S. M. The mycolic acids of [0198] Mycobacterium leprae harvested from experimentally infected nine-banded armadillos. Ann Microbiol (Paris) 133,39-47 (1982).
26. Glickman, M. S., Cox, J. S. & Jacobs, W. R., Jr. A novel mycolic acid cyclopropane synthetase is required for coding, persistence, and virulence of [0199] Mycobacterium tuberculosis. Mol Cell 5, 717-27 (2000).
27. Melancon-Kaplan, J., et al. Immunological significance of the cell wall of [0200] Mycobacterium leprae. Proc. Nad. Acad. Sci. USA 85,1917-1921 (1988).
28. Cox, J. S., Chen, B., McNeil, M. & Jacobs, W. R., Jr. Complex lipid determines tissue specific replication of [0201] Mycobacterium tuberculosis in mice. Nature 402, 79-83 (1999).
29. Camacho, L. R., Ensergueix, D., Perez, E., Gicquel, B. & Guilhot, C. Identification of a virulence gene cluster of [0202] Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 34, 257-267 (1999).
30. Peterson, J. A. & Graham, S. E. A close family resemblance: the importance of structure in understanding cytochromes P450. [0203] Structure 6,1079-1085 (1998).
31. Wheeler, P. R. & Ratledge, C. in [0204] Tuberculosis: Pathogenesis, protection, and control. (eds. Bloom, B. R.) 353-385 (American Society for Microbiology, Washington DC 20005, 1994).
32. Honer Zu Bentrup, K., Miczak, A., Swenson, D. L. & Russell, D. G. Characterization of activity and expression of isocitrate lyase in [0205] Mycobacterium avium and Mycobacterium tuberculosis. Journal of Bacteriology 181,7161-7167 (1999).
33. McKinney, J. D., et al. Persistence of [0206] Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735-738 (2000).
34. Wheeler, P. R. Oxidation of carbon sources through the tricarboxylic acid cycle in [0207] Mycobacterium leprae grown in armadillo liver. J Gen Microbiol 130, 381-9 (1984).
35. Ratledge, C. R. in [0208] The Biology of the Mycobacteria (eds. Ratledge, C. & Stanford, J.) 53-94 (Academic Press Limited, San Diego, Calif., 1982).
36. De Voss, J. J., et al. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc. [0209] Natl.Acad. Sci. USA 97, 1252-7, (2000).
37. Quadri, L. E., Sello, J., Keating, T. A., Weinreb, P. H. & Walsh, C. T. Identification of a [0210] Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. Chemistry & Biology 5, 631-45 (1998).
38. Hall, R. M. & Wheeler, P. R. Exochelin-mediated iron uptake into [0211] Mycobacteriurn leprae. Int J Lepr Other Mycobact Dis 51, 490-4 (1983).
39. Makui, H., et al. Identification of the Escherichia coli k-12 Nramp orthologue (MntH) as a selective divalent metal ion transporter. [0212] Molecular Microbiology 35, 1065-1078 (2000).
40. Shimoji, Y., Ng, V., Matsumura, K., Fischetti, V. A. & Rambukkana, A. A 21-kDa surface protein of [0213] Mycobacterium leprae binds peripheral nerve laminin-2 and mediates Schwann cell invasion. Proceedings of the National Academy of Sciences of the United States ofAmerica 96,9857-62 (1999).
41. Rambukkana, A., et al. Role of alpha-dystroglycan as a Schwann cell receptor for [0214] Mycobacterium leprae. 282 2076-9 (1998).
42. Rambukkana, A., Salzer, J. L., Yurchenco, P. D. & Tuomanen, E. I. Neural targeting of [0215] Mycobacterium leprae mediated by the G domain of the laminin-α2 chain. Cell 88,811-821 (1997).
43. Arruda, S., Bomfim, G., Knights, R., Huima-Byron, T. & Riley, L. W. Cloning of an [0216] M. tuberculosis DNA fragment associated with entry and survival inside cells. Science 261, 1454-1457 (1993).
44. Eigimeier, K., Fsihi, H., Heym, B. & Cole, S. T. On the catalase-peroxidase gene, katG,of [0217] Mycobacterium leprae and the implications for treatment of leprosy with isoniazid. FEMS Microbiol. Lett. 149, 273-278 (1997).
45. Eiglmeier, K., Honoré, N., Woods, S. A., Caudron, B. & Cole, S. T. Use of an ordered cosmid library to deduce the genomic organisation of [0218] Mycobacterium leprae Mol. Microbiol. 7,197-206 (1993).
46. Smith, D. R., et al. Multiplex sequencing of 1.5 Mb of the [0219] Mycobacterium leprae genome. Genome Research 7, 802-819 (1997).
47. Bonfield, J. K., Smith, K. F. & Staden, R. A new DNA sequence assembly program. [0220] Nucleic Acids Res. 24, 4992-4999 (1995).
48. Altschul, S. F., Boguski, M. S., Gish, W. & Wooton, J. C. Issues in searching molecular sequence databases. [0221] Nature Genet. 6,119-129 (1994).
49. Parkhill, J., et al. Complete DNA sequence of a serogroup A strain of [0222] Neisseria meningitidis Z249 1. Nature 404,502-505 (2000).
50. Rutherford, K, et al Artemis: sequence visualization and annotation. [0223] Bioinformatics 16, 944-945 (2000).
51. Andersen, P. Host responses and antigens involved in protective immunity to [0224] Mycobacterium tuberculosis. Scandinavian Journal of Immunology, 45, 115-31 (1997).
52. Pugsley, A. P. The complete general secretory pathway in gram-negative bacteria. [0225] Microbiological Reviews, 57, 50-108 (1993).
53. Stanley, N. R., Palmer, T. & Berks, B. C. The twin arginine consensus motif of Tat signal peptides is involved in Sec-independent protein targeting in Escherichia coli. [0226] J. Biol. Chem., 275, 11591-61 (2000).
54. Berks, B. C., Sargent, F. & Palmer, T. The Tat protein export pathway. [0227] Mol. Microbiol., 35, 260-74 (2000).
55. Lalvani, A., et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for [0228] Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 95, 270-5 (1998).
56. Pollock, J. M. & Andersen, P. The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. [0229] J. Inf. Dis., 175, 1251-1254 (1997).
57. Gordon, S. V., et al. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. [0230] Molec. Microbiol., 32, 643-656 (1999).
58. Harboe, M., Oettinger, T., Wiker, H. G, Rosenkrands, I & Andersen, P. Evidence for occurrence of the ESAT-6 protein in [0231] Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovid BVG. Infection Immun., 64 16-22 (1996).
59. Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D.C> & Stover, C. K. Molecular analysis of genetic differences between [0232] Mycobacterium bovis BCG and virulent M. bovis, J. Bacteriol., 178, 1274-1282 (1996).
60. Brandt, L., Elhay, M., Rosenkrands, I., Lindblad, E. B. & Andersen, P. ESAT-6 subunit vaccination against [0233] Mycobacterium tuberculosis. Infect Immun., 68, 791-795 (2000).
61. Tekaia, F., et al. Analysis of the proteome of [0234] Mycobacterium tuberculosis in silico. Tubercle Lung Disease, 79, 329-342 (1999).

62. Berks, B. C., et al. A novel protein transport involved in the biogenesis of bacterial electron transfer chains. Biochim. Biophys. Acta., 1459, 325-330 (2000).


M. leprae proteins that are potential targets for the diagnosis,
prophylaxis or treatment of mycobacterioses.
>BL;ML0007, ML.tab 11195:12106 forward MW:32204
VTSPNESRAFNAADDLIGDGSVERAGLHRATSVPGESSEGLQRGHSPEPNDSPPWQRGSARASQSGYRPSDPLTTTRQSN	(SEQ ID NO:1)
PAPGANVRSNRFISGMTAPALSGQLPKKNNSTQALEPVLMSNEVPFTESYASELPDLSGPVQRTVPCKPSPDRGSSTPRM
GRLEITKVRGTGEIRSQISRRSHGPVRASMQIRRIDPWSMLKVSLLLSVALFFVWMIAVAFLYLLLGGMGVWAKLNSNVG
DLLNNTGGNSGELVSNSTIFGCAVLVGLVNIVLMTTMAAIAAFVYNLSSDLVGGVEVTLADLD

>BL;ML0012, ML.tab 16566:16979 reverse MW:14690
MQQTAWGPRTARIAGCGGAGIVIAIACSTLDIDTPGFMLTGIAALGLILFAGLSWRARPKLAINPDGLAVQGWFRTRLFG	(SEQ ID NO:2)
PADIKIIRITEFRRFGRKVRLLEIEAINGDLVILSRWDLGTGPLEVLDALITAGYAG

>BL;ML0013, ML.tab 17134:17415 reverse MW:10464
MPKSKVRKKNDFTITSVSRTPVKVKVGPSSVWFVTLFVGLMLIGLVWLMVFQLAALGTQAPTALHWMAQLGPWNYAIAFA	(SEQ ID NO:3)
FMITGLLLTMRWH

>BL;ML0022, ML.tab 27173:28639 reverse MW:52748
MDNQKELIQRIERKLESSIDDAFARMFGGSIVPQEVEALLRREASDGVRSLQGNRLLAPNEYIITLGVHDLEKNKADPDL	(SEQ ID NO:4)
TSSAFASDLADYINEQGWQTYGDVVVRFDQSSSLHTGQIRARSVVNPDVEPRPTVNDPVRTQSNQAFSAEPGVPPMTDNS
SYRGGQGQGRPSDDYYGRPQDDPRGADPQGGQDPRGCYPPKPGSYPQQAGHPPLHRPDQGGYPGQGGYEDQRAYHDQGQG
GYPSPYEQRPATPGGYGSQGHDQGYRPGSYGPPSGGQPGYGGYGDYGRGPARPDEGSYTPSGFPAPPEQRVAYPDQGGGY
DQGYQHSGLGYGREDYGRQEYTQYAENLPGGVYAPSSGGYAEPAGRDYDYGQPGAANDYSQPVIGGYGGYGALGSAVILQ
LDDGSGRTYQLREGSNIVGRGQDAQFRLPDTGVSRRHLEIRWDGQVALLSDLNSTNGTTVNNAPVQEWQLADGDVIRLGH
SEIIVRIH

>BL;ML0030, ML.tab 34750:35091 reverse MW:11383
MLIAGTLCVCAAVISAVFGTWALIHNQTVDPTQLAMRAMAPPQLAAAIMLAAGGVVALVAVAHTALIVVAVCVTGAVGTL	(SEQ ID NO:5)
AAGSWQSARYTLRRRATATSCGKNCAGCILSCR

>BL;ML0031, ML.tab 35287:36123 reverse MW:28788
MIQSTQTWRVLAGGLAATAMGVTVFAGGTAAADPSPPAPPPAIPGVLPPASLPPIQSVTAVPGGITTNNRFVATPQAPGP	(SEQ ID NO:6)
AALGQPPLAVAAPVSESLHDYFKAKNIKLVAQKPHGFKALDITLPVPTRWTQVPDPNVPDAFAVIADRLGNSLYTSNAQL
VVYNLVGNFDPKEAITHGFVDTQQLSAWQTTNASKADFDGFPSSIIEGTYRENGMTLNTSRRHVIASSGPDKYLVSLSVT
TALSQAVADAPATNAIVNGFRVSSPTVSAPVPPQLGTR

>BL;ML0042, ML.tab 51993:53396 forward MW:51453
MRNPVWLRFSMGRALLVTALVPPCIILFFHTQYWWAGIALVVLVVILTLVEFSGRWLSGWLMALYSFFRRSSKPLDTPSE	(SEQ ID NO:7)
PVIGATVKPADQVIMRWQDGFLVSVVELIPRPFTPTVIVDGEAQTDDLLETQLLEHLLSVHCPDLEAVVVSAGYRVGHVA
SLDVVNLYQQVIGADPAPAHRRTWIMLRADPVRTRKSAQRRDAGVAGLARYLIASTTRIADQLASHGVDAVCGHSFESVD
HATDVGFMQEKWSMMRGQNAYSVAYTAPAGPDAWWSARADHTITRVWVAPGKTPQATVVLTTLGKPKTPCGFYRLHGAQQ
PALLGRSFVAYQHCQMPIGSAGVLVGETVNRCSVYMPFDDVDVSVSLGDVQTFTQFVVRAAAAGGIVTLGQQFEKFARMI
GGQIGSVAKVAWPNATTYLDPYPGSERVILKHDIIGTPRHRKLPIRRISPPEEGHYQMVLPKSSYEL

>BL;ML0044, ML.tab 54698:55039 forward MW:12157
MDLDPTQAQTMALLGQFQSALDEQCNRMTDGVFKASDQEKTVEVTINGYQWLTGIRIESGALREFGHAVVADRINEALQN	(SEQ ID NO:8)
AQGVATAYNEVSGEQLAARLSALSCSIGEPPPT

>BL;ML0047, ML.tab 58020:59558 reverse MW:54486
LSAPAVTAGPATAGITPARPSATRVTILTGKRMTDLVLPSTVSIEAYIDETVAVLSDLLEDAPADVLAGFDFSAQGVWTF	(SEQ ID NO:9)
ARPGSPPMKLDQSLDDAGVVDGSLLTLVSTSRTERYRPLVEDVIDAIAVLNESPEFNRKAVDRFIGVAIPVLSLPITAVA
VWAWWVTGRSPFWSLAIGILSIVALTGSIVAEKFYKNLDLSESLLLTSYPLIASAAALVTPLPNGVDSLGPPQVAAAAAA
VLFLTLLTRGGARRHSGYASFTAITTIAIVVIAIAYGFGYQHWVPTGAVAFGLFIVTNAAKLTVAVARIALPPIPVPGET
VDNEELLDPVVTPHEATHEETPTWQAIIASVPDSAVRLTERSSLAKRLLIGYVISGTLILCSGAIAVIVRGHFFAHSLVV
AFLLTVVCTFRSRLYAERWCAWALLAAAVVIPTGLTVKLCIWYTQIAWLLLTSYLVAAIIALMVFGATVRVRRVSPVTKR
IMELIDGAVVASIIPLLLWIAGVYDMVRNLSF

>BL;ML0048, ML.tab 59555:61315 reverse MW:63226
MAADYDKLFRLDDGAYASPDQAAEQLFDDAPLYPPPIIPTCTTTPNGEVASPMPDWSEQLPPNPPAASKSPLPPMPIGSS	(SEQ ID NO:10)
VQPPPASSESPRAPMPVSAPPRSPAASLMPISEPPQWPPAEAPEHQFAKAEPPSVPIPINEPSPAKPATPMPMTPIDGSQ
RTPVTSPEPSLAEFEAQPPATPKPSLLPRPMSSPPEAPRPSANQHSRHARRGHHHRDETQQANPASATEPMIAPRARTAE
LRQAPHAAAEPAPTQHLTRPDGLVSHRTALHDSTATSAIGVQTGRSTGAKKPSKVVAKRGWRHWVHTVTRINLGLSPDER
YELDLRTRVRRPPRGSYQIGILGLKGGAGKTTVTVTLGSMFARVRNDRILVVDADTSCGNLADRAGRFSEANIADLLADK
DVKSYNDIRTHTSVNAVNLEVLPAAEYSTAQHALSGEDWNFAAATVSKYYNVMLADCGVGLFDPVTRGVLSTASGVVIVT
STSVDAARQAAIALDWLRHNGYQDLLSRACVVINHVMPKEPNIASKDLVQQFEQQIQPGRVVVLPWDKHIAAGTEIRLOR
LDPLYRRRILELAAALSDDFERAGRH

>BL;ML0049, ML.tab 61406:61693 reverse MW:10464
MIQAWHFPALQGAVNELQGSQSRIDALLEQCQESLTKLQSSWHGSGNESYSSVQRRFNQNTEGINHALGDLVQAINHSAE	(SEQ ID NO:11)
TMQQTEAGVMSMFTG

>BL;ML0050, ML.tab 61720:62022 reverse MW:10964
MAEMITEAAILTQQAAQFDQIASGLSQERNFVDSIGQSFQNTWEGQAASAALGALGRFDEAMQDQIRQLESIVDKLNRSG	(SEQ ID NO:12)
GNYTKTDDEANQLLSSKNNF

>BL;ML0051, ML.tab 62201:63109 reverse MW:32135
MTWPMLWPASVPSECPPNYWHTPAPSAKCEPEQAAVAPIAAAKPMITWLQSAAEQTTTQAEAHRQAMASTPGMAVITENH	(SEQ ID NO:13)
ITQAILATINFFGINMAPIAFTEAGDFICMRTQTALAMNSYQAETLLNTAFQKLEPMAAILNPSSYSPPSALTSQVNQFT
QMISGFSAALPSTQVLQQTVGQVAELARPMQQVKSLFTSIDSTGVYTSAQRGDTESAHRIGLFGASTLSSHPLVGITGTT
TDTRLLCAESLPSASGSLAWTPLMTQFQLIDKSIAPEPRQRVMLPPWAAGSPGHNAQDGGTT

>BL;ML00S4, ML.tab 67417:68862 reverse MW:51875
MGLRLTTKVQVSGWRFLLRRVEHAIVRRDTRMFDDPLQFYSRSIALGIVVAVALLIGAVLLAYFKPQGKLGASTLLTDRA	(SEQ ID NO:14)
TNQLYVLLSGHLYPVYNLTSARLALGKPANPAAVKSSELTKLPIGQTIGIPGAPYATPVSGDSSSTWTLCDTVAKIESES
PAVQTSVIARSLQIDPAINPLQPNEALLASYRDKTWLVNSKGRHSIDLADRALTSAIGISVNVKPTPLSEGLFNALPDVG
RWELPTIPDTGAPNSLGLSPDLVIGSVFQIQMEKSPQYYVVLSDGIAQVNATTADALRATQSHGLVAPPSLVPNVVVQIP
ERVYDSPLPDEPLKMVARDDYPTLCWAWERKASDQAPKRTMLIGQHLPLQPSANSTGIKQIRGTATVYIDGGRYVALQSP
DPRYSESLYYVDPEGVRYGLANSEAVKALGLASPQTAPWVIVRLLVEGPVLSRDAALLEHDTLIADPSPRKVPAGYSGVR
P

>BL;ML0056, ML.tab 70584:71093 reverse MW:18452
VNLLGNDDDNHLASLDFYSANRYYEESLFFDELDGYAPTTPVGIEANDLDVFQSLTEPEEELEVELLAVTNPAKSVSALM	(SEQ ID NO:15)
NGRVHQVELTDQVTRIGEKKPATEAFVLASLARQKARTSQGTCILDSLQGGGENTTARCELVGLTLNLPTSEQAAAEAEM
FSNNILRQK

>BL;ML0068, ML.tab 89620:90336 reverse MW:26088
MGLFHKRRSRAMRRAEARAIKARAKLEARLAAKNEARRLNSAQRATNKALKAQLKAKRNSDRVALKVAETELKAAKECKL	(SEQ ID NO:16)
LSPTRIRRVLTVSRLLAPIVVPLIYRAAIATRALIDQRRADQLGIPLAQIGQFSGPSARLSARIARSEQSVLLVQEKKPK
DAETKQFVSTITERLIDLSAAVAAVENMPATRRRAVHSTISSQLDGIEADLMARLGVDLTTSMADNRSVADSTRKAAT

>BL;ML0069, ML.tab 90521:90919 reverse MW:14807
MSTTFAARLNRLFDTVYPPGRGPHTSAEVIAALKAEGITMSAPYLSQLRSGNRTNPSSATISALANFFRIKPAYFTNDEY	(SEQ ID NO:17)
YEKLDQELAWLATMRDEGVRRIAMRTIGLSAQAQQDIVDRVDELRRAEHLDV

>BL;ML0071, ML.tab 91913:92446 reverse MW:18446
METGSGLPIGVVPFHARGALKGFVISGRWPDSTKEWAQLLMVAVRIASLPGLLSTTTVFGAREELPDEPEPGTVGLVLAE	(SEQ ID NO:18)
GTVFGESAIQPGYFADHQPPALLMLHPPSETMPSLPECTGAASGCVLLPGLPYLGLEHRAAWVEAEADGTITSMVSRVGV
DPISHPDTAILAMLLAA

>BL;ML0073, ML.tab 94092:95126 forward MW:38124
VIQVCSQCGTRWNVRERRREWCLRCRGALIAPQAEMPTAVKQWSSHVGLPAGIVPEALGWQRTPPGFRWIAVRPGAAPPN	(SEQ ID NO:19)
RRRQRHHVPTPRYAVMPRWGLADRVDQDSTWIQAPLKPGPSSAKVRTTLFVAVLVFTLAALVYVVRYVLLVINRNTLLNF
GVAAIADWLGVIASLAAIAATLACVMALSRWLIARRAAAYAHHAVPEQRSSWELRAGCLLPLVNLLWAPVYVIELALMEN
HYTQLQKPIFMWWIVWVFSYVISVVAVVTSWAKDAQGIANNTVAMVFAYLFAAAAVAAVARVFEGFECKSIKRPVHRWVV
VHLGGSVVHPSPGSVELEGQEPAA

>BL;ML0081, ML.tab 100648:102000 reverse MW:48150
MLDAPEEEPALADDLTGEDEQPPVEFQWPSTLQARATRRGLLLTALGGLLIGGLVTAIPTVGTGSGLLATYIDSNPVPST	(SEQ ID NO:20)
GAKSNVAFNRATNGDCLMWPDSTPHTAVIVNCADDHRFEVAESIDMRTFPGSEYGPNAAPPSPARIQQISEEQCETAVRR
YLGTKFDPNSKYTISMLWSGDRAWRQSGERRMLCGLQLPGVNNQQVAFKGKVANIDQSKVWPAGTCLSIDLTTNQPIDIP
VDCVAPHAMEVTGTVNLADKFPNALPAASEQDTFIKDACTRLTDIYLAAIELRTTTLTLIYPTLSLSSWAAGSRKVACSI
GATMGNGGWATLVNSAKGPLLINNQPPTPPPDIPEERLGMPPIPLHHLQVPNSQSNVPVNPIPPGNQQHRKQQPIVTVPQ
SPASTAPAASVSPAKHLPKARHTRQMSKRRGRPISPHPWAGRASPGGLAE

>BL;ML0091, ML.tab 113153:113863 reverse MW:23752
VPNRRRCKLSTAISTVATLAIASPCAYFLVYEPTASAKPAAKHYEFKQAASIADLPGEVLDAISQGLSQFGINLPPVPSL	(SEQ ID NO:21)
TGTDDPGNGLRTPGLTSPDLTNQELGTPVLTAPGTGLTPPVTGSPICTAPDLNLGGTCPSEVPITTPISLDPGTDGTYPI
LGDPSTLGGTSPISTSSGELVNDLLKVANQLGASQVMDLIKGVVMPAVMQGVQNGNVAGDLSGSVTPAAISLIPVT

>BL;ML0093, ML.tab 115371:117302 forward MW:72371
MTAVSLLARVILPRPGDPLDVRKLYLVESITNARRAHALSPTTLQIGAESEVSFATYFNAFPASYWRRWTICKSVVLRVE	(SEQ ID NO:22)
VTGAGRVDVYRTKANGARIFVEGREFAGVEDDASKAQVVELEVGLQPFEDGGWIWFDITAETRVTLCSGGWYATSPAPGR
ANIAVGIPTFNRPADCTNALAELTADPLVDEVIGAVIVPDQGVRKVRDHPDFPEAAARLGDRLSIHDQPNLGGSGGYSRV
MYEALKNTDCQQILFMDDDIRIEPDSILRVLAMHRFAKSPMLVGGQMLSLQEPSHLHIMGEVVNRSNFIWTAAPHAEYDH
DFVEYPLNDKEDKSKLLHRRIDVDYNGWWTCMIPRQVAEELGQPLPLFIKWDDADYGLRAAEHGYPTVTLPGAAIWHMAW
SDKDDAIDWQAYFHLRNRLVVAAMHWDGDVTGLVRSHLKATLKHLACLEYSTVAIQNKAIDDFLAGPDHIFSILESALPE
VHRMRKEYPDAVVLPAATELPPPVHKNKVMKPPENPLSIVYRLLRGIFHNLTAADPECHKRPEFNIPTQDARWFRLCTVD
GTTVTTADGCGVVYRQRDRAKNFLLLFSSLHRQLQLARRFDELRKIYRDALPVLSSKQKWEMALLPLPDSPTRFPAEQEP
EHA

>BL;ML0094, ML.tab 117295:117873 forward MW:19928
MPEDKAPTGELAAIAAVQSVLVDRPGVLPTARGMSHFGEHSIGWLAISLLGAILVPCRRRYWLVAGAGVFAAHVAAVLIK	(SEQ ID NO:23)
RMVRRIRPNHPAVTVNVGTPSPLSFPSAHATSTAAAAILIGRASRLPKGIVAAVLVAPMALSRIVLGVHYPSDVAFGVVL
GAAVAGTTARFDSRLSRRWTVQHGLSSGSAVK

>BL;ML0096, ML.tab 118819:120768 forward MW:71091
MRRRMVSRQVGWPLFPYHIVVRVSLWASVLLVAALFGWGAWQRRWIADDGLIVLRTVRNLLAGNGPVFNQGERVEANTST	(SEQ ID NO:24)
VWTYLLYAGSWVGGPMRFEYVALAAALVLSVLGMVLLMLGTGRLYAPSLQGRQAIMLPAGALVYVALPPARDFATSGLES
GLVLTYLGLLWWMMVCWAQPLRNRSQSRRFIGALAFVAGCSVLVRPELALMGGSALIMLMIAARTCWLRALIVVAGGSLP
VAYQLFRMGYYGLLVPGTALAKDAAGDKWSQGIIYLSNFNQPYVLWVPLVLLVLLGLLLMLIHRWPSFMHPLETPDSGRV
ARAVQSPPAVVVFVVFSGLLQAFYWIRQGGDFMHGRVLLAPLFCLLAPVVVIPVVISEGADFSRQTGNWLAGVTSLLWLG
VAGWSLWAANSPGMGDDATNVSYSGIVDERRFYAQATGHAHPLTAADYLGYPRMAAVLVALNNTPDGALLLPSGNYIKWD
LVPMIQLSPSSPGSPPDSLVSQKPQHTVFFTNLGMLGMNVGLDVRVIDQIGLANPLAQHTERLQHGRIGHDKNLFPDWVI
ADGPWVKWYPGIPGYLDQAWIAQAVAALQCSGTQAVLSSVRAPMALHRFISNLLNSFEFTRYRFDRVPLYELVRCGLPVP
DVLPATPPE

>BL;ML0099, ML.tab 123370:124380 forward MW:35611
MVEKVPRKRHRVLAWTAALSMAAVVALAIVAVVILLRSAESPRSSLPPGVLPIPSTAPHPRKPRPAFQDVSCPDVQLLVV	(SEQ ID NO:25)
PGTWESSLQDNPLDPVQFPDALLRNSTMTIGQQFPTSRVQTYTIPYTAQFHNPLSGDKQMTYNDSRAEGTRAMVQEMINV
NNKCPLTSYVLVGFSQGAVIAGDITSDIGNGHGPVDDDLVLGVTLIADGRRQQGVGNDIGPNPPGEGAEVTLHEVPVLSG
LGMTMTCARPGGFGVLHSRTNEICAPGDLICAAPAEAFSVANLPATLNTLASGAGQPIHANYATAQFWDLDGAPATVWTL
NWVHRLIEGAPHPKHG

>BL;ML0107, ML.tab 147460:149358 reverse MW:68650
MRNALASFGQIVLAAVVASGVAAVSLIAIARVHWPAFPSSNQLHALTTVGQVGCLTGLLAVGGVWQAGRFRRLAQLGGLV	(SEQ ID NO:26)
FVSAFTVVTLGMPLGATKLYLFGISVDQQFRTEYLTRLTDSAALQDMTYLGLPPFYPPGWFWIGGRVAALTGTPAWEIFK
PWAITSITIAVAITLVLWWQMIRFEYALLVTIATAAVTLVYSSPEPYAAMITVLLPPALVLTWSGLRAAEREADRTLGNK
RGWATVVGAGIFLGFAATWYTLLLAYTAFTVVLMTLLLATALCRRAGFRATFDPLRRLAGIVVIAAAIGAITWLPFLARA
AHDPVSDTGSAQHYLPADGAELAFPMLQFSLLGMICMLGTLWLIVRTSSSVRASALMISVLAVYLWSLLSILTTLARTTL
LSFRLQPTLTVLLVTAGVFGFIETAQSLAKHNRAVLSVASAIGLAGAIAFSQDIPNVLRPDLTIAYTDTDGHGQRGDRRP
PGSEKYYWAIDEAVLHITGKPRDQTVVLTADYSFLAYYPYWGFQGLTSHYANPLAQFDLRAAQIQQWSRLTTASELIHAL
DTLPWPPPTVFVMRHGAGNTYTLRLAKNVYPNQPNVRRYTVDLPAALFADQRFAVQDIGPFVLAIRKPMGNA

>BL;ML0115, ML.tab 155413:155937 reverse MW:19053
LNNDNDDSIEIIGGVDPRTMATRGEDESRDSDEPSLTDLVEQPAKVMRIGTMIKQLLEEVRAAPLDEASRNQLREIHATS	(SEQ ID NO:27)
IRELEDGLAPELREELDRLTLPFNESTAPSNAELRIAQAQLVGWLEGLFHGIQTALFAQQMAARAQLEQMRNSALPPGMG
KPGQAGGQGTGQYL

>BL;ML0116, ML.tab 155965:157929 reverse MW:70767
VGLCCGTLIALFLLIVPETIVARFAALTWPIAIAVSPALTYGVIALVIIPFGAVGIPWNSWTALAALVAVSMLMIAFRLL	(SEQ ID NO:28)
LVRYRDTAAETRGISGWPAVTVAVGVLLGALLIGWAAYRGLLHWQSIPSTWDAVWHANTVRFILDTGQASPTHMGELRNV
ETHSVLYYPSVLHALAGVYCQLTGAAPTTGYTVSSLAVAVWLFPVSAATLTWHLLRPVTTQKRAAGASATAAALSAAFTS
VPYVEFGVAANPNLAAYGVAVPTMVLITSTLRHRDRIPVAILALVGTFSVHLTGGIVVSLFLLGWWLMNALLHPVRSRAA
DARTLAAVVMPTALILAPQFIAVLNQADIIAGHSFPSFKSVKQGVIDALLLHTRHLNDFPIQYGLVVLAAIGMAILLYQK
IWWPSIAWLVLTVATVYSAAPFRGPIGSAIESFSQFFYNDPRRLSAVVTMLLTPMAGIALFAGVLLLVVGARRVTARFTA
LPRPVWTTATVVLLVAATVLTAWHYLFRHLVLFGDKYDSVMVNQKDLDAMSYLATLPGAHNTIIGNSNTDGSSWMYAVAD
LHPLWTHYDFPQQTGPGYFRYAFWAYARTGNPWVVEAVRVFNIRYILTTSPTVQGFAIPDGLVSLEESKSWTKIYDNGAA
RIFEWSGNATATRA

>BL;ML0124, ML.tab 166949:167389 reverse MW:16448
MPVLSKTVEIDTDTATIMAIVTDFESYPQWHEWIKGVWVLAHYDDGRPSQLRIDINFQGMQGTYIQAVYYPGVNQIQTVM	(SEQ ID NO:29)
QOGOLYSKQEQLFSVTQAEGGSVLTVDLDVELTMPVPAPMVKNLLNTALDRLAEKLKLYAEHLAPS

>BL;ML0133, ML.tab 179256:179888 forward MW:24045
MTNRTLSREEIRKLDRDLRILVATNGTLTRVLNVVANEEIVVDIINQQLLDVAPKIPELENLKIGRILQRDILLKGQKSG	(SEQ ID NO:30)
ILFVAAESLIVIDLLPTAITTYLTKTHHPIGEIMAASRIETYKEDAQVWIGDLPCWLADYGYWDLPKRAVGRRYRIIAGG
QPVIITTEYFLRSVFQDTPREELDRCQYSNDIDTRSGDRFVLHGRVFKNL

>BL;ML0151, ML.tab 213175:213492 reverse MW:11830
MRPEPPHHENAELTEMNTEVVEAPLLTDIEELREEIDRLDAQILATVKRRAEVSQAIGKVRMASGGTRLVHSREMKVIER	(SEQ ID NO:31)
YSELGPDGKDLAILLLRLGRGRLGH

>BL;ML0158, ML.tab 221657:222601 forward MW:31355
LHCSSGAVTALEITGGVNTYLPGSPGYPLVQPAGSYPGATPSFVKSDVGESQLYHYLTIAVVVLGLAVYLGNFGPTFTSS	(SEQ ID NO:32)
SDIGPGSGGFAGDAGTAVVVALLAALLAGLDLLPKAKSSAGVVGAIAVLGALLAISEMINMPAGFSIGWANWFILVCSVL
QAIAAVAALLLEAGIITAPAPRLSYDPYLQYGQYGAQSYYGQPNRQLQVGLNAHSPQQSPAGYGAQYGAYTSSPTQIQAG
MPATGGFSAQHSAQQGPSTPPTGFPSFSPPPSVGAAAGSQAGSAPVSYSNPTDSKQGFGQGRESTSSSSGSAPV

>BL;ML0159, ML.tab 222650:223942 forward MW:44093
VGDNRAAGVRQARDLVKVAFGPAVVALAIIAAITLLQLLIANSDMTGALGAIASMWLGVHQVPIAIGGRELSIMPLLPVL	(SEQ ID NO:33)
LMVWATAHSTSQATSAYSSWLVIRWVVASALGGPLLIAAISLAVIHDASSVLTELQTPKALRAFTGVLVVHAIGAAIGVN
SRVGRRVLTASRLPDWVGDSVHAATAGVLALLGLSGLVTAGSLVVHWATMQEFYGITDSIFGQFSLTVLSVLYAPNVIVG
TSAVAVGSSAHLGFATFSSFTVFGGDIPALPVLAAAPTPPLAPVWVALLIVGAASGVAVGQQCTRHPLPLLAALAKLLVA
AATGALMMALLGYAGSGRLGNFGDIDVDQGALVVGVFFWFAVVGWVTVVVACGIKRFPRHLKPPPALSSEEHADASSKDH
EAYFGVDLNVPFDLSGEDEIPKAEPGEAAD

>BL;ML0169, ML.tab 234932:235534 forward MW:22082
MSNSAQRDAKGARDEPLRAADTDRIQIAQLLAYAAEQGRLELKDYEDRLAKAYAATTYQELEQLRDDLPGSQVSARRGGN	(SEQ ID NO:34)
PNPAPSTLLLALMSGFERRGRWNVPRKLTTFSLWGSGVLDLRYADFTSTEVELHAYSVMGVQTILLPPEVNVEISGHGVM
GSFDRQVRGQGTPGAPTVKIRGFSLWGGVGIKRKARRPRR

>BL;ML0185, ML.tab 250221:251249 forward MW:38250
MPSIPQSLLWISLVVLWLFVLVPMLISKRDVVRRISDVALATRVLNGVAGARLLKRGGPATGHRSDHNWELDEDWRQNPV	(SEQ ID NO:35)
DGEFADADQDIGEEQDQNVDDTQRTRPVVMEVAVAELTGTDYLDVDVVEDSVALPIEDSADVTESVLLAVGEGGSPGEEA
EAEQRQSDRYGYVDASSGLGLEQKDDKSPVPVAPTVSRQRRYDTKTATAVSARKYAFRKRVLMVMAIILVGSAAAAFEVD
SNAWWICGSSTTVTVLYLAYLRRQTRIEEKVRSRRMHRIARARVDVENAHDREFDVVPSRLRRPGAVVLEIDDEDPIFEH
LDYEMPIRTFGWPRDLPRAVGQ

>BL;ML0187, ML.tab 252658:253719 forward MW:38375
VAGSWQCGHCESCASPLGPRDIAVVELIADRAEEFAAMDIFRGLPAEDLMSVAVSVEPVLAAAGEVLMQQGEQAVSFLLI	(SEQ ID NO:36)
SSGNVEVRRVDDDGAVIVGQASHGMIIGEIALLRDGRRTATVITTEPLTGWVGDIDAFAQMVQIPSITRRLLLTVRQRLA
AFITPIPVQLRDGTHLMLRPVLPGDTERSLRGHVRFSRETLYLRFMSARAPSDELMHYLSEVDYVDHFVWVVTDGGDPVA
DARFVRDESDPTLAEIAFTVADAYQGRGVGNFLISALSIAAHVNGVNRFSARMLTDNGPMRAIMDHHGAVWRRYDVGVIT
TVIDVPRQRDLIIGRAMADQIAGVVRQVIGAVG

>BL;ML0190, ML.tab 255125:255742 reverse MW:22988
MCDMLVDVGIAFQGSLFEYHERRQLGDGAFIELRSGWLTDGVELLDTLLSEVPWRIERRRMYDKVVNVPRLVSFHDLTTD	(SEQ ID NO:37)
DPPHPLLTRLRRRLNDIYAGELGEPFTSVGLCCYRDGSDSIAWHGDTIGRNSSEDTMVAIISLGATRVFALRKRGGGPSL
RLPLTHGDLLVMGGSCQRTWEHSVPKTSASTGPRVSIQFRPRNVH

>BL;ML0199, ML.tab 265213:265815 forward MW:21217
VSQLSFFTAESLLPAIADLAGVLAASGQIVVVSASGQSPAPAARLSVVVDQLWRASALAEMISEAGLVPEISRTEEDTPL	(SEQ ID NO:38)
VRTAVDPLLCPIAAEWTRGAVKTVPPRWLPGPRELRAWILAAGVPEAANRYLLGLDPHAPDTHSPLASALMRVGIAPTLI
GTRSGRPALRISGRRRLSRLLENVGEPPDWAEALALWPRV

>BL;ML0208, ML.tab 279784:280125 forward MW:12884
MNWIQVLLIGSIIVLLIYLLRSRRNVRSRAWVKVGYIAFVLGGVYAVLRPNDTTVVAHWFGVCRGTDLMLYALIMAFSFT	(SEQ ID NO:39)
TLSIYIRFKDLELRYACLARVVALEGARAPEPF

>BL;ML0227, ML.tab 298516:298992 forward MW:17121
MGPTRKRDLTAANIGAAVVGYLLVLVLYRWFPPITVWTGLSLLAVAIPEALWARYVRTKISDGEIGDGPGWLHPLAVAHS	(SEQ ID NO:40)
LMVAKASAWVGALVLGWWVGVLVYFLPRWPWLRVADKDTSGTVVAALSALALLVAALWLQHCCKSPQDPTEHGEGAEN

>BL;ML0229, ML.tab 300537:301466 forward MW:32734
MVQFDGLRSARLNIAILSTGRVGVALERADQVVVACSAVSHASRQWVQFRLPETSVASPPEVASSAELLLLAVPDCEFAG	(SEQ ID NO:41)
LMSGVAVTSVPRPGTIVAHTSWANGVGILAQLGKDGCIPLAIHPANMFSGSDEDLSQCQLRDTYFGITKTDDVGYAIAQS
LVLEMGGEPFCVVEYARILYHSVSPHVGNNIVTVLADALEVRRSALRGSELLGLGVPPACRGEVVDDQLDVIVERIVGSL
ARAACENTLQRGQAGLTKLVARGDLDALAGHLVALMRIGPELAQAYRVNALRKTQRAHAPYDVVEALAP

>BL;ML0256, ML.tab 335129:335812 forward MW:24402
MSEAKRLDPKRRSPASRPGKAGDSVRGRRSTKPVAKLSVKPSRTTPASSHSGRNSTRMLTQHVVEPIRQSIIESRERRSD	(SEQ ID NO:42)
QQLGFTARRAAVLAAVVCVLTLTIAGPVRTYFAQHAEIEQLAATEATLRRQIADLEQQKGKLADSAYIAARARERLGFVM
PGDVPFQVQLPSTAAVSSQPGGRAAKPANNDPWYTSLWHNIADAPHLPPGAGTPPFSLTPLSTTSGG

>BL;ML0257, ML.tab 335805:336308 forward MW:17960
VVDRADLEAVARHLGREPRGVLEIAYRCPSGEPGVVKTAPKLDDGTPFPTLYYLTHPVLIAAASRLESTGLMREMTERLG	(SEQ ID NO:43)
QDPELAAGYRRAHESYLTERDAIESLGTTFSAGGMPDRVKCLHVLIAHSLAKGPGLNSLGDEVLALLAADPKTAATLVAG
QWKECDR

>BL;ML0271, ML.tab 354849:355220 reverse MW:12992
MRLGQALAWLATDIVAVSVFCAVGRCSHAEGLTVADLAVTLWPFLTGTAIGWLASRGWQRPTAVVPTGVVVWLCTVVVGV	(SEQ ID NO:44)
ALRKASSAGVVANFMVVAASTTAALFLGWRAVVELILRRRSTR

>BL;ML0279, ML.tab 361297:361953 reverse MW:24062
VTYYSSLRPEDLPPERPKHEHYSGFPEYELANPGVGFRRFVATMRRLQDLAVSADPSDEVWYAAADRAVALVELLGPFAT	(SEQ ID NO:45)
DEGKAPAGRVPDMPGMGSLLLPPWTLTRSGPDSVEMTGYFTRFHVGFNHAVIIGGVLPLVFDHLFGMISYTAGRSISRTAF
LHVDYRKITPIDEPLVMRGRVTRTEGRKAFVSAELVDGDEMLLAEGNGMMVRLLAGQP

>BL;ML0281, ML.tab 363432:364121 forward MW:25240
LNTSDSAPGVAVLLFGDDRTRQRWNTLTALSTYRAGGPDDIDSIDATIGPYRRLVVVGGDGDLAAVLGRLLRADRLDIEV	(SEQ ID NO:46)
AYVPHQRTAATRVYRLPTGRRAARRARRGYATRVPLIRDETGSVIVGRADWLPVVDRQPLNGEAIVDDIPLFDGDVAGVR
IAPTLANPGLRARLHTSRTGIGIWSRWLTGRAVQLGSTGVAVVRDGVPTRRRERRSTFYRNVEGWMLVR

>BL;ML0284, ML.tab 365860:366273 reverse MW:14541
MTSMGDLLGPDPILLPDDSAAEVELRANKDPGTVAAAHIPSASVAWAALAEGALADDKATTAYAYARTGYHRGLDQLRCNG	(SEQ ID NO:47)
WKGFGPVPYSHEPNRGFLRCVAALARAANAIGETDEYRRCLNLLDDCDPAARNELGL

>BL;ML0285, ML.tab 366385:367263 forward MW:31593
MPNASEPERGITLNRPGLAPRTLDKNVVSNLPEAKDNPANTHGEEIAAGYPLAHSDSETEAMVLTKTEPDQDPGADRQHH	(SEQ ID NO:48)
ERRFTAPGFDARATAIMATAPDPATEAIHPPLSSSDPPGHLGISPKAAVPQSIPPVLGTKLRSARHFHWGWVVALLMMVL
ALAAIAILGTVLLTRGKHVKASPAEQVRHAIQSFDVAVQTGNLTALRSITCGTTRDGYVEYDESSWDETYHRVSAAKQYP
VIASIDQVVVNGQHAEANITTFMAYDPQVRSTRSLDLQFCDDQWKICQSPSG

>BL;ML0298, ML.tab 381423:381647 reverse MW:7851
MIVXTVNERPVEVNEQTTVAALLESLGFPASGIAVAVEFSVLPRSYWATKISELPAVTGRSEPIRLEVVTAVQGG	(SEQ ID NO:49)

>BL;ML0370, ML.tab 461945:462814 reverse MW:30055
VRYRRQVAHTRKLLAALSRRGPHRVLRGDLSFAGLPGVVYTPAGGLNLPGVAFGHDWLTGTARYAGLLEHLASWGIVTGA	(SEQ ID NO:50)
PDTQRGLTPSVLNLAFDLGSALDIVAGVRLGPGNISVHPAKLGLVGHGFGGSAAVLAAAGLPGLAGLPAKSAVAIFPTVT
SPAPEQPAATCKVPGLILTAPGDPKTLNSNALSLYRAWDDATLRIVSKAKAGGLVEGWRMTKVVGLAGPHRATQKAVRSL
LTGYLLYALGGDKEYRDFADPDMHLPHTVPVDPEAPLVTPEQKIVTLLK

>BL;ML0383, ML.tab 476440:477285 forward MW:29301
VTSVSIVVEIGHTSAAEPMLAAAAFGNQPGRWPLPTATTPHQLWLRAVAAGGQGHYSSAYRDLAVLRRSVPAGRLASLAH	(SEQ ID NO:51)
STEGSFLRQLGWHSLARGWDGRALVLAGTDSEARADALIGLAADALGVGRLAAAATLLRRVGSALAPAQLPAQVADRLAV
RRRWVAAELAMAVGDGATAVRNAREAVELAQVGRVSVRHQVKSDVVLALCSAATEPRVVAEAALAATGRLGLIPLR
WALACLLIDIGSVTFSEPELSELRDVCADQVRRAGGTWRTA

>BL;ML0386, ML.tab 480093:480506 reverse MW:15294
VRDHLPPGLPPDPFADDPCDPSAALDAVEPGQPLDQQERIAVEADLADLAVYEALLAHKGIRGLVVCCDECQQDHYHDWD	(SEQ ID NO:52)
MLRANLLQLLIDGTVRPHEPAYDPEPDSYVTWDYCRGYADASLNQATSDADGYRRRH

>BL;ML0405, ML.tab 503217:504401 forward MW:40754
MSGAFIIDPTLKAIEAWHALLGIGVPNDGGVLYSSLSFFEKALEHLAAAFPGDGWLGSAADKYAGQNRKRVDIFQELAEL	(SEQ ID NO:53)
DKELIELIHNQANSVQTTRGILDGAKKALLFVRPVAIDLNYIPLVGSVMSASIQAQACAAAMAAVSGGLAYLLVQTAIHT
AKFVALLARLAHLLASAVADVVSDGVAIIKGIVDHLWHFIAGALTGLKDIVEKIIHWFFGLFSHWWSRLHSFFGGIPGLS
GATSGLSQVTGLFGVPGLAGSSGLLSGESLLSTENLPSLAGVGAGLGLGSLPQLAQLHAASTRQGTRSQAGVSAELSTEQ
FGGQQEPVSAQGSQGMGGSQGMGGMTPASTKSKKDERKKKKYSEGAAAGTDDAERAPIEVQSGGGKRALAQHVV

>BL;ML0406, ML.tab 504459:504779 forward MW:11110
MRSMIDNLTVQSEHLNSLASQHENEAACASSGVSAAAGLANAVSTSHGSYCAQFNDTLKMYEDAHRTLGESLHTGGIDLA	(SEQ ID NO:54)
RVLRVAAANYCDADEICGSDIKSAFG

>BL;ML0407, ML.tab 504793:505443 forward MW:24227
MGSRRRINRRLLPMSTFPAWQEFRRDVVVVFPGNDFDRDDCDTVDPWGVGGAAHWTIDPIVGFASSSAPQDRGTDVDNTR	(SEQ ID NO:55)
GQAEEDEKQKEPEVAIFTVTNPPRTVSVSVLMDGRIDHVELSKRVTWMSESQVASEILVLADLARQKAQSAQYTFILDKL
SQLADGDEHRVALLRESVGNTWNLPSPEQAAEAEAEVFATRYSDYCPAQDTENDQW

>BL;ML0410, ML.tab 508327:508629 forward MW:10951
MSFFLRVEVGGLMMAAGRLERITSESMACNAKLTPVTTKVVPPAADQVSKLVSQVFSSYGKQYEGYAAQGVDQSRLFVQS	(SEQ ID NO:56)
LKDAAGDYMDSDHMYLNTED

>BL;ML0411, ML.tab 508755:509981 forward MW:42466
MFDFMVYSPEVNAFLMSRGPGSTPLWGAAEAWISLAEQLMEAAQEVSDTIVVAVPASFAGETSDMLASRVSTFVAWLDGN	(SEQ ID NO:57)
AENAGLIARVLHAVAYAFEEARAGMVPLLTVLGNIIHTMALKAINWFGQVSTTVAALEADYDLMWVQNSTAMTTYRDTVL
RETGKMENFEPAPQLVSRYCMDRRDSVNSFHSSSSSDSLYESIDNLYDSVAQSEEHGSDSMSQSYNTCGSVAQSELCDSP
FGTPSQSSQSNDLSATSLTQQLGGLDSIISSASASILLTTNSISSSTASSIMPIVASQVTETLGRSQVAVEKMIQSISSTA
VSVDVAASKVVAGVGQAVSVGALRVPENWATASQPVMATAHSVPAGCSAITTAVSGPLEGVTQPAEEVLTASVAGGSGTG
GPAFNEAV

>BL;ML0418, ML.tab 517644:518276 forward MW:23558
LLSVDEVLTTTRSVRKRLDFDKPVPRDVLMECLQLALQAPTGSNSQGWHWVFVEDAEKRKAIGDIYLVNARCYLSQPAPEY	(SEQ ID NO:58)
PEGDTRGERMRLVRDSATYLAEHMHEVPVLLIPCLLGRAEESPLGAVSYWASLFPAVWSFCLALRSRGLGTCWTSLHLLG
DGEQRAAEVLGIPSDKYSQGGLFPIAYTKGTDFRPANRLPAENVTHWDIW

>BL;ML0425, ML.tab 524416:524643 forward MW:8231
VADRHPDTIKLEIDVAREQFAATVDSLAERANPRRLAGDLKARVVEFGRRPAVIAALVSCAVLTVIVVVRKVKNR	(SEQ ID NO:59)

>BL;ML0431, ML.tab 530916:531695 reverse MW:27233
MNNPRRSEWLGPSLAGSGPIEPQVHQYPPLTDPAYAEQAPYAPAYGASLPPWTPKKPPQQLPRYWQQDQPPPTDIPPEGL	(SEQ ID NO:60)
TLPPPHEPKSPHWFLWVVAGASVVLVVGLVMALIIANGAIKTQTAVPPLPAITESSSATPTPTTKTSPTPTAGPAPSTTG
SGTLTQTIGPSAMLDVVYSITGQGRAISVTYMDTGDVIQTEFNVVLPWSKQVSLSKSAVHPASVTIVNIGHDVTCSVTVA
GVQIRQHTGVGLTICDAPR

>BL;ML0451, ML.tab 551191:552240 reverse MW:37930
MLTLLVLLVALATLAGGWGYQTANRLNRLHVRYDLSWQALDGALARRAVVARAVAIDAYSGTSPGRRLAALADAAECAPR	(SEQ ID NO:61)
HTRENAENELSAALAMVDPASLPTALIAELADAEARVLLARRFHNDAVRDTLALGEQRLVRTLRLRGTASVPTYFEIVER
PHALTHGDHGVPNQRTSARVVLLDETGAVLLLCGSDPAITNGHAPRWWITVGGEVRPGERLAAAAARELAEETGLRVIPT
HMVGPIWRRDAIFEFNGSVIDSEEFYLVYRTRRFEPSTVGWTELEHLCLHGSRWCDANDIAELVASGEQVYPRQLGELLP
VANQLADASTGTARGTAAARNTYVLLSIC

>BL;ML0486, ML.tab 589652:589996 forward MW:12749
MESLVLLLLFLLIMGGFMFFASRRQRRSMQATIDLYNSLQPGDRVNTTSGLQATIIVVGDDTVDLEIAPGVVTTWMKLAI	(SEQ ID NO:62)
RDRILPDDAYMDEHEAEPGDFVYCDELEESDGSS

>BL;ML0520, ML.tab 631179:631787 reverse MW:21872
MNNWMLRGLVFAALMIVVRLMQGTMINVWQAQSVLISVVLLAVFIIAVVVWAARDGRADAIANPDPDRRRDLAMTWLLTG	(SEQ ID NO:63)
ILVGVLSDAVAWVISLLYNGIYTGGLVSELTTFSAFTALIVFLTGIIGVACGRWRVDRRSPPVPEHSRSGQNRADSNVFA
AVCTDDDTPTGELSAAQTKEQTAAVATAESEAPTEIIYIIQRA

>BL;ML0542, ML.tab 657980:658312 forward MW:11942
VSIPQSNTSLSAVIAVDQFDPSSGGQGVYDTPLGITNPPIDELLDRVSSKYALVIYAAKRARQINDHYNQLGEGILEYVG	(SEQ ID NO:64)
PLVEPGLQEKPLSIANREIHADLLEHTEGE

>BL;ML0561, ML.tab 678085:678555 forward MW:17254
MTAQLDRDDWDVELRPYWTPLFAYAAAFLIAAAHITVGLLLRIKSSGVVFRTADQVAIGALGLVIASAVLLLTRPRLRVG	(SEQ ID NO:65)
AAGLLVRNIMFYRIIPWSHVVDVSFPLGSHWARIDLPDDEYIPLMAIQAVDKERAVEAMDAVRALLARYRAGPYGP

>BL;ML0577, ML.tab 699950:700183 forward MW:8150
MELALQITLVVTSILVVLLVLLHRAKGGGLSTLFGGGVQSSLSGSTVVEKNLDRLTLFVTGIWLVSIIGVALLTKYR	(SEQ ID NO:66)

>BL;ML0580, ML.tab 704001:704798 reverse MW:29039
MSRVLTLVITPYSKANLKESIEAANGASHKYPNRIIIANRVNSYANKARLDAQLWVGADTGAGVVVSRTLAVYAHSVVIS	(SEQ ID NO:67)
ILLPDIPMVAWWPNIAPTMSGQDSLGKLAIQRITNATNSIDPLATIKSRLSDYTADDTHLAWDLITYWRALLTSAVNLPP
HEPIDLALVSGMKTEPALDVLAGWLANRINRPLRRAVADLKVELIRNSETIVLSRPQTWVTSTLIRTVKPDALVPWGAQG
SRGVPSRKSATTGSRQVLLQCLRRH

>BL;ML0603, ML.tab 735002:736117 forward MW:39051
VLVLWRCFRVANISALMVAVACLPDWLSGFLTGGLIAGSSARRATIYGVSNKFSSLHLVLGNEELLVERAVGEVLRSARQ	(SEQ ID NO:68)
RAGTQDVPVSRMRAGDVGTYELTELLSPSLFADERIVVLEAAAEAGKEAAALIVSAAADIPQGTVLVVVHSGGGRAKALA
NELQSLGATVHPCARITKLSERTDFVRKELRSLRVKVDEGAVTALLNAVGSDVRELASACSQLVADTAGDVDADAVQRYH
SGKAEVKGFDIADKAVGGDVSGAVEALRWANMRGEPLVVLADALAEAVHTIGRVGPLSGDSYRLASRLGMPPWRVQKAQQ
QARRWSRDTVAAAMRVVAALNADVKGAAADAYYALESAVRKVAELAADGSR

>BL;ML0630, ML.tab 763032:763358 forward MW:11114
MAELLNTEDAKLVVLVRAAMARTEAGSGAVVRDFDGRTYAAAPVTLSTLELIGLQEEAAAAFSASSVVSGLEVGVLVAGS	(SEQ ID NO:69)
VDEPDIAMVRELASTAVVILIDRNGNRV

>BL;ML0642, ML.tab 774506:775945 reverse MW:50246
VAHSGSPVSTVDGVANPPFGFSSGNDSPNDESGRDKHGKNGPDSGSSGSDPLASFGMSGDFGMSDLGQIFTHLGQMFTNA	(SEQ ID NO:70)
GTAMTADKQLGPVNYELARRVASSSIGFVAPIPATTSSAIGDAVHLAETWLDGVTALPAGTTKAEGWTPDDWVNNTLETW
KRLCDPMAQQISTVWAASLPEEAKSMASPLLSMMSQMGGMAFGSQLGQAFGQLSREVLTSTDIGLPLGPRGVAAIMPQAV
ESFADGLEQPRCEILTFLATREAAHHRLFSHVPWLASQLLGAVEAYAAGMKIDMNGIEELARDFNPASLSDPTAIEELLG
QGVFEPQATPAQTQALERLEALLALIEGWVQVVVTAALGDRIPGAAALGETLRRRRASGGPAEQTFATLVGLELRPRKLR
EAAVLWERLTQAAGVDARDAVWQHPDLLPSGKDLDDPASFIDRIIGGDTSGIDEAIAKLDLDRGNSDGRTPGSGGPVDN

>BL;ML0676, ML.tab 811815:812291 reverse MW:16889
MFLRLMLSALKALQRLGAVMNSLARIDHWIWLFRCQPLTIRLLVATAALFTAATAFEVPAEADAIDDTFIKALNHAGVNF	(SEQ ID NO:71)
GEPRSAMTMGHYVCPILAKSGGNFAAAVQRIRGNSDMSPQMAETFAKIAISIYCPTMMANVASGNLPSLPPGPGIPGI

>BL;ML0703, ML.tab 840882:842153 reverse MW:46028
MVADLVPICLSLPAGDRYTVWAPRWRDGGDEWEAFLGKDDNLYACETVADLVAFVRTDSDNDLVDHPAWKDLTSVHAHKL	(SEQ ID NO:72)
DPSEDNQFDLVVVEELVAEKPTAESVTTLAATLAIVASIGSVCELPAVSKFFNGNPSLGAVSGGIEHFTGRAGQRRWNSI
AEIIGRSWDDVLSAIDKVISTPRVNAAMSAKAADELAEEPVEPEVEPDDEDGADSATAQANNSDDTEDESRTAGDTVVLG
SDKDFWLQVGIDPVRIMTGAGTFYTLRCYLDDHPIFLGRNGRISVFSSERALARYLADEHDHDLSYLSTYDDIRTAATDG
SLAIDITDDNIYVLSGLSDDLADGPDAVDRDQLDLAVELLRDIGQYSEESAVDTALETNRPLGKLVAHVLSPSAVDKPVA
PYSAAVREWEKLEQFVESRLRLE

>BL;ML0730, ML.tab 871757:872011 reverse MW:9373
VSAANDGSETNKLPTTQNPHIQITKGQPTDQELAALIVVLSSIGGASQVKQPEPTRWGLPVDKLRYPVFSWQRITLHEMT	(SEQ ID NO:73)
HMRR

>BL;ML0733, ML.tab 874677:875195 forward MW:19913
MRYPGNTLVAGEQVVLHRHPHWKRLIWPAVVLILATGLVSFGSGYVNSTHWAQVAKNVIYGVLWGVWLVIVGWLTLWPFL	(SEQ ID NO:74)
NWLTTHFVVTNRRVMFRQGTLTRSGVDIPLARINSVEFRDRLFERMFRTGTLIIESASQDPVEFYNIPRLRQMYALLYHE
VFDTLGSEESPS

>BL;ML0734, ML.tab 875150:875836 reverse MW:25515
VSFPDATITRLPTVLQPYAQRYHELIKFAIVGGTTFIIDSAIFYTLKLTILEPKPVTAKVVAGIVAVIASYVLNREWSFR	(SEQ ID NO:75)
DRGGRERHNEALLFFAFSGIGVLLSNAPLWFSSYVLQLRAPTVSLTVENLADFLSAYIIGNLLQMAFRFWAFRRWVFPDA
FARNPEKTLESALTAGGIAEVFEDAIDGVFEDFGDALLRAWRNRSRRLDLSPASQLGDSSEPRVSKTS

>BL;ML0748, ML.tab 890981:891259 reverse MW:9830
MVQGLLAKAATMVITGLTGVTAYEMLRKAVTKVPLHQIAVSALELGLRGSRKAEEAAESARLKLADVMAEARERIGKETT	(SEQ ID NO:76)
APAVSDIHQHDH

>BL;ML0761, ML.tab 903525:904028 reverse MW:18775
VSNSCSSSRHGQWSRRFSSRRAAKRGRDIRGPLLPPTVPGWRSRAERFDMAVLEAYEPIEQRWQGRVSELDVAVDEIPRI	(SEQ ID NO:77)
AARNPENVQWPPEVIADGPIALARLIPAGVDVRSNATRARIVLFRKPIERRAHDTVELGELLHDILVAQVAIYLDVEPSA
IDPTMDD

>BL;ML0762, ML.tab 904068:904565 forward MW:17248
MRVSGASATFSHDSLSVVNVPRRCCRPGCPHYAVATLTFVYSDSTAVVGPLATVREPHSWDLCVDHAARITAPRGWELVR	(SEQ ID NO:78)
HAGPLPSNPDEDDLVALADAVREGPGGEHGSYGNGARASLGGFADPQLQSAGAHATVPSGGLLAPSELRSGRRRGHLRVL
PDPSD

>BL;ML0764, ML.tab 906078:907175 forward MW:37464
VNATRLIDLEDTKGLIAADRDGLLRAASSAGAQVRAIAAAAEEGALETLRAHDRPRTVIWVAGRGTAETAGAMLAATSGG	(SEQ ID NO:79)
ATTEPIVVASEAPPWVGPLDVLIVAGDDPGDPALVGAAATAVGRGARVVVVAPYEGPLRDATAGRVAVLEPRLRIPNEFG
LCRYLAAGLAALQTVDPRLRLDLANLADELDSEALHNSVGYEVFTNPAKTLAASVSGHRVALAGDCAATLALARHGSSVL
LRIAHQVTSATGLSDAVVAVRSSVDVADYAPTSVDVLFHDEEIDGSLPERLRVLALTLASERTVVAARVVGLDDVYLVAA
EDVPDGPSGLAGLPVSGGADRAEQELANLAVRLEMAAVYLRLVRG

>BL;ML0776, ML.tab 920258:920515 forward MW:8946
VAGCGVFATRWSDACTAELSVAAGEPRVVSLCVDPLVPVVVLGRYVGARRQAILAMKEHGRRNLVALPTRQCVSRLGSCT	(SEQ ID NO:80)
LPGRG

>BL;ML0806, ML.tab 955206:955727 forward MW:17808
VDRVIALLSSGAIVGPCDYADVVTLPHKRAVFSRAPAAVRGAGLIVVVQGAVALVVAAALVVRGLTGADQRIVNGLGTAI	(SEQ ID NO:81)
WFVVVGVAVLAAGCALLVGKRWGRGLAVFTQLLLLPVAWYLVVGSHQSAFGFPMGIVALIALILLFSPPAVRWSAGAYQR
SVASSANRKADSR

>BL;ML0810, ML.tab 958882:960105 reverse MW:42979
MVRPERRTKADTIAAMTITVVMAAMVSLIWWTSDAQATHSRPATIPAPNPTPAREVPTAFNQLWAAASPATTAPVVVGGA	(SEQ ID NO:82)
VITGDGHQIDGRNPVTGESRWSYARDSDLCGVSWVYHYAVAVYRDDRGCGQVSTIDGSTGRREAARSSYADPNVRLSSDG
TAVLSAGDTRLELWRSDMVRMLAYGEIDARVKPPARGLHSGCTLESTAASSSAVAVLEACANQDDLQLVLLRPGKEDDEP
QQHLVAEPRVRSGSGARVLTVSDTHTAVYLPGEAGTQPRVDVIDETGTTVASTLLTKPPSSSAVVSQAGNLVTWWTGDTL
MVFNQSNLTLRYTIAAGETTAPVGPGVMMAGQLLVPVTGKIGVYDLFSGANNRYIPVRRPPSSSAVIPAVSGSTVFEQRG
DTLVALG

>BL;ML0813, ML.tab 962707:963294 reverse MW:20353
MRLTETTSIRRTTTTSYSGHPIVDGRQVAALLGSVAALCAIATAVIINSGDNATTKAIVGAPTPRPVLTTPSIPLPATPS	(SEQ ID NO:83)
STPPLLLLFDTATATIPHKAAPPALHPRTVVYNVTGMKELLDLVTVVYTDARGYPKTEFNVVLPWTKAVVLNLGVKTQSV
VATSFHSQLHCSIVNAEGQPVVASTNNAVIATCTR

>BL;ML0814, ML.tab 963593:963841 forward MW:8652
VEVKIGITDSPRELTFSSAQTPGEIEELVSAALREGLGLLVLTDERGRRFLIHGAKIAYVEIGVADARRVGFGIGAESAT	(SEQ ID NO:84)
NG

>BL;MLO816, ML.tab 964701:965726 forward MW:37443
VSSPGPVGSPGRVPVLREEWRAPLRAQREPLARGEGRVRVNRGRSRRWRKQTRLGRFVSVFGWRAYALPFLMALTAVVLY	(SEQ ID NO:85)
QTVTGTNAPEPAASEPITEPPVIGAVGTAIMDVPPRGLAAFDANLPAGTLPDGGAFTEAGDKTWHVVPGTMPQISQSATK
VFKYSIEIENGLDPTMFGGDGAFAQMVDQTLANPKGWTHNPQFAFTRIDTGMPDFRISLVSPLTIRAGCGYEFRLETSCY
NPSFGPDRQARVLINEARWLRGALPFEGDVGSYRQYVINHEVGHAIGYVRHEPCDKQGGLAPVMMQQTFSTSNNDGAKFD
PEWVKPDGKTCRFNPWPYPIA

>BL;ML0818, ML.tab 967172:968065 forward MW:32374
LRSPRSGSTRLTRVTVEPPPEHVLSAFGLTGVQPVPLGASWEGGWRCGEVVLSMVADNARAAWSARVRETLFVDGIRLAR	(SEQ ID NO:86)
PVRSTDGRYVVSCWRANTFVAGTPEARHDEVVSAAVRLHEATGKLERPRFLTQGPTARWADVDIFIAADRAAWEGRPLQS
VPSGVWAAPMTTDGQRSVDLINQLAGLRKPTRSPNQLVHGDLYGTMLFVGTAAPGITDITPYWRPASWAAGVVVVDALSW
GEADDGLIERWNALPEWPQMLLRALMFRLAVHALHPRSTAEAFPGLARTAALVRLVL

>BL;ML0834, ML.tab 990401:990703 reverse MW:10909
VRQDGASRTVVGGTALIRYVIVLGLGYVLGAKAGRRRYEQIVGIYRTLTGSPMAKSMIAEGRRKVANRISPDEGFVTLAE	(SEQ ID NO:87)
IDNQTTVIERSAEWRENGGN

>BL;ML0857, ML.tab 1019690:1020442 reverse MW:26808
MAKPRNAAAHKAARAEAKAARKAASRQRRLQLWQAFTIQRTEDKRLIPYMIAAFSLMVSASVTAGVLVGGLTMITLILLG	(SEQ ID NO:88)
VVLGALVAFIIFGRRTQQSVYHKAEGQTGGAAWALDNLRGKWRVSPGVAANGHFDAVHRVIGRPGVIFVAEGSAARVKPL
LAQEKKRTARLVGDVPIYDI IVGNGDGEVALVKLERHLARLPANISVKQVDILESRLAALGSRAGASLIPKCPLPNACKN
RGVQRTVRRK

>BL;ML0869, ML.tab 1033201:1033575 reverse MW:13804
MMAGEEAYLPPRDQGPVRRYIRDLVDARRNALGLFTPSALVLLFITFGVPQLQLYMSPAMLVLLSVMGIDGIILGRKISK	(SEQ ID NO:89)
LVDVKFPSNTESHWRLGLYAAGRASQMRRLRVPRPQVEHGSSVG

>BL;ML0872, ML.tab 1035615:1036130 reverse MW:19047
MLPPAVSYPRRRSKRLI ISVLVAIALVAAMTAVI IYGVRTNGSKTGGTFSEVTAKTAI EDYLKALEQSNINTIARNALCG	(SEQ ID NO:90)
MYDSVRDQRPDQALAQLSSDAFRKQFSQVELTS IDQIVYWSPYQAQVLFTMRTSPATGGPKRRQIQGIAQLLYRRNQVLV
CSYMLRTADSH

>BL;ML0876, ML.tab 1040896:1041315 forward MW:14969
MHI EARLFEFVAVFFVIMAVLYGVLTSMFATGGVDWVGTTALALTGGLALIVATFFRFVARRLDI RPEDYEGAEISDGAG	(SEQ ID NO:91)
ELGFFSPHSWWPVLVALSGSVAAVGIALWLPWLIVAGVVFVLASAAGLVFEYYVGPEKH

>BL;ML0878, ML.tab 1042383:1043021 forward MW:22756
MMNRYSPY2RGSDTIASDVIDRILVGVCAAVWLVLIGVSVAAAVALEDLGRGFHKIASDPHTTWVLYGIIVVSVLIIAGA	(SEQ ID NO:92)
VPVLLWARRVARVEPPIRPAGVPERGGVRQLVSAGRSTARIEVERVCAEERVQSVAQPGEWFDAAVDRIWLRGTVGLTGT
MGAALVAVAASTYLMAVGRDGASWVGYVLAGIVTAVMPVIEWIYVRQLRRVG

>BL;ML0888, ML.tab 1055260:1055667 forward MW:15125
MNSTNS IQIADETYVAADRALIGAAVADRSSWHRWWPDLRLQVVEDRAEKGIRWAVTGTLTGTMEIWLEPLTEELDGVVL	(SEQ ID NO:93)
HYFLHAEPAGVAAWQLAKMNMAKVTHRRRVAGKAMAFEVKKTLERSRSIGVSPVI

>BL;ML0889, ML.tab 1055786:1056220 forward MW:16483
VADKTTQTFYIDANPGEVMKTIADIESYPQWISEYKEVEVLEVDDEDFPKRARMLMDAKIFKDTLIMSYDWTADHQSVSW	(SEQ ID NO:94)
ILESSSLLKSLEGSYRLVPKGSTTEVTYELAVDFAIPMIGMLKRKAEHRLIDGALKDLKKRVEG

>BL;ML0891, ML.tab 1057485:1057877 forward MW:13550
MSGGYADIGPELRKLAQMTLDGIGPAVRSAAALVAGARGTGKCQQAWCPVCALTALVIGEQHPLLTVIADHSVALLDVIR	(SEQ ID NO:95)
AIVDDIDQSNKIPPDSPHGGGLDTETPAQTNTSNGTVRRRYQPIPVSVED

>BL;ML0895, ML.tab 1061008:1061523 forward MW:19954
MRYPYDTEFIEDGRTIELVSIGVVAEDGREYYAVSNEFDPERAGNWVRVNVLSKLPPLASQLWRSRRQIRLDLEEFFGVD	(SEQ ID NO:96)
GSEPTEPIELWAWVGAYDHVALCQLWGPMPDLPEALPRFTREIRQLWEDRGCPRMPPRPRDLHDALVDARDQLRRFRIIM
SADDVGSLPTH

>BL;ML0898, ML.tab 1064343:1064747 forward MW:14698
VGSIPAGDDVLDPDEPTYDLTQVAELLGIPVSRVHRKLCEGYLVAVRRGDSLVVPQIFFTNSGAVVKSLPGLLTILHDGS	(SEQ ID NO:97)
FHETEIVRWLFTPDPSLTLTRDGSRDVVSNARPVDALHTHQAREVVRRAQAMAY

>BL;ML0902, ML.tab 1068511:1069230 reverse MW:25542
VRARFPPLFTRGCTAQRRRTLTIALLLVAMVPLATGCLRVTASITISPDNLVSGKIIAAAKPKNKNDAGPQLNDNLPFSQ	(SEQ ID NO:98)
KIAVSNYNSDGYVGSQAVFSDLTFAELPQLANMNSSTTDVTLSLRRNGNLVILESRADLTSVTDPDADVELTVAFPGVVT
STNGDRIETKVVAWKLKPGVVSTMSARARYTDPDTRSFTGAAVWLGIASFSAASVVVLLAWNERKSSARLQIPRDSSSS

>BL;ML0903, ML.tab 1069302:1069934 reverse MW:23864
LAIFLINLSPNEMERRLNEALEVYVDAMRYPRNTENLRAGIWLEHIRRPGWQAVAAVEVRIEVADVADMADGPAHPAPSA	(SEQ ID NO:99)
DELNNAPLRGVAYGYPGAPGQWWQQQVVQGLQRSGLSTLEIARLMNSYFELTELHIHPHTQGRGIGEALTRRLLAHRREN
NVLLSTPETNGETNRAWRLYRRLGFMDIIRRHYFAGDPRAFAILGRTLPL

>BL;ML0904, ML.tab 1070251:1070655 forward MW:14614
MPLSDHEQRMLDQIESALYAEDPKFVSSVRGGGLRVPTARRRTQGAALFVIGLGMLVCGVAFKATMIGSFPILSVFGFVV	(SEQ ID NO:100)
MFGGVLFAITGSRLSGREDHPGLAPGTSRQRRSKGAAGSFTSRMEDRFRRRFDE

>BL;ML0907, ML.tab 1072702:1073835 forward MW:39543
MKAQRDTPIRRGDSGRPGGRDGAARSGKRTANEAGSRRLRTHAGKISASAREVGVPKSGPRTSPMSRPVERPARPRNTTQ	(SEQ ID NO:101)
AKARAKARKAKAPKVVRPRLGECLIARLALIDLRPRTLVNKVPFVVLVISSLGVGLGLTLWLSTDSAERSYQLGDAREQA
RMLQQQKEALERDVREAESAPALAETARKQGMIPTRDTAHLVQGPGGNWVVVGTPKPADGVPPPPLNTKLPDAGPPSLKP
PEIPLEVPVRVVPGPGGPPPPARSGPQMWLRVPDGATTLGGQHLPQELPQLPGMLNGPAAAQVQVPGFMPTPGLPIPGST
MRVPVPAPAPTEVPVRLQPGLVSPAVTSPVISTSPVPTPVNSEQFGPVTATAPGTSR

>BL;ML0920, ML.tab 1090054:1090686 forward MW:24016
MSTLHKVKAYFGMAPMEDYDDEYYDDRSPTHGYGRSRFEEGYGRYEGRDYSDLRGDPTGYLPLGYRGGYGDEHRFRPREF	(SEQ ID NO:102)
DRPDLSRPRLGSWLRNSTRGALAMDPRRMAMLFDEGSPLSKITTLRPKDYSEARTIGERFRDGTPVIIDLVSMDNADAKR
LVDFAAGLAFALRGSFDKVATKVFLLSPADVDVSPEERRRIAETGFYAYQ

>BL;ML0921, ML.tab 1090811:1091101 forward MW:10769
LALFYQILGLALFVFWLLLIARVVVEFIRSFSRDWRPNGVTVVILETIMSITDPPVKLLRRLIPQLTIGAVRFDLSIMVL	(SEQ ID NO:103)
LLVAFIGMQLALSAAA

>BL;ML0923, ML.tab 1092221:1092613 forward MW:13650
MLIIALVLALIGLVVLVFAVATSNLLMAWVCIGASVLGVLLLIVDAVREHQCIDAANNEDKEDTDQDDGAVYVDYLDEVP	(SEQ ID NO:104)
AGTSTEAPDAGSQEGDTNSGELSGYWGRLTIDTGEQSAVAADDHDNDRAT

>BL;ML0984, ML.tab 1151024:1151473 reverse MW:16902
VAIAELTEASVQGVENIRTVEVFLAALQDAGLRNRIRDVGRQPRVYQNVGLPTIHGRSKTITLWRKMADCIGFEIKIHRI	(SEQ ID NO:105)
AAVAIAVLCERADAVIVGPLWMQFWVCGTFEVQNKRIMLWPNYFDLFDLFKATMRSLVALRIPSLNAAF

>BL;ML0986, ML.tab 1152702:1152905 forward MW:7514
LAGVRLTEFHERVVLRFGAAYGASVLVDHVLTGFDGRTVAQAIEDGVELRDVWRALCVDFDVPRDQW	(SEQ ID NO:106)

>BL;ML0990, ML.tab 1157281:1157910 forward MW:22743
MNEEPNIVDFPDSNPLQAALEAEELRVVREIDSGAKIFVLIAVLVFMLLGSFILPHTGQVRGWDVLFDSHGAGAAAVALP	(SEQ ID NO:107)
LRIFAWLSLVFGVGFSMLALMTRRWVLAWIALAGAANASIVGLLAVWSRQTVAVGQPGPGVGLIVAWITLILLTFHWARV
VWSSTIVQLATEEQRRRVVAQQQSKTLLDGLYSAGNRDTRTRSDPQVGS

>BL;ML0994, ML.tab 1162620:1163318 forward MW:23576
VLSAIAIVPSAPVLVPELTGAAAAEVADLRSAVLAVAACLPPCWIVVGTGRADDVVGPGGCLGTFAGFGADVRVRLSPQV	(SEQ ID NO:108)
GGEAELLVDFPVCALIAAWVRGQSQLDASAQVRVYCGDHDPDMALACGRQLRVEIEQAPDPIGVLVVADGATTLTSSSPG
GYDPSAADAELVLDDALASGDVAALTRLSCQISGRVAFQVLAGLVEPGPRLAKELYRGAPYGVGYFVGVWQP

>BL;ML1001, ML.tab 1172599:1172874 reverse MW:10150
MPDPVVMPVPCPTSGFTQYSPYYRGAQITLLQQTILAKLNQKYYNNRYRVDVEMVLSHTGVEADSAASHTILGLSSSILP	(SEQ ID NO:109)
PYGCRTKKQRS

>BL;ML1004, ML.tab 1176008:1176502 forward MW:17108
MLVIYAVPPLIGNVRHPMSRPILGPRCGSGESAGSRRPAPSRSASAPMRYSGASVANLVAPHRGRTVSLAKTIGLALLAG	(SEQ ID NO:110)
MITLWLGLMADVSQVIDGDATGFVTHVPNRLAVVRVEAGESLQDVAARVAPDAPVRQVSERIRELNVLDSSMLVAGQTLI
APVG

>BL;ML1009, ML.tab 1179519:1180499 reverse MW:36153
MSHSHYQDPDDEQHYQPGQPGMYVLEFPAPQLLASDGRGPVLIHALEGFSDAGHAIRLAATHLKAALNTELVASFAIDEL	(SEQ ID NO:111)
LDYRSRRPLMTFKTDHFTHYDDPELSLYALRDSVGTPFLLLAGMEPDLKWERFITAVRLLAERLGVRQTISLGTVPMAVP
HTRPITLTAHSNNGELIADFTPWITEIQVPGSASNLLEYRMGQHGHEVVGFTVHVPHYLTQTDYPAAAQALLEQVAKTGA
LQLPLSALAEAAAEIRAKIDEQVQASTEVAQVVAALERQYDAFIDAQENRSLLRRDEDLPSGDELGAEFERFLAQQAEKK
RDDDLT

>BL;ML1015, ML.tab 1185456:1185875 reverse MW:15761
VGKLSTAPNRGTTDTFDDNSRPVLITTAAPSYEEERRTRVRKYMTLMAFRIPALMLTTVAYSAWHNGLISLLIVAASVPL	(SEQ ID NO:112)
PWMAVLIANDRPLRRTEEPRRFDSRRRRTPLLLTTEQPAFKSLRRPPPKPTSLATDSRS

>BL;ML1016, ML.tab 1185903:1186226 forward MW:11848
VSGFCFSVGRVRRHNVTMLGRHNVTMLGMQTQTIEHTYTDEHVDDGTGSDTPKYFHYVKKDKIVESAVMGSNVVALCGEV	(SEQ ID NO:113)
FPVTRAAKPGSPVCSDCKRVYDMLKKG

>BL;ML1O2S, ML.tab 1192722:1193372 reverse MW:22931
VVTQITEGTAFDKHGRPFRRRNARPAIFVVVFLVIVAGVSWTIALTRPAKVREPEVCNPPTQSTGSVPTQLGKQVPRTEM	(SEQ ID NO:114)
TDVTPAKLSDTKVHVLNASGRDGQAADIAGALRDLGFAQPTAANDPMYADTLLNCQGQLRFGTAGQATVAAVWLVAPCTE
LLHDNRTDDSVDLALGTDFTALAHNDDIDAVLASLRPGATEPSDPALLQKIHANSC

>BL;ML1026, ML.tab 1193568:1193870 forward MW:10969
MPTDYDAPRRTETDNVPEDSLEELKARRNEAASAVVDVDESESAESFELPGADLSGEELSVRVIPKQADEFTCSSCFLVQ	(SEQ ID NO:115)
NRSRLASEKNGVMICTDCTA

>BL;ML1027, ML.tab 1193875:1194348 reverse MW:17131
VSGTPVAPHNVRYRERLWVPWWWWPLAFALASLIAFEVNLSGATLPSWLPFAVAAGTLLWLGRVEIQVIADAPLGGSVEL	(SEQ ID NO:116)
WAGNAMLPITAIAQSAAISRSAKSAALGRQLDPAAYVLHRAWVGPMILVVLDDPDDPTPYWLVSCRHPERVLSALRS

>BL;ML1029, ML.tab 1194835:1195656 forward MW:29018
VTADDDAERSDEDGAAVMATFGKRTGKDGASRTLTEPADPEATELPAASEPDSEEVDELEGPFDIDDFEDPAVAVLARLD	(SEQ ID NO:117)
LGSVLIPLPEGSQLQVELTDVGVPNAVWVVTANGRFTITAYAAPKTGGLWREVAGELADSLRNDSAKVTVKDGPWGREVV
GTNTGVVRFIGVDGYRWMIRCVVNGPLETIDVLSEEARAALADTVVRRGDTPLPVRTPLPVQLPEQMAEQLREAAVAQQS
AQHADARQQSRELAPRRGAAGSAMQQLHNTTGG

>BL;ML1030, ML.tab 1195701:1196399 reverse MW:23579
VAVDLRNVTTVLLPGTGSDDDYVYRAFSGPLHRVGAAVLTPPPQPNRLIDGYLSALDDAARAGPIGVGGVSIGAAVAAAW	(SEQ ID NO:118)
ALAPERAVAVLAALPAWNGAPESAPAALAARYSASHLRRDGLAATTLQMQASSPPWLADELARSWCGQWPLLPDANEEA
AAYIAPSCAELARLATPLGVAAAVDDPIHPLQVGVDWVTAAPHAALQTVTLNQIGTNAAALGTACLAALALT

>BL;ML1037, ML.tab 1200579:1201133 reverse MW:19903
VSHEYWSTAVSCNPGIHHIVRLDVAJ4TPRTTQTYRHSMLAEDIAEDFPAISINSSALDAARMLAEHGLPGLLVTDMSDKP	(SEQ ID NO:119)
YAVLPASQVVRFIVPRYIQDDPSLAGVLNESTADQAAEKLSSKKVRDVLPDHLVNVSPVNADDTIIEVAATMSRQRSPLL
AVVKGGQLLGVITASRLLRAALKH

>BL;ML1O41, ML.tab 1206538:1207128 reverse MW:21153
VAPVTAAEPTPFREAVAAMNAFTVRPEIELGPIRPPQRLAPYSYALGAQVKHPELDIVPEQSEDNAFGRLILLYDPDGSD	(SEQ ID NO:120)
AWDGTIRLVAYIQSDLDSREAIDPLLPEVAWSWLIEALESRIDHVTALGGTVTATTSVRYGDISGPPRAHQLELRASWTA
TTPEVGVNVKAFCEVLENAAGLPPAGVIDLGSRSRS

>BL;ML1053, ML.tab 1220374:1220673 forward MW:10117
MPLFLNAEPQALTAAANTLEGLSAATVASNAAAAQLTTEIAPPAADDVSILLAHFFSGHGRQYQAHASQGATNHQDLIQS	(SEQ ID NO:121)
LLTSSSAYAGTETANIHDSL

>BL;ML1055, ML.tab 1221433:1221735 forward MW:11298
MTAAHFMTDPQAMRDMARKFDMHAQNVRDESHKNFMSSMDIAGAGWSGTAQLTSHDTMGQINQAFRHIVTLLQDVRDQLG	(SEQ ID NO:122)
TAADRYEHQEENSRKILSGS

>BL;ML1056, ML.tab 1221787:1222074 forward MW:10260
MGNINYQFGEIDAHGAAIRAQAAALETTHQAILATVRDAAEFWGGQGSTAHEMFIADLGRNFQMIYEQANSHGQKVQRAS	(SEQ ID NO:123)
SSMADTDRSVSSAWS

>BL;ML1065, ML.tab 1230644:1230988 forward MW:11933
VALVLLYLVVLVLVAIVLFGAASLLFGRGERLPPLPRGTTATVLPAHGVTGADVDAVKFTQVLRGYKPSEVDWVLDRLGR	(SEQ ID NO:124)
ELEALRGQLAAIADAEADADVSNVPSGDDGQDVT

>BL;ML1067, ML.tab 1231777:1232004 forward MW:7998
MLGAEWVREGGPARVWREHTMAAMKPRTGDGPLEATKEGRGIVMRVPLEGGGRLVVELTPDEAAALSDELKGVTS	(SEQ ID NO:125)

>BL;ML1077, ML.tab 1240278:1240697 forward MW:15219
VMADRGQVFRRVFSWLPAQFASQNDAPVGAPRRFGSTEHLSVEAIAAFVDGELRMNAHLRAAHHISLCAQCAAEVDDQSR	(SEQ ID NO:126)
TRAALRDSHPIRIPSTLFGLLTAIPRCSPDYTSPVSEPFSEGSVSDRFVDGVAREQGKR

>BL;ML1079, ML.tab 1242373:1242735 forward MW:13348
VFANIGWGEMLVLVVVGLVVLGPERFPGAIRWTLGALRQTRDYLSGVTNQLREDIGPEFDDLRGQFGELQKLRGMTPRAA	(SEQ ID NO:127)
LTKHLLDGDDSLFTGNFDRPAAAKQQDRDNHQTPFDTDAT

>BL;ML1093, ML.tab 1257729:1258586 forward MW:29736
MRVGRLAALLLAGVGVFVAGGCATDRGDRHPELVVGSKPDSESTLLAAIYVAALRSYGFGARGETGADPMAMLDSGGFTV	(SEQ ID NO:128)
VPGFTGKVLQILQPRAAVLSAARVYRANVSALPEGIAAGDYTTAAEDKPTLVVTPDTAKAWSGSOLSLVLSHCNELVVGI
VAGTHTPSAVGSCRLPAAREFPDYPTMFAALRAGQLTAGWTTTANPDLPADLIVLTDGKATLIQAENVVPLYRRNVLTDR
QMLAINEVAGVLDTAALIEMRRQVIRGADSQAIADGWLAEHPMGR

>BL;ML1096, ML.tab 1263932:1264606 reverse MW:23505
LAQVIERSVWIQGPAAEAYVARLRRTHPSASPTEIVAKLEKHYLAALTASGAVVGSVATLPGIGTLAAVSANAGETVFFL	(SEQ ID NO:129)
EATAVFVLTIASVYGIPANHRERRRALVLAVLAGDDTRLTIGELIGPGRTNGGWLLEGMASLPLSTWSQLHTRMLRYAAK
RCTVRRGALMFGKILPIGIGAAVGGAGNRVVGKKIISNTRNAFGTAPSRWPATLILLPTVHNAG

>BL;ML1098, ML.tab 1266648:1270106 reverse MW:126012
VFVTDETIVYSASDLAAASRCEYALLRDFDARLGRGPVVATTEDELFARTSALGADHEQRHLDQLRHEFGDAVAVIGRPA	(SEQ ID NO:130)
YTYAGFAAAAEATQRAIANRAPAVYQAANFDGRFVGFIDFLVRDGEQYRVVDTKLARSPKVTALLQLAAYADALAHSGVP
VAPEAELRLGDGMVVSYRICDLIPVYRSQRSLLQRLLDRHYTAGTAVRWQDDEVRSCFRCPQCTEQLRATDDLLLIAGMR
ISQRSKLLNVGITTIAELADHSGPVPDLSSSALSELTAQAKLQVQQRNTGTPQFEIVDPQPLALLPDPDPGDLFFDFEGD
PLWTVDGQEWGLEYLFGVLDSEISGTFRPLWAHNRVEERKALTEFLKMVTKRRKQRPHMHVYHYAPYEKTALLRLAGRYG
VCEDEVDELLRSGTLVDLYPLVSKSIRVGAESFSLKALEPLYMGKQLRSGDVTTATDSITCYGRYCELLSAGNFDEAATV
LKEIEDYNHYDCRSTRELRNWLLLQAYEAGVVPVGAQPVPEGNTVKDDDELSAILSALSGFTGDVAVGDRTPEQTAIALV
AAARGYHRREDKPFWWGHFDRLNFPVGEWADNTDVFVADDASIIIDWHTPPRARKPQRRVRLRGRLARGNLGSAVFALYD
PPAPLANDVHPGRRAAGRAEVVEADDLSIPTEVVIVERVGNDGNTFHQLPFALTPGPPIATTALRDSIESTATTLAASLP
QLPRTALIDILLRRIPRTHSGATLPRGTDTVADITAAVLDLDSSYLAVHGPPGTGKTHTAAHVITQLVSNHSWRIGVVAQ
SHAAVENLLDGVITAGLDARQVAKKRHDRSAPPWQEIDGNDYPTFIADPMGCVIGGTAWDFANRNRVPPGSLDLLVIDEA
GQFCLANTIAVAPAAANLMLLGDPQQLPQVSQGTHPEPVNTSALDWLVEGQRTLPNERGYFLDRSYRMHPAICAAVSTLS
YEGKLHAHTEYTAARRLNEYQPGVHVLAVHHQGNSTESPEEAGAITAEIERLLGTPWTDEHGTRPLDVSDILVLAPYNAQ
VALVRQQLMSAGFSGVRVGTVDKFQGGQAPVVFISMTSSSVEVVPRGISFLLNRNRLNVAVSRAQYAAVIVRSETLTEYL
PATPVGLIDLGAFLTLTTFNGTGRLESRLDKP

>BL;ML1099, ML.tab 1270157:1270765 reverse MW:20773
VRDVWSLPCRKSLLGVAAVVLVSGTLTGCSSGDSTVAKTPVPPSTTTGTISTIISSAPSPPFATAAPPTSNTPPDDPCAV	(SEQ ID NO:131)
NLASPTIARVVSELPRDPRSAQPWNPEPLAGNYNECAQLSAVIIKANTNAVNPTTRAVLFHLGRFIPQGVPDTYGFNGID
PAQTTGDTVALTYPSSIDGLATAVRFHWNGNAVELISNIAGG

>BL;ML1105, ML.tab 1279262:1279951 forward MW:24905
VLSGGAGSIPELNAQISVCRACPRLVDWREEVAVVKRRAFADQPYWGRPVPGWGSEQPRLLIVGLAPAAhGANRTGRMFT	(SEQ ID NO:132)
GDRSGDQLYAALHRAGLVNLPISMDAADGLQANQIRITAPVRCAPPGNAPTQAEWVTCSPWLEAEWRLVSEYVRAIVALG
GFAWQIVLRLPGVSANRKPRFSHGVVAQLYAGVRLLGCYHPSQQNMFTGRLTPANLDDIFRDAKKLAGI

>BL;ML1115, ML.tab 1291563:1292129 forward MW:19913
VRCDVRALALAARGLIELMIVIPMVAGCSNAGSNKSVGTISSTPGNTEGHHGPMFPRCGGISDQTMSQLTKVTGLTNTAR	(SEQ ID NO:133)
NSVGCQWLAGGGIVGPHFSFSWYRGSPIGRERKTEELSRASVDDININGHSGFIAVGNEPSLGDSLCEVGIQFQDDFIEW
SVSFSQKPFPSPCGIAKELTRQSIANSK

>BL;ML1116, ML.tab 1292138:1292701 forward MW:19839
MRLSVRGRRSVFAGVAVLVSAALVVTGCSRSIGGTAVKAGSHDVPRNNNSQQQYPNLLKECEVLTTDILAKTVGADSLDI	(SEQ ID NO:134)
QSTFVGAICRWQAANPASLIDITRFWFEQGSLANERKVADFLKYKVENRSIAGVDSIVMRPDDPNGACGVASDAAGVVGW
WINPQASGIDACGQAIKLMELTLATNS

>BL;ML1117, ML.tab 1292709:1293194 reverse MW:17617
MRHAKSSYPRGFPDHIADHDRRLAPRGVREASLAGGWLRTNVPAIEKVLCSTAMRARETLTHSGIEAPVRYTERLYRADP	(SEQ ID NO:135)
DTVIKEIKAISDEVTTSLIVSHEPTISAVALALTGSGTNNDAAQRISTKFPTSGIAVLNVAGRWQHLELESAELVAFHVP
R

>BL;ML1119, ML.tab 1294763:1295914 forward MW:41281
MRFLHTADWQLGMTRHFLAGDAQPRYSAARRDAVAGLGALAAEVGAEFVVVAGDVFEHNQLAPQVVSQSLEAIRAIGIPV	(SEQ ID NO:136)
YLLPGNHDPLDASSVYTSALFTAECFDNINVLDRAGVHQVRPGLEIVAAPWRSKAPTTDLVAEMLGGLTADIVTRVLVAH
GSIDVFDPDRDKPSLIRLAGIDDALAGGAVHYVALGDRHSLTQVGSSGRVWYSGSPEVTNFDDIESNSGNVLVVEIDEND
PRRPVTVTARHVGHWRFFTLHWQVDNGRDIADLDMNLDQMMDKDRSVVRLALTGSLTITDRAVLDACLDRYARLFAWLGL
WERRSDLAVIPADGEFTDIGIGGFAAAAVDELVATAREGDTESAIDAQAALALLLRLADRGVA

>BL;ML1120, ML.tab 1295911:1298532 forward MW:94011
MKLHRLALTNYRGTARREIEFPDRGVILVCGANEIGKSSMIEALDLLLEFRDRSTKKEVKQVKPANADIGSEVCAEISSG	(SEQ ID NO:137)
TYRFVYRKRFNKKCETALTVLAPHREQLTGDEAHERVRAMLAETVDNDLWHAQRVLQAASTAAVDLSGCDALSRALDLAA
GDHAELSGTEPLLIERIEAEYRRYFTSTGRPTGEWAVAISRLSDAETAVGECAAAVAEVDDRVRRHAVLTERVAGLAQQR
FAAGPRLAVAQAAADKVAVLTRQAREAELVAAAATATNAAAVAAHTSRLRLLAEIDTRAVVLAATQDEAQEAVDAVSTMR
ADAEASDAAVEESTEALMAAQQRADIARSTVDQLVDRQEADRLSTRLAKIDAIQGERDLICAELSAVTLTEQLLQRIENA
AAIVDRTGEQLKLISAAVEFTATADIEISVGQQRVSLEAGQSWSTTATGPTEVEVLGVLTACVIPGATALDAQSKYVAAQ
EELSVALADGGVVDLAAARCANQRRRELQSSLDQLSAALAGVCGDDQIDQLRARLEQLRDGYPGEPDLLAVDIGSARAEL
EAAETVRAAVDFEREVCRRTAAAANCRLVETSARANFLLKKAETQRAELDQDIDQLAQQRASVSDEDLASAAEAGLRAVQ
IAEQRVAKLTEELVAAEPEAVTAELVAATAAAESLRDQHEDAAGALREISIELSVFGTEGRQGKLDTAEAEREHAISQNT
QIGRRARAAQLLRSVMARHRDTTRLRYVEPYRTELQRLGRPVFGPTFEVDIDSDLRIRSRTLDGITVPFESLSGGAKEQL
GILARFAGATLVAKEDNVPVVVDDALGFTDPDRLAKMGEMFDTVGAHGQVIVLTCSPDRYDGFTGAHRIDLNV

>BL;ML1138, ML.tab 1329962:1330423 forward MW:16168
VTTPAQDAPLVLPAVAFRPVRLFIINIVLTGLANLAAGLSGHLMVGVFFGIGLLLGLLNALLVRCSVESITAQGHPLKRS	(SEQ ID NO:138)
MALNSASRLAIITVFGLIIAYAFPLAGLGVVFGLALFQVLLVLSTMLPVWRKFRFGEADGGVLKGSEGEEQQR

>BL;ML1147, ML.tab 1337937:1338380 forward MW:16518
MSAPMVGMVVLVVTLGAAVLALSYRLWKLRQGGTAGIMRDIPAVGGHGWRHGVIRYRGEAAAFYRLSSLRLWPDRRLSRR	(SEQ ID NO:139)
GVEIVARRGPRGDEFDIMTDKIVVLELRDTTQDRRSGYEIALDQGALAAFLSWLESRPSPRTRRRSV

>BL;ML1159, ML.tab 1354280:1355185 forward MW:31923
MAGAVDLSGLKQRARQKASTSDPASRATLGARGTGSSENTSVIEITEANFEDEVLVRSHEVPILVLVWSPRSDACVKLLE	(SEQ ID NO:140)
TLSGLAVADSGTWLLATVNVDAVPRVAQIFGVDAVPTVVALAAGQPLSSFQGMQSVDQLRRWLDSLLSVTAGKLRGPTRS
EDSAEIDPAIAQARQQLEAGDFLTAKQSYHAILDADPASVEAKAAIRQIDFLTRATAQHPDAVAVADAAPGDIAAAFAAA
DVQILNQDVTAAFERLIVLVRSTSGDERSSVRTRLIELFELFDPDDPNVIVGRRNLANALY

>BL;ML1166, ML.tab 1364964:1365551 forward MW:21484
VRKWKRVETANGPRFRSVVAPHEVALLKHLVGALLGLLNERESSSPLDELEVITGIKAGNAQRPEDPTLRRLLPDFYTPD	(SEQ ID NO:141)
DKDQLDPAALDAVDSLNAALRSLHEPEIVDAKRSAAQQLLDTLPESDGRLELTEASANAWIAAVNDLRLALGVILEIDRP
APERVPAGHPLSVIIFDVYQWLTVLQEYLVLALMAT

>BL;ML1176, ML.tab 1372485:1372844 reverse MW:13792
MTRPETPQAPDFDFEKSRTALLGYRIMAWTTGIWLIALCYEIVSNLVFHHEIRWIEVVHGWVYFVYVLTAFNLAIKVRWP	(SEQ ID NO:142)
IGKTVGVLLAGTVPLLGIIVEHFQTKflVKTRFGLRRSRT

>BL;ML1177, ML.tab 1372841:1373221 reverse MW:14447
VSTTRRRRPALVALVTIAACGCLALGWWQWTRFQSASGTFQNLGYALQWPLFAGFCLYTYHNFVRYEESPPQPRHMNCIA	(SEQ ID NO:143)
EIPPELLPARPKPEQQPPDDPALRKYNTYLAELAKQDAENHNRTTT

>BL;ML1180, ML.tab 1380300:1380587 reverse MW:10260
MGNINYQFGEIDAHGAAIRAQAAALETTHQAILATVRDAAEFWGGQGSTAHEMFIADLGRNFQMIYEQANSHGQKVQRAS	(SEQ ID NO:144)
SSMADTDRSVSSAWS

>BL;ML1181, ML.tab 1380639:1380941 reverse MW:11298
MTAAHFMTDPQAMRDMARKFDMHAQNVRDESHKMFMSSMDIAGAGWSGTAQLTSHDTMGQINQAFRHIVTLLQDVRDQLG	(SEQ ID NO:145)
TAADRYEHQEENSRKILSGS

>BL;ML1182, ML.tab 1381004:1382269 reverse MW:43120
MFDFAALSPETNSTRMYLGPGSSPILTAAAAWVVLAKELTAAAQGLQSAVEALLTTFEGESAAALAERVTPYEKWLTQNA	(SEQ ID NO:146)
ASAELTATQLTVAANAYETAFTMTVPPLMVFVNRAQACLLIMSNIFGQNSTAIAEKEAEYTEMWIQDAAAMTSYQASVLE
AVGATKAFTAPPLGVNEVGLAQEVVEEVVEEVVEEVVEEVVEAEQAISQAALDQAVNEGMEATVVPQVDQQVNVDVATPQ
TAVPDSSSAAAPQLWGGFAQHLSPINDTLSMINNHAGMANAGLSLVNGMGSANKSLAPTTTKAAESAFKANGSAVQSTGR
GLLGSSSGGHVTAQLGRAASIGSLRVPQTWTTASQPVTAATRALSPARVAVATESESAPLLGGGLPMAPMVPGGGSGTGG
VNTALRLQPRAFVMPRNPAAG

>BL;ML1183, ML.tab 1382326:1382625 reverse MW:10117
MPLFLNAEPQALTAAANTLEGLSAATVASNAAAAQLTTEIAPPAADDVSILLARFFSCHGRQYQAHASQCATNHQDLIQS	(SEQ ID NO:147)
LLTSSSAYAGTETANHDSL

>BL;ML1190, ML.tab 1395291:1396010 forward MW:25342
MSVSRRDVLKFATVTPGLLGLGVAAAALCAVPASTAGSLGTLLDYAAGVIPASQIRATGAVGAIRYVSDPRGTWAVGKPI	(SEQ ID NO:148)
QVTEARDLINNGLKIVSCYQYGKGNTADWLGGATAGLRHAQRGVQLHTAAGGPVSAPIYASIDSNPTYEQYKQQVAPYLR
SWESVIIGHQRTGVYANSRTIAWALQDGLASYFWQHNWGSPKGYTHPAANLHQVEIDRRTVGGVGVDVNTILKPQFGQWA

>BL;ML1221, ML.tab 1443565:1443807 forward MW:8793
VVQDLPTPIGAGIYNIYTGVHRDELAGASMPTVAQLGLEPPRFCAECGRRMVVQVRPDGWRAKCSRHGQVDSVDMEAKR	(SEQ ID NO:149)

>BL;ML1222, ML.tab 1443804:1444400 forward MW:20601
VTEHCASDISDVSCPPRGRVIVGVVLGLAGTGALIGGLWAWIAPPIHAVVGLTRTGERGHDYLGNESEHFFVAPCLMLGL	(SEQ ID NO:150)
LTVLAVTASVLAWQLRQHRGPGMVIGLAIGLMICAATAAAVGALLVWMRYGALNFDAVPLSYDHKVAHVIQAPPVFFAHG
LLQVAATVLWPAGIAALVYAVLAAANGRDDLGGRLCSR

>BL;ML1232, ML.tab 1465612:1466688 reverse MW:38687
MKRLLATTLAALTVGTVSGFGSTVASSEPGEPWLPPSPVPVRENSPAKIVYALGGARPPTFDWDYYTIRAGDEFFPDVNR	(SEQ ID NO:151)
KLIDYPARAPFRYVPTFLVPGPRDEVTIGEAIAVATKNLNQAIHRGTEPAAVVGLSQGSLALDTEQEQLATDPTAPPPDQ
LTFNTFGDPSGYHGFGKSVLASIFRPGDYIPLIDYTMPQRMDSQYDSNRVVAAYDGLSEFPDRADNLLAQLNCFAGGAIS
HTPSGFFNPEDVPPQNIRTTVNSRGAKTTTYLIPVNHLPLTLPLRYLGWSDALVDQIDAVLQPKIDAAYAYNDNPLNKPI
SVDPVNGMDPIAGIDAELRDSILNVFAQLRSILPPPPG

>BL;ML1233, ML.tab 1466853:1467545 reverse MW:24400
MWITILLMAIAISLEPFRIGMTVLMLNRPRPTLQLLVFLCSGFTMGMTVGFVVLFVFRRRLMASMQLTLPKVQILIGVLA	(SEQ ID NO:152)
LLVAAVLTVQVCISSEPPAESPVDSASGPPKPSKWAPRPLARLLNGDSLWVAGVAGLGIALPSVDYLAALAVILTSGAAA
TTQVGALLMFNVVAFALIEIPLAAYLLAPDTTRAWTAALNNWIRSRRRLEVATLLAGVSCLLLAVGIAGL

>BL;ML1244, ML.tab 1482817:1484292 forward MW:52449
MADSVEGIGPFDELGALDYLLHRGEANPRTRAGIMAVELLDTTPDWNRFRSRIEDVSQRVLRLRQKVVVPTLPTAAPRWV	(SEQ ID NO:153)
VDPDFELDFHVRRVRVPDPGTLREVFDLAEVIQQSPMDVSRPLWTATLVEGLAAGRAANLLQISHAITDGVGSVEMFAENI
YDLERDPPSRPRSPQPIPQDLSRNDLMLQGINHLPVALAGGVXTGGLSGVASVAGRAILRPASTVSGVVGYVRSGIRVLSQ
AAEPSPLLRQRSLATRTEAIEIQLSDLHKAAKAGDGSINDAYLAGLVGALRRYNEALGVSISTLPMAVPVNVRTEADVVG
SNRFVGVTLAAPLGTNDPAARMQKIRSQMTQRRDEPAMNIIGSLAPLMTVLPASVLDFIVDSVASSDVNASNIPAYPGDT
YFAGAKILRQYGIGPRPGVAMMAVLMSRGGFCTVTVRYDRASVKSEALFARCLLEGFDEVLALAGDPTPHAVPASFAARS
SGSPAGWLSSS

>BL;ML1249, ML.tab 1490899:1495767 forward MW:177878
MTIDPGATHVAELCTTFTQGADVPDWISKAYIDSYRGSHGDVREAPETSRVNPNALVTPAMLSAHYRLGQCRPNGRNCVR	(SEQ ID NO:154)
VYPADDPAGFGPALQIVTDHGGMVMDSITVLLHRLGVTYTAMMTPVFMVLRSPTGELLGVEPRASSTSHSIEGTWVGEVW
IYIQLLPAVDSKSLAEVEQLLPRTLVDVQRVAADAAALNATLSGLAADVKTNKEGHFSASDRDDVAALLHWLGNGNFLLL
GYQRCRVHYGLVSCDRSTGLGVLRARTGSRPRLTDDNELLVLAQAAVGNYLRYGAYPYAIAVREYDDGGDCGIIEHRFVG
LFTVAAMNADVLEIPSISHRVRAALAMANSDPIYPGQLLLDVIQTVPRSELFTLSAERLFTMAKEVVDLGSGRRALLFLR
ADRLQYFVSCLVYVPRDRYTTGVRLQIEDILVREFGGTQVEFTARVSESPWALMHFMVRLSEGAATGSVDVSEGNRIRIQ
AMLSEAARTWSDRLIAAAASFSEGSVSYAEAEHYAATFSETYKQAVTPADAIDHIAIIKELADDSVKLVFFERKADGFAQ
LTWFLGGRSASLSQLLPMLQSMGVVVLEERPFTVARTDGLPVWIYQFKISPHPTIPLASTANERELTAKRFSDAVTAIWQ
GRVEIDRFNELVMRARLTWQQVVLLRAYAKYLRQAGFNYSQSYIESVLNEHPSTARSLVALFEALFDPSPLSSSTNCDAQ
AAAAAVAADIDALVSLDTDRILRAFASLVQATLRTNYFVTQKFSARSKGVLVLKLDAQLINELPLPRPKFEIFVYSPRVE
GVHLRFGAVARGGLRWSDRLDDFRTEILGLVKAQAVKNAVIVPVGAKGGFVLKRPPLPTGDAAADRDAMRAEGIACYQLF
ISGLLDITDNVDHATGKVNAPPQVVRRDSDDAYLVVAADKGTATFSDIANDVAKSYGFWLGDAFASGGSVGYDHKAMGIT
AKGAWEAVKRHFREMGVDTQNEDFTVVGIGDMSGDVFGNGMLLSKHIRLIAAFDHRHVFLDPDPDAAVSWAERQRMFDLP
RSSWDDYNKSLISEGGGVYSREQKAIPTSPQVRTALGIDGEVTEMAPPNLIRAILQAPVDLLFNGGIGTYIKAETESVAD
VGDRANDPVRVNANQVRAKVIGEGGNLGVTALGRVEFDLSGGRINTDAMDNSAGVDCSDHEVNIKILIDSLVTAGKVKVE
ERKHLLESMTDEVARLVLTDNEDQNDLIGTSRANAANMLSVHAMQIKYLVDERGVNRELEALPSEKEIQRRSEAGIGLTS
PELSTLMAHVKLALKEQMLATELPDQOVFVSRLPRYFPKPLRERFTPEIRSHQLRREIVTTMLINDLVDTAGISYAFRIA
EDIGVGPIOAIRTYVATDAIFGVGOVLRRIRAANLSVVLSDRMTLDTRRLIORAGRWLLNYRPQPLAVGAEINRFAAKVK
ALTPRMSEWLRGODQAIVEQQATEFVSQGAPEDLAYRVAVGLYRYSLLDIIDIADITELDPAEVADTYFSLMDRLGTDGL
LTAVSKLPQNDRWHSLARLAIRDDIYASLRSLCFDVLAVGEPDESGEEKIAEWEHISASRVERARLMLAEIHASGEKDLA
TLSVAARQIRRMTRTSGRGSSG

>BL;ML1255, ML.tab 1499768:1500259 forward MW:16842
MGNQSSQSEVAPVVRGDVVTELPKGWVITTSGRVSGVTEPGDRSVHYPFPIKDLVALDDALTYSSRASHARFAVYLGDLG	(SEQ ID NO:155)
NDTAALAREILAQVPTPDDAVLVAVSPNQCAIEVVYGSQVRGRGAESAAPLGVAAASSAFEQGNLIDGLISAVRVLSAGI
SRS

>BL;ML1270, ML.tab 1513725:1514522 forward MW:27833
VMAPDIKSARAGRLTIQIAQLLLVVAAGALWMAARLPWVVIRSFDGLGPPKEVALSGASWSAVLLPLALLMLAATVAAIA	(SEQ ID NO:156)
VRGWPLRVLAGLLAVASFLVGYLGVSLWVLPDVTVRGAVLAHVSLLSLVGSQRHHLGAGAAVAASGCTLIAAVLLMRSAS
VIGSARQGTSKYVVPAQRRSIARRDGAATAISQMSERMIWDALDEDRDPTDRLREPDTEGRWWTACRRSLPFMNVVEIGG
CTGSVAGRWVTSGKGNDTHVSGNCA

>BL;ML1296, ML.tab 1545740:1546075 forward MW:12349
MYRFGMRYLDSMTVDRHVAGNEFTVEEISTGIFASGYGQVGDGRSFSFHIEHWSLWEIYRTRLAGLVPQTEEVVPRA	(SEQ ID NO:157)
IRGLVNIDLTDERSLAAAVRDLVARTLTVSG

>BL;ML1299, ML.tab 1547791:1548381 forward MW:21454
MARAIHVFRTPDRFVAGTVGQPGNRTFYIQAVHDSRVVSVVLEKQQVAVLAERIGALLLEVHRRFGTPVPPEPAEINDLN	(SEQ ID NO:158)
PLVMPVDAEFRVGTMGLGWDSEAQTVVVELLAVTDAEFDASVVLDDTDEGPDAVRVFLTPESARQFATRSNRVILAGRPP
CPLCDEPLDPEGHVCARTNGYKRSALLGPKDDDTEW

>BL;ML1300, ML.tab 1548392:1549180 forward MW:28681
VLRNGELTVLGRIRSASNATFLCESTLDQRSVHCVYKPVSGEQPLWDFPEGTLAGRELSAYLVSTDLGWNIVPYTVIRDG	(SEQ ID NO:159)
PAGPGMLQLWVQQPGDVADSAPRSGPDMVDLFPADKLQSGYLPVLRSYNYAGDEVILMHADDTQLRRLAVFDVLINNADR
KGGHILYGLDGHVYGVDHGVSLHVEDKLRTVLWGWAGKPIDNQTLEEVAGLADALSGPLADTLAGQITWAEIIALRRRAY
ANLDNPVMPGPNRDRAIPWPAF

>BL;ML1306, ML.tab 1555819:1556643 reverse MW:30377
VAAFEGWNDASDAASGALEHLNAVWEADPIVEIDDEAYYDYQVNRPVIRQVDGVTRELVWPAMRISYCRPPGSDRNVVLM	(SEQ ID NO:160)
HGVEPNMRWRTFCTELLTIADRLNVDTVVILGALLADTPHTRPVPVSGAAYSPESARRFGLEETRYEGPTGIAGVFQDAC
VAARIPAVMFWAAVPHYVSHPPNPKATVALLRRVEDVLDVEVPLADLPTQAEDWEQAITEIAAEDDELAEYVHSLEQRGD
AEVDVNDALGKIDGDALAAEFERYLRRRRPGFGR

>BL;ML1315, ML.tab 1567372:1567956 reverse MW:20428
VSRWTHRTFFIALSAIVTTAGFGSSGCAHGNSSTSESAVPSTFPGISSSITAPPATGLPAPEVLTNVLSRLADPNIPGID	(SEQ ID NO:161)
KLPLIESATPDSAVTLDKFSNALRONGYLPMTFTANNIAWSNKNPSDVLATISVNIAQTNNSVFSFPMEFTPFPPPQQSW
QLSKRTADMLLEFGNSSGLTNPAPIKAPTPTPSH

>BL;ML1321, ML,tab 1575493:1575684 forward MW:7067
MAQEQTRRGGGGDDDEFTSSTSVGQERREKLTEETDDLLDEIDDVLEENAEDFVRAYVQKGGQ	(SEQ ID NO:162)

>BL;ML1334, ML.tab 1587322:1588140 forward MW:29047
MSEPQGSDPGKQWQSPGEGVENHSSDQPTQAASPWQQQPSTQDSTWHPPAYASPECYNYPQLTEPVYPHQYPSATPGYGQ	(SEQ ID NO:163)
PGYFGAQFSQCGIPGQYPQSGSPGQYGSPGQYGPPGQYGPPGQYGPPGQYGPPGQYGPPGQYGPPGQYSQQFQPYEQPGT
KGFVALIGSIAGVIGVLIFAAILVTGFLWPAWLVTTKLDVNKAQASVQQVLTDETNGYGAKNVKDVKCNNGADPTVKKGD
TFDCSVSIDGMQKRVTVTFQDDKGTYEVGRPQ

>BL;ML1338, ML.tab 1595449:1596771 reverse MW:50163
VYGALVTAADSTQTGLRNWLLAVFHPRTHTPSTATIVRSALWPAAILSVLHRSTVITTNGNITDDFKPVYRAVLNFRHGW	(SEQ ID NO:164)
DIYNEHFDYVDPHYLYPPGGTLLMAPFGYLPFAPSRYLFILINTGAILIAWYLILRLFKYTLSSVAAPTLLLAMFCTETV
TSTLVFTNINGCIMLLEVLFLWWLINGSEPKTVSQQWWAGGAIGLTLVLKPLLGPLLCLPLLNRQWQALVPAIALPVVIN
LAALPLVSHPMDFFTRTVPYILGTRDYFNSSIEGNGVYFGLPTWLIVFLRLLFTVLAICSLWLLNRYYRTRDPLFWFTCS
TGVLLLWSWLVLPLAQGYYSMMLFPFLMTVVLPNSLIRNWPAWLGIYGFLTLDRWLLFNWMRYGRALEYLKITYGWSLLL
IVVSTVLCFRYLDAKAENRLDHGIDPAWLTAERERASVNA

>BL;ML1357, ML.tab 1617916:1618101 forward MW:6609
MTIDPDQIRAEIDALLAQLPDFADLEDSVSGLSLAQLEEVALRFSEVHSVLLQALESAEKG	(SEQ ID NO:165)

>BL;ML1361, ML.tab 1621823:1623004 forward MW:42405
MRMSALLSRNNSRPGLVGTARVDRNIDRLLRRICPGDIVVLDVLDLDRITADALVEADIVAVVNASPSVSGRYPNLGPEV	(SEQ ID NO:166)
LVNNGVTLIDETGPEVFKKIKDGAKIRLHEGGVYSGDRRLICGTERTDHDIADLMREAKSGLATHLEAFAGNTIEFIKSE
SPLLIDGIGIPDIDVDLRRRHVVIVADEPSAADDLKSLKPFIKEYQPVLVGVSGGADVLRKAGYRPQLIVGDPEQISTEA
LRCGAHVVLPADADGHAPGLERIQDLGVGAMTFPAAGSATDLALLLADHHGAALLVTAGHTANIETFFDRTRTQSNPSTF
LTRLRVGEKLVDAKAVATLYRNHISFGAIALLALIMLIAVIVALWVSRTDGVVLNGVIDYWNRFSLWIQRLIA

>BL;ML1362, ML.tab 1623026:1623979 forward MW:32360
MISLRQHAFSLAAVFLALAVGVVLGSGFLSDTLLSSLRDEKRDLYTQISGLNDQKNMLNEKVSAANNFDNQLLGRIVHDV	(SEQ ID NO:167)
LGGTSVVVFRTPDAKDDDVAAVSKIVVQAGGTVTGTVSLTQEFVDANSTEKLRSVVNSSILPAGAQLSTKLVDQGSQAGD
LLGITLLVNANPAVPNVGDAQRSTVLVALRDTGFITYQTYNRNDHLGAANAALVITGGLLPQDAGNQGVSVARFSAALAP
HGSGTLLAGRDGSATGVAAVAVARADAGMAATISTVDNVDAEPGRITAILGLHDLLSGGHTGQYGVGHGATSITVPQ

>BL;ML1389, ML.tab 1665174:1666757 reverse MW:57894
VTSIMSVSALEQSAADVGDNSARQHAHGALPDSLAIAMLATVISGAWASRPSLWFDEAATISASASRTVPELWRLLSHID	(SEQ ID NO:168)
AVHGLYYLLMHGWFAIFPSTEFWSRVPSCLAIGAAAAGVTVFTRQFATRTTAVYAGIVFAILPRITWAGIEARSSALSVA
AANWLTVLLVASVQRNRPRLWLCYALTLMLSILLNLTLATLVLVYAVILPWLAPNKFRNSPFIWWAVTSVVALGTITPFI
LFAHGQVWQVDWIFRVSWHYVFDITQRQYFDHSVSFAIATAVIIVPAIATRLAGLRAPAGDLRSLVIICTAWIVIPTTLM
VGYSAVIEPVYYPRYLILTAPAAAIVIAVCIVTVARKPWPIAGVLVLFAVAAFPNYLFTQRGRYAKEGWDYSQVADVISS
QAAPGDCLIVDNTVPWRPGPIRALLAARPAAFRSLIDIERGFYGPTVGTLWDGHVPVWLVTAKINKCSTVWTVSDRDTSL
PDHQAGQLLSPGLILGRAPAYQFPSYLGFRIVERWQFHYSQVIKSTR

>BL;ML1399, ML.tab 1679214:1680188 forward MW:34653
LPPSAKSTYPGQVEGAPHDGTPSAPQEPDEDTVTVPAPALIRRSSVSMPNAAQWLHTTNRSPRLVANVRRARRLLPGDPD	(SEQ ID NO:169)
FGDPLSTAGEGGPRAAARAADRLLGDRGAASREVSLSVLQVWQALTEAIARRPVNPEVTLVFTDLVGFSGWSLQAGDEAT
LALLRQVARAVESPLLDAGGHIVKRMGDGIMAVFRDPSVAVQAVLAATEAMKSVEVGGYTPRIRVGIHTGRPQRLAADWL
GVDVNIAARVMERATKGGIMISGPTLDLIPQSDLKELGIITRRVRKPMFTSKFTGIPPDMVIYRIKARRELTASDETAQT
NSLT

>BL;ML1439, ML.tab 1733347:1733682 forward MW:12946
MADRVLRGSRLGAVSYETDRNHDLAPRQIARYRTDNGEEFEVPFADDADIPGTWLCRNCMEGTLIEGDLPEPKMVKPPRT	(SEQ ID NO:170)
HWDMLLERRSIEELEELLKERLDLIRSRRRG

>BL;ML1444, ML.tab 1738595:1739293 forward MW:25220
MTKIQIDAPDGPIDALLSVPPGPEPWPGVVVIHDAIGYEPDKESTNNHIAMAGYVAITPNLYSRGSRARCITRVMRELLT	(SEQ ID NO:171)
KRGRAFDDILATRDYLLAMPKCSGRVGIAGFCMGGRFALVMSPKGFDASAPFYGTPLPRNLSETLNGACPIVASFGGRDP
LGIGAPKRLRQATQTRHITTDIKVYPDAGHSFANKLPGQPLMRITGFGYNQAATEDAWSRVFAFFDKHLRTD

>BL;ML1446, ML.tab 1740098:1740484 reverse MW:13769
VTPTFADLAKAKYILLTTFTKDGRPKPTPIWAAADGDRLLAISAGKAWKVKRIRNNPRITLATCNVRGCATSAGVQGNAT	(SEQ ID NO:172)
ILDKLQTGSVYDAICKQYGIQGRLFNFVSKLRGGMQNNVGLELRVSGS

>BL;ML1470, ML.tab 1768618:1768989 reverse MW:12909
MTDSPGEHGPQKPLPSADPWKSFAGVMAAILFLEAIVVLLALPVLGASGGLTLSALSFLIGLAGLLIVLVGLQRKAWAIW	(SEQ ID NO:173)
VNLGVQVVVLVGCAVYPVLGFVGVLFAGLWALIVYFRAEVSRR

>BL;ML1485, ML.tab 1787915:1788538 reverse MW:23064
MPEKASVKYQADLWFDPLCPWCWITSRWILEVEKVRDVEVHFHVMSLAILNENREDLTENYLENITKAWGPARVVIAAEQ	(SEQ ID NO:174)
ANGASVLDPLYTAMGIRIHNEDNKNLDEVIKRSLADTGLPAELAAAAQSNAYDDALRESHHAGMDPVGDDVGTPTVHVNG
VAFFGPVLSKIPRGEEAGKLWDASLTLAAYPHFFELKRTRTEPPQFA

>BL;ML1494, ML.tab 1801370:1801723 reverse MW:12353
MRIVVLVLFAADGVLSAVVGANLMPLYIGSVPFPISGLISGLVNAVLVWAARLWTRSPWLVALPLWVWLLTVGLLSLGGP	(SEQ ID NO:175)
GVDVVSGQSVMASGALWLILLGVSPPACVLWRCNRYG

>BL;ML1503A, ML.tab 1815091:1815375 forward MW:10624
MTVLTDEQVDAALLDLNDWKHTDGALCRSIKFPTFLAGIDAVCRVAEHAETKDHHPDIDIRYRTVTFILVTHYADGITKK	(SEQ ID NO:176)
DITMARDIDRLIGD

>BL;ML15OS, ML.tab 1816758:1817306 forward MW:17516
MATIWTYLRATAIVVGSSAALLTGGIAHADTAPAPAPAPAPAPAPALNIPQQLISSAANAPQILQNLATALGATPPVTPS	(SEQ ID NO:177)
APGISFPGLTPAAATVPTSSAATLPSLPGIMAPAISNTPTTPGLPASTPGFPQARVDMPAMPPLPVSVPPQISLPGDLQA
LASSASAAAAPVAAPTLLSALP

>BL;ML1506, ML.tab 1817334:1818380 forward MW:34620
LKTGGFVTSAWNLPKGLVAVVTASTAAFGLCQNAAADPANPYGTPPNPTQQLPGLPALAQLSPIVQQAANNPQQATQLLM	(SEQ ID NO:178)
EAVSALTQNPTAPIASKNLATSVSQFMQEPNNPNPGASALDIPTSGVPAPAANGITPLDVVLVPHLPSAGAEPGAQAHLP
TGIDPVHAAGPATAATPTPGSPTNRTAAPPTPVASPAPTTPELPATTPGFGPDAPPTQDFIYPSISTNCLADGSSSIATA
LSVAGPAKIPLPGPGPGQAAYVFTAVGTPGPADVQKLPLNVTWVNLTTGKSGSATLKPRPDINPEGPTTLTVIADTGSGS
IMSTIFGQVTTKEKQCQFMPTIGSTVVP

>BL;ML1508, ML.tab 1819557:1820048 reverse MW:18221
MRFGASLLRVRRRLYGMGSQVFDDKLLAVISGNSIGVLATIKRDGRPQLSNVQYHFDPRDLAVRVSITEPGVKTRNLRRD	(SEQ ID NO:179)
PRASILVDVDDGWSYAVAEGTAELTPPAAAPDDDTVEALIVLYRNIVGEHLDWDEYRQAMVTDRRVLLTLPILHVYGLPP
GIR

>SL;ML1525, ML.tab 1840011:1840466 reverse MW:15892
MTKTLLVVHHTPSPTTRELLEAVLAGANDSEIDGVEVVSRPALAATIPDMLNADGYLFGTTANFGYMSGALKHFFDTVYY	(SEQ ID NO:180)
PILDNVSGRPYGLWVHGMNDTVGAAVAVGKLATGLSLTHAADVLEVVGPVDAMVCERAHELGGTLAAMLME

>BL;ML1526, ML.tab 1840474:1840956 reverse MW:17670
MNDTVMTKRSLYILYIQLLIAALCFANLAYLVLLGRMAVANIGSGQAAAVSLGLALLIMPVIGLWANIATLRAGFAHQKL	(SEQ ID NO:181)
ARLIAADGMELDTSVLLRRPSGRIQRDAADALFATVRAELAGDPDNWRCWYRLARAYDYAGDRRRAREANKTALELHGRD

>BL;ML1537, ML.tab 1853559:1854764 reverse MW:43686
MKAQRRLGLALSWSRVTTVFVVAIVVLVLASHVPELWQAGHHVAWCVGVGITVVVMVLVLVSYHGITLMSGLATWVWDCF	(SEQ ID NO:182)
ADPRAALAAGCTPAIDHQRRFGRDVVGVREYKGRLVTVIAVDDGEDDPVGRHRHRTTPAGLPVQAVADGLRQFDIRLDSI
DIVSVKIRRGGNAAKFSALDNWGSEEWGLVCACPPTYQRCTWLVLRMNPQHNVVAVAARDSLASTLVAATERLAQDLDGQ
NCAARPLAAGELAEVDSAVLADLEPTWSYPGWRHIKYVNGFATSFWVTPSDIDSETLNELWLSDLPDIKATVITIRLASR
SCQTRLSAWVRHHSETRLSKEACRGLNQLTGRQLAAVRASLPAPATRPVLVVPSRELSDHDELVLPVGQGREGSASLFAG
Q

>BL;ML1540, ML.tab 1858295:1859197 reverse MW:32551
MDHQSTRTDITVNVDGFWLLQALLDIRHVAPELRCRPFVSTDSNDWLHEHPGMAVMREQGIVVNGNVNEHVATRMRVFAA	(SEQ ID NO:183)
PDLEVVALLSRGKLLYGAVNDENQPPGSRDIPENEFRVVLVRRGSHWASAVRVGNDITIDDVAIADSASITSLVMDGLES
IHHADPAAINAVNVPLEEMLEATKSWQDAGFNVFSGRDLRRMGISAATVAALGQALSDPAAEAAVYARQYRDDAKGPSAS
VLSLKDSSSGRIAIYQQARTAGLGDAWLAICPATPQLVQLGLKTVLDTLPYGDWKTHSRV

>BL;ML1544, ML.tab 1866369:1867889 reverse MW:53849
VAEESSGRRGSEYGLGLSTRTQVTGYQFLARRTAMALTRWRVRMEVEPGRRQTLAVVASVSAALLGCLGALLWSFISPSG	(SEQ ID NO:184)
QLNESPIIIDRDSGALYVRVGDRLYPALNLASARLITGRPDNPHAVRSSQIATLPHGPLVGIPGAPSELSPETPQTSSWL
VCDTVATSTGIGSSSGVTVTVIDGSPDLSGHRRVLTGSDAVVLHYGGDAWVIRQGRRSRIDAMNRSVLLPLGLTPEQVSQ
ARPMSRALFDALPVGPDLVVPDVPNEGNPASFPGAPGPVGTVIVTPQISGPQQYSLVLADGVETVSPLVAQIMQNAGKPG
NTKLITVAPSVLVKMPVVNKLDLSVYPDTPLQVVDLRENPSTCWWWERTAGESRSRIQVITGSTIPINSADVKKVVSLVK
ADTTGREADQVYFGSNYANFVAVTGNNPAAQTTESLWWVTRTGARFGVEDTKDVRDALGLNGTPNLAPWVALRLLSQGPT
LSRADALMEHDTLPMDMTPAELVVPK

>BL;ML1548, ML.tab 1872638:1873603 reverse MW:37427
VAKQEPMCGVEPTLWAISDLHTGHVGNKPVAESLYPLSPDDWLIVAGDVAECTDEIRWTLELLRRRFAKVIWVPGNHELW	(SEQ ID NO:185)
TTNRDPMQIFGRARYDYLINMCDQMGVVTSEHPFPLWTERGGPATIVPMFLLYDYTFLPTGADSKAKGLAIARERNVVAT
DEYLLSSEPYATREAWCRDRLDVTRSRLEQLDWMTPTVLVNNFPLVREPCDALFYPEFSLWCGTTKTADWHIRYNAVCSV
YGHLHIPRTTWYNEVRFEEVSVGYPREWRRRKPYSWLRQVLPDPQYAPGYLNDFGGHFVITSEMRAQAVQFRERLRQKQS
R

>BL;ML1557, ML.tab 1883016:1883336 reverse MW:11540
VRTCVGCRKRELAVELLRVVAPSTGKGSYAVIVDTASSLSGRGAWLHPDMQCVQQAIRRRAFTGALRIAGSPDTSAVVEH	(SEQ ID NO:186)
IEFLSELDRPGNRTGSKEHEHTVKSR

>BL;ML1560, ML.tab 1885239:1885775 forward MW:17494
MLLVPSAVPVINRRGVLAGGATLTVLGVCFSACSKSPSKTPEIEELLGPLDQARHDSALASAAAAAIGNLPQITAALAVV	(SEQ ID NO:187)
ATQFAAHARALVTEISRATGKLASSSSDTTSPGLSPASPPSKPPPPVSDVIDALRTSAEGAGRLVSTASGYRAGLLASIA
ASCTASYTVALVSGGPSI

>BL;ML1561, ML.tab 1885772:1886269 forward MW:17495
MTSIEPSAPTPVATPKRTPVSQDSDNAGLSEALVVEHSTIYGYGIVLALSPPNANSLVVDALIQHRQRRDDIIVMLTARR	(SEQ ID NO:188)
VSPPVAASGYQLPMLVGSAADAARLAVRMENDGATAWRAVAEHAETADDRTFAAMALAQSAVMAARWNKMLGAWPITTTF
PGSNE

>BL;ML1584, ML.tab 1909590:1909844 forward MW:9465
VASTEGEHNAGVDPAEVPSVAWGWSRINHHTWHIVGLFAIGLLLANLRGNHIGHVENWYLIGFAALVFFVLIRDLLGRRR	(SEQ ID NO:189)
GWIR

>BL;ML1607, ML.tab 1932700:1932990 reverse MW:11018
MTTHKAMTRVQLEANGEVFAVDNLTRMGLRGLHCNWRCRYGECDVIASETAHRTVVSRLRSIAATVMEGSRRSAPEQKVR	(SEQ ID NO:190)
WLRWLAGLWPANQDEF

>BL;ML1610, ML.tab 1935020:1935325 reverse MW:12258
MSAEDLEKYETEMELSLYREYKDIVGQFSYVVETERRFYLANSVEMMPRNTDGEVYFELRLADAWVWDMYRPARFVKQVR	(SEQ ID NO:191)
VVTFKDVNIEEVEKPELRLPE

>BL;ML1624, ML.tab 1947637:1949427 forward MW:65207
MTQSDHRHTRPSSYGGTVLTQRVSQATVEDSRPLRGWQRRAMVKYLASQPRDFLAVATPGSGKTTFALRVMTELLNSHAV	(SEQ ID NO:192)
EQVTVVVPTEHLKVQWTRAAATHGLALDPKFSNTNPRTSPEYHGVTMTYAQVAAHPTLHRVRTEGRRTLVIFDEIHHCGN
AKAWGDAIREAFSDATRRLALTGTPFRSDDKPIPFVTYALDADGLMHSQADHTYSYAEGLADGVVRPVVFLVYSCQARWR
NSAGEEHAARLGEPLSAEQTARAWRTALDPSGEWMPAVISAADQRLRQLRTHVPDAGGMIIASDQTAARAYANLLAQMTS
ETPTLVLSDDPGSSARITEFAKNTSQWLIAVRMVSEGVDIPRLSVGIYATSASTPLFFAQAIGRFVRSRHPGETASIFVP
SVPNLLQLASELETQRNHVLGKPHRESTDNPLGGNPATMTQTEQDDTEKYFTAIGADAELDQIIFDGSSFGTATPAGSEE
EAYYLGIPGLLDADQMRALLHRRQNEQLQKRTAAQQASSTPDRTSGAPASVHGQLRELRRELNSLVSIAHHHTGKPHGWI
HNELRRRCGGPPIAAATHDQLKARIDAVRQLNAEPS

>BL;ML1638, ML.tab 1975122:1975820 reverse MW:25842
LSKLDDELSRIAHRANYLPQREAYERMRVERTGANDRLVAVQIALEDVDTQVFLLESEIDAMRQREDRDRLLLNSGATDA	(SEQ ID NO:193)
KQLSDLQPEFGTWQRRKNSLEDSLREVMKRRGELQDQLTAELGAIERMQTDLVGARQTLDVAPAEIDQVGQPHSSQCDVL
IAELAPALSAPYERLCAGGGLGVGQLQGHRCGACRSEIGRGELSCISVDVDDEVVKYPESGAIQLLDKGFFQ

>BL;ML1644, ML.tab 1978961:1979773 forward MW:30049
MRHLALLLRPGWIALTLVVTAFTYLCFMVLAPWQLGKNTRMSRENNQIEYSLNTPPVPVKTLLSHQDLSTSKSQWRQVTA	(SEQ ID NO:194)
TGRYLPDVQVLARLRVVDSGQAFEVLAPFVVDDGPTVLVDRGYVRPEPGSHVPPIPRPPNEAVSITARLRDSEPVMKDKE
PFSRDGVQQVYSINIEQVARLTKIPLAGSYLQLVDNQPGGLGVIDIPHLDAGPFLSYGIQWISFGIIAPIGLGYLAYAEI
RTHRQEKLAKPSQAPMAVEEKLADRYGHPR

>BL;ML1649, ML.tab 1987829:1988251 reverse MW:15144
VVAADHTPSFARKLGIQQGQVVQEWGWDEDTDDDIRASVEEACGGELLDEDTDEVVDVVLLWWRDGDGDLVDTLMDAITP	(SEQ ID NO:195)
RAEDGVIWVLTPKTGKPGHVPPAEIAEAAPTAGLMLTSSVNLGDWSASRLVQPKSRIGKR

>BL;ML1652, ML.tab 1992060:1993304 forward MW:44873
VNNNHFVPAPFRRLPLELLDTVPDSLLRRLKQYSGRLATEAVTAMQERLPFFADLEASQRASVTLVVQTAVVNFVQWMQN	(SEQ ID NO:196)
PHSDVSYTAQAFELVPQDLARRIALRHTVDMVRVTMEFFEEVVPLLARSEEQLTALTVGILKYSRDLAFTAATAYADAAE
ARGTWDSRMEASVVDAVVRGDTGPELLSRAAALNWDTTAPATVVVGTPTPNHDGPNGQVSSERASQEVREIAARHGRAAL
TDVHGTWLVAIISGQLAPTDKFFSDLLHAFSDGPVVIGPTAPMLTAAYHSASEAVSGMNAVAGWSGAPRPVQARELLPER
ALMGDASAIVALNTDVMLPLADAGPTLIETLDAYLDCGGAIEACARKLFVHPNTVRYRLKRITDFTGHDPTLPRDAYVLR
VAATVGKLNYPTHH

>BL;ML1660, ML.tab 2001607:2002260 reverse MW:23449
VTVALALRDGCRRISTMTRQYGVTTQRHLISPVVFDITPLGRRPGAIIALQKTVPSLARIGLELVVIEWGAPINLDLRVE	(SEQ ID NO:197)
SVSEDVLVAGTVTAPTVSECVRCLTAVHGHVQVTLNQLFAYPYSATKVTTEEDAVGHVVDGTIDLEQSIIDAVGIELPFA
PMCRSDCPGLCAECGTSLVVEPGHPHDRIDPWWAKLTDMLAPDVPQTSETDGSRSEW

>BL;ML1666, ML.tab 2009601:2010245 reverse MW:23370
VSAQPVERPGDLKPAPASVLPMPVPTAWWVLIAGVIGLVASMMLTVEKIRILLNSAYVPSCNVNPIVACGSVMSTPQASV	(SEQ ID NO:198)
LGFPNPLLGIVGFTLVTVTGVLSVAEVSLPQWYWIGLAVGTLAGVGFVHWLIFQSLYRIGALCAYCMVIWAVSVSLLVVV
TAIVFRPLLEVLPGRTSAIARGIYQWRWSIATLWFITVFLLIMVRFWNYWQTLL

>BL;ML1677, ML.tab 2021235:2021810 forward MW:19668
VTSNSDAGSAVDAGGPPRTVIIAAVVLTAATIGTILVLAATLHEPPQPVVITAVPAPQATTAACRSLTQALPQRLGDYER	(SEQ ID NO:199)
APVAQPAPDAVAAWRTGSDTEPVVLRCGLDGPAEFVVGSPIQAVDQVQWFEVDAKPKPAIDAGRSTWYTVDRPVYVALTL
PSGSGPTPIQELSDVIDRTLAAIPISPAQSH

>BL;ML1698, ML.tab 2046984:2047817 reverse MW:29424
VTGQSHDEHWRRPGECPEPIPGRPASASLVDPEDDLTPVGYPGDFGTTTVIPYSDPDHLKGPGGTGYNLLDQQEPLPYVQ	(SEQ ID NO:200)
PQARHAVAEPTEIDSDQDNERLHTVGRRGTQHLGLLVLRVGLGVVLAAQGLHKLFGWWGGQGLTGFKNSLTQVGYQHADI
LAYVSAGGEAVAGVLLVLGLFAPVVAAGALAFLINGLLAAWPHSPLFSFFLPDGNEHQITLIVMDVTVILCGPGRYGLDA
GRRWAYRPFIGSFIVLIAGIAAGIAVWVLLNGVNPLA

>BL;ML1704, ML.tab 2055043:2055741 forward MW:24598
VEMPLTQRYATVLAVPSYLLRIELADRPGSLGSLAVALGSVGGDILSLDVVERSGGYAIDDLVIEVPSGAMPDKLITAFE	(SEQ ID NO:201)
SLPGVRVDSVRPHSGLLEAHRELELLDQVAAADDNASKLQVLADEAPKVLRVSWCTVLRSSQGKLLRLAASVGAPETRAN
SAPWLPIERAAPLDGTAEWVPQSLRDMNTTMIAAPLGDPHTAVVLGRPGPEFRPSEVARLGYLAGIVATMLR

>BL;ML1706, ML.tab 2057887:2058900 reverse MW:34564
MSVFATASGVGSWPGSSPYPAAKVVVGELAGALAHIVELPARGVGADMLGRAGALLIDVAIDTVPRGYRIAARPGAVTRR	(SEQ ID NO:202)
AFSLLDEDMDAFEAAWEMAGLRGRGRVVKVQAPGPITLAAGLELANGHRAITDSCAVRDLAESLAEGVAAHRAALARRLD
TQVVVQFDEVSLPAALGGLLTGVTAFSPVAPLDETLAATLFDSCVATVGADVLLHSCAAELPWNFLQRSAIRAVSVDVNV
LRTGDLDGIAAFVESGRTVVLGVVPATAPQRLPSVEQVAAAVVGVTDRLGFGRSALRDRIGVSPACGLAGATPHWACTAI
ELARKTAEAFAQDPDAI

>BL;ML1720, ML.tab 2076101:2077195 forward MW:38298
LAAGPALSARGYLAMNAQTQAGCSLMEWENNDNGRQRWCVRLVQGGGFGGPLFDGFENLYVGEPGTIFSFPMTQWTRWRQ	(SEQ ID NO:203)
PVIGMPSTPRFLGNGQLLVTTHLGQVLVFDAHRGMVVGSPLDLVDGVNPTDPTRGLADCVSAQRGCPVASAPAYSPASOT
VVLDIWQPGAPTAGLIGLKYHSRQTPLLARAWTSDAIGAGVLASPVLSADGSTVYVNGRDQHLWALHAANGKPKWSVPLE
FLAQTPPTVTPQGLIVSGGGPDTRLAAFKDAGDHAQQIWRRDDLTPLSTSSLAGVSVGYTVVSSSPAADAPGMSLLAFDP
RNGHTLNSYPLPAATGYPVGVSIANNRRVITVTSDGQLYSFAPT

>BL;ML1723, ML.tab 2079775:2080758 reverse MW:36615
MTRSTEISANAVPNPHATAEQVAAARKDSKLAQVLYHDWEAENYDEKWSISYDQRCVDYVRHCFDAIVPDELFTELPYDC	(SEQ ID NO:204)
ALELGCGTGFFLLNLIQSGVARRGSVTDLSPGMVKIATRNGQSLGLDINGRVADAEGIPYDDNTFDLVVGHAVLHHIPDV
ELSLREVLRVLKPGGRFVFAGEPTDVGNRYARVFADLTWKVTIRVVQLPGLSAWRRTQVEIDENSRAAALEWVVDLHTFE
PKVLETMATNAGAVQVKTVTEEFTAAMLGWPLRTFESTMPPSKLGWGWARFAFTSWKTLSWVDANVWRRVIPKSWFYNII
ITGVKPS

>BL;ML1781, ML.tab 2157673:2158185 reverse MW:18049
MRASNQFADATAGVVYVHASPAAVCPHVEWALSSTLQTKAINLVWTPQPAMPGQLRAVTNWTGPVGTGARLANALRSWSVL	(SEQ ID NO:205)
RFEVTEDPSPGVDGQRFSHTPQLGLWSGSMSANGDIMVGEMRLRANMAHGADTLAAELDSVLGTAWDDALEVYRDGGDVG
EVTWLSRGVG

>BL;ML1782, ML.tab 2158324:2159145 reverse MW:29017
MVALDALDDWPVPTTAAAVVGPTGVLAARGDTEQVFPLASVTKPLVARAVQIAIEEGVVDLDTVAGPPGSTIRHLLAHAS	(SEQ ID NO:206)
GLAMHSKYVMAPPGTRRIYSNYGFRVLAETVQREAGIGFSRYLTEAVLEPLAMTATKLEDGTWAAGFGATSTVADLAAFA
NDLLRPATVSAQIHAEATSVQFPDLDGVLPGHGVQRPNDWGLGYEIKNSKLPHWTGTLNSARTYGHFGQSGGFIWADPEA
ELALVVLTDRDFGEWALQLWPAISDAVISEYAR

>BL;ML1791, ML.tab 2165620:2166063 reverse MW:16468
LGKIFIMLPTVTHQAITCTVRRVRWIVDAMNVIGTRPDCWWKDRRGAMVRLVGKLERWASTERNHVTVVFERPPSPSIRS	(SEQ ID NO:207)
SVIVIAHAPKAFPDSADDEIVRLVQADPEPQGICVVTSDSALTDRVQEVGALAYPAARFRKHIDSID

>BL;ML1813, ML.tab 2194277:2194849 reverse MW:20227
MTGQDVVVQQPQTIPMLPIYIPQDVDMTVVKSEVAAAGVSASPAAMPGLLEVVSHAQAEGINLKIVLLDHNLPNDTPLRD	(SEQ ID NO:208)
IATVVGADYPDVTVLTLSPNYVGSYSTHYPRVTLEAGEDISKTGNPVQSAQNFLGELNVPEFPWTVLTIVLLIGVLVAAI
GTRFMQLRSKRLATSLDAAGILAEDVNRAD

>BL;ML1908, ML.tab 2293144:2293644 reverse MW:18864
VALKTDIRGMVWRYSDYFIVGREQCREFARAIKCDHPAYFSEDAAAELGYDAIVAPLTFVTIFAKYVQLDFFRNVDVGME	(SEQ ID NO:209)
TNQIVQVDQRFVFHKPVLVGDKLWARMDIHSVSERFGADIVVTKNSCTSDDGELVMEAYTTLMGQQGDNSSQLKWDKESG
QVIRSA

>BL;ML1909, ML.tab 2293648:2294076 reverse MW:14875
MARREFSSVKVGDLLPEKTYPLTRQDLVNYAGVSGDLNPIHWDDEIAKVVGLDTAIAHGMLTMGIGGGYVTSWVGDPGAV	(SEQ ID NO:210)
IEYNVRFTAVVPVPNDGQGAVLVFSGKVKSVDPDTKSVTIALSATTGGKKIFGRAIASAKLA

>BL;ML1910, ML.tab 2294063:2294542 reverse MW:17608
VGLTTNIVGMHYRYPDHYEVEREKIREYAVAVQNEDTSYFEEDAAAELGYKGLLAPLTFICLFGYKAQSAFFKHANIAVT	(SEQ ID NO:211)
DQQIVQIDQVLKFVKPIVAGDKLYCDVYVDSMREAHGTQIIVTKNVVTNEVGDIVQETYTTLAGRVGEGGEEGFSDGAA

>BL;ML1911A, ML.tab 2295156:2295371 reverse MW:7998
MLKKVEIEVDDDLVQEVIRRYGLLGRREAVHLALKALLGEPGVGGLSEQDPEYDEFSNPDAWRTRRSSDTG	(SEQ ID NO:212)

>BL;ML1918, ML.tab 2301835:2302626 reverse MW:27133
VLDLEPRGPLPTEIYWRRRGLAVGITVIVIVIAAIVAVVGNGAAAQPANVDKPGSSQNHPGSATPKVLPPNGHEGNLAPA	(SEQ ID NO:213)
PPQGRNPESSTSTAAVQPPPVLREGDDCPDSTLAVKGLTNVPQYFLGDQPKFTMVVTNIGLVSCKRDVGAAVLAAYVYSL
DNKRLWSNLDCAPSNETLVKTFTPGEQVTTAVTWTGMGSSPHCPLPRPAIGPGTYNLVVQLGNLHSMPVPFILNQPPPPP
GSSGPALAPSPEAPPANVPVSGG

>BL;ML1926, ML.tab 2311558:2312061 reverse MW:17296
LVDTVGLVNKCVPDSSGLPLRAMVMVLLFLGVIFLLLGWQALGSSGNSDDYSALPMSSMPNTPTTPAATSTSSTSAANQA	(SEQ ID NO:214)
EVRVYNISSKEGIAARTRDQLTTAGFKVTEVDNLVVSDVSATTVYYSDAEGEYATADAVGQKLGAPVEPRIAAITNQPPG
VIVLVTS

>BL;ML1927, ML.tab 2312092:2312400 reverse MW:11799
MDGAMARAHRAGDDVEIVDGLTRREHDILAFERQWWKFAGVKEEAIKELFSMSATRYYQVLNALVDRPEALAVDPMLVKR	(SEQ ID NO:215)
LRRLRASRQKARAARRLGFEVT

>BL;ML1937, ML.tab 2323320:2324552 forward MW:46582
MERPNEYMARQRSILNKVFTGFSAYCRYGQHVSKQQARSTVESTYRSILPNIPGVPWWAALLIATTASAIGYAIDAGNTD	(SEQ ID NO:216)
LTTVFTGFYITGCVAAVLAVRQSGLFTAVIQPPLILFCAVPAAYWLFHGSKIKSLKDLLINCGYPLIERFPLMLGTAGSV
LLIGLVRWFFQLMYRTTASSNSEDDTVSKPNSLISGITAVLNSILCIYSNDQNHRANQDTADTELMHSDPPLRTRQTARD
NRSARTHSGQARRVVEYTSEPLVEPWQHSSQRSSEQARDFDAGESPRRSRRQPTPQSDPELRSQPPREIRRDAYGHRSGP
YEWPTNHSSHLEPYRRYKQPGPPEHFTEHGQLYERYKQPRRRATPPRASSVNPISQVRYRGSTARDDPRVDRQRSQTPRR
PVTESWEFDV

>BL;ML1945, ML.tab 2331776:2332549 reverse MW:27316
MVNDCPRSRSATWSWALAVNQQGWDTRRVTFEWQPNSEVANKPGSVSWSAKPRLLQDGRDMFWSLVPLVVGCILLAGMAG	(SEQ ID NO:217)
TCTFAPGGTTKSTVSSYDAAAALRADARALGFPVRLPELPTGWRSNSGSRGSIEDGRMDLSTGKRLPAVTSTVGYITPTG
MYLSLTQSNADEDRLVASIHPSSHPTGTVDVAGTKWVVYQGSDQKKDHSGAAAEPVWTSRFASPVGAAQIAITGAGCSSQ
FRMLASATQSQQPLPAR

>BL;ML1983, ML.tab 2367418:2367885 forward MW:16955
MSNRKFSFEVTRTSSASAAVLFRLVTDGANWAKWAKPIVLQSSWARLGDLRPGGIGAVRKIGIWPILVREETVEYEQDRR	(SEQ ID NO:218)
HLYKLIGPPNPAKDYLGEVLLAPNAAGGTNIHWSGSFTENIPGTGPVMRAALKGAVRCLTVRLVKTAERESDGVQ

>BL;ML1988, ML.tab 2375705:2376418 reverse MW:25568
MDCEVAREALSARLDGEREAVPSVRVDEHLGECSACRAWFDQVADQARDLRQLVDSRPAITPVDALGIVAPPRRRRPLMT	(SEQ ID NO:219)
WQRWALLCVGIAQIVLATVQGLGVSVGLTHDRAMSFGSYLLHESTAWSASLGVIMMAAVLWPGVAAGLAGVLTVFVGLLT
VYVVVDVVAGATITLRILMHLPVAIGAVLAIAVWRHSSTPRPTFDDEVDVDLDIVLPRNASRGRRRGHLWPTDGSAV

>8L;ML1993, ML.tab 2380915:2381466 forward MW:20576
MSAELAPSLQNAAESTNTFPMAEDLLGSILEPYSYKGCRYLIDAQYRASPDSVFAYGNFGIEESAYIRGTGHFNAVELML	(SEQ ID NO:220)
CFNQLGYSAYAQSVVNKDISALRGWSIADYCRNQLSGILIKNTSSRFKKLINPQKFSARLHVYDLRIVERTWRYLQLSNT
IEFWDDNGGSAIGEFEVAILNIP

>BL;ML1995, ML.tab 2383087:2383323 forward MW:8810
VTETARERILTAVCEVLYIAESDLVDGDETDLRDLGLDSVRFTLLMKQLGLSQEAEMQSKLMDNFSIANWVRQLESST	(SEQ ID NO:221)

>BL;ML1997, ML.tab 2387532:2388164 reverse MW:23261
MIDDLLLRWVTGLFVLSAAECGFACLACRRPWTLVPSNGLHFAMAIAMAVMAWPRGAQLPTTGTVVFCGLVGAWFVILA	(SEQ ID NO:222)
TVSSRRIAERAAYAYPALMMLANVWMYVIMDSHLHDHWATGHHTSPHTSMLGVDMTTTWPASGIPGWISIINWLWFAFF
CIATVFWTYRSFATSRRNAGFSRYCSLHPSGQAMMSTGMAIMFGVLLFHV

>BL;ML2010, ML.tab 2402973:2403434 forward MW:15613
MWLTAAPAAARFVVASVIAASCAASTGVAGADPQSPSAPKTTIDHDGTYAVGTDIAPGTYSSAGPVGNGTCYWKRIDNPD	(SEQ ID NO:223)
GPIDNAMSKKPKIVQIEASNKAFKTTGCQPWQQTSNTTVSTDLPGPIAGIQLESNLGILNGLLASNGQQVPRS

>BL;ML2022, ML.tab 2413644:2414168 reverse MW:18955
MSGPSSSCRCLPCCPHDRSSQPRCGESLGWQGYGRVYLESPWPFGLKQILQILRYGAEYAGKILAQPSKPTDVSSGPRRK	(SEQ ID NO:224)
TQVFAKATVVPKILQPKETQMTFDPKNAVNAARDIATNFVEKASDIVENVSDIIKGDIAGGANDIVQNSIDIATHAVDKA
KEIFIGKGEYDELE

>BL;ML2023, ML.tab 2414264:2414668 reverse MW:14091
MIRELLAISAIASGAVNSAPRAAANPHYDGDVPGMSYDASLSAPCFSWERYIFGRGPSGQAEACHFPPPNQFPPANTGYW	(SEQ ID NO:225)
VISYPLYGVQQAGAPCPKTQAAAQSADGLPMLCLGGQGWQPGWFTDKGFFPPAG

>BL;ML2030, ML.tab 2420647:2421120 forward MW:16613
LDMPGEMLDVRKLCKLFVKSAVVSGIVTASMALSTSTGMANAVPREPNWDAVAQCESGRNWRANTGNGFYGGLQFKPTIW	(SEQ ID NO:226)
ARYGGVGNPAGASREQQITVANRVLADQGLDAWPKCGAASDLPITLWSHPAQGVKQIINDIIQMGDTTLAAIALNGL

>BL;ML2031, ML.tab 2421151:2421606 forward MW:17306
MEGSVTVHMAAPADKVWNLIADVRNTGRFSPETFEAEWLDDVTGPALNAKFRGHVRRNEIGPVYWTTCKVTACEPGREFG	(SEQ ID NO:227)
FTVLLGNKPVNNWHYRLVTSGDGTYVTESFRFNRSPLLTVYWLLGGFLRKRRNIRDMTKTLRRIKDVVEAE

>BL;ML2048, ML.tab 2437805:2438062 forward MW:9877
MTNLWDLKQKVIYSIQWLWNSLGHQLPRTMLETIRRKTGQPWRTAAGVHPVDNQFGMVCENSEYSDYVYNIKANTAVRT	(SEQ ID NO:228)
HKSKI

>BL;ML2054, ML.tab 2442182:2442481 reverse MW:10350
MDVMAATEYLARSTTLTSVGWIGYIIIGGIAGWIAGKIVQGGGSGILMNIVIGVVGALIGGFLLSFFVNTAAGGWWFTLF	(SEQ ID NO:229)
TSILGSVILLWVVGRVRKT

>BL;ML2063, ML.tab 2450656:2451084 forward MW:16160
MAKLTRLGDLERAVMDHLWSRQEPQTVRQVHEALSARRDLAYTTVMTVLQRLAKKNLVSQIRNNRAHRYAPVHGRDELVA	(SEQ ID NO:230)
GLMVDALDQAEDSDSRQAALVHFVERVGADEADALRRALAELETHQRHVRHLVALQRTTEGD

>BL;ML2064, ML.tab 2451089:2452039 forward MW:32995
VSALAFTILAVLLVGPTPTLVARSTWPLRAPRAAMVLWQTIALAAALSTFSAGIAIASRVLMPGPDGRLLTASVIGAAGRL	(SEQ ID NO:231)
GWPLWAAYVAAFALTVLVGARLIVAIVRVAIATRRRRAHHRMVVDLVGVGHNAALAQPCARARDLRVLEVAQPLAYCLPG
VRSRVVVSEGALTKLNDTEVTAILTHERAHLRARHDLVLEAFTAVHAAFPRLVRSSAALSAVRLLVELLADDAAVRAAGR
TPLARALVACASGQAPSGALAAGGNTTVLRVRRLSGRSNSAVVSAAAYLAAAIVLLVPTVALAVPWLTELQRLFNI

>BL;ML2070, ML.tab 2460317:2462518 forward MW:77018
MTKLGAEFKPDQTRINRKAANTGMGRHSMPDPEDSIDQPSNQFAASGPDQSDEIDHGYQSRMGYPEPVFEPAATGSPSYR	(SEQ ID NO:232)
SYPHGAEHPADSTPEALDETIDYQSYWAEDRNEDLFVDGAADDHPDFPPRPAGSSTSSQAPTSLSHLFKASHRSVGKWQG
GHRSDGGRRGVSIGVIATLVAVVVLVGAVIMWSFLGHILNNRKHQAAARCVGGHQTVAVVADPSIADYLQEFAQSYNASA
RPVGDHCMMVTVKPVGSEAALTGFNDSWPANLGDKPALWIPGSSISAARLAVTADQKTISESHSLVTSPVLLAVRPEFEQ
ALANKGWAALPGLQTNPNSLADLNLPAWGSLRLALPMNGNSDATFLAGEAVATASVPAGAPAIQGVGAVRTLMSAQPKLA
DSTWAEAMSTLLKPGDVATAPVHAVITTEQQLFQRGQSLSDAKSALGSWLPHGPAPVADYPAVLLNGSWLTQEQAAAASE
FARFVQKPDQLAKLAKAGFRVNGVTPPSSSVTSFAAVPSTVSVGDDGMRATLVEEMIQPSSGVAATIMLDQSMPTDEGGK
TRLANVVAALDDKINAMPPTSVMGLWTFDGHKGQTEVTTGQLADPVNGQPRSAALTAALDKQYSSNGGAVSFTTLRMIYQ
EMLANYHVGQTNSVLVITAGPHTDQTLDGARLQDFIRTSADPAKPIAVNVIDFGTDPDQATWKAVAQISGGSYQNLSTSA
SLDLATAINTFLS

>BL;ML2073, ML.tab 2466445:2467140 reverse MW:24857
MTHLVTRARSARGNTVSEQPRQGQLDLADYRDTPTATTHGDIGLNGPTAVSGPAQPGLFPDDSVPDELVGYRGPSACQIA	(SEQ ID NO:233)
GITYRQLDYWARTSLVVPSIRGAAGSGSQRLYSFKDILVLKIVKRLLDTGISLHNIRVAVDHLRQRGVQDLANITLFSDG
TTVYECTSAEEVVDLLQGGQGVFGIAVSGANRELTGVIDDFRGERADGGESIAAPEDELASRRKHRDRKIG

>BL;ML2075, ML.tab 2467984:2468739 reverse MW:26531
VSAPDSPALVOMSIGAVLDLLRSDFPDVTISKIRFLEAEGLVTPQRSASGYRRFTAYDCARLRFILTAQRDHYLPLKVIR	(SEQ ID NO:234)
AQLDAQPDGELPSFGSPYVAPRLFSVTGGPGAGVGSGVGSDIPAVSPAGVRLSREDLLDRSGVADDLLTALLKAGVITTG
PGGFFDEHAIVILQCARALSEYGVEPRHLRAFRSAADRQSDLIVQIAGPIVKAGKAGARDRADDLAREVAALAITLHTSL
IKSAVRGVLHR

>BL;ML2111, ML.tab 2512539:2512973 reverse MW:15031
MIHRLRLGWLVAFFATIVLISVWIPWLTTKVNDEGWANAIGGTNGNLELPSGFGAGQLIVLLSSTLLVAGAMMGRGLSVK	(SEQ ID NO:235)
VASIAALIISLLIVVIVVWYYQLNVNPPWAECGLYLGAAGAVCAMVCSVWAVIAAVAAGRSSL

>BL;ML2113, ML.tab 2513870:2514415 reverse MW:19748
VTSRIKRMAKLTGSIDVPLPPNEAWMCASDLARFGEWLTIHRAWRSKLPEVVEKGTVIESYVEVKGMPNRIRWTVVRYKA	(SEQ ID NO:236)
PEANTLNGOGVGGVKVKLIAKVSPKDDGSVVSFDVNLGGSALFGPIGMIVAVALRTDIRESLQNFVTAFSRPEPGLIRSR
ALVVDQHSRAVVEQRSASAGL

>BL;ML2114, ML.tab 2514412:2514582 reverse MW:6182
VLDKAKDILVQNADKVETVLDKAGEFVDEKAKGKYTDTIYQVAEETKKAASFDTFC	(SEQ ID NO:237)

>SL;ML2135, ML.tab 2537496:2538521 reverse MW:40179
MARTRMVRRWRNNMEVRDDTDYVGMLTTLSEGSVRRNFNPYTDIDWESPAFAVKDNDPRWILPDTDPLGRHPWYLAQPEQ	(SEQ ID NO:238)
RKIEIGMWRQANVAKVGLHFESILVRGLMNYTFWMPNGSPEYRYCLHECVEECNHTMMFQEMVNRVGADVPGMPRRLRWL
SPLVPLVAGPLPVAFFIGVLAGEEPIDHMQKNVLREGKSLHPIMERVMAIHVAEEARHISFAHEFLRKRLTHLTKRQLFW
VSLYYPLTMRVLCNAIMVPPKAFWQEFNIPREVKKELFFRSPESRKLLRDIFADVRMLAYDTRLMETRSARLMWHICKID
GQPSRYRGEPQRQHPATTSAA

>BL;ML2137, ML.tab 2539983:2540738 forward MW:27365
MRELKVVGLDPDSKTILCEGDIPGERFKLPADDRLRAAVRGDTTLLDQPQLDIQVTNMLSPKEIQARIRAGASVEQVANA	(SEQ ID NO:239)
SGSDIARIRRFAHPVLLERSRAAELATAAHPVLADGPAVLTLLETVSAALVKRGLEPDKLSWDAWRNEDSRWTVQLMWHA
GRSDNLAHFCFTPGAHGGTVTASDDAANELIDPDFNRPLRPLARVAHLDFVEPATPATVTPDNQLVSSRRGKPTIPAWED
VLLGVRSAGQP

>BL;ML2141, ML.tab 2542620:2542895 forward MW:9766
MLVEPDRSREPPPLPSMLLEVWPVIMVGALAWLIAVVAAFVVSSLQSWRPVALAGLVVGLFGTGIFVWQLAAARRGARGA	(SEQ ID NO:240)
QGGLETYLDPR

>BL;ML2142, ML.tab 2543007:2543816 reverse MW:28190
VTGPVEDSAVATVAEWPEELAAVLTNAADDARAAIEEFSGSVTVGDYLGVGYEDPNAATHRFLAHLPGYQGWQWAVVVAA	(SEQ ID NO:241)
YPGAEHATVSEVVLVPGPTALLAPEWVPWEQRVRPGDLGPGDLLAPTSEDLRLVPGYNASGDPAVDEIAAEIGLGRRWVM
SVWGRSAAAERWHGGDYGPDSPMARSTKRVCRDCGFFLSLVGSLGANFGVCGNEMSADGHVVDKLYGCGAHSDTPAPAGS
GSSVYEPYDDGVLDILEPSTVQLPESPAD

>BL;ML2143, ML.tab 2543926:2545665 forward MW:61675
VSGRRRNHPGRLASIPGLRTRTGSRNQHPGIANYPADSSDFRPAQQRRALEQREQQAGQLDPARRSPSMPSANRYLPPLG	(SEQ ID NO:242)
QQQSEPQHNSAPPCGPYPGERIKVTRAAAQRSREMGYRMYWMVQRAATADGADKSGLTALTWPVVTNFAVDSAMAVALAN
TLFFAAASGESKSKVALYLLITIAPFAVIAPLIGPALDRLQHGRRVALATSFVLRTGLATLLIMNYDGATGSYPSMVLYP
CALAMMVLSKSFSVLRSAVTPRVMPPSIDLVRVNSRLTVFGLLGGTIAGGAIAAGVEFVCAHLFKLPGALFVVAAITISG
ALLSMRIPRWVEVTAGEIPATLSYRLHRKPLRQSWPEEVKKVSGRLRQPLGRNIITSLWGNCTIKVMVGFLFLYPAFVAK
EHQANGWVQLGMLGLIGTAAAIGNFAGNFTSARLQLGRPAVLVVRCTIAVTVLALAASVAGNLLMTTIATLITSGSSAIA
KASLDASLQNDLPEESRASGFGRSESTLQLAWVLGGALGVMVYTDLWVGFTAVSALLILGLAQTVVSFRGDSLIPGLGGN
RPVMIEQESMRRAAAVSPQ

>BL;ML2144, ML.tab 2545673:2546161 forward MW:18046
VQRRVTVLLPAVVMLLAAAAGFGVWLLVREPDPQRPEISVYSHGHLTRVGPYLHCNMLNLDECQTPQAQGVLSADEHNPV	(SEQ ID NO:243)
QLSVPETISRAPWRLLRIYEDPTGTTSTLYRPNTRLAVTIPTLDPHRGRLTGIVVQLLTLVVDPAGEVHDVPHTEWLVRL
TF

>BL;ML21S1, ML.tab 2554745:2555269 forward MW:17666
MSESYRKLTTSSIIVAKITFTGAMLDGSIALAGQASPATDSEWDQVARCESGGNWSINTGNGYLGGLQFSQGTWASHGGG	(SEQ ID NO:244)
EYAPSAQLATREQQIAVAERVLATQGSGAWPACGHGLSGPSLQEVLPAGMGAPWINGAPAPLAPPPPAEPAPPQPPADNF
PPTPGDVPSPLARP

>BL;ML2155, ML.tab 2556716:2556940 reverse MW:8095
MKSVNYYVVADIAKSKAHKSRYVDNGWPTTDPDHHAVSELVTDCAGALSPFGDLVFPVPADDLPYVHPVTVVNR	(SEQ ID NO:245)

>BL;ML2156, ML.tab 2557038:2559299 forward MW:80254
MTDNTPDIPLGSWLADLSDERLIQLLELRPDLAQPPPGSIAALAARAQARQSIKAATDELNFLQFAVIDALLVLQADSTP	(SEQ ID NO:246)
VPTTKLKALIGDRAPQADVVSALDNLRQRALAWGETTVRIAAAAAAALPWHPGQVTLEDISSTGEQIAELIARLSQTQRD
VLQKLLEGSPLGRTRDAAPGAPPDRPVPQLLAMGLLRRIDADTVILPRRVGQVLRGEQSGPTQLTQPYPVVSVTTPNDAD
AEAAGAVIEALHELDVLLETLGSAPVYELRNGGLGVREFKRLAKATGINEPRLGLLLEVTAAAGLIASGIPDPEPATGDS
PYWAPTVATDRFTANPPAERWHLLASTWLDLQCRPALIGSRGPDAKSYGALSNSLYSTAAPLDRRLLLGMLAELPAGVGV
EAAEASAALIWRRPRWARRLQPGPVADMLAEGHTMGLVGRGAISTPGRALLDEAIASADPAIAVAAMTRALPEPIDHFLV
QADLTVVVPGPLQRNLAKELGTVATVESAGTANVYRISEQSIRHALDIGKTRDWMHALFTNHSKTPVPQRLTYLINDVAR
RHGQLRIGMAASFVRCEDPALLTQTVAAAEELQLRALAPTVAVSPAPIAEVLVTLQSAGFAPAAEDSSGSIVDVRPRRAR
LPTPQHRRPYRPLQRPNLETLNAVIAVLRKVAATPFGGIRVDPTVTMSLLQRATKEKTTLVIGYLDAAGIATQRMVSPIA
IRGGQLVAFDPGTGRLRDFVIHRITSVVSSDSQ

>BL;ML2193, ML.tab 2608113:2609048 reverse MW:33819
MVLNWRFALSADEQRLVREIISAATEFDEVSPVGEQVLRELGYDRTEHLLVTDSRPYAPIIGYLNLSSPRDAGVANAELV	(SEQ ID NO:247)
VHPRERRRGVGAANVRAALAKTGGRNRFWAHGTLASARATASVLGLVPVRELVQMQRSLRTIPDPMVPDQLGVWVRTYVG
TVDDAELLRVNNAAFAGHPEQGGWTATQLAERRSEPWFDPAGLFLAFGDSSSNQPGKLLGFHWTKVHAAHPGLGEVYVLG
VDPSAQGRGLGQMLTSIGIASLAQRLVGPSAEPTVMLYVESDNVAAARTYERLGFTTYSVDTAYALARIDD

>BL;ML2195, ML.tab 2609965:2610816 forward MW:30382
MVKDATCIKVRHNMRMRKVLTSVIATVVTMAVLVVGVLGIDYGTSIYAEYLLSVNVRNAANLGSDPFVAILAFPFIPQAM	(SEQ ID NO:248)
RDHYTELEIKANAVDHANVGKASLEATMYSIDLTYASWLIKPDAKLPVDRLESRIIIDSMHLGQYLGISDLMVEAPHRET
NNATGGTTESGISSGHGLVLSGTPKSANFDHRVSVLVDLSIAPEDQATLVFTPTGIATGPDTANQPVPDDKRNPVLRAFS
ARMSDQRLPFGVAPTSEGARGSDVIIEGITQGVTITLDGFKQS

>BL;ML2199, ML.tab 2612896:2613198 forward MW:10570
MCSEPKQRLALPANVNLEKETVITGRVVDRKGQAVGGAFVRLLDSSNEFTAEVVTSATGDFRFFAAPGSWTLRALSSVGN	(SEQ ID NO:249)
GDAMMSPSGTGIHKVDVKIT

>BL;ML2200, ML.tab 2613457:2614143 forward MW:24489
VTSDEVRDGAGSPADSSKGNKCTAAGMFQAAKRSTVSAARNIPAFDDLPVPSDTANLREGANLNSTLLALLPLVGVWRGE	(SEQ ID NO:250)
GEGRGPNGDYHFGQQIVVSHDGGNYLNWEARSWRLNDAGEYQETSLRETGFWRFVSDPYDPTESQAIELLLAHSAGYVEL
FYGRPRNASSWELVTDALACSKSGVLVGGAKRLYGIVEGGDLAYVEERVDADGGLVPNLSARLYRFAG

>BL;ML2204, ML.tab 2619139:2619327 forward MW:7054
MGRGRAKAKQTKVARELKYSSPQTDFQRLQRELSSTGAADPGQLDGDDRVSEDSWDEDAWRR	(SEQ ID NO:251)

>BL;ML2207, ML.tab 2622297:2622692 reverse MW:13959
MAVCDRADPAKTRQAVLALADWLKDRTLPAPDRDAVATAVRLTVRTLATLAPGASVEVRIPPYVAVQCVSGPSHTRGTPP	(SEQ ID NO:252)
NVVETDSRTWLLVATGLMQLVEAVATGALRMSGSRAGDIEVWMPLINLRCT

>BL;ML2219A, ML.tab 2636676:2636915 reverse MW:8613
VARAVVMVMLRAEILDPQGQAIAGALGRLGHTGISDVRQGKRFELEIDDTVDDSELAMIAESLLANTVIEDWTITRESQ	(SEQ ID NO:253)

>BL;ML2228, ML.tab 2645990:2646610 forward MW:21778
MNSRFLPYATSPGRLTIQLLSDIAVVMWTTFWVLVGIAVYNTISTIADTGAQVESGAHGIADNLASASHGMQLIPVLGNA	(SEQ ID NO:254)
VSKPLTLTSAAALDIADAGHSLNTTASWLAVLLALAVIALPILVAVVPWLVLRFWFFRHKWTVTTLAATPAGKQLLALRA
LTLRSPSKLAAVSADPVGGWRREDPGTIRGLAALELQSSGITLRVH

>BL;ML2253, ML.tab 2676319:2676534 reverse MW:8295
MPNNIAFSRSYIGKRCYSEQEVGVFIDLAEQERTRHIEEDVEFRNRNAELRNQDGAPQPRSCADRARNCHV	(SEQ ID NO:255)

>BL;ML2258, ML.tab 2682528:2682830 reverse MW:11299
VNRFLTSIVSWLRAGYPEGIPATDTFAVLALLARRLTNDEVKIVARELIRRGEFDKIDIGVMISHLTDELPSPQDIERVR	(SEQ ID NO:256)
TRLNAKGWLLDNARDNGEPT

>BL;ML2259, ML.tab 2682860:2683150 reverse MW:10541
LSPWFNYEATLKILLFSTLAGAALPGLFALGIRLQVNDAGDASTNNATPNRKPILVTLAWVIYALVLMVVILGVLYIVSR	(SEQ ID NO:257)
DFIAHHTHYPFLGIKP

>BL;ML2261, ML.tab 2684489:2684905 reverse MW:15612
MEILASRMLLRPTDYQRSLSFYRDQIGLAIAREYGTGTVFFAGQSLLELAGYVIQGAPDHSRGAFPGALWLQVRDIAVTQ	(SEQ ID NO:258)
ADLEGRGVSITREPRREPWGLHEMHVTDPDEITLIFVEVPANHPLRRDTRSERPRTPD

>BL;ML2271, ML.tab 2695503:2696030 forward MW:19222
VILSKSLLRILIHGRSDEPPSTRARVIMRWGRIAVLIVTGLITLQSVLLVAGAWRNDLTIQHNMGVAQAEVLSAGPRRST	(SEQ ID NO:259)
IEFVTPERVTYRPELGVLYLSELSTGMRIYVEYNKNDPNLVRVRHRNAGLAIIPAGSIAVVCWLAATVVLVALAVLDKRL
DRHTESSAVPSQPTS

>BL;ML2274, ML.tab 2698017:2698355 reverse MW:11815
MKGTGLAANVAMAAAATVLAAPALADDYDAPFNAQLHSYGIYGAQDYNAWLGKIACQRLAKGVDGDVNKSATF IQRNLPL	(SEQ ID NO:260)
YTTEGQSLQFLGAAINHYCPNQIGILQRAGAR

>BL;ML2289, ML.tab 2713408:2714178 reverse MW:26191
VTADLLAPLMELPGVATASDRARDALGRAHRHRANLRGWPVTAAEAALRAARASSVLDGGPVRLDHLPGASPQAGGVSDP	(SEQ ID NO:261)
VFGGALRVAQALEGGAGPLVGVWQRAPLQALARLHVLAAADQVGDEWLGRPRMDAEVGLRLGLLVDVVSGRTFAAAPVVA
AVVHGELLTLQPFGSADGVVARAVSRLVTIATGLDPHGLGVPEVSWMRRAAVYRDAACGFAGGTPKGVAAWLVLCCRALH
AGAQEALSIAESLPSR

>BL;ML2295, ML.tab 2720556:2721260 reverse MW:23836
LVLRRGHWCILVALVAVLLAVVSMPAKTVFADGRLPMGGGAGIVINGDTMCTLTTIGTDSAAELIGFTSAHCGGPGAQVA	(SEQ ID NO:262)
AEGAENRGPMGTMIAGNDNLDYAVIKFDPAKVMPVAAYNGFVISGIGQDPAFGQIACKQGRTTGNSCGVAWGMGETSGTL
VMQVCGRPGDSGAPVTVNNLLVGMIHGAFTDNLPVCITKFIPLHTPAVVMSMNAILADVNKNNRPGAGFVPQPV

>BL;ML2296, ML.tab 2721464:2722009 forward MW:20041
MSKGDRKNGVPSTLTTIPLVDPHAEPTEPSIGDLIKDATTQVSTLVRAEVELARAEIIRDVKKGLTGSVFFIAALVVLFY	(SEQ ID NO:263)
STFFFFLFLAELLDTWLWRWVALLIVFAIMVMVTAALALLGYVKIRRIRGPHQTIESVKETRTALTPGHDKAQARPRKLT
GSGTNPENNPDRRTPADPSGW

>BL;ML2306, ML.tab 2730213:2731358 forward MW:40804
MTAPTSHRPPTLDMAAILADTSNRVVVCCGAGGVGKTTTAAAMALQAAEYGRTVVVLTIDPAKRLAQALGVNDLGNTPQR	(SEQ ID NO:264)
VPLAPEVPGELHAMMLDMRRTFDEMVVQYSGPERAQAILNSEFYQTVATSLAGTQEYMAMEKLGQLLSQDRWDLVVVDTP
PSRNALDFLDAPKRLGNFMNSRLGRLLLTPGRGIGRLVTGANGLAMRALSTVLGSQMLADAATFVQSLDATFGGFRGKAD
RTYALLKQRGTQFVVVSAAEPDALREASFFVDRLSQENMPLAGLMLNRTHPTLCALPVEQAIDASKTLQDEITNSAAASL
ATAVLRINDRGQTAKREARLLSRFTGANPHVPVIGIPLLPFDVSDLEALRAIADRLTASH

>BL;ML2307, ML.tab 2731463:2731708 reverse MW:9325
LCRATDPDELFVRGAAQRKAAVICRHCPVMQECRADALDNKVEFGVWGGMTERQRRALLKQHPEVVSWADFFDTRKHRNV	(SEQ ID NO:265)
S

>BL;ML2320, ML.tab 2747152:2747799 reverse MW:22771
VSWVIRISAVVMSVGLGLGVPVASARPSEPGVVSYAVLGKGSVGNIIGRPMGWESLLTEPLQAYSVDLPMCNNWADIGLP	(SEQ ID NO:266)
EVYHDVDLASFNGAITQTSANDQTHFVKQAVGVFATNDAAVRAFHRVVDRTVGCSGQTTAMHLDNGTTQVWSFVGGTPTY
ADANWTKQEAGTDRRCFVQTRLRENVLLQTKVCQPGNAGPAVNVLAGAMQNALGQ

>BL;ML2330, MLtab 2761253:2761603 reverse MW:11931
MQPGGDMSALLAQAQQMQQKLLETQQQLANAQVHGQGGGGLVEVVVKGSGEVVSVAIDPKVVDPGDIETLQDLIVGAMAD	(SEQ ID NO:267)
ASKQVTKLAQERLGALTSAMRPTAPPPTPPTYMAGT

>BL;ML2332, ML.tab 2762489:2762926 reverse MW:15496
MGPVSAVSTILVNVEPVATLAAVADYQKNRPKILSPQYNEYQVVQGGQGPGTVVKWKLQVTRSRVRDVQVNVDVAGHTVI	(SEQ ID NO:268)
EKDANSSMVTSWTVAPAGPGSSVTMKTAWTGAGGVKGFFEKTFAPLGLKKIQAEVLANLKNELER

>BL;ML2337, ML.tab 2769442:2770194 forward MW:27248
MGYKVATLWHASFSIGAGVLYFYFVLPRWPELIGETTHTLGTTLRIVTGVLFGLAALPVVFTLLRSQTSELGIPQLALSI	(SEQ ID NO:269)
RTWSIVAHVLSGVLIVSTAIGEIWLSSDTAVQCLFGIYGAAAASAVLGFVAFYLSFVAALPPPSPKPVKLKKANQRRIRR
RKGRKDNEAEDEEADAGEHNEAETPAQAEEVTSENPQPAPESGAQKEPDELLANKTEETDEPRRGLHNRRPTGKVSHQRR
RARSGIAVEN

>BL;ML2366, ML.tab 2834617:2834958 reverse MW:11956
MAFMTSNPSGPPSQPAPAVGLTPGERAVPVTRAGALWSALFAGFLILILLLIFIAQNTTSTPFTFFGWHWSLPLGVAIML	(SEQ ID NO:270)
SAVGGGLLAVAVGTARILQLRRTVKKRYVAAHR

>BL;ML2377, ML.tab 2846366:2846830 forward MW:16863
MSKRQRGKGISIFKLLSRIWIPLVILVVLVVGGFVVYRVHSYFASEKRESYADSNLGSSKPFNPKQIVYEVFGPPGTVAD	(SEQ ID NO:271)
ISYFDANSDPQRIDGAQLPWSLLMTTTLAAVMGNLVAQGNTDSIGCRIIVDGVVKAERVSNEVNAYTYCLVKSA

>BL;ML2380, ML.tab 2850483:2850944 reverse MW:17491
MSRLSTSLCKGAVFLVFGIIPVAFPTTAVADGSTEDFPIPRRQIATTCDAEQYLAAVRDTSPIYYQRYMIDMHNKPTDIQ	(SEQ ID NO:272)
QAAVNRIHWFYSLSPTDRRQYSEDTATNVYYEQMATHWGNWAKIFFNNKGVVAKATEVCNQYQAGDMSVWNWP

>BL;ML2388, ML.tab 2858302:2858607 forward MW:10942
VAAGDNRLIGNDTPEIAVGAIGGVATGYVLWLVVMSIGYNITTVSQWSLIVLILSMVSVFCSGMCGWWLRQRRKHAWGAF	(SEQ ID NO:273)
TFGLPVFPVVLTLAVLAKIYL

>BL;ML2390, ML.tab 2861300:2861605 reverse MW:10840
VSHIFLTLIADGELQYHGPDFGKASPMGLLVIVLLLVATLLLLWSMNRQLKKIPASFDSEHPELDQAADEGTELGGYLDE	(SEQ ID NO:274)
EPSDTDRNGPSLPPEPGADSG

>BL;ML2392, ML.tab 2862579:2863013 forward MW:15303
MNQAFTPLTETRYGRSRLPGRSRHRGVIALTVLAVAASTGIAVIGYQRLGTSDVAGSLASYRVLDDETVSVTISVMRSDP	(SEQ ID NO:275)
SRPVDCIVRVRAKDGSETGRREVLVAPAEATTVQVVTTVKSARPPVMADIYGCGTDVPGYLRPA

>BL;ML2407, ML.tab 2878350:2878685 reverse MW:12141
VSKGPNSICAADHNRDHLVVNVLLYAAARLLLVILLGSVIYGVARLLGVTQLPIVVAALFALIIAMPLGIWLFSPLRRA	(SEQ ID NO:276)
TAALAVVGERRRSEREQLRARLRGEPLPDEE

>BL;ML2410, ML.tab 2881021:2882649 reverse MW:59195
LMQVLMRLLAWVRNTWRALTSMGTALVLLFLLALGAIPGALLPQRDLNVGKVDDYVAAHPVIGSWLDQLQAFNVFSSVWF	(SEQ ID NO:277)
TAIYTLLFVSLVGCLTPRMIEHARSLRAMPVIAPRNLARLPKHASFQVIGDDKTLAGTIAGRLRGWRTVIRTQDGVVPET
VVSAEKGYLREFGNLVFHFSLLGLLVAVAVDKLFGYEGNVVVIADGGPGFCSASPAAFDAFRAGNTVDGTSLHPICIRVN
DFAAHYLPSGQAMSFTADIDYQDGHDLTVNSWRPYRLEVNHPLRVAGNRVYLQGHGYAPTFTVTFPDGQTRTSTVQWRPE
NQQTLLSSGVVRIDPPAGSYPNMSERRQHEIAIQGLLAPTEQLDGTLLLSRFPALNAPAVAIDIYRGDTGLDSGRPQSLF
TLDPRLINQGRLTKEKRVNLQAGEQVRLGQGPGAGTVVRFDGAVPFVNLQVSHDPGQAVFVFAIAMMVGLVVSLMVRRR
RVWVRLTPAAGTVNVELGGLARTDNSGWGDEFERLTERLLAGLVAADRTLAAARRSSQMDVK

>BL;ML2425, ML.tab 2901005:2901505 forward MW:18654
MTVPLEAEGLIGKYRQLDHFQVGREKIREFAIAVKDDHPTHYNETAAFEAGYPALVAPLTFLAIACRRVQLEIFTKFNI	(SEQ ID NO:278)
PINVARVFHRDQKFRFYRTILAQDKLYFDTYLDSVIESHGTVIAEVRSEVTDTEGKAVVTSIVTMLCELARQDATAEETV
AAIASI

>BL;ML2428A, ML.tab 2904745:2904846 reverse MW:4145
MGSVIKKRRKRMSKKKHRKLLRRTRVQRRKLGK	(SEQ ID NO:279)

>BL;ML2432, ML.tab 2907135:2907977 reverse MW:30442
LRPVIKVGLSTASVYPLRAEAAFEYAAKLGYDGVELMVWGESVSQDIDAVKGLSRRYRVPVLSVHAPCLLISQRVWGANP	(SEQ ID NO:280)
VPKLERSVRAAEQLGAQTVVVHPPFRWQRRYAEGFSDQVAELEAASDVMIAVENPFPFRADRFFGADQSRERMRKRGGGP
GPAISVFAPSFDPLAGNHAHYTLDLSHTATAGSDSLEMVRRMGSGLVHLHLCDGSGLPADEHLVPGRGTQPTAAVCQLLA
GADFAGHVVLEVSTSSVRSATERETMLTESLQFARTYLLR

>BL;ML2433, ML.tab 2908008:2909075 reverse MW:37938
MTGPHNDTESPHARPISVAELLARNGTIGAPAVSRRRRRRTDSDAVTVAELTCDIPIIHDDHADEQHLAATHAHRANIGV	(SEQ ID NO:281)
RVVEPAAQSPLEPVCEGIVAEPPVDDHGHVPPGCWSAPEPRWPKSPPLTHLRTGLQRSACSRPLPHLGDVRHPVAPDSIA
QKQSDAEGMSPDPVEPFADIPVDVMGSEVRAAELVAEESAYARYNLQMSAGALFSGHTLTNELAERRGDEHAAGGLLAVG
IDLDEDHLDLHTDLAGITSPARGWQSRFEALWRGSLIVLQSILAVVFGAGLFVAFDQLWRWNSIVALVLSVLVILGLVVG
VRVVRRTEDIASTLIAVVVGALITLGPLALSLQSG

>BL;ML2435, ML.tab 2910195:2911028 forward MW:31007
VSSCPESGSTFEYVANSHLEPVHPGEEVDLDFTREWVEFYDPDNSEQLIAADLTWLLSRWTCVFGTPACRGTVAGRPDDG	(SEQ ID NO:282)
CCSHGAFLSDDADRTRLDDAVKKLSHDDWQFREKGLGRKGYLELDEHDGQSQFRTRKHKNACIFLNRPGFPIGAGCALHS
KALKLGVPPRTMKPDICWQLPIRHSQEWVTRPDGTEILKTTVTEYDRRSWGSGGADLHWYCTGDPASHVDSKQLWESLAD
ELTELLGAKAYAKLAAICKRRNRLGIIAVHPATQEAK

>BL;ML2442, ML.tab 2917372:2917926 reverse MW:20820
MSTAWDTVWHACSVIEHALQASHLTYSEFSGVPDGLLRLVVELPGERRLKTNAILSIGEHSVNVEAFVCRKPDENHEGVY	(SEQ ID NO:283)
RFLLKRNRRLFCVSYTLDNVGDIYLVGRMSLASVDTDEIDRVLGQVLEAVESDFNTLLELGFRSSIQKEWDWRISRGESL
NNLQAFAHLIDDEGDGDASIYARP

>BL;ML2446, ML.tab 2921383:2922708 reverse MW:46863
VIASTPRQNRESINRRVALTALGVGVFAPSVFVACAGSAIKPSEKKTTPAPHLTFQPATATDDVIPVAPISVQIADGWFQ	(SEQ ID NO:284)
RVTLTNPVGKVVAGVFNQDRTVYTITEPLGYDTTYTWNGSAVGHDGKAVPVTGKFSTVTPVKKVNGGFQLADGQTVGVAA
PITIQFDAPISDKSAVEKALTVTTTPPVEGSWAWLPDEAKGARIHYRPREYYPAGTTVNVDAKLYGLPFGDGAYGLQDMS
LNIQIGRRQVVKAEVSSHRIQVVTDAGVIMDFPCSYGEADQARNVTRNGIHVVTEKYSDFYMSNPAAGYSNVYERWAVRI
SNNGEFIHANPASVGAQGNTNVTNGCINLSTGDAEQFYRSAIYGDPVEVTGSSIQLSYSDGDIWDWAVDWDTWVGMSALL
SFPTVHQPATQIPVTAPVTPPGAPILSGTPTSGSGTARPGG

>BL;ML2450, ML.tab 2925762:2926499 forward MW:26174
LLRDPLAIVLILIIVVALVISGLIGAELFARHTANSKVARVVTCEIKDQATAKFGVTPLLLWQFATQHFTNISVETAGNQ	(SEQ ID NO:285)
IRDAKGMKIAIDIQNVQIRDTPTSRGTIGVLDAIITWSSDGIRQSVQNSIPVLGGVVTTSVTTHPTNGTIELKGMLNDIV
AKPVVSNGGLQLQIVSFNTLGFSLPKETVQFTLDDFTTNLTKNYPLGIHADNVEVTSTGVTSHFSARNTNIPNSTGGQDP
CFANL

>BL;ML2452, ML.tab 2927236:2927607 reverse MW:13492
MSSPLSPLYVLPFVDHTKWTRWRSLISLQAYSNLFGRTSAMQPDVAAGDEAWGDVLTLSPDADTADMHAQFICHGQFAEF	(SEQ ID NO:286)
VQPSNTSSNLEPWRPVVDDSEIFAAGCHPGISEGIQQADEGPR

>BL;ML2453, ML.tab 2927710:2927997 reverse MW:10004
MSHLVGTVMLVLQLAVLVTAVYAFVHAALQRPDAYTAAEKLTKPVWLVILGAAVSLTSILGFVFGVLGIVIAACAAGVYL	(SEQ ID NO:287)
VDVRPKLLDIQGKSR

>BL;ML2454, ML.tab 2928117:2928683 reverse MW:20421
MAENPNVDDLRAPLLAALGAADLALTTVNELVGNMRERAEETRIDTRSRVEESRARVAKLQEVLPEHLSELREKFTADEL	(SEQ ID NO:288)
RKAAEGYLEAATNRYNELVERGEAALERLRSRPVFEDASARAEGYVDQAVELTQEALGTVASQTRAVGGRAAKLVGIELP
KKAAAPARKAPAKKAPAKKAPAKKVTQK

>BL;ML2463, ML.tab 2936751:2937545 reverse MW:30332
VSLDKIMMPVPEGHPDVFDREWPLRVGDIDRTGRLRLDAGVRHIQDIGQDQLREMGFEETHPLWIVRRTMVDLIRPVEFQ	(SEQ ID NO:289)
EMLRLRRWCSGTSNRWCEMRVRIDGRKGGLIESEAFWININRETQMPARIADDFLAGLHRTTSVDRLRWRGYLQPGSRDD
ASEIHEFPVRVTDIDLFDHMNNSVYWSVIEDYLVSHSELLKGPLRTTIEHEAPVALGDKLEIVLHVHPAGSTDQFGPGLV
DRSVITLTYTVGDETKAIAAIFAL

>BL;ML2465, ML.tab 2939177:2939743 forward MW:21174
MSGGTGTGPVGRIPPGSLRQLGPINWVIAKLAASLLRTSEMHLFTILGQRQLLFWAWLIYGGRLLRGKLPRVDTELVILR	(SEQ ID NO:290)
VAHLRTCEYELQHHRRMARKRGLDTKIQAMIPAWPDVPTGAGLSVRQQALLAATDEFVKDRKITSSSWQQLETHLDRRRL
IEFCMLISQYDGLAATISSLDIPLDNSC

>BL;ML2473, ML.tab 2948272:2948751 forward MW:17160
MPDGFGVAVVREEGQWRCSAMASKSLTSLTAAETELRELRSVGAVFGLLDVDDEFFIILRPAPSGTRLLLSDATAALDYD	(SEQ ID NO:291)
IAAEILDSLDAEIDPEDLEDAYPFEEGDLGLLSDVGLPEATLGVILDQTDLYADEQLGHIAREMGFAEQLSAVINRLGR

>BL;ML2489, ML.tab 2962275:2963135 reverse MW:32001
MVPLWFTLSALCFVGAVVLLYVDIDRRRGRSRRRKSWARSHGFDYERESTEILQRWKRGVMSTVGDISAHNVVLGQIRGE	(SEQ ID NO:292)
AVYIFDLEEVATVIALHRKVGTNIVVDLRLKGLKEPRESDIWLLGAIGPRMVYSTNLDAARRACDRRMVTFAHTAPDCAE
VMWNEQNWTLVSMPIGSTRVQWDEGLRTVRQFNDLLRVLPPLPADTSQEAGASARNAAPSRPLASVGRAELPPDRGVESD
VAGLLGSGVQAGRSAEPISRDEGRWDGIRRPPSVERNGHQTTNYQY

>BL;ML2491, ML.tab 2966697:2967698 forward MW:36545
VTGPNSPNKTLQRFGISGTDLGIPWDNGDPTNHQVLMAFGDSFGYCSVKGQQRRYNILFRSSNQDLSHGIRIADGVPNDK	(SEQ ID NO:293)
YSGSPVWTTGLAKQVVNTIHRAPHETGIIPTTAISIGKTQYMNYMSIKKWGRDGEWTTNYSAIARSIDNGQSWGTYPGTI
RTASPDAIPGTHFVPGNQNFQMGAFMRGNDGYLYSFGTPSGRSGAAYLARVPQNLVPDLSKYQYWNGNWVPNNPGAATPL
FSGPVGEMSAQYNDYLKQYIILYSNGDSNDVVARTAPAPQGPWSPEQPLVSSFQMPGGIYAPMIHPWSSGRDLYFNLSLW
SAYDVVLMHTVLP

>BL;ML2518, ML.tab 2999816:3000208 reverse MW:14353
VGEYSAFGFDPDDFDRLIKEGSEGLRDAFERISRFVGGPGVRTAWSAIFEDLSRRARPAQETADEAGDGVWAIYTVTGDG	(SEQ ID NO:294)
AARVEQVYATELDALRANKNNVDPKRKVRFLPYGIAVSVLDSHQESTQQL

>BL;ML2522, ML.tab 3004590:3005246 reverse MW:22735
MCRLIALLSAVVCAAWATLILAPIGAAAGAAWFANKVGNATQVVSVVSTGGSNAKMDIYQRTGTGWQPLKTGIPTYVGSA	(SEQ ID NO:295)
GLVAQAKSGYPATPMGVYSLDSAFGTAPNPGSQLPYTQVGPNHWWSGDDHSPTFNTMQVCQKSHCRFNTAESENLQIPSY
KHAVVMGVNKAKVPGSGSAFFLHTTGGGPTEGCVAIDDVTLVQILRWLRPGAVIAITK

>BL;ML2527, ML.tab 3009256:3010275 reverse MW:36773
VSAHRSRPAAMWPGSSRITLALLAVMPALMAYPWWFTRSYWLLGIVALVVVVLFGWWRGLYLTTILRRRLAMMWRRGRPV	(SEQ ID NO:296)
SASGSATRTTVLLRLGPPVGGSDVIPLPLITRYLNCYGIRADSIRITSRNNESDGALCETWIGLTVSAAKNLAALQARSS
RIPLQETAQVAARRLADHLREIGWEVSLAVPDGIPRLITAAGDETWRGMQQGSDYLTAYRVNVDDELPGTLDAVRLYPAR
ETWTALEIACPDSSSNRNTIAAACAFLTDTAPQGAAPLAGLTPQHGNHRPALAVLDLFSAQRLDGHTDTDADLLTRLRWP
APAAGVSSCTATRSPAVSA

>BL;ML2529, ML.tab 3011710:3013167 reverse MW:49866
MVYVFAEEFCEGPVTSGAVMPIVRVAILALSRLIEMALPTELPLREILPAVKRLVVPAASDNDSPLAANASLHLSLAPIG	(SEQ ID NO:297)
GAPFSLDASLDTVGVVDGDLLALQPVPVGPAAPGIVEDIADAAMIFSTARLQSWGPTHIRRGALAATTAVTFAATGLGVT
YRAVTGALTGLLVVIVIAVLIALGGLVLRSRAARTGLVLSIAALVPIGAVFALAVPGIFGPAQVLLASAGVTAWSLIALI
VPGPERVRIVAFFTATVVIGVAVMLEAGAALLWQLTPLTIGCGLILAALLVTVEAAQLSALWARFPLPVIPAPGDPTPSA
PSFQVLEDLPRRVRISSAHQSGFIAAATLLSMLGSVAIALRPEAVSSVGWYLVAATAVAATLRARVWDSVACKAWLLAQP
YLVASVLLGLYTATGRYVAASAALLVLVVVVLAWAVVALNPRIASSDSYSLPLRRLLGMVASGLDASLIPAMAYLVSLFS
WVLNR

>BL;ML2530, ML.tab 3013309:3014178 reverse MW:31518
MKVDPNAVELTVDHAWFIAEVIGAGSFPWVLAITTPYRDAGERSAFVERQVDELTRMGLLVAENSVDPTVADWIRVVCFP	(SEQ ID NO:298)
DRWLDLRYLRSTSAVGDSELLRGMVAQRAGVSDKTVVALRSAQLITFTAMDIDDPLRLVPILGAGLAQRPPARFDEFSMP
MRVGVRADERLRSGTSLAEVADYLGIPKSAQPVVESVFSGPRSYVEIVAGCRRDGKHATTEVGMSIVDTTTGRVLVNPSR
AFDGEWVSTFSPGTPFAIAVGIEQLTATLPEGQWFPGQRLCRDFSGQTS

>BL;ML2531, ML.tab 3014189:3014479 reverse MW:10392
MTQIMYNYPAMLDHAGNMSACAGALQGVGIDIAAEQAALQACWGGDTGISYQAWQVQWNQATEEMVRAYHAMANTHQNNT	(SEQ ID NO:299)
LAMLTRDQAEAAKWGG

>BL;ML2532, ML.tab 3014518:3014814 reverse MW:10191
VSLLDVHIPQLVASESAFAAKAALMRSQINQAECEAISAQAFHQGESSAAFQSAHAQFVTAAEKINALLDIAQQHLGEAA	(SEQ ID NO:300)
ETYVATDATAASTYTTGL

>BL;ML2534, ML.tab 3016103:3016411 reverse MW:10243
MTLRVVPEKLAATSEAMKALTARLEAAHAAAFPCLVAVVPPAADPVSLQTAAGFSARGQEHALVAAQGVEELGRAGIGVG	(SEQ ID NO:301)
QSSTHYAISDALAASTYGIVES

>BL;ML2536, ML.tab 3020432:3022090 reverse MW:57975
MTSNELPGEWSGERRSFFSRTPVNDNPDKVVYRRGFVTRHQVTGWRFVMRRIASGIALHDTRMLVDPLRTQSRSVLVGAL	(SEQ ID NO:302)
LVITGLIGCFVFSFIRPNGAAGNNAVLADRSTAALYVRVGDELHPVLNLTSARLIVGRSVNPITVKSSELDRFPRGNLIG
IPGAPERMVQNTTHDANWTVCDVVSGEGGHAAHSMGVTVIAGPPDSHGMRAAVLGSAHGVLVDAPSERGGsTWLLWDGKR
SEIDLADHAVTDALGFGVGFAEVPAPRPIGAOLFNAIPEAPPLKAPVIPNAGATPSFGVRAPIGAVVVSFGLAALGKNPY
DSVRYYAVLPDGLQPISPVLAAILRNINSYGLQQPPRLGADEVDKLPVSRMLDTERYPEQQISLIDAGYAPVSCAYWSKP
AGAATSFLSLMSGAALPVPDAARAVELVSAPSRGDSSTASRVVLTPGTGYFAQTVGVGSAAPATASLFWVSDTGVRYGID
TEADARSEATAGPGKIVEALGLKLPAVPIPWSILSLFAVGPTLSRADALLEHDGLAPDTRAGRTTTAYGEHR

>BL;ML2557, ML.tab 3049294:3049590 forward MW:10997
LYATTELAELHDLIGRMRRSVASFKARYGDSPNRRIAIDADRILSDIELLDADISELDLARATVQQSNEKIAIPDTQYD	(SEQ ID NO:303)
SDFWRDVDDEGVGGHSRS

>BL;ML2566, ML.tab 3061369:3062271 forward MW:32889
LTFGFVLRRLRRHFSVKENTVNQPSGLKNILRAIVGALPLLPRTDQLPSRTVTIEELPIDHTNVSAYASVTGLRYGNHVP	(SEQ ID NO:304)
LTYPFALTFPANMSLVTGFDFPFAANGSVHTENHITQYRPIAVTDVVGVQVHAENLREHRKGLLVDLVTDVSVGNDTAWH
QVTTFLHLQRTSLSDEPKPPSQKQPKLLPPSAVLQITPRQIRRYAAVGGDHNPIHTNPIVAKLFGFPTTIAHGMFSAAAV
LANIEARLPDAVHYSARFVKPVVLPATTGLYVDESAGNWDLTLRNIAKGYPHLAGTVQGV

>BL;ML2569A, ML.tab 3065268:3065441 forward MW:5896
MSRIVAPAAASVVVGLLLGAATIFGMTLMVQQDTKPPLPGGDPQSSVLNRVEYGNRT

>BL;ML2570, ML.tab 3065557:3069774 forward MW:147681
VAAMSRWWLVLVGVVAVALTFAQSPGQISPDTKLDLTTNPLRFLARATNLWNSDLPFGQVQNQAYGYLFPHGTFFLIGQL	(SEQ ID NO:305)
LGSPGWITQRLWWALLLTAGFWGLLRVAETLSIGSPTSRAIGAVAFALSPRVLTTLGSISSETLPMMLSPWVLLPTILAL
QGAPGRSVRTRAAQAGLAVALMGAVNAIATLAGCLPAVIWWACHRPNRLWWRYTGWWLLALCLATLWWVVALVLLHGVSP
PFLDFIESSGVTTQWSSLVEMLRGTDSWTPFVAQTATAGTPLVTESVAILGTCLVAAAGLAGLASTGMPARGRLVTMLVI
GVVLLSAGYSGGLGSPLAQAVQAFLDSSGAALRNVHKLESVIRTPFALGIAGLLGRIPLPGSAPVLVWLSSFAHPERDKR
VAATVAVLTALLVSTSSAWTGRLTPPGTFSAIPQYWNDTSDWLSEHNTGIPTPGRVLVVPGAPFATQVWGTSHDEPLQVL
GNSPWGVRDSIPLTPPQAIRALDSVQRLFASGRPSVGLADTLARQGISYVVLRNDLDPDTSRSARPILVHRAIAGSPQLE
KVAQFGAPVGTNMLKGFVADSELRPWYPAVEIYRVAVSDGTNPGKPYFADTDQLPRIDGGPEVLLRLDERRRLLGQPALG
PALMTADAQFAGLPLPSRAEVTITDTPVARETDYGRVDQNSSAIRAVNDARHTFNRVPDYPVPGAEMVFGGWSGGRITAS
SSSSDATSMPDVAPATSPAAAIDGDPATSWVSNALQPAVGQWLQVDFDHPVNNAVITVTPSATAVGAQVRRIEIETVNGT
TNLRVDEAGKPLAVALPYGETPWVRITAAATDDGSSGVQFGITDLTITQYDASGFAHPVNLRHTALVPGSPPGWAVAGWD
LGSELLGRPGCAPAPDNVRCAASMTLAPEEPVNFSRTLTVPYPISVTAMLWVRPRQGPKLADLIAEPKTTRAYGEADTVD
ILGSAYAATDGNPATSWTAPQRVVQHKTPPTLTLVLPRPTEVNGLRLAPSRSALPARPTLVAVNLGNGPQVRELQAGEPQ
ALSLKPRITDTVTISLLDWHDVIDRNALGFDQLKPPGLAEVTVLGTDGNPTAPANASENRIREVTVDCDHGPIIAVAGRF
VHTSIRTTAAALLDGEPVAAVPCERAPIVLPAGQQELLISPGAAFIVDGAQLSTQDGTELPSARTISADTGKWGPSRREV
RAPGSATSQVLVMPDSINPGWVAHTSTGVRLMPVAVNGWQQGWLVPAGNPGTITLTFTANSLYRPGLAAGLALLPLLALL
ALWGRRNERAADAAAQPWTPGAWSAVAVLSAGAVIAGAAGVVVVGAALSLRYALRHQQRWRNGLTVGLSAGGLVLAGAAL
SRQPWRSVDGYSGHSANVQLLALISLAALAASVVSPRCGSTGVAT

>BL;ML2581, ML.tab 3081538:3082821 forward MW:46681
VNRAVILRFTACGIIGLGAAFLIAALLLATYTSSRITKIPLDIDATLVSEGNGTALDSSSLSSEHIIVNQNVPLVSQQQI	(SEQ ID NO:306)
TVESPANVDVVTFQVGVSIRRTDKQKDTGLLLAVVDTVTLNRKTANAVSDDTHTGGSIQKPRGFTDENPPTAIPLRHDGL
SYRFPFHTEKKTYPYFDPVAQKTFDVNYQNQEDINGLTTYRFTQNVGYDADGKLVAPITYPSLYASDEDGKITTTAJUWG
LSGDPSEQITMTRYYAAQRTFWVDPVSGTIVKETEHVNIYFARDTLKPEVTLADYKVTSTEETIESQVNSARDERDRLAL
WSRVLPITFTAVGLITLLSGGFLASFSLRTESALTESGLDRANRDAFGHCRTEEPVPGAEAETEKLPTQRPELRDSSILS
VSAHRRRSSESSPPNSGPADPGHPERG

>BL;ML2582, ML.tab 3082923:3084725 forward MW:61888
VSRELYHRSMSWSRPSYALGMALLVVGPLMRPGYLLLRDAVSTPRSYLSDAALGLTSAPRSTPQDFAVAMASHLVDGGIV	(SEQ ID NO:307)
VKSALVLGLWLAGWGAARLVVTALPSAGVAGQFVASTLAVWNPYVAERLLQGHWSLLVGYGCLPWVAEAMLMLRSSDNAS
RPGLLGFFALACWIALAGLTPTGLMLAATVALICVAVPVEGPGEPRPRWLCAAATLGSALGAALPWLTASAVGTSLTAHT
VANTLGVTVFAPRAEPGLGTLASLASLGGIWNGEAVPTSRTTLFAVLSATVLLGVVVAGLPVAVRRPAVVPLLVLAAVAV
ATPAALATGPGIDMLKAVVNAVPGLGVLRDGQKWVALAVPGYSLAGAGAVVTLGRWLRPSRPLSPVVTALACCLALILAL
PDLAWGVWGKVQPVHYPSGWAAVAATINDRGEGPGWVAVLPAGTMRRFSWSGTAPVLDPLPRWVRDDVLTTGDLIISGVM
VAGEGNHARAAQDLLLSGPNPSALTAAGVAWLVVESDTAGDMGASARTLAALQPTYRDDAIGLYRIGGSNAKTAPSPYRG
LLIAAHLTWLVILVMAVVGMQITRHTHFRDVSSVALLSRR

>BL;ML2595, ML.tab 3100808:3101356 forward MW:19619
LPESQVAADDSGVTLNRSRLGRGWLTGIAVALLLAGCGIGTGGYCMLRYHQDSQAMARNDNAALKTALDCVAATQAPDTN	(SEQ ID NO:308)
TMAASEQKIIDCGTDAFHAQALLYTNMLVQAYQAANVHVQVSDMRAAVERHNNDGSIDVLVALRVKLSNDRAHNQETGYR
LRVKNALAEGQYKISKLDQVTK

>BL;ML2596, ML.tab 3101353:3102330 forward MW:35970
VTVVVAKSQTAAVIPEPLSNRLAPWHLRLVALAVDVLPGLVAVSTMTLVVFTVPLRSAWWWLCMAVGGIVILSMLVNRLL	(SEQ ID NO:309)
LPTIIGWSLGRALCGISVIMRDGVAIGPWRLLLRDLTNLLDTAAVFAGWLWPLWDSRRRTFADILLRTEVRCVQAVERQR
TIRWWASVALLTAAGVSLGGASVSWAVVYSHDRAIDQTRSEIAIQGPKMVAQMLTYNPKSLRDDFTHAQSLASDKYRRQL
AAQQDVVKKGHPVINEYWPTAGAIQSATRDRATMLLFMQGRRGAAPGERYISATVRVSFAKGEHNHWLVDDLTVLTKPKT
TGNGR

>BL;ML2597, ML.tab 3102327:3102881 forward MW:20340
MSPRRKFQAGEGLLLVSHTVASQRRWGLPLAATFAALVMVAAITASTLMSISHASRELAVAKDQQVLSYVKWFMTQFTTL	(SEQ ID NO:310)
DPYHANDYVARILAQATGDFAKQYNEKVNEILLQVAQAEPATGTVLDAGVERWNDDGSANVLVATEVTSKYPDEKQVLEN
TNRWTATATRECNQWKISNLLQVI

>BL;ML2598, ML.tab 3102971:3103525 forward MW:19619
VAAAEGGGSWRNRRAGQRTAIAVVVAAVLFVGSAAFAGAAVQPYLADRATVAVKLEVARTAANAITVLWTYTPENMDTLA	(SEQ ID NO:311)
DRAATYLSGDFGAQYRKFVDAIVGPNKQAKITNSTEVTGVAVESLDASNAIAIVYTNTTSTSPLTKNIPALKYLSYRLFM
KRSAVRWLVTRMTTITSLDLTPQL

>BL;ML2604, ML.tab 3108446:3109195 forward MW:26859
MTDNKMLARIAALLRQAEGTDNAHEADAFMATAQRLATAASIDLAVARSHVANRSTAQAPTQRTITIGTAGTRGLRTYVQ	(SEQ ID NO:312)
LFVLIAAANDVRCDVASNSTFLYAYGFAEDIDATHALYASLVVQMVRESDAYLASGAYRPTPTITARLNFQLGFGMRVGQ
RLTEARDHIRSAVTEAWDRPTATAIALRDKEIELIDYYRSASKARGTWQAARASAGYSSAARNAGDQAGRRAWIDNSTEL
PGARAALGR

>BL;ML2605, ML.tab 3109192:3109698 forward MW:18602
MNLLDSVRDAQRSKVYAAEEFIRTLFDRAVEHGSPAVEFFGAQLSLPPEARFGSVAAVQRYVDDVLALQAVRQRWPRMLP	(SEQ ID NO:313)
LTVRARRAATAAHYENLDGAGVIAVPGNNADWAMRELVVLHEVAHHLCKDPPPHGPEFVATICALTELVMGPELGYVFRV
VYAKEGVR

>BL;ML2614, ML.tab 3120828:3121502 forward MW:24144
VNWPKTPGTLAAMPDEEQTELPVHKEFAGIADYSDPGLSDGSVFSQYGIASTVLAVLSAAAVVFGVVIWRAHHDNSAERA	(SEQ ID NO:314)
YLTHVMQTAFDWTGVLINMNTSNVDASLQRLHAGTVGELNTDFDAAVQPYRKVVEKLQTQSRGQIEAVAIESVHHDLDTQ
PGVAHPVVTTKLLPPAARTDSVMLVATSVSENVGGKPTTVHWSLRLDVSDVDGKLMISHLESIR

>BL;ML2615, ML.tab 3121499:3122188 forward MW:24416
MRNRWRLLAFDVVAPLVAIAALVMIGVVLDWPRWWVSACSVLVLLIVEGVGVNFWLLRRDSVTIGTDDDAPGLRLAXIXISV	(SEQ ID NO:315)
CTAALCAAVLIGYMHWTSPDRDFSLDSREVVQIATGMAEAFVIASFTPSAPTSSIDRAAAMIMPDQAGVFKEQYRKSSADLA
RRNVTAQASVLAAGVEAIGSSAASVAVILRVTQNTPGQPPSQAAPAVRVTLIKRGSDWLVTDVLSINAR

>BL;ML2616, ML.tab 3122267:3122779 reverse MW:18682
VTLADDHRRPAAPPEQPAADQGRYDPDQPVEFWSTAAIRSALHAGSIEIWKLITAAVKHDPYGRTAHQVEEVLEGTRPYG	(SEQ ID NO:316)
ICKALGEVLQRARTHLEINERAEVARHVRLLIDRSGLGHQEFASRIGVAPEGLASYLDGSTSPSAALMVRMRRVSDRFVK
VKAARSANSD

>BL;ML2621, ML.tab 3131780:3132367 reverse MW:21956
MLIWDAPNLDMGLDAIVDHHHRNALERPCFDALGRWLFTCNTEVAVGYPDSTIGLKGTMFTNIAQASADVVRLWVDTLRN	(SEQ ID NO:317)
VEFVIFVKPKIDEDSHMLGRIKGRYNEGLAVQVVVSAYSQALRQTLERTAHAVIDVQMIGFREHTSWALASAILEFADLE
DIAGVFRESLPRISLDSLPAQGEWCAPFPGRWLRY

>BL;ML2627, ML.tab 3140261:3141280 forward MW:36081
VTANGHAGRREGGPYFDDLSIGQVFDWAPAVTLTSGMAAVHQAILGDRMRLALDAELSTTVIGTHAMLAHPGLVDDVAIG	(SEQ ID NO:318)
QSTLVTQRVKANLFYRGLTFHRFPVIGDTLYTSTEVVGLQANSAKPGRPPTGMAALRITTTDQHDRLVLDFYRCAMLPAS
AAWHPHDALNRNDDLANVGADAVASASDPTGQWDAAAFRERVPGPHFDAGITGAVLRSTGDIVSSAPDLARLTLNIASTH
HDSRVRGLRLVYGGHTIGLALAQAGRMLPNLATVLNWRSCDHTGPVHEGDTLYSELHVESAEATEQGGVLGLRSLVYAVS
AAGGSDHLVLDWRFTVLQF

>BL;ML2629, ML.tab 3144572:3145042 reverse MW:17022
LGSVPGYASPMPVMSKTVEVRATAASIMAIVTDFEAYPQWNDGVKGVWVLARYDDGRPSQLRLDTEIQGTKCTYIQAVYY	(SEQ ID NO:319)
PATNQIQTIMQQGDLFTKQEQLFSAVEIGAASLLTVDIDVESSMPVPAPMVKALLNNVLDNLAENLKLRAEQLAAN

>BL;ML2630, ML.tab 3145226:3145597 reverse MW:12982
LLTDGVLLPELLFGYLNKCCLLPQLFDTAINTSVGVTSPNESRAFNAADDLIGDGSVERAGLHRATSVPGESPEGLQRGH	(SEQ ID NO:320)
SPEPNDSPPWQRGSAQASQSGYRPSDPLTTTRQSNPAPGANVR

>BL;ML2640, ML.tab 3159055:3159987 reverse MW:34454
MRTHDDTWDIKTSVGTTAVMVAAARAAETDRPDALIRDPYAKLLVTNTGAGALWEAMLDPSMVAKVEAIDAEAAAMVEHM	(SEQ ID NO:321)
RSYQAVRTNFFDTYFNNAVIDGIRQFVILASGLDSRAYRLDWPTGTTVYEIDQPKVLAYKSTTLAEHGVTPTADRREVPI
DLRQDWPPALRSAGFDPSARTAWLAEGLLMYLPATAQDGLFTEIGGLSAVGSRIAVETSPLHGDEWREQMQLRFRRVSDA
LGFEQAVDVQELIYHDENRAVVADWLNRHGWRATAQSAPDEMRRVGRWGDGVPMADDKDAFAEFVTAHRL

>BL;ML2664, ML.tab 3190775:3191530 forward MW:26919
MYQAVRYLLVMAAIILMAVAESGSPSVAAIPALKPTPEVASVLPTNGAVVGVAHLVVVTFTAPVTDRSAAERSIRITSPN	(SEQ ID NO:322)
NMTGHFEWLDGDVVQWIPTKYWPAYTHVSVEVQALTTGFETGDALLGVASLSTHTFTVSRNGEVLRTMPASMGKPTRPTP
IGKFTALSKERTVVMDSRTIGIPLNSPEGYLITAQYAVRVTWSGVYVHSAPWSVNSQGYTNVSHGCINLSPDDATWYFNT
VNVGDPIEVVA

>BL;ML2687, ML.tab 3234968:3236662 reverse MW:61392
VINAQTHSTTISPRPLAADRQSADNRDCPSRTDYLGAALADAIGGPVGCHALIGRSWLMTPLRVMFLIGLVFLALGWSTK	(SEQ ID NO:323)
AACLQTTGTGPGGQRVPNWDNQRAYYELCYSDIVPLYGTELLSQGKFPYKSSWIETDSSGTPRTRYDGRLAVRYMEYPVL
TGIYQYVSMAVAKSYTALSEPVSLPAVAEVVMFFDVVAFGLALAWLATIWATAGLAGLRIWDAALVAASPLVIFQVFTNF
DALAIAFATGGLLAWSRCRPISAGVLIGLGAAAKLYPLLFLVPLFVLGVRTGRLGGVACAAVTAATTWLLVNLPVLLLFP
RGWSEFFRFNTRRGDDMDSLYNVVKSLTGWRGFDTKLGFCELPLVLNTVVTVLFALCCAAVAYIALTAAQRPRVVQLAFL
LVAVFLLTNKVWSPQFSLWLVPLAVLALPHRRVLLAWMTIDALVWVPRMYYLYGNPSRSLPEQWFTATVLLRDIAVVALC
ALVIRQIYRPDEDPVRLGGRVDDPAGGPFDRAPYAPPSWLPDWLHPAGMRRVVTLAASSVTETELAAAATPSGPMHHPHA
PSSI

>BL;ML2689, ML.tab 3239183:3239599 reverse MW:15278
VVNYSLRRRFLLAEVYSGRTGVSEVCDANPYLLRAAKFHGKPSQVMCPICRKEQLTLVSWVFGNQLGAISGSARTAEELV	(SEQ ID NO:324)
LLATRYEEFAVYVVEVCRTCSWNYLVRSYVLGAARSAPPPRGTPVTRTACNGARMAIE

>BL;ML2699, ML.tab 3250667:3253060 forward MW:84667
VTASRLRLAGSLSIALVVDIVASFAVLLVAPTATPHAAADEPRATSFVRVRIDKVTPDVVTTSSEPVVTVSGVVTNIGDR	(SEQ ID NO:325)
PVRDLMVRLEHESAVISSAVLRTYLDDGADQFQTAADFVTVAEELQRGQEAGFTLVAPIRSTTKPSMAIDQPGIYPVLVN
VNGTPDYGTPARLDNARFLLPVAGVPPAKSDAMDSAVAPDITKPVWITMLWPLADRPRLSPGAPGGTIPVRLVDDDLASS
LAPGGRLDILLTAAETATGRDVDPDGAVSRALCLAVDPDLLVTVNAMTGGYIVSNSPDGPAQQPGTPTHPGTGQDAAVIW
LNRLRALAHRMCVASLPYAQADLDALQRINDTELSTTATTSVGDIVDHILDVTSIRGVTMLPDSPLTNRVVDLLNDNNST
VAIAAAAFSAQDSTSGSLVDIDTEPRRLSPRVVVAPFDPAVGAALAAAGTDPIVPTYLDSSLNIRIVHDSDTARRQDALS
SILWRALERDAAPRSQILVPPTSWHLQADDARVMLTTLSTVIRSGLAVARPLPTVIADALARTKLSDTVGSYTSARGRFN
DDIIADIASQVGRLWGLTSALTADGRTGLTGVQYTAPLREDMLRALSQLEPPATRNGLAQQRLAVVSKTIKDLIGAVTIV
NPGGSYTLATEHSPLPLALHNGLAVPIRVRLQVDAPPGMTVTDVSQIELPPGYLPLRVPIEVNFTQRVAVDVALQTPEGI
QLGEPVRLLVHSNAYGKVLFEITLTAATILIVLAGRRLWHRFRIQTEGADSNRPDPLIVDAHPQHQYDDWVDEENRI

>BL;PE, ML.tab 654129:654437 forward MW:10295
MTLGVIPEGLEGASAVIEALTAHLATVHAEAAPFIMEVIPPGSGSVSVQNQVGFNVHGCQYVAMTAHGAEELGRWGVGVA	(SEQ ID NO:326)
ESGVSYALRDAFAVASYLGGGL

>BL;desA2, ML.tab 2339270:2340097 reverse MW:31139
MAQKPVPNALILQLEPVVKDNMARHFANEELWFAHDYVPFDRGENFAFLGGRDWDPSQATLAKAVTDACEILLILKDNLA	(SEQ ID NO:327)
GYHRELVEHFILEGWWGRWLGRWTAEEHLHAIALREYLVVTREVDPVANEQVRVEHVMKGYRVNSYTQIETLVYMAFLER
SYAFFCGSLAAQIKEPALFGLINQIVKDEVRHEEFFANLVAHCLECNRDETVAAIAARAAGLDVLGADIDAYHDKVENIS
AAGIFGSVELRQVISDRITAWGLINEPQLAQFVTS

>BL;embA, ML.tab 139821:143156 reverse MW:118457
VPHDGHEPPQRIIRLIAVGAGITGLLLCAVVPLLPVKQTTATIRWPQSATRDGWVTQITAPLVSGTPRALDISIPCSAMA	(SEQ ID NO:328)
TLPDSVGLVVSTLPSGGVDTGKSGLFVRANKNAVVVAFRDSVAAVAPRPAVAAGNCSVLHIWANTRGAGANFVGIPGAAG
ILTAEKKPQVGGIFTDLKVPVQPGLSAHIDIDTRFITAPTAIKKIAVGVGAAAVLIAILALSALDRRNRNGHRLINWRVS
MAWLAQWRVILATPPRAGGASRIADGGVLATLLLWHIIGATSSDDGYNLTVARVSSEAGYLANYYRYFGATEAPFDWYFT
VLAKLASVSTAGVWMRIPATLAGIACWLIINHWVLRRLGPGTGGLSTNRVAVLTAGAMFLAAWLPFNNGLRPEPLIALGV
LFTWVLVERAIALRRLASAATAAVVAILTATLAPQGLIAIAALLTGARAITQTIRRRRTTDGLLAPLLVLAASLSLITLV
VFHSQTLATVGESARIKYKVGPTIACYQDFLRYYFLTVESNADGSMTRRFPVLVLLLCMFGVLVVLLRRSRVPGLASGPT
WRLIGTTATSLLLLTFTPTKWAIQFGALAGLTGTFGAIAAFAFARISLHTRRNLTVYITALLFVLAWATAGINGWFGVSN
YGVPWFDIQPVIAGHPVTSIFLTLSILTGLLAGGQHFRLDYAKHTEVKDTRRNRFLATTPLVVVATTMVLCEVGSLAKGA
VARYPLYTTAKANLAALRSGLAPSVCAMADDVLTEPDPNAGMLQPVPGQIFGPTGPLGGMNPIGFKPEGVNDDLKSDPVV
SKPGLVNSDASPNKPNVTFSDSAGTAGGKGPVGVNGSHVALPFGLDPDRTPVMGSYGENTLAASATSAWYQLPLHWKESI
ADRPLVVVSAAGAIWSYKEDGNFIYGQSLKLQWGVTRPDGIIQPLAQVMPIDIGPQPAWRNLRFPLTWAPPEANVARVVA
YDPNLSPDQWLAFTPPRVPVLQTLQQLLGSQTPVLMDIATAANFPCQRPFSEHLGIAELPQYRILPDHKQTAASSNLWQS
SEAGGPFLFLQALLRTSTISTYLRDDWYRDWGSVEQYYRLVPADQAPEAVVKQGMITVPGWIRRGPIRALP

>BL;embB, ML.tab 136573:139824 reverse MW:117159
MSVIYRAHRVAIANRTASRNVRVARWVAAIAGLIGFVSSVVTPLLPVVQTTATLNWPQNGQLNSVTAPLISLTPVDITAT	(SEQ ID NO:329)
VPCAVVAALPPSGGVVLGTAPKQGKDANLNALFIDVNSQRVDVTDRNVVILSVPRNQVAGDAGAPGCSSIEVTSTHAGTF
ATFVGVTDSAGNPLRGGFPDPNLRPQIVGVFTDLTGGAP5GLRLSATIDTRFSSTPTTLKRFAMMLAIITTVGALVALWR
LDQLDGRRMRRLIPARWSMFTLVDVAVIFGFLLWHVIGANSSDDGYQMQMARTADHSGYMANYFRWFGSPEDPFGWYYNL
LALMIHVSDASMWIRLPDLICGVACWLLLSREVLPRLGPAIVGFKPALWAAGLVLLAAWMPFNNGLRPEGQIALGALITY
VLIERAITYGRMTPVALATLTAAFTIGIQPTGLIAVAALLAGGRPMLYILVRRHRAVGAWPLVAPLLAAGTVVLTVVFAE
QTLSTVLEATKVRTAIGPAQAWYTENLRYYYLILPTVDGSLSRRFGFLITALCLFTAVLITLRRKQIPGVARGPAWRLIG
TILGTMFFLTFAPTKWVHHFGLFAALGAAVAALTTVLVSHEVLRWSRNRMAFLAALLFVMTLCFATTNGWWYVSSYGVPF
NSAMPRIDGITFSTIFFILFAIVALYAYYLHFTNTGHGEGRLIRTLTVSFWAPIPFAAGLMTLVFIGSMVAGIVRQYPTY
SNGWANIRALTGGCGLADDVLVEPDSNAGYMTALPSNYGPLGPLGOVNAIGFTANGVPEHTVAEAIRITPNQPGTDYDWE
APTKLKAPGINGSVVPLPYGLNPNKVPIAGTYTTGAQQQSRLTSAWYQLPKPDDRHPLVVVTAAGKITGNSVLHGHTYGQ
TVVLEYGDPGPNGGLVPAGRLVPDDLYGEQPKAWRNLRFARSQMPFDAVAVRVVAENLSLTPEDWIAVTPPRVPELRSLQ
EYVGSSQPVLLDWEVGLAFPCQQPMLHANGVTDIPKFRITPDYSAKKIDTDTWEDGANGGLLGITDLLLRAHVMSTYLAR
DWGRDWGSLRKFDPLVDTHPAQLDLDTATRSGWWSPGKIRIKP

>BL;embC, ML.tab 144115:147327 reverse MW:114723
VSGAGANYWIARLLAVIAGLLGALLAMATPFLPVNQNTAQLNWPQNSTFESVEAPLIGYVATGLNVTVPCAAAAGLTGPQ	(SEQ ID NO:330)
SAGQTVLLSTVPKQAPKAVDRGLLIQRANDDLVLVVRNVPVVSAPMSQVLSPACQRLTFAAYFDKITAEFVGLTYGPNAE
HPGVPLRGERSGYDFRPQIVGVFTDLSGPIPTGLNFSATIDTRYSSSPTLLKTIAMILGVVLTIVALVALHLLDTADGTQ
HRRLLPSRWWSIGCLDGLVITILAWWHFVGANTSDDGYILTMARVSEHAGYMANYYRWFGTPEAPFGWYYDLLALWAHVT
TTSAWMRVPTLAMALTCWWLISREVIPRLGHAAKASRAAAWTAAGMFLAVWLPLDNGLRPEPIIALGILLTWCSVERAVA
TSRLLPVAVACIVGALTLFSGPTGIASIGALLVAVGPLLTILQRRSKQFGAVPLVAPILAASTVTAILIFRDQTFAGESQ
ASLLKRAVGPSLKWFDEHIRYERLFMASPDGSVARRFAVLALLVALSVAVAMSLRKGRIPGLAAGPSRRIIGITVTSFLA
MMFTPTKWTHHFGVFAGLAGSLGALAAVAVASAALRSRRNRTVFAAVVLFVVALSFASVNGWWYVSNFGVPWSNSFPKLR
WSLTTALLELTVIVLLLAAWFHFVATTNGSAKTRFGVRIDRIVQSPIAIATWSLVIFEVASLTMAMIGQYPAWTVGKSNL
QALTGQTCGLAEEVLVEQDPNAGMLLPVSTPVADALGSSLAEAFTANGIPADVSADPVMEPPGDRSFVKENGMTTGGEAG
NEGGTNATPGINGSRAQLPYNLDPARTPVLGSWQSGIQVVARLRSGWYRLPARDKAGPLLVVSAAGRFDHHEVKLQWATD
SGAASGQPGGAFQFSDVGASPAWRNLRLPLSAIPSMATQIRLVADDEDLAPQHWIALTPPRIPQLRTLQDVVGYQDPVFL
DWLVGLAFPCQRPFDHQYGVDETPKWRILPDRFGAEANSPVMDNNGGGPLGVTELLLKATTVASYLKDDWSRDWGALQRL
TPYYPNAQPARLSLGTTTRSGLWNPAPLRH

>BL;1ppS, ML.tab 524929:526143 forward MW:43242
VGTATRRVQPKAWRALLTLLVISVVMPGVACNRGGGNVPVNVIGDKGTPFADLLVPKLTASVTDGAVGVNVDMPVTVTVA	(SEQ ID NO:331)
DGVLAAVTMINDNGRMINGQFSPDGLRWSTTEPLGFNRCYTLSAKALGLGGVVNRQMTFQTSSPAHLTMPYVNPGNGEIV
GIGEPVAIRFDENIANRLAAQKAITITANPPVEGAFYWLNNREVRWRPEHFWKSGTAVDVAVNTYGVDLGEGMFGEDNVK
THFTIGDEVFATADDATKMLTVRVNGEVVKIMPTSMGKDSTPTANGIYIVGARFKHIIMDSSTYGVPVNSPNGYRADVDW
ATQLSYSGVFLHSAPWSVGAQGHTNTSHGCLNVSPSNAQWFYDHVKRGDIVEVVNTVGDTLPGAEGLGDWNIPWEQWKAG
NANI

>BL;1ppX, ML.tab 188551:189252 forward MW:24411
MNDRKWVTSSVMLVTLSACLALGLSGCSSTKPDAQEQSSSSSPASSDPALTAEIKQSLETTKALSSVHVVVQTTGKVDAL	(SEQ ID NO:332)
LGISNADVDVQANPLAVKGTCTYNDQPGVPFRVLGDNISVKLFDDWSNLGSISDLSTSHVLDPNTGITQVLSGVINLQAQ
GTEVVDRIPTNKITGTVPTSSVKMLDPKAKGSKLATVWIAQDGSHHLVRASIDLGSGSIQLTQSKWNEPVNTN

>BL;1pqB, ML.tab 918368:920137 forward MW:61768
VMRGVLVIMRLLCLGMLFTGCAGVPNSSAPQAIGTVERPVPSNLPKPTPGMDPDVLLREFFKATADPANRHLAARQFLTQ	(SEQ ID NO:333)
SASNAWDDAGRALLIDHVVFVETRGAERVSATMRADILGSLSDMGVFETAEGVLPDPGPVELIKTSGCWRIDRLPNGVFL
DWQQFQATYKRNTLYFADPTGKTVVPDPRYVAVLGHDQLATELVSKLLAGPRPEMAHAVRNLLAPPLRLRGPVTRADGSK
SGIGRGYGGARIDLEKLSTTDPHSRQLLAAQIIWTLARADIRGPYVINADGAPLDDRFADGWTTSDVAATDPGVADGAGA
GLHALVGGALVSLIGQNTTTVLGAFGRMGYQTGAALSRSGRQVASVVTLRRGAPDMAASLWIGDLGGEAVQSADGHSLSR
PSWSLDDAVWVVVDTNNVLRAIPEPASGQPARIPVDSAAVASRFPGPITDLQLSRDGTRAAMVIGGQVILAGVEQTQAGQ
FALTYPRRLGFGLGSSVVSLSWRTGDDIVVTRTDATHPVSYVNLDGVNSDAPARGLQVPLSVIAANPSTVYVAGPQGVLQ
YSASVAESQQGWSEVAGLTVMGAEPVLPG

>BL;1pqE, ML.tab 409442:409993 reverse MW:19242
VSRFKISLPALATRVAVLGFLTLMASVLGGCGAGQISQTATQEPAVNGNRVTLNNLALRDIRIQAAQTGDFLQSGRTVDL	(SEQ ID NO:334)
MLVAINNSPYVTDRLVSITSDIGTVALNGYTQLPTNGMLFIGTSEGQRIKPPPLQSNNIAKAIVTLAKPITNGLTYNFTF
NFEKAGQANVAVPVSAGLAPRQT

>BL;1pqT, ML.tab 322399:323055 reverse MW:23455
MQAIRLGLHTAAAVVTLSISAVSCGTKTPDYQLILSKSSTTTTTTPDKPIPLPQYLESIGVTGQQVAPSSLPGLTVSIPT	(SEQ ID NO:335)
PPGWSPYSNPNITPETLIIAKSGKYPTARLVAFKLRGDFDPTQVIKHGNDDAQLFENFRQLDVSTANYNGFPSAMIQGSY
DLEGRRLHAWNRIVIPTGPPPSKQQYLVQLTITSLANEAVAQSNDIEAIIRGFVVAPK

>BL;1prG, ML.tab 674679:675395 reverse MW:24874
MQAPKHHRRLFAVLATLNTATAVIAGCSSGSNLSSGPLPDATTWVKQATDITKNVTSAHLVLSVNGKITGLPVKTLTGDL	(SEQ ID NO:336)
TTHPNTVASGNATITLDGADLNANFVVVDGELYATLTPSKWSDFGKASDIYDVASILNPDAGLANVLANFTGAKTEGRDS
INGQSAVRISGNVSADAVNKIAPPFNATQPMPATVWIQETGDHQLAQIRIDNKSSGNSVQMTLSNWDEPVQVTKPQVS

>BL;1sr2, ML.tab 305368:305706 forward MW:12164
MAKKVTVTLVDDFDGAGAADETVEFGLDGVTYEIDLTNKNAAKLRGDLRQWVSAGRRVGGRRRGRSNSGRGRGAIDREQS	(SEQ ID NO:337)
AAIREWARRNGHNVSTRGRIPADVIDAFHAAT

>BL;mihF, ML.tab 656895:657212 forward MW:11474
VALPQLTDEQRAAALEKAAAARRARAELKDRLKRGGTNLTQVLKDAESDEVLGKMKVSALLEALPKVGKVKAQEIMTELD	(SEQ ID NO:338)
IAPTRRLRGLGERQRKALLEKFGSA

>BL;mmpS3, ML.tab 1041502:1042383 forward MW:30891
MSGPNPPGRENEESDSGNELSGELDPHNGVESVDELVPVPDSDLVTASDHTSETEVYSQAYSAPEAEHFTAVPYVPADLR	(SEQ ID NO:339)
LYDYDESSVYDEPGAAPRWPWVVGVAAILAAISLVVSVSLLFTRTDTSKLSTPTTGRSTPPVQDEITTVKPPPPSTETST
ATETQTVTVTPLPPPSATSTAVPPSSVVPPPPTTPTTTVTTLTGPRQVTYSVTGTKAPGDIISVTYVDASCRRRTQHMVY
IPWSMTVTPISQSDVGSVEAFSLFRVSKLNCLITTSDGTVLSSNSNDAPQTSC

>BL;mtb12, ML.tab 753532:754035 forward MW:17130
MTMKSIATYAALAIIGAAVDGLTSMAIPTGPAASHIQPVAFGVPLPQDPAPAADVPTAAELTSLLNKIVDPDVSFMHKSQ	(SEQ ID NO:340)
LVEGGIGSAEAHIGDRELKNAAQKGELPLLFSVTNIRPGTSGSATADVSVSGPKLNPPVTQNITFINKGSWVLSRHSAME
LLQAAGR

>BL;whiB1, ML.tab 953665:953919 reverse MW:9318
MDWRHKAVCRDEDPELFFPVGNSGPAIAQIADAKLVCNRCPVTTECLAWALNTGQDSGVWGGMSEDERRALKRRNTRTKA	(SEQ ID NO:341)
RSGV

>BL;whiB2, ML.tab 903227:903496 forward MW:10119
VVPKALVAFEVESEPESSDQWQDRALCAQTDPEAFFPEKGGSTREAKKICLGCEVRHECLEYALAHDERFGIWGGLSERE	(SEQ ID NO:342)
RRRLKRGVI

>BL;whiB3, ML.tab 475771:476079 reverse MW:11576
MPQPKQLPGPNATIWNWQLQGLCRGVDSSMFFHPDGERGRARMQREQRAKEMCRRCPVIEECRAHALDVGEPYGVWGGLS	(SEQ ID NO:343)
ESERDLLLKGDLARSRSIPRSA

H. tuberculosis proteins that are potential targets for the diagnosis,
prophylaxis or treatment of mycobacterioses.
>BL;RV0007, H37RV2.tab 9914:10825 forward MW:31041
VTAPNEPGALSKGDGPNADGLVDRGGAHRAATGPGRIPDAGDPPPWQRAATRQSQAGHRQPPPVSHPEGRPTNPPAAADA	(SEQ ID NO:344)
RLNRFISGASAPVTGPAAAVRTPQPDPDASLGCGDGSPAEAYASELPDLSGPTPRAPQRNPAPARPAEGGAGSRGDSAAG
SSGGRSITAESRDARVQLSARRSRGPVRASMQIRRIDPWSTLKVSLLLSVALFFVWMITVAPLYLVLGGMGVWAKLNSNV
GDLLNNASGSSAELVSSGTIFGGAFLIGLVNIVLMTALATIGAFVYNLITDLIGGIEVTLADRD

>BL;Rv0010C, H37RV2.tab 13136:13558 reverse MW:15166
MQQTAWAPRTSGIAGCGAGGVVMAIASVTLVTDTPGRVLTGVAALGLILFASATWRARPRLAITPDGLAIRGWFRTQLLR	(SEQ ID NO:345)
NSNIKIIRIDEFRRYGRLVRLLEIETVSGGLLILSRWDLGTDPVEVLDALTAAGYAGRGQR

>BL;Rv0011c, H37RV2.tab 13717:13995 reverse MW:10429
MPKSKVRKKNDFTVSAVSRTPMKVKVGPSSVWFVSLFIGLMLIGLIWLMVFQLAAIGSQAPTALNWMAQLGPWNYAIAFA	(SEQ ID NO:346)
FMITGLLLTMRWH

>BL;RV0020C, H37RV2.tab 23864:25444 reverse MW:56880
MGSQKRLVQRVERKLEQTVGDAFARIFGGSIVPQEVEALLRREAADGIQSLQGNRLLAPNEYIITLGVHDFEKLGADPEL	(SEQ ID NO:347)
KSTGFARDLADYIQEQGWQTYGDVVVRFEQSSNLHTGQFRARGTVNPDVETHPPVIDCARPQSNHAFGAEPGVAPMSDNS
SYRGGQGQGRPDEYYDDRYARPQEDPRGGPDPQGGSDPRGGYPPETGGYPPQPGYPRPRHPDQGDYPEQIGYPDQGGYPE
QRGYPEQRGYPDQRGYQDQGRGYPDQGQGGYPPPYEQRPPVSPGPAAGYGAPGYDQGYRQSGGYGPSPGGGQPGYGGYGE
YGRGPARHEEGSYVPSGPPGPPEQRPAYPDQGGYDQGYQQGATTYGRQDYGGGADYTRYTESPRVPGYAPQGGGYAEPAG
RDYDYGQSGAPDYGQPAPGGYSGYGQGGYGSAGTSVTLQLDDGSGRTYQLREGSNIIGRGQDAQFRLPDTGVSRRHLEIR
WDGQVALLADLNSTNGTTVNNAPVQEWQLADGDVIRLGHSEIIVRMH

>BL;Rv0039C, H37RV2.tab 42007:42351 reverse MW:11292
MFLAGVLCMCAAAASALFGSWSLCHTPTADPTALALRAMAPTQLAAAVMLAAGGVVAVAAPGHTALMVVIVCIAGAVGTL	(SEQ ID NO:348)
AAGSWQSAQYALRRETASPTANCVGSCAVCTQACH

>BL;Rv0040c, H37RV2.tab 42434:43365 reverse MW:31923
MIQIARTWRVFAGGMATGFIGVVLVTAGKASADPLLPPPPIPAPVSAPATVPPVQNLTALPGGSSNRFSPAPAPAPIASP	(SEQ ID NO:349)
IPVGAPGSTAVPPLPPPVTPAISGTLRDHLREKGVKLEAQRPHGFKALDITLPMPPRWTQVPDPNVPDAFVVIADRLGNS
VYTSNAQLVVYRLIGDFDPAEAITHGYIDSQKLLAWQTTNASMANFDGFPSSIIEGTYRENDMTLNTSRRHVIATSGADK
YLVSLSVTTALSQAVTDGPATDAIVNGFQVVAHAAPAQAPAPAPGSAPVGLPGQAPGYPPAGTLTPVPPR

>BL;Rv0049, H37RV2.tab 52831:53241 forward MW:15000
VDYTLRRRSLLAEVYSGRTGVSEVCDANPYLLRAAKFHGKPSRVICPICRKEQLTLVSWVFGEHLGAVSGSARTAEELIL	(SEQ ID NO:350)
LATRFSEFAVHVVEVCRTCSWNHLVKSYVLGAARPARPPRGSGGTRTARNGARTASE

>BL;Rv0051, H37RV2.tab 55696:57375 forward MW:61209
VTGALSQSSNISPLPLAADLRSADNRDCPSRTDVLGAALANVVGGPVGRHALIGRTRLMTPLRVMFAIALVFLALGWSTK	(SEQ ID NO:351)
AACLQSTGTGPGDQRVANWDNQRAYYQLCYSDTVPLYGAELLSQGKFPYKSSWIETDSNGTPQLRYDGQIAVRYMEYPVL
TGIYQYLSMAIAKTYTALSKVAPLPVVAEVVMFFNVAAFGLALAWLTTVWATSGLAGRRIWDAALVAASPLVIFQIFTNF
DALATGLATSGLLAWARRRPVLAGVLIGLGSAAKLYPLLFLYPLLLLGIRAGRLNALARTMAAAAATWLLVNLPVMLLFP
RGWSEFFRLNTRRGDDMDSLYNVVKSFTGWRGFDPTLGFWEPPLVLNTVVTLLFVLCCAAIAYIALTAPHRPRVAQLTFL
TVASFLLVNKVWSPQFSLWLVPLAVLALPHRRILLAWMTIDALVWVPRMYYLYGNPSRSLPEQWFTTTVLLRDIAVMVLC
GLVWQIYRPGRDLVRTGGPGALPACGGVDDPVGGVFANAAPPGRLPSWLRPRLGDEHRERTPDAGRDRTFSGQHRA

>BL;RV0093C, H37RV2.tab 102818:103663 reverse MW:29599
VLAQATTAGSFNHHASTVLQGCRGVPAAMWSEPAGAIRRHCATIDGMDCEVAREALSARLDGERAPVPSARVDEHLGECS	(SEQ ID NO:352)
ACRAWFTQVASQAGDLRRLAESRPVVPPVGRLGIRRAPRRQHSPMTWRRWALLCVGIAQIALGTVQGFGLDVGLTHQHPT
GAGTHLLNESTSWSIALGVIMVGAALWPSAAAGLAGVLTAFVAILTGYVIVDALSGAVSTTRILTHLPVVIGAVLAIMVW
RSASGPRPRPDAVAAEPDIVLPDNASRGRRRGHLWPTDGSAA

>BL;RV0098, H37RV2.tab 107600:108148 forward MW:20528
MSHTDLTPCTRVLASSGTVPIAEELLARVLEPYSCKGCRYLIDAQYSATEDSVLAYGNFTIGESAYIRSTGHFNAVELIL	(SEQ ID NO:353)
CFNQLAYSAFAPAVLNEEIRVLRGWSIDDYCQHQLSSMLIRKASSRFRKPLNPQKFSARLLCRDLQVIERTWRYLKVPCV
IEFWDENGGAASGEIELAALNIP

>BL;Rv0100, H37RV2.tab 109783:110016 forward MW:8660
VRDRILAAVCDVLYIDEADLIDGDETDLRDLGLDSVRFVLLMKQLGVNRQSELPSRLAANPSIAGWLRELEAVCTEFG	(SEQ ID NO:354)

>BL;Rv0116c, H37Rv2.tab 140270:141022 reverse MW:26915
MRRVVRYLSVVVAITLMLTAESVSIATAAVPPLQPIPGVASVSPANGAVVGVAHPVVVTFTTPVTDRRAVERSIRISTPH	(SEQ ID NO:355)
NTTGHFEWVASNVVRWVPHRYWPPHTRVSVGVQELTEGFETGDALIGVASISAHTFTVSRNGEVLRTMPASLGKPSRPTP
IGSFHAMSKERTVVMDSRTIGIPLNSSDGYLLTAHYAVRVTWSGVYVHSAPWSVNSQGYANVSHGCINLSPDNAAWYFDA
VTVGDPIEVVG

>BL;Rv0146, H37Rv2.tab 172211:173140 forward MW:34016
MRTHDDTWDIKTSVGATAVMVAAARAVETDRPDPLIRDPYARLLVTNAGAGAIWEAMLDPTLVAKAAAIDAETAAIVAYL	(SEQ ID NO:356)
RSYQAVRTNFFDTYFASAVAAGIRQVVILASGLDSRAYRLDWPAGTIVYEIDQPKVLSYKSTTLAENGVTPSAGRREVPA
DLRQDWPAALRDAGFDPTARTAWLAEGLLMYLPAEAQDRLFTQVGAVSVAGSRIAAETAPVHGEERRAEMRARFKKVADV
LGIEQTIDVQELVYHDQDRASVADWLTDHGWRARSQRAPDEMRRvGRWVEGVPMADDPTAFAEFVTAERL

>BL;Rv0164, H37Rv2.tab 193626:194180 forward MW:20165
MTAISCSPRPRYASRMPVLSKTVEVTADAASIMAIVADIERYPEWNEGVKGAWVLARYDDGRPSQVRLDTAVQGIEGTYI	(SEQ ID NO:357)
HAVYYPGENQIQTVMQQGELFAKQEQLFSVVATGAASLLTVDMDVQVTMPVPEPMVKNLLNNVLEHLAENLKQPAEQLAA
S#GMCGLSRRLRSQPGPPSACVPHR

>BL;Rv0175, H37Rv2.tab 206814:207452 forward MW:22324
VKAADSAESDAGADQTGPQVKAADSAESDAGELGEDACPEQALVERRPSRLRRGWLVGIAATLLALAGGLGAAGYFALRS	(SEQ ID NO:358)
HQESQSIAREDLAAIEAAKDCVAATQAPDAGANSASMQKIIECGTGDFGAQASLYTSMLVEAYQAASVHVQVTDMRAAVE
RNNNDGSVDVLVALRVKVSNTDSDAHEVGYRLRVRMALDEGRYKIAKLDQVTK

>BL;Rv0176, H37Rv2.tab 207452:208417 forward MW:35405
VTVVVEKTPTTLPQATPNGAAPWHVRAGAFAIDVLPGLAVAATMALTALTVPPGSAWRWLCACLLGLTILLLAVNRLLLP	(SEQ ID NO:359)
TITGWSLGRALTGIRVVRRDGSAIGPWRLLVRDLAHLVDTLSLFVGWLWPLWDSRRRTFADLLLRTEVRRVEPVQRPAVI
RRLTAAVALAAAGACASATAVGAAVVYVNEWQTDHTRAQLATRGPKLVVDVLSYDPETVQRDFERARSLATDRYRPQLSI
QQDSVRESGPVRNQYWVTDSAVLSATPAQATMLLFMQGERGTPPNQRYIQSTVRAIFQKSRGQWRLDDLAVVMKPRQPTG
EK

>BL;Rv0177, H37Rv2.tab 208417:208968 forward MW:20164
MSPRRKFEPGEGALLAPQSIEPSRRWGLPLALTASAVVMAAAISACALMRISHESHQRAAHKDIVMLSDVRSFMTMFTSP	(SEQ ID NO:360)
DPFHANEYAERVLSHATGDFAKQYHERANDILIRISGVEPTTGTVLDAGVQRWNEDGSANVLVVTQITSKSADGKRVVSN
ANRWLVTAKQEGNEWKISSLLPVI

>BL;Rv0178, H37Rv2.tab 208938:209669 forward MW:25879
VEDQQSASGDLTQKSVANGESTDTASAATEGHRGEIDAAGEPDERGAAVADSQADEDDSAATAARGGKTRARRSRGRRLA	(SEQ ID NO:361)
ITVGVAAALFVGSAAFAGATVEPYLSERAVVATKLMVARTAANAITTLWTYTPENMDTLADRAANYLSGDFAAQYRRFVD
QIAAANKQAXITNDTEVTGAAVESLSGRDAVAIVYTNTTTTSPVTKNIPALKYLSYRLFMKRYDARWLVTRMTTITSLDL
TPQV

>BL;Rv0184, H37Rv2.tab 214969:215715 forward MW:26826
MTNDKMLARIAALLRQAEGTDNPHEADAFMSTAQRLATAASIDLAVARSHAGNRSPAQAPTQRTITIGAAGTRGLRTYVQ	(SEQ ID NO:362)
LFVLIAAANDVRCDVASNSTFVYAYGFAEDIDTSHALYASLVVQMVRASDAYLASGAHRPTPTITARLNFQLAFGARVGQ
RLADAREQTRQEATKDRDRPPGTAIALRDKDIELHEYYRRSSKARGAWRASRATAGYSSAARRAGDRAGRQARLGNNPEL
PGARAALGR

>BL;Rv0185, H37Rv2.tab 215715:216221 forward MW:18365
VIGADVPRDSQRARVYAAEAFVRTLFDRvTAHGSPTVEFFGTQLTLPPEGRFGSVASVQRYVDDVLALPAVGQNWPTVSP	(SEQ ID NO:363)
VRVRARRAATAAHYENHGGTGTIAVPDRHTAGWANRELVVLHEVAHHLCQVPPPHGPEFVATVCTLTELVMGPEVGHVFR
VVYAQEGVR

>BL;Rv0199, H37Rv2.tab 236550:237206 forward MW:23520
MPDGEQSQPPAQEDAEDDSRPDAAEAAAAEPKSSAGPMFSTYGIASTLLGVLSVAAVVLGAMIWSAHRDDSGERTYLTRV	(SEQ ID NO:364)
MLTAAEWTAVLINMNADNIDASLQRLHDGTVGQLNTDFDAVVQPYRQVVEKLRTHSSGRIEAVAIDTVHRELDTQSGAAR
PVVTTKLPPFATRTDSVLLVATSVSENAGAKPQTVHWNLRLDVSDVDGKLMISRLESIR

>BL;Rv0200, H37Rv2.tab 237206:237892 forward MW:24029
MRNAWRLVVFDVLAPLATIAALAAIGVLLGWPLWWVSTCSVLVLLVVEGVAINFWLLRRDSVTVGTDDDAPGLRLAVVFL	(SEQ ID NO:365)
CAAAISAAVVTGYLRWTTPDRDFNRDSREVVHLATGMAETVASFSPSAPAAAVDRAAANMVPEHAGGFKEQYAKSSADLA
RRGVTAQAATLAAGVEAIGPSAASVAVILRVSQSIPGQPTSQAARALRVTLTKRGSGWLVLDVTPINAR

>BL;Rv0201c, H37Rv2.tab 237895:238395 reverse MW:18484
VTLAAEPHPAPPQQPTVAWSEPDVDRRVEFWPTVAIRSALESGDIATWQRIAAALKRDPYGRTARQVEEVLEGIPATGIA	(SEQ ID NO:366)
NAFWEVLDRARTHLDANERAEVARQVGLLLDRSGLQRQEFASRIGVTAQDLTAYLDGIVSPSASLMIRMRRLSDRFVRAK
SVRAADS

>BL;Rv0207c, H37Rv2.tab 247387:248112 reverse MW:26175
MSLTEDVTSQTSESLARHSVLAEDLSQDGLTSLGAPGARvLLVWDAPNLDMGLGSILGRRPTALERPRFDALGRWLLART	(SEQ ID NO:367)
AEIVAGRPGISTEPEATVFTNIAPGSAEVVRPWVDALRNVGFAVFAKPKVDEDSDVDRDMLAHIDERYREGLAALVVASA
DGQAFRQPLEAVARSGTPVQVLGFREHASWALASDTLEFVDLEDIAGVFREPLPRIGLDSLPEQGAWLQPFRPLSSLLTS
RV

>BL;Rv0216, H37Rv2.tab 258913:259923 forward MW:35756
VASGYGGIRvGGPYFDDLSKGQVFDWAPGVTLSLGLAAAHQSIVGNRLRLALDSDLCAAVTGMPGPLAHPGLVCDVAIGQ	(SEQ ID NO:368)
STLATQRVKANLFYRGLRFHRFPAVGDTLYTRTEVVGLRANSPKPGRAPTGLAGLRMTTIDRTDRLVLDFYRCANLPASP
DWKPGAVPGDDLSRIGADAPAPAADPTAHWDGAVFRKRVPGPHFDAGIAGAVLHSTADLVSGAPELARLTLNIAATHHDW
RVSGRRLVYGGHTIGLALAQATRLLPNLATVLDWESCDHTAPVHEGDTLYSELHIESAQAHADGGVLGLRSLVYAVSDSA
SEPDRQVLDWRFSALQF

>BL;Rv0226c, H37Rv2.tab 269837:271564 reverse MW:59107
VRWFRPGYALVLVLLLAAPLLRPGYLLLRDAVSTPRSYVSANALGLTSAPRATPQDFAVALASHLVDGGVVVKALLLLGL	(SEQ ID NO:369)
WLAGWGAARLVATALPAAGAAGQFVAITLAIWNPYVAERLLQGHWSLLVGYGCLPWVATAMLTMRTTVGAGWFGLFGLAF
WVALAGLTPSGLLLAATVAVVCVANPGAGRPRWQCGVAALGSALVGALPWLTASALGSSLTSHTAANQLGVTAFAPRAEP
GLGTLGSLASLGGIWNGEAVPSSRTTLFAVASAVVLLANVAIGLPTVARRPVAVPLLTLAAVSVMVPAVLATGPGLHALR
VVVDAAPGLGVLRDGQKWVALAVPGYTLSGAGTVLTLRRWLRPATAAVVCCLALVLTLPDLAWGVWGKVAPVHYPSGWAA
VAAAINADPRTVAVLPAGTMRRFSWSGSAPVLDPLPRWVRADVLTTGDLVISGVTVPGEDAHARAVQELLLTGPHPSTLA
AAGVGWLVVESDSAGDMGAAARTLGRLAAAHRDDELALYRVGGQTSGASSARLKATMLAHWAWLSMLLVGGAGAAGYWVR
RHLHHCEDTPASRAQD

>BL;Rv0227c, H37Rv2.tab 271577:272839 reverse MW:45528
MLRFAACGAIGLGAALLIAALLLSTYTTSRIAEIPLDIDATLISDGTGTALDSASLATEHIVVNQDVPLVSQQQVTVESP	(SEQ ID NO:370)
ANADVVTLQVGSSLRRTDKQKDSGLLLAIVDTVTLNRKTAMAVSDDTHTGGAVQKPRGLNDENPPTAIPLRHDGLSYRFP
FHTEKKTYPYFDPIAQKAFDANYEGEEDVNGLTTYRFTQNVGYTPEGKLVAPLKYPSLYAGDEDGKVTTSAANWGLPGDP
NEQITMTRYYAAQRTFWVDPVSGTIVKETERANNYFARDPLKPEVTFADYOVTSTEETVESQVNAARDERDRLALWSRVL
PITFTAAGLVALVGGGLFASFSLRTEGALMAASGDRDDHDYRRGGFEEPVPGAEAETEKLPTQRPDFPREPSGSDPPRLG
SAQPPPPPDAGHPDPGPPERR

>BL;Rv0236A, H37Rv2.tab 286898:287071 reverse MW:5833
MNRIVAPAAASVVVGLLLGAAAIFGVTLMVQQDKKPPLPGGDPSSSVLNRvEYGNRS	(SEQ ID NO:372)

>BL;Rv0236c, H37Rv2.tab 282652:286851 reverse MW:146250
VAPLSRKWLPVVGAVALALTFAQSPGQVSPDTKLDLTANPLRFLARATNLWNSDLPFGQAQNQAYGYLFPHGTFFVIGHL	(SEQ ID NO:373)
LGVPGWVTQRLWWAVLLTVGFWGLLRvAEALGVGGPSSRvVGAVAFALSPRVLTTLGSISSETLPMMLAPWVLLPTILAL
RGTSGRSVRALAAQAGLAVALMGAVNAIATLAGCLPAVIWWACHRPNRLWWRYTAWWLLAMALATLWWVMALTQLNGVSP
PFLDPIESSGVTTQWSSLVEVLRGTDSWTPFVAPNATAGAPLVTGSAAILGTCLVAAAGLAGLTSPAMPARGRLVTMLLV
GVVLLAVGHRGGLASPVAHPVQAFLDAAGTPLRNVHKVGPVIRLPLVLGLAQLLSRVPLPGSAPRPAWLRAFAHPERDKR
VAVAVVALTALMVSTSLAWTGRVAPPGTFGALPQYWQEAADWLRTHHAATPTPGRVLVVPGAPFATQVWGTSHDEPLQVL
GDGPWGVRDSIPLTPPQTIRALDSVQRLFAAGRPSAGLADTLARQGISYVLVRNDLDPETSRSARPILLHRSIAGSPGLA
KLAEFGAPVGPDPLAGFVNDSGLRPRYPAIEIYRVSAPANPGAPYFAATDQLARvDGGPEVLLRLDERRRLQGQPPLGPV
LMTADARAAGLPVPQVAVTDTPVARETDYGRVDHHSSAIRAPGDARHTYNRVPDYPVPGAEPVVGGWTGGRITVSSSSAD
ATAMPDVAPASAPAAAVDGDPATAWVSNALQAAVGQWLQVDFDRPVTNAVVTLTPSATAVGAQVRRILIETVNGSTTLRF
DEAGKPLTAALPYGETPWVRFTAAATDDGSAGVQFGITDLAITQYDASGFAHPVQLRHTVLVPGPPPGSAIAGWDLGSEL
LGRPGCAPGPDGVRCAASMALAPEEPANLSRTLTVPRPVSVTPMVWVRPRQGPKLADLIAAPSTTRASGDSDLVDILGSA
YAAADGDPATAWTAPQRvVQHKTPPTLTLTLPRPTVVTGLRLAASRSMLPAHPTVVAINLGDGPQVRQLQVGELTTLWLH
PRVTDTVSVSLLDWDDVIDRNALGFDQLKPPGLAEVVVLSAGGAPIAPADAARNRARALTVDCDHGPVVAVAGRFVHTSI
RTTVGALLDGEPVAALPCEREPIALPAGQQELLISPGAAFVVDGAQLSTPGAGLSSATVTSAETGAWGPTHREVRVPESA
TSRVLVVPESINSGWVARTSTGARLTPIAVNGWQQAWVVPAGNPGTITLTFAPNSLYRASLAIGLALLPLLALLAFWRTG
RRQLADRPTPPWRPGAWAAAGVLAAGAVIASIAGVMVMGTALGVRYALRRRERLRDRvTVGLAAGGLILAGAALSRHPWR
SVDGYAGNWASVQLLALISVSVVAASVVATSESRGQDRMQ

>BL;2V0241c, H37Rv2.tab 289815:290654 reverse MW:30163
VTQPSGLKNLLRAAAGALPVVPRTDQLPNRTVTVEELPIDPANVAAYAAVTGLRYGNQVPLTYPFALTFPSVMSLVTGFD	(SEQ ID NO:374)
FPFAAMGAIHTENHITQYRPIAVTDAVGVRVRAENLREHRRGLLVDLVTNVSVGNDVAWHQVTTFLHQQRTSLSGEPKPP
PQKKPKLPPPAAVLRITPAKIRRYAAVCGDHNPIHTNPIAAKLFGFPTVIAHGMFTAAAVLANIEARFPDAVRYSVRFAK
PVLLPATAGLYVAEGDGGWDLTLRNMAKGYPHLTATVRGL

>BL;Rv02500, H37Rv2.tab 301738:302028 reverse MW:10878
LSTTAELAELHDLVGGLRRCVTALKARFGDNPATRRIVIDADRILTDIELLDTDVSELDLERAAVPQPSEKIAIPDTEYD	(SEQ ID NO:375)
REFWRDVDDEGVGGHRY

>BL;Rv0257, H37Rv2.tab 309699:310071 forward MW:13053
MTRVSWLPDRCLPRLPACGRGLRGSLPGDSGGTAPDSHRLPASSSPDGKNIGMQSVDLHVERHLPSRGRSNRTVATVTCV	(SEQ ID NO:376)
TALGDIRSAQLSATGAWPAVLFPSWSWLCGIGGGVDLQKPSCRA

>BL;Rv0283, H37Rv2.tab 344022:345635 forward MW:55943
MTNQQHDHDFDHDRRSFASRTPVNNNPDKVVYRRGFVTRHQVTGWRFVMRRIAAGIALHDTRMLVDPLRTQSRAVLMGVL	(SEQ ID NO:377)
IVITGLIGSFVFSLIRPNGQAGSNAVLADRSTAALYVRVGEQLHPVLNLTSARLIVGRPVSPTTVKSTELDQFPRGNLIG
IPGAPERMVQNTSTDANWTVCDGLNAPSRGGADGVGVTVIAGPLEDTGARAAALGPGQAVLVDSGAGTWLLWDGKRSPID
LADHAVTSGLGLGADVPAPRIIASGLFNAIPEAPPLTAPIIPDAGNPASFGVPAPIGAVVSSYALKDSGKTISDTVQYYA
VLPDGLQQISPVLAAILRNNNSYGLQQPPRLGADEVAKLPVSRVLDTRRYPSEPVSLVDVTRDPVTCAYWSKPVGAATSS
LTLLAGSALPVPDAVHTVELVGAGNGGVATRVALAAGTGYFTQTVGGGPDAPGAGSLFWVSDTGVRYGIDNEPQGVAGGG
KAVEALGLNPPPVPIPWSVLSLFVPGPTLSRADALLAHDTLVPDSRPARPVSAEGGYR

>BL;Rv0288, H37Rv2.tab 351848:352135 forward MW:10390
MSQIMYNYPMLGHAGDMAGYAGTLQSLGAEIAVEQAALQSAWQGDTGITYQAWQAQWNQANEDLVRAYHAMSSTHEANT	(SEQ ID NO:378)
MAMMARDTAEAAKWGG

>BL;Rv0289, H37Rv2.tab 352149:353033 forward MW:31559
MDATPNAVELTVDNAWFIAETIGAGTFPWVLAITMPYSDAAQRGAFVDRQRDELTRMGLLSPQGVINPAVADWIKVVCFP	(SEQ ID NO:379)
DRWLDLRYVGPASADGACELLRGIVALRTGTGKTSNKTGNGVVALRNAQLVTFTAMDIDDPRALVPILGVGLAHRPPARF
DEFSLPTRvGARADERLRSGVPLGEVVDYLGIPASARPVVESVFSCPRSYVEIVAGCNRDGRHTTTEVGLSIVDTSAGRV
LVSPSRAFDGEWVSTFSPGTPFAIAVAIQTLTACLPDGQWFPGQRvSRDFSTQSS

>BL;Rv0290, H37Rv2.tab 353083:354498 forward MW:47944
MSGTVMQIVRVAILADSRLTEMALPAELPLREILPAVQRLVVPSAQNGDGGQADSGAAVQLSLAPVGGQPFSLDASLDTV	(SEQ ID NO:380)
GVVDGDLLVLQPVPAGPAAPGIVEDIADAANIFSTSRLKPWGIAHIQRGALAAVIAVALLATGLTVTYRvATGVLAGLLA
VAGIAVASALAGLLITIRSPRSGIALSIAALVPIGAALALAVPGKFGPAQVLLGAAGVAAWSLIALMIPSAERERVVAFF
TAAAVVGASVALAAGAQLLWQLPLLSIGCGLIVAALLVTIQAAQLSALWARFPLPVIPAPGDPTPSAPPLRLLEDLPRRV
RVSDAHQSGFIAAAVLLSVLGSVAIAVRPEALSVVGWYLVAATAAAATLRARVWDSAACKAWLLAQPYLVAGVLLVFYTA
TGRYVAAFGAVLVLAVLMLAWVVVALNPGIASPESYSLPLRRLLGLVAAGLDVSLIPVMAYLVGLFAWVLNR

>BL;Rv0292, H37Rv2.tab 355880:356872 forward MW:35932
MNPIPSWPGRGRVTLVLLAVVPVALAYPWQSTRDYVLLGVAAAVVIGLFGFWRGLYFTTIARRGLAILRRRRRIAEPATC	(SEQ ID NO:381)
TRTTVLVWVGPPASDTNVLPLTLIARYLDRYGIRADTIRITSRVTASGDCRTWVGLTVVADDNLAALQARSARIPLQETA
QVAARRLADHLREIGWEAGTAAPDEIPALVAADSRETWRGMRHTDSDYVAAYRVSANAELPDTLPAIRSRPAQETWIALE
IAYAAGSSTRYTVAAACALRTDWRPGGTAPVAGLLPQHGNHVPALTALDPRSTRRLDGHTDAPADLLTRLHWPTPTAGAH
RAPLTNAVSRT

>BL;Rv0309, H37Rv2.tab 377931:378584 forward MW:22528
MSRLLALLCAAVCTGCVAVVLAPVSLAVVNPWFANSVGNATQVVSVVGTGGSTAKMDVYQRTAAGWQPLKTGITTHIGSA	(SEQ ID NO:382)
GMAPEAKSGYPATPMGVYSLDSAFGTAPNPGGGLPYTQVGPNHWWSGDDNSPTFNSMQVCQKSQCPFSTADSENLQIPQY
KHSVVMGVNKAKVPGKGSAFFFHTTDGGPTAGCVAIDDATLVQIIRWLRPGAVIAIAK

>BL;Rv0313, H37Rv2.tab 382490:382873 forward MW:13916
VGDYGPFGFDPDEFDRVIREGSEGLRDAFERIGRFLSSSGAGTGWSAIFEDLSRRSRPAPETAGEAGDGVWAIYTVDADG	(SEQ ID NO:383)
GARVEQVYATELDALRANKDNTDPKRKVRFLPYGIAVSVLDDPVDEAQ

>BL;Rv0356c, H37Rv2.tab 434833:435474 reverse MW:22879
VTDASVHPDELDPEYHHHGGFPEYGPASPGAGFGQFVATMRRLQDLAVAADPGDAVWDEAAERAAALVELLSPFEADEGK	(SEQ ID NO:384)
APAGRTPGLPGMGSLLLPPWTVTRYGTDGVEMRGSFSRFHVGGNSAVHGGVLPLLFDHMFGMISHAAGRPISRTAFLHVD
YRRITPIDVPLIVRGRVTNTEGRKAFVCAELFDSDETLLAEGNGLMVRLLPGQP

>BL;Rv0358, H37Rv2.tab 436860:437504 forward MW:23102
MYTAENAPGVAVLLSGDADVPGPLTGLPTHQDNLDTVIGRYSRLIVVGADADLGAVLTRLLRTDRLDVEVGYVPRRRSPA	(SEQ ID NO:385)
TRAYRLPAGRRAARRARCGVARRVPLIRDETGSVIVGRAQWLPAEEQALIHGEAVVDDTVLFDGDVAGVCIEPTLTLPGL
RAAVDGAGKWRRWIGGRAAQLGTTGAAVLRDGVAAPFPVRRSTFYRNVEGWLLVR

>BL;Rv0360c, 1137Rv2.tab 438305:438739 reverse MW:15297
VTKRTITPMTSMGDLLGPEPILLPGDSDAEAELLANESPSIVAAAHPSASVAWAVLAEGALADDKTVTAYAYARTGYHRG	(SEQ ID NO:386)
LDQLRRHGWKGRGPVPYSHQPNRGFLRCVAALARAAAAIGETDEYGRCLDLLDDCDPAARPALGL

>BL;Rv0361, H37Rv2.tab 438822:439646 forward MW:29982
MSNAPEPDRSAGESGSEPAGERSADPGEERTESYPLVPHDAETETVVITTSDNDAAVTQPEAQRERRFTAPGFDAKETQV	(SEQ ID NO:387)
IVTAHEAATEVFQTNQAPTTPPRMPTGMPPKTAVPQSIPPRTEATSVRQRTWGWALAVVVIVLALAAIAILGTVLLTRGK
HSKMSQEDQVRQAIQSLDIAIQTGDLTALRSLTCGSTRDGYVDYDERDWAETYRRvSAAKQYPVIASIDQVVVNGAHAEA
NVTTFMAFDPQVRSTRSLDLQFRDDQWKICQSSSN

>BL;Rv0383c, H37Rv2.tab 458464:459315 reverse MW:31801
MVPLWFTLSALCFVGAVVLLYVDIDRRRGRSRRRKSWARSHGFDYERESTEILKRWTRGVMSTVGDVAAHNVVLGQIRGE	(SEQ ID NO:388)
AVYIFDLEEVATVIALHRKVGTNVVVDLRLKGLKEPRESDIWLLGAIGPRMVYSTNLDAARRACDRRMVTFAHTAPDCAE
IMWNEQNWTLVSMPIASTRAQWDEGLRTVRQFNDLLRVLPPLPQEMPQQTGVGPRGAAPGRPVAPGGPAELPPRRAQPDP
ATTVLPDPARRAPEPIRRDEGRSEGVRRPPPAGRNGQQATNYQH

>BL;Rv0401, H37Rv2.tab 479789:480157 forward MW:12641
MRPRRALAGLAADVVAVLVFCAVGRRSHAEGLSVTGLAATAWPFLTGTGIGWVLARGWRRPTALAPTGVIVWLCTIWGM	(SEQ ID NO:389)
VLRKVSSAGVAASFVVVASAVTAVLLLGWRAAVALMAPHRADG

>BL;Rv0416, H137Rv2.tab 502167:502370 forward MW:7367
MIVVVNEQQVEVDEQTTIAALLDSLGFGDRGIAVALNFSVLPRSDWATKICELRKPVRLEVVTAVQGG	(SEQ ID NO:390)

>BL;Rv0430, H37Rv2.tab 518733:519038 forward MW:11723
MDSAMARAIRSGDDAEVADGLTRREHDILAFERQWWKFAGVKEEAIKELFSMSATRYYQVLNALVDRPEALAADPMLVKR	(SEQ ID NO:391)
LRRLRASRQKARAARRLGFEVT

>BL;Rv0431, H37Rv2.tab 519073:519564 forward MW:16905
VLVTVGSMNERVPDSSGLPLRAMVMVLLFLGVVFLLLVWQALGSSPNSEDDSSAISTMTTTTAAPTSTSVKPAAPRAEVR	(SEQ ID NO:392)
VYNISGTEGAAARTADRLKAAGFTVTDVGNLSLPDVAATTVYYTEVEGERATADAVGRTLGAAVELRLPELSDQPPGVIV
VVTG

>BL;Rv0455c, H37Rv2.tab 545378:545821 reverse MW:16639
MSRLSSILRAGAAFLVLGIAAATFPQSAAADSTEDFPIPRRMIATTCDAEQYLAAVRDTSPVYYQRYMIDFNNHANLQQA	(SEQ ID NO:393)
TINKANWFFSLSPAERRDYSEHFYNGDPLTFAWVNHMKIFFNNKGVVAKGTEVCNGYPAGDMSVWNWA

>BL;Rv0463, H37Rv2.tab 554016:554306 forward MW:10111
MTRRASTDTPQIIMGAIGGVTGYILWLAAISVGDGLTTVSQWSRVVLLLSVLVAVCGAAGGLRLRSRGKLAWSAFAFSL	(SEQ ID NO:394)
PIPPVVLTVAVLADIYL

>BL;Rv0464C, H37Rv2.tab 554316:554885 reverse MW:21304
MTGQNGQVARISPGKFRQLGPVNWLVAKLAARAVGAPQMHLFTTLGYRQYLFWTFAIYTGRLLHGRLPGVDTELVILRVA	(SEQ ID NO:395)
HLRSCEYELQHHRRMARRRGLDANTQATIFAWPDVPDGDGPRKVLSARQQALLQATDELIKDRTITAGTWERLATNLDPR
LLIEFCLLATQYDAIAATITALAIPPDNPQ

>BL;Rv0466, H37Rv2.tab 556458:557249 forward MW:30153
VSLDKKLMPVPDGHPDVFDREWPLRVGDIDRAGRLRLDAACRHIQDIGQDQLREMGFEETHPLWIVRRTMVDLIRPIEFG	(SEQ ID NO:396)
DMLRCRRWCSGTSNRWCEMRVRVDGRKGGLIESEAFWIHVNRETEMPARIADDFLAGLHRTTSVDRLRWKGYLKPGSRDD
ASEIHEFPVRVTDIDLFDHMNNAVYWSVIEDYLASHAELLRGPLRVTIEHEAPVALGDKLEIISHVHPAGSTEIFGPGLV
DRAVTTLTYVVGDEPKAVASLFNL

>BL;Rv0476, H37Rv2.tab 566508:566768 forward MW:9166
MLVLLVAVLVTAVYAFVHAALQRPDAYTAADKLTKPVWLVILGAAVALASILYPVLGVLGMAMSACASGVYLVDVRPKLL	(SEQ ID NO:397)
EIQGKSR

>BL;Rv0477, H37Rv2.tab 566776:567219 forward MW:15658
MKALVAVSAVAVVALLGVSSAQADPEADPGAGEANYGGPPSSPRLVDHTEWAQWGSLPSLRVYPSQVGRTASRRLGMAAA	(SEQ ID NO:398)
DAAWAEVLALSPEADTAGMRAQFICHWQYAEIRQPGKPSWNLEPWRPVVDDSEMLASGCNPGSPEESF

>BL;Rv0479C, H37Rv2.tab 567924:568967 reverse MW:37016
VTNPQGPPNDPSPWARPGDQGPLARPPASSEASTGRLRPGEPAGHIQEPVSPPTQPEQQPQTEHLAASHAHTRRSGRQAA	(SEQ ID NO:399)
HQAWDPTGLLAAQEEEPAAVKTKRRARRDPLTVFLVLIIVFSLVLAGLIGGELYARHVANSKVAQAVACVVKDQATASFG
VAPLLLWQVATRHFTNISVETAGNQIRDAKGMQIKLTIQNVRLKNTPNSRGTIGALDATITWSSEGIKESVQNAIPILGA
FVTSSVVTHPADGTVELKGLLNNITAKPIVAGKGLELQIINFNTLGFSLPKETVQSTLNEFTSSLTKNYPLGIHADSVQV
TSTGVVSRFSTRDAAIPTGIQNPCFSHI

>BL;Rv0483, H372V2.tab 571710:573062 forward MW:47858
VVIRVLFRPVSLIPVNNSSTPQSQGPISRRLALTALGFGVLAPNVLVACAGKVTKLAEKRPPPAPRLTFRPADSAADVVP	(SEQ ID NO:400)
IAPISVEVGDGWFQRVALTNSAGKVVAGAYSRDRTIYTITEPLGYDTTYTWSGSAVGHDGKAVPVAGKFTTVAPVKTINA
GFQLADGQTVGIAAPVIIQFDSPISDKAAVERALTVTTDPPVEGGWAWLPDEAQGARVHWRPREYYPAGTTVDVDAKLYG
LPFGDGAYGAQDMSLHFQIGRRQVVKAEVSSHRIQVVTDAGVIMDFPCSYGEADLARNVTRNGIHVVTEKYSDFYMSNPA
AGYSHIHERWAVRISNNGEFIHANPMSAGAQGNSNVTNGCINLSTENAEQYYRSAVYGDPVEVTGSSIQLSYADGDIWDW
AVDWDTWVSMSALPPPAAKPAATQIPVTAPVTPSDAPTPSGTPTTTNGPGG

>BL;2V0487, H37Rv2.tab 576787:577335 forward MW:20684
VTSSLPTVQRVIQNALEVSQLKYSQHPRPGGAPPALIVELPGERKLKINTILSVGEHSVRVEAFVCRKPDENREDVYRFL	(SEQ ID NO:401)
LRRNRRLYGVAYTLDNVGDIYLVGQMALSAVDADEVDRVLGQVLEVVDSDFNALLELGFRSSIQREWQWRLSRGESLQNL
QAFAHLRPTTMQSAQRDEKELGG

>BL;Rv0495c, H37Rv2.tab 585427:586314 reverse MW:32960
VWRPAQGARWHVPAVLGYGGIPRRASWSNVESVANSRRRPVHPGQEVELDFAREWVEFYDPDNPEHLIAADLTWLLSRWA	(SEQ ID NO:402)
CVFGTPACQGTVAGRPNDGCCSHGAFLSDDDDRTRLADAVHKLTDDDWQFRAKGLRRKGYLELDEHDGQPQHRTRKHKGA
CIFLNRPGFAGGAGCALHSKALKLGVPPLTMKPDVCWQLPIRRSQEWVTRPDGTEILKTTLTEYDRRGWGSGGADLHWYC
TGDPAAHVGTKQVWQSLADELTELLGEKAYGELAANCKRRSQLGLIAVHPATRAAQ

>BL;Rv0497, H37Rv2.tab 587377:588306 forward MW:33092
MTGPHPETESSGNRQISVAELLARQGVTGAPARRRRRRRGDSDAITVAELTGEIPIIRDDHHHAGPDAHASQSPAANGRV	(SEQ ID NO:403)
QVGEAAPQSPAEPVAEQVAEEPTRTVYWSQPEPRWPKSPPQDRRESGPELSEYPRPLRHTHSDRAPAGPPSGAEHMSPDP
VEHYPDLWVDVLDTEVGEAEAETEVREAQPGRGERHAAAAAAGTDVEGDGAAEARVARRALDVVPTLWRGALVVLQSILA
VAFGAGLFIAFDQLWRWNSIVALVLSVMVILGLVVSVRAVRKTEDIASTLIAVAVGALITLGPLALLQSG

>BL;Rv0498, H37Rv2.tab 588325:589164 forward MW:30433
VRPAIKVGLSTASVYPLRAEAAFEYADRLGYDGVELMVWGESVSQDIDAVRKLSRRYRVPVLSVHAPCLLISQRVWGANP	(SEQ ID NO:404)
ILKLDRSVRAAEQLGAQTVVVHPPFRWQRRYAEGFSDQVAALEAASTVMVAVENMFPFRADRFFGAGQSRERMRKRGGGP
GPAISAFAPSYDPLDGNHAHYTLDLSHTATAGTDSLDMARRMGPGLVHLHLCDGSGLPADEHLVPGRGTQPTAEVCQMLA
GSGFVGHVVLEVSTSSARSANERESMLAESLQFARTHLLR

>BL;RvO500B, H37Rv2.tab 591475:591573 forward MW:4145
MGSVIKKRRKRMSKKKHRKLLRRTRVQRRKLGK	(SEQ ID NO:405)

>BL;Rv0504c, H37Rv2.tab 594805:595302 reverse MW:18360
MTVPEEAQTLIGKHYRAPDHFLVGREKIREFAVAVKDDHPTHYSEPDAAAAGYPALVAPLTFLAIAGRRVQLEIFTKFNI	(SEQ ID NO:406)
PINIARVFHRDQKFRFHRPILANDKLYFDTYLDSVIESHGTVLAEIRSEVTDAEGKPVVTSVVTMLGEAAHHEADADATV
AAIASI

>BL;Rv0528, H37Rv2.tab 618305:619891 forward MW:57131
MWRSLTSMGTALVLLFLLALAAIPGALLPQRGLNAAKVDDYLAAHPLIGPWLDELQAFDVFSSFWFTAIYVLLFVSLVGC	(SEQ ID NO:407)
LAPRTIEHARSLRATPVAAPRNLARLPKHANARLAGEPAALAATITGRLRGWRSITRQQGDSVEVSAEKGYLREFGNLVF
HFALLGLLVAVAVGKLFGYEGNVIVIADGGPGFCSASPAAFDSFRAGNTVDGTSLHPICVRVNNFQAHYLPSGQATSFAA
DIDYQADPATADLIANSWRPYRLQVNHPLRVGGDRVYLQGHGYAPTFTVTFPDGQTRTSTVQWRPDNPQTLLSAGVVRID
PPAGSYPNPDERRKHQIAIQCLLAPTEQLDGTLLSSRFPALNAPAVAIDIYRGDTGLDSGRPQSLFTLDHRLIEQGRLVK
EKRVNLRAGQQVRIDQGPAAGTVVRFDGAVPFVNLQVSHDPGQSWVLVFAITMMAGLLVSLLVRRRRVWARITPTTAGTV
NVELGGLTRTDNSGWGAEFERLTGRLLAGFEARSPDMAEAAAGTGRDVD

>BL;Rv0531, H37Rv2.tab 622329:622643 forward MW:11436
VSEAPNDKTTRGVVDILVYATARLLLVVAVSAAIFGVARLIGLTEFPVVVATLFGLIIAMPLGIWVFSPLRRRATAALAV	(SEQ ID NO:408)
AGERRRAERERLRARLRGESLPEEQ

>BL;Rv0543c, H37Rv2,tab 635576:635875 reverse MW:11279
VNRFLTSIVAWLRAGYPEGIPPTDSFAVLALLCRRLSHDEVKAVANELMRLGDFDQIDIGVVITHFTDELPSPEDVERVR	(SEQ ID NO:409)
ARLAAQGWPLDDVRDREEHA

>BL;2V0544c, H37Rv2.tab 635938:636213 reverse MW:9747
VSAWFNYTATLKILIFSLLAGALLPGLFAVGVRLQAAGDGADATARRRPLLVAVSWAIFALVLAVVIIGVLYIARDFIAH	(SEQ ID NO:410)
HTGWAFLGATPK

>BL;RvOS46c, H37Rv2.tab 637586:637969 reverse MW:14346
MEILASRMLLRPADYQRSLSFYRDQIGLAIAREYGAGTVFFAGQSLLELAGYGEPDNSRGPFPGALWLQVRDLEATQTEL	(SEQ ID NO:411)
VSRGVSIAREPRREPWGLHEMHVTDPDGITLIFVEVPEGHPLRTDTRA
>BL;Rv0556, H37Rv2.tab 647959:648471 forward MW:18725
VISPKPLLHILIHGLSDELPDTRGRIVLRWLRIAVLIVTGLVTLQSVLLVAGAWRNDIAIQRNNGVAQAEVLSAGPRRST	(SEQ ID NO:412)
IEFVTPDRITYRPQLGVLYPSELSTGMRIYVEYNKRDPNLVRvQHRNAGLAIIPAGSIAVVAWLIAAAALVVLAVLDKRL
ERRENSASATG

>BL;Rv0559c, H37Rv2.tab 650410:650745 reverse MW:12116
MKGTKLAVVVGMTVAAVSLAAPAQADDYDAPFNNTIHRFGIYGPQDYNAWLAKISCERLSRGVDGDAYKSATFLQRNLPR	(SEQ ID NO:413)
GTTQGQAFQFLGAAIDHYCPEHVGVLQRAGTR

>BL;Rv0634A, H37Rv2.tab 731113:731364 forward MW:9408
LGSDCGCGGYLWSMLKRVEIEVDDDLIQKVIRRYRVKGAREAVNLALRTLLGEADTAEHGHDDEYDEFSDPNAWVPRRSR	(SEQ ID NO:414)
DTG

>BL;Rv0635, H37Rv2.tab 731930:732403 forward MW:17448
VALSADIVGMHYRYPDHYEVEREKIREYAVAVQNDDAWYFEEDGAAELGYKGLLAPLTFICVFGYKAQAAFFKNANIATA	(SEQ ID NO:415)
EAQIVQVDQVLKFEKPIVAGDKLYCDVYVDSVREAHGTQIIVTKNIVTNEEGDLVQETYTTLAGRAGEDGEGFSDGAA

>BL;Rv0636, H37Rv2.tab 732393:732818 forward MW:14934
MALREFSSVKVGDQLPEKTYPLTRQDLVNYAGVSGDLNPIHWDDEIAKVVGLDTAIAHGMLTMGIGGGYVTSWVGDPGAV	(SEQ ID NO:416)
TEYNVRFTAVVPVPNDGKGAELVFNGRVKSVDPESKSVTIALTATTGGKKIFGRAIASAKLA

>BL;Rv0637, H37Rv2.tab 732825:733322 forward MW:18929
MALKTDIRGMIWRYPDYFIVGREQCREFARAVKCDHPAFFSEEAAADLGYDALVAPLTFVTILAKYVQLDFFRHVDVGME	(SEQ ID NO:417)
TMQIVQVDQRFVFHKPVLAGDKLWARMDIHSVDERFGADIVVTRNLCTNDDGELVMEAYTTLMGQQGDGSARLKWDKESG
QVIRTA

>BL;Rv0779c, H37Rv2.tab 872675:873292 reverse MW:21572
MRSRFLPYATTPGRLLAQLISDITVAVWTTLWMLVGLAVHDAISIIGEAGRQIEIGSHGIAGNLAAAGQDAQRIPVVGDA	(SEQ ID NO:418)
LSNPITAASQAALDIAGAGHNLDTTAGWLAVVLALAVAATPILAVAMPWLFLRLRFCRRKWTVTTLAATPAGRQLLALRA
LANRPPGKLAAVSTDPVGAWRREDPATMRALAALELRAAGIPLRGD

>BL;Rv0807, H37Rv2.tab 901635:902021 forward MW:13480
MSARDRVDPAKTRQVVLALADWLRDETLPAPDTDVLAAAVRLTARTLAALAPGASVEVRIPPFAAVQCISGPRHTRGTPP	(SEQ ID NO:419)
NVVQTDPRTWLLVATGLSGVAQARGSGALQLSGSRAGEIEAWLPLVDLG

>BL;Rv0810c, H37Rv2.tab 904908:905087 reverse MW:6900
MGRGRAKAKQTKVARELKYSSPQTDFQRLQRELSGTGTDRLDGDGPSDDDSWNDEDDWRR	(SEQ ID NO:420)

>BL;Rv0813C, H37Rv2.tab 907341:908018 reverse MW:23868
VSSGAGSDATGAGGVHAAGSGDRAVAAAVERAKATAARNIPAFDDLPVPADTANLREGADLNNALLALLPLVGVWRGEGE	(SEQ ID NO:421)
GRGPDGDYRFGQQIVVSHDGGDYLNWESRSWRLTATGDYQEPGLREAGFWRFVADPYDPSESQAIELLLAHSAGYVELFY
GRPRTQSSWELVTDALARSRSGVLVGGAKRLYGIVEGGDLAYVEERvDADGGLVPHLSARLSRFVG

>BL;Rv0817C, H37Rv2.tab 910033:910842 reverse MW:28567
MPMRKVLVGVTGAAIVVAVLIVGAVGADFGASIYAEYRLSTTVRKAANLRSDPFVAILRFPFIPQAMREHYAELEIKAFA	(SEQ ID NO:422)
VEHAGSGTATLEATMHSIDLSYASWLIRPDAKLPVGELESRIIIDSMHLGRYLGISDLMVAAPRQESNDATGGTTESGIS
GSRGLVFSGTPISANFAHRVSVLVDLSVASDDRATLVITPTAVVTGPDTADQPVPDDKRDAVLHAFASKLPNQKLPFGVV
PNTVGARGSDVIIEGITRGVTISLDEFKQS

>BL;Rv0819, H37Rv2.tab 911736:912680 forward MW:33567
VTALDWRSALTADEQRSVRALVTATTAVDGVAPVGEQVLRELGQQRTEHLLVAGSRPGGPIIGYLNLSPPRGAGGANAEL	(SEQ ID NO:423)
VVHPQSRRRGIGTAMARAALAKTAGRNQFWAHGTLDPARATASALGLVGVRELIQMRRPLRDIPEPTIPDGVVIRTYAGT
SDDAELLRVNNAAFAGHPEQGGWTAVQLAERRGEAWFDPDGLILAFGDSPRERPGRLLGFHWTKVHPDHPGLGEVYVLGV
DPAAQRRGLGQMLTSIGIVSLARRLGGRKTLDPAVEPAVLLYVESDNVAAVRTYQSLGFTTYSVDTAYALAGTDN

>BL;Rv0862C, H37Rv2.tab 960345:962612 reverse MW:79667
MTEHTPDIPLGSWLAALPDERLTQLLELRPDLAQPPPGSIAALAARAQARQSVKAATDELDFLRLAVFDALLVLQADTAP	(SEQ ID NO:424)
VPIVRLLAVIGDRAAQADVLGALADLKQRALAWGETAVRVATDAGTALPWHPGQVTLEGSSRSGDQLADLIAGLDPAQRD
VLDKLLQGSPVGRTRDAAPGAPSDRPVPRLLAMGLLRRIDAETVILPRHVGQVLRGEQPGPMELTAPDPVVSTTTPDDAD
AAAAGAVIDLLREVDVLLENLGATPVAELRSGGLGVREFKRLAKATGIDEPRLGLILEIAAAAGLIASGMPDPEPPHSDG
PFWAPTVAADRFATMSPAERWHLLASAWLDLPGRPALIGTRGPDAKPYGALSDSLFSTAAPLDRRLLLGMLAELPAGAGV
DASRASATLIWRRPRWARRLQPAPIADLLTEGHALGLVGRGAISTPARALLDEALEPATAPAAAVGVMARALPKPIDHFL
VQADLTVVVPGPLQRELADDLTTVATVESAGTAMVYRVSEQSIRHALDVGKSRDWLQEFFANRSKTPVPQGLTYLIDDVA
RRHGQLRIGMAASFVRCEDPTLLAQVVAAPEADGLALRALAPTVAVSPAPISEVLVTLRCAGFAPAAEDSTGAVVDVRTR
GARVPTPQRRRPYRPPPRPNSEALKAVVAVLREVTAAPFANVRVDPAVTMSLLQRAAKDQATLVISYLDAAGVATQRVVA
PITLRGGQLVAFDSSSGRLRDFAIHRITLVVSAHDR

>BL;Rv0863, H37Rv2.tab 962599:962877 forward MW:10079
VCSVIADQRRPDQPCGVGGCKTCQNGFVADIAEGKARKTRYVDHGWPTTDPDDHAVSELVTDRTGALSPFGELTFPVPSD	(SEQ ID NO:425)
DLPYIHPVTVINR

>BL;Rv0875c, H37Rv2.tab 973809:974294 reverse MW:17800
VKRGVATLPVILVILLSVAAGAGAWLLVRGHGPQQPEISAYSHGHLTRVGPYLYCNVVDLDDCQTPQAQGELPVSERYPV	(SEQ ID NO:426)
QLSVPEVISRAPWRLLQVYQDPANTTSTLFRPDTRLAVTIPTVDPQRGRLTGIVVQLLTLVVDHSGELRDVPHAEWSVRL
IF

>BL;Rv0876C, H37Rv2.tab 974294:975937 reverse MW:57938
MAPTPGRRTRNGSVNGHPGMANYPPDDANYRRSRRPPPMPSANRYLPPLGEQPEPERSRVPPRTTRAGERITVTRAAAMR	(SEQ ID NO:427)
SREMGSRMYLLVHRAATADGADKSGLTALTWPVMANFAVDSAMAVALANTLFFAAASGESKSRVALYLLITIAPFAVIAP
LIGPALDRLQHGRRvALALSFGLRTALAVVLIMNYDGATGSFPSWVLYPCALANMVFSKSFSVLRSAVTPRVMPPTIDLV
RVNSRLTVFGLLGGTIAGGAIAAGVEFVCTHLFQLPGALFVVVAITIAGASLSMRIPRWVEVTSGEVPATLSYHRDRGRL
RRRWPEEVKNLGGTLRQPLGRNIITSLWGNCTIKVMVGFLFLYPAFVAKAHEANGWVQLGMLGLIGAAAAVGNFAGNFTS
ARLQLGRPAVLVVRCTVLVTVLAIAAAVAGSLAATAIATLITAGSSAIAKASLDASLQHDLPEESRASGFGRSESTLQLA
WVLGGAVGVLVYTELWVGFTAVSALLILGLAQTIVSFRGDSLIPGLGGNRPVMAEQETTRRGAAVAPQ

>BL;Rv0877, H37Rv2.tab 976075:976860 forward MW:27437)
VTGPTEESAVATVADWPEGLAAVLRGAADQARAAVVEFSGPEAVGDYLGVSYEDGNAATHRFIAHLPGYQGWQWAVVVAS	(SEQ ID NO:428)
YSGADHATISEVVLVPGPTALLAPDWVPWEQRvRPGDLSPGDLLAPAKDDPRLVPGYTASGDAQVDETAAEIGLGRRWVM
SAWGRAQSAQRWHDGDYGPGSAMARSTKRVCRDCGFFLPLAGSLGAMFGVCGNELSADGHVVDRQYGCGAHSDTTAPAGG
STPIYEPYDDGVLDIIEKPAES

>BL;Rv0879c, H37Rv2.tab 978484:978756 reverse MW:9512
MSVENSQIREPPPLPPVLLEVWPVIAVGALAWLVAAVAAFVVPGLASWRPVTVAOLATGLLGTTIFVWQLAAARRGARGA	(SEQ ID NO:429)
QAGLETYLDPK

>BL;Rv0883C, H37Rv2.tab 980509:981267 reverse MW:27373
MRELKVVGLDADGKNIICQGAIPSEQFKLPVDDRLRAALRDDSVQPEQAQLDIEVTNVLSPKEIQARIRAGASVEQVAAA	(SEQ ID NO:430)
SGSDIARIRRFAHPVLLERSRAAELATAAHPVLADGPAVLTMQETVAAALVARGLNPDSLTWDAWRNEDSRWTVQLAWKA
GRSDNLAHFRFTPGAHGGTATAIDDTAHELINPTFNRPLRPLAPVAHLDFDEPEPAQPTLTVPSAQPVSNRRGKPAIPAW
EDVLLGVRSGGRR

>BL;Rv0885, H37Rv2.tab 982762:983781 forward MW:39798
MDRTRIVRRWRRNMDVADDAEYVEMLATLSEGSVRRNFNPYTDIDWESPEFAVTDNDPRWILPATDPLGRHPWYQAQSRE	(SEQ ID NO:431)
RQIEIGMWRQANVAKVGLHFESILIRGLMNYTFWMPNGSPEYRYCLHESVEECNHTMMFQEMVNRvGADVPGLPRRLRWV
SPLVPLVAGPLPVAFFIGVLAGEEPIDHTQKNVLREGKSLHPIMERvMSIHVAEEARHISFAHEYLRKRLPRLTRMQRFW
ISLYFPLTMRSLCNAIVVPPKAFWEEFDIPREVKKELFFGSPESRKWLCDMFADARMLAHDTGLMNPIARLVWRLCKIDG
KPSRYRSEPQRQHLAAAPAA

>BL;Rv0909, H37Rv2.tab 1014681:1014857 forward MW:6403
MGILDKVKNLLSQNADKVETVINKAGEFVDEQTQGNYSDAIHKLHDAASNVVGMSDQQS	(SEQ ID NO:432)

>BL;Rv0910, H37Rv2.tab 1014866:1015297 forward MW:15754
MAKLSGSIDVPLPPEEAWMhASDLTRYREWLTIHKVWRSKLPEVLEKGTVVESYVEVKGMPNRIKWTIVRYKPPEGMTLN	(SEQ ID NO:433)
GDGVGGVKVKLIAKVAPKEHGSVVSFDVHLGGPALLGPIGMIVAAALRADIRESLQNFVTVFAG

>BL;Rv0912, H37Rv2.tab 1016236:1016682 forward MW:15438
MTRRLRPGWLVALSAAVIAASTWMPWLTTTVGGGGWVNAIGGTHGSLELPHGFGPGQLIVLLSSTLLVVGAMAGRGLSVK	(SEQ ID NO:434)
LSSIAALVVSLLIVALTVWYYKLNVNPPVSAEYGLYFGAAGGVCAVGCSLWAAVSAASPGRRRHREVVR

>BL;Rv0948C, H37Rv2.tab 1057649:1057963 reverse MW:11770
MRPEPPHHENAELAAMNLEMLESQPVPEIDTLREEIDRLDAEILALVKRRAEVSKAIGKARMASGGTRLVHSREMKVIER	(SEQ ID NO:435)
YSELGPDGKDLAILLLRLGRGRLGH

>BL;Rv0954, H37Rv2.tab 1065127:1066035 forward MW:30203
MTYSPGNPGYPQAQPAGSYGGVTPSFAMADEGASKLPMYLNIAVAVLGLAAYFASFGPMFTLSTELGGGDGAVSGDTGLP	(SEQ ID NO:436)
VGVALLAALLAGVALVPKAKSHVTVVAVLGVLGVFLMVSATFNKPSAYSTGWALWVVLAFIVFQAVAAVLALLVETGAIT
APAPRPKFDPYGQYGRYGQYGQYGVQPGGYYGQQGAQQAAGLQSPGPQQSPQPPGYGSQYGGYSSSPSQSGSGYTAQPPA
QPPAQSGSQQSHQGPSTPPTGFPSFSPPPPVSAGTGSQAGSAPVNYSNPSGGEQSSSPGGAPV

>BL;Rv0955, H37Rv2.tab 1066078:1067442 forward MW:46056
VNRVSASADDRAAGARPARDLVRvAFGPGVVALGIIAAVTLLQLLIANSDMTGAWGAIASMWLGVHLVPISIGGRALGVM	(SEQ ID NO:437)
PLLPVLLMVWATARSTARATSPQSSGLVVRWVVASALGGPLLMAAIALAVIHDASSVVTELQTPSALRAFTSVLVVHSVG
AATGVWSRvGRRALAATALPDWLHDSMRAAAAGVLALLGLSGVVTAGSLVVHWATMQELYGITDSIFGQFSLTVLSVLYA
PNVIVGTSAIAVGSSAHIGFATFSSFAVLGGDIPALPILAAAPTPPLGPAWVALLIVGASSGVAVGQQCARRALPFVAAN
AKLLVAAVAGALVMAVLGYGGGGRLGNFGDVGVDEGALVLGVLFWFTFVGWVTVVIAGGISRRPKRLRPAPPVELDADES
SPPVDMFDGAASEQPPASVAEDVPPSHDDIANGLKAPTADDEALPLSDEPPPRAD

>BL;Rv0966c, H37Rv2.tab 1077236:1077835 reverse MW:22210
MSNSAQRDARNSRDESARASDTDRIQIAQLLAYAAEQGRLQLTDYEDRLARAYAATTYQELDRLRADLPGAAIGPRRGGE	(SEQ ID NO:438)
CNPAPSTLLLALLGGFERRGRWNVPKKLTTFTLWGSGVLDLRYADFTSTEVDIRAYSIMGAQTILLPPEVNVEIHGHRVM
GGFDRKVVGEGTRGVPTVRIRGFSLWGDVGIKRKPRKPRK

>BL;Rv0970, H37Rv2.tab 1081052:1081681 forward MW:22887
MIHDLMLRWVVTGLFVLTAAECGLAIIAKRRPWTLIVNNGLHFANAVAMAVMAWPWGARVPTTGPAVFFLLAAVWFGATA	(SEQ ID NO:439)
VVAVRGTATRGLYGYHGLMMLATAWMYAAMNPRLLPVRSCTEYATEPDGSMPANDMTAMNMPPNSGSPIWFSAVNWIGTV
GFAVAAVFWACRFVMERRQEATQSRLPGSIGQANMAAGMAMLFFAMLFPV

>BL;Rv0996, H37Rv2.tab 1112384:1113457 forward MW:39519
MPSIPQSLLWISLVVLWLFVLVPMLISKRDAVRRTSDVALATRvLNGGAGARLLKRGGPAAGHRWGYLPPEGQGDDPDWK	(SEQ ID NO:440)
PEEDWRDDPVEDGFADVEHDIDEDQEADDARRRGAVVMKVAAPQTAGADEPDYLDVDVVEEDSEALPVGAGAAVGESADE
ADAEAADGVAGHADPEADPVEYEYEYEYVEDTCGLELEEDDQEAPPTVASGTSRRRRFDTKTAAAVSARKYTFRKRALIV
MAVILVGSAAAAFELTPVAWWICGSATGVTVLYLAYLRRQTRIEEKVRRRRMQRIARARLGVENTRDREYDVVPSRLRRP
GAVVLEIDDEDPIFTHLESAAPIRNYGWPRDLPRAVGQ

>BL;Rv0998, H37Rv2.tab 1114748:1115746 forward MW:35608
LDGIAELTGARVEDLAGMDVFQGCPAEGLVSLAASVQPLRAAAGQVLLRQGEPAVSFLLISSGSAEVSHVGDDGVAIIAR	(SEQ ID NO:441)
ALPGMIVGEIALLRDSPRSATVTTIEPLTGWTGGRGAFATMVHIPGVGERLLRTARQRLAAFVSPIPVRLADGTQLMLRP
VLPGDRERTVHGHIQFSGETLYRRFMSARVPSPALMHYLSEVDYVDHFVWVVTDGSDPVADARFVRDETDPTVAEIAFTV
ADAYQGRGIGSFLIGALSVAARVDGVERFAARMLSDNVPMRTIMDRYGAVWQREDVGVITTMIDVPGPGELSLGREMVDQ
INRVARQVIEAVG

>BL;Rv1000, H37Rv2.tab 1116531:1117148 reverse MW:22648
MCDKLGGVAIAVQGALFEHNERRQLGDGAFIDIRSGWLTGGEELLDALLSTVPWRAERRQMYDRVVDVPRLVSFHDLTIE	(SEQ ID NO:442)
DPPHPQLARMRRRLNDIYGGELGEPFTTAGLCYYRDGSDSVAWHGDTIGRGSTEDTMVAIVSLGATRVFALRPRGRGPSL
RLPLAHGDLLVMGGSCQRTFEHAVPKTSAPTGPRVSIQFRPRDVR

>BL;Rv1024, H37Rv2.tab 1145858:1146541 forward MW:24570
MPEAKRPESKRRSPASRPGKAGDSVRGGRATKPSAKPSTPAPHASRKTTRTPHEHIVEPIKRAITESVEKRSEQRLGFTA	(SEQ ID NO:443)
RRAAILAAVVCVLTLTIARPVRTYFAQRAEMEQLAATEANLRRQIADLEEQQVKLADPAYIAAQARERLGFVMPGDIPFQ
VQLPSTPLAPPQPGSDAATATNNEPWYTALWHTIADDPHLPPAAPPAPEPGRPGPLPPASPNPEQPGG

>BL;Rv1025, H37Rv2.tab 1146561:1147025 forward MW:16593
VVTRQLGRAPRGVLAIAYRCPNGEPGVVKTAPRLPDGTPFPTLYYLTHPVLTAAASRLETTGLMREMNRRLGQDAELAAA	(SEQ ID NO:444)
YRRAHESYLSERDALEPLGTTVSAGGMPDRvKCLHVLIAHSLAKGPGLNPFGDEALALLAAEPRTAATLVAGQWR

>BL;Rv1081c, H37Rv2.tab 1205987:1206418 reverse MW:15384
MTHTPIPRPDARYGRPRLSRRARRRvAIALGVLVAAAGIVIAVIGYQRISTSAVTGSLVGYRLVDDETASVTISVTRSDP	(SEQ ID NO:445)
SRPVACIVRVRATNGSETGRRELLVPPSEATTVQVTTTVKSSQPPVMADVYGCGTEVPSYLRLP

>BL;Rv1083, H37Rv2.tab 1207383:1207646 forward MW:9263
VNQILLSVIAEGGPGNTGPDFGKASPVGLLVIVLLVIATLFLVRSMNQQLKKVPKSFDRDHPELDQAADEGTDRDGPARP	(SEQ ID NO:446)
PGPPHESG

>BL;Rv1100, H37Rv2.tab 1228683:1229381 forward MW:24562
MVGDCPRSRTVRWSWDTGHVTAEPQPTPRPAKPRLLQDGRDMFWSLAPLVVGCILLAGLVGMCSFQLGGTKRGPIPSYDA	(SEQ ID NO:447)
AQALRADAKTLGFPIRLPQLPGGWTPNSGGRGGIENGRADPATGQRRNAATSIVGFISPTGRYLSLTQSNADEDKLVGSI
HPSMYPTGTVDVGGTRWVVYEGSDENGAVEPVWTTRLTGPGGATQLAITGAGSIDQFRTLASATQSQPPLPAR

>BL;Rv1109c, H37Rv2.tab 1235460:1236095 reverse MW:22957
MATAPYGVRLLVGAATVAVEETMKLPRTILMYPMTLASQAAHVVMRFQQGLAELVIKGDNTLETLFPPKDEKPEWATFDE	(SEQ ID NO:448)
DLPDALEGTSIPLLGLSDASEAKNDDRRSDGRFALYSVSDTPETTTASRSADRSTNPKTAKHPKSAAKPTVPTPAVAAEL
DYPALTLAQLRARLHTLDVPELEALLAYEQATKARAPFQTLLANRITRATAK

>BL;Rv1111c, H37Rv2.tab 1237212:1238192 reverse MW:36985
VSAQRARSAVQASHRSIHPHIPGVPWWAAILIAVTATAIGYAIDAGSGHKALTLVFTGCYIAGCVGAVLAVRQSDLFTAL	(SEQ ID NO:449)
VQPPLILFCAVPGAYWLFHGGTIGKFKDLLINCGYSLIERFPLMLGTAAGVLLIGLVRWYLGTALFDSIARKLSSLMTGD
SDDDGGRRSAQRPARTRSRHARPPSEDNREPIAERRSRRRPRPQNDPHPRRNAMERPAPRSSRFDSYRSYQPSEPSGPAE
PVNRYERRGARYQPYARYEPTYEPQRRRARPSEPTNPTHHPISQVRYRCSATRDARRDNYREEQRFDRRDRSRAPRRPPA
ESWEYDV

>BL;Rv1155, H37Rv2.tab 1281429:1281869 forward MW:16300
MARQVFDDKLLAVISGNSIGVLATIKHDGRPQLSNVQYHFDPRKLLIQVSIAEPRAKTRNLRRDPRASILVDADDGWSYA	(SEQ ID NO:450)
VAEGTAQLTPPAAAPDDDTVEALIALYRNIAGEHSDWDDYRQAMVTDRRvLLTLPISHVYGLPPGMR

>BL;Rv1157c, H37Rv2.tab 1283059:1284171 reverse MW:36448
VRRLTNTEHRENTTVASTWSVCKGLAAVVITSAAAFALCPNAAADPATPQPNPTQQLPGLPALAQLSPIIQQAAMNPAQA	(SEQ ID NO:451)
TQLLMAAASAFAGNPAVPTESKNVASSVNQFVAEPTNPDSAALGVPAPHGVALPEAIPVPHVPPLGAEPGVQAHLPTGID
PSHAAGPAPAVAPTVTPPVAAPPASAPAPAPDAAQPVAVPGPPPAPPAPRAAAPAPASAAPAPAAAPAPASGFGADAPPT
QDFMYPSIGPNCVADGSNSIATALSVAGPAKIPLPGPGPGQTAYVFTAVGTPGPADVQRLPLNVTWVNLTTGKSGSATLR
PRSDINPDGPTTLTVIADTGSGSIMSTIFGQVTTKDRQCQFMPTIGSTVVP

>SL;Rv1158c, H37Rv2.tab 1284182:1284862 reverse MW:21401
MPTIWTFVRAAAVLVGSSAALLTGGIAHADPAPAPAPAPNIPQQLISSAANAPQILQNLATALGATPPLSAPKVAEPAPA	(SEQ ID NO:452)
APGITATFPGLTPAAPAAAAAPALTPSIPGVNAPIPGITPAAPALPVTAPAAAPTIPGVNAPIPGITAPAPAAAAVPASV
PGVPSAKVDLPQLPYLPLQVPQQLSLPADLPALASGVIPAAPIAPTPPAPGAPALPPGPPSLLAALP

>BL;Rv1159A, H37Rv2.tab 1286284:1286568 reverse MW:10379
MAVLTDEQVDAALHDLNGWQRAGGVLRRSIKFPTFMAGIDAVRRVAERAEEVNHHPDIDIRWRTVTFALVTHAVGGITEN	(SEQ ID NO:453)
DIAMAHDIDANFGA

>BL;Rv1171, H37Rv2.tab 1301307:1301744 forward MW:15185
VGHRVDTLSDRQRANLTTGATDRAIRLVVLALLTVDGVVSALAGALLMPWYIGSAPFPISALISGLVNAALVWAAARWTT	(SEQ ID NO:454)
SSRVAALPLWAWLLTVAAMSFGGPGDDVILGGQGLLVYGALVFVVAGAVPPAWVLWRRRVQADGSG

>BL;Rv1184c, H37Rv2.tab 1324535:1325611 reverse MW:37818
MKRvIAGAFAVWLVGWAGGFGTAIAASEPAYPWAPGPPPSPSPVGDASTAKVVYALGGARMPGIPWYEYTNQAGSQYFPN	(SEQ ID NO:455)
AKHDLIDYPAGAAFSWWPTMLLPPGSHQDNMTVGVAVKDGTNSLDNAIHHGTDPAAAVGLSQGSLVLDQEQARLANDPTA
PAPDKLQFTTFGDPTGRHAFGASFLARIFPPGSHIPIPFIEYTMPQQVDSQYDTNEVVTAYDGFSDFPDRPDNLLAVANA
AIGAAIAHTPIGFTGPGDVPPQNIRTTVNSRGATTTTYLVPVNHLPLTLPLRYLGMSDAEVDQIDSVLQPQIDAAYARND
NWFTRPVSVDPVRGLDPLTAPGSIVEGARGLLGSPAFCG

>BL;Rv1209, H37Rv2.tab 1353157:1353522 forward MW:13089
VALVLVYLVVLVLVAIVLFAAASLLFGRGEQLPPLPRATTATTLPAFGVTRADVDAVKFTQVLRGYKTSEVDWVLERLGR	(SEQ ID NO:456)
ELEALRSQLGAIHASSEDAEAESDASNPSRGETVVHYRSDPA

>BL;Rv1211, H37Rv2.tab 1354243:1354467 forward MW:7810
MLGADQARAGGPARIWREHSMAAMKPRTGDGPLEATKEGRGIVMRVPLEGGGRLVVELTPDEAAALGDELKGVTS	(SEQ ID NO:457)

>BL;Rv1222, H37Rv2.tab 1365344:1365805 forward MW:16250
MADPGSVGHVFRRAFSWLPAQFASQSDAPVGAPRQFRSTEHLSIEAIAAFVDGELRMNAHLRAAHHLSLCAQCAAEVDDQ	(SEQ ID NO:458)
SRAPAALRDSHPIRIPSTLLGLLSEIPRCPPEGPSKGSSGGSSQGPPDGAAAGFGDRFADGDGGNRGRQSRVRR

>BL;Rv1249c, H37Rv2.tab 1393197:1393982 reverse MW:27571
MSARRIRSWKRFDNRSANAAEPDPQLAGTGGRPKVSTRALAQVIERSSRIQGPAAQAYVARLRRAHPGASPAKIVAKLEK	(SEQ ID NO:459)
RFLSVVTASGAAVGAAATLPGIGTLAAWFAAAGEVVVFLEATALFVLALASVHAIPLDHRERRRALVLAVLVGDNTTAVA
DLLGPGRTSGGWVSETMASLPLPAISSLNSRMLKYVVKRFALKRGALMFGKLVPMGIGAIIGAIGNRLVGKKLVRNARSA
FGTPPARWPVTLNVLPTVRDAS

>BL;Rv1251c, H37Rv2.tab 1395824:1399240 reverse MW:123118
VFVTGDSIVYSASDLAAAARCQYALLREFDAKLGRGPAVAVDDELMARAAVLGSAHEGRRLDQLRHEFGDAVAIIGRPAY	(SEQ ID NO:460)
TPAGLAAAADATRRAIANHAPVVYQAAMFDGRFVGFADFLIRDGHRYRVADTKLARSPTVTALLQLAAYADALVHSGVPV
AADAELELGDGTIVRYRVGELIPVYRSQPALLQRLLDGHYTAGTAVRWDDERVQACFRCPQCTERLRASDDLLLVGGMRV
RQRDKLLEAGITTIAELADHTAPVPGLTTNALGKLTAQAKLQIRQRDTGAPQFEIVDPRPLTLLPEPNPGDLFFDFEGDP
LWTADGKQWGLEYLFGVLEAGRAGVFRPLWAHDRTAERQALTDFLAIVARRRRRHPNMNIYHYAPYEKTALLRLVGRYGI
GEDDVDDLLRNGVLVDLYPLVRKSIRVGTDSFSLKALEPLYLGTQPRSGDVTTAADSINSYARYCELRAAGRIDEAATVL
KEIEGYNHYDCRSTRALRDWLLMRAWEAGVTPIGAQPVPDADPIDDGDSLASVLSKFTGDAAAGERTPEQTAVALLAAAR
GYHRREDKPFWWAHFDRLNYPVDEWSDSTDVFLASEASVTVDWHMPPRARKPQRRVRLTGELARGDLNGNVFALYEPPAP
PGMTDNPDRRAAGPAAVVETDDPTVPTEVVIVERTGSDGNTFQQLPFALAPGPPVPTTALRESIESTAAAVASGSPQLPS
TALMDVLLRRPPRTRSGAALPRSSDPVTDIAAAALDLDSSYLAVHGPPGTGKTYTAARVIAELVTEHAWRIGVVAQSHAT
VENLLEGVISAGLDPGQVAKKPHDHTAGRWQSIDGSQYTEFIRDTAGCVIGGTAWDFANGNRvPKASLDLLVIDEAGQFC
LANTIAVAPAATNLLLLGDPQQLPQVSQGTHPEPVDTSALSWLVDGQHTLPDERGYFLDRSYRMHPAVCAAVSALSYEGR
LCSHTERTAVRRLDGYPPGVHTRGVHHKGNSIESPEEAEAILAELRQLLGSPWTDEHGTRPLAASDVLVLAPYNAQVALV
RRRLASAGLGGADGVRVGTVDKFQGGQAPVVFISMTASSADDVPRGISFLLNRNRLNVAVSRAQYAAVIVRSELLTQYLP
ATPDGLVDLGAFLGLTSTS

>BL;Rv1259, H37Rv2.tab 1407339:1408235 forward MW:31783
MNIAAESSAKPVWGPPNFCAAAARMQDVRVLMHPKTGRAFRSPVEPGSGWPGDPATPQTPVAADAAQVSALAGGAGSICE	(SEQ ID NO:461)
LNALISVCRACPRLVSWREEVAVVKRRAFADQPYWGRPVPGWGSKRPRLLILGLAPAAHGANRTGRMFTGDRSGDQLYAA
LHRAGLVNSPVSVDAADGLRANRIRITAPVRCAPPGNSPTPAERLTCSPWLNAEWRLVSDHIRAIVALGGFAWQVALRLA
GASGTPKPRFGHGVVTELGAGVRLLGCYHPSQQNMFTGRLTPTMLDDIFREAKKLAGIE

>BL;Rv1276c, H37Rv2.tab 1425441:1425914 reverse MW:16461
MRHAKSAYPDGIADHDRPLAPRGIREAGLAGGWLRANLPAVDAVLCSTATRARQTLAHTGIDAPARYAERLYGAAPGTVI	(SEQ ID NO:462)
EEINRVGDNVTTLLVVGHEPTTSALAIVLASISGTDAAVAERISEKFPTSGIAVLRvAGHWADVEPGCAALVGFHVFR

>BL;Rv1277, H37Rv2.tab 1426164:1427414 forward MW:44758
VSPRPGPAGRGPAPCRCADLHSLCVDSHALRRDGMRFLHTADWQLGMTRHFLAGDAQPRYSAARRDAVAGLKALAADVGA	(SEQ ID NO:463)
EFVVVAGDVFEHNQLAPQIVGQSLEANRVIGLPVYLLPGNHDPLDASSVYTSTLFRAERPDNVVVLDRAGVHEVRPGVQI
VAAPWRSKAPTTDPVAEVLAGLPTDAAIRLLVAHGGVDALDPDHDKPSLIRLAALDDALTRQAIHYVALGDKHSLTQVGS
SGRVWYSGAPEVTNFDDVEPDPGHVLVVDIDESDPRHPVTVDARRIGRWRFVTLHHQVDTSRDIADLDLNLDLMTDKDRT
VVRLALTGSLTVTDRAALDTCLDKYARLFAWLGLWERNTDLAVIPVDAEFTDLGIGGFAAAAVDELVATARGGODESAVD
AQAALALLLRLADRGAA

>BL;Rv1278, H37Rv2.tab 1427414:1430038 forward MW:93319
VKLHRLALTNYRGIAHRDVEFPDHGVVVVCGANEIGKSSMVEALDLLLEYKDRSTKKEVKQVKPTNADVGSEVIAEISSG	(SEQ ID NO:464)
PYRFVYRKRFHKRCETELTVLAPRREQLTGDEAHERVRTMLAETVDTELWHAQRVLQAASTAAVDLSGCDALSRALDLAA
GDDAALSGTESLLIERIEAEYARYFTPTGRPTGEWSAAVSRLAAAEAAVADCAAAVAEVDDGVRRHTELTEQVAELSQQL
LAHQLRLEAARVAAEKIAAITDDAREAKLIATAAAATSGASTAAHAGRLGLLTEIDTRTAAVVAAEAKARQAADEQATAR
AEAEACDAALTEATQVLTAVRLRAESARRTLDQLADCEEADRLAARLARIDDIEGDRDRVCAELSAVTLTEELLSRIERA
AAAVDRGGAQLASISAAVEFTAAVDIELGVGDQRVSLSAGQSWSVTATGPTEVKVPGVLTARIVPGATALDFQAKYAAAQ
QELADALAAGEVADLAAARSADLCRRELLSRRDQLTATLAGLCGDEQVDQLRSRLEQLCAGQPAELDLVSTDTATARAEL
DAVEAARIAAEKDCETRRQIAAGAARRLAETSTRATVLQNAAAAESAELGAAMTRLACERASVGDDELAAKAEADLRVLQ
TAEQRVIDLADELAATAPDAVAAELAEAADAVELLRERHDEAIRALHEVGVELSVFGTQGRKGKLDAAETEREHAASHHA
RVGRRARAARLLRSVMARHRDTTRLRYVEPYRAELHRLGRPVFGPSFEVEVDTDLRIRSRTLDDRTVPYECLSGGAKEQL
GILARLAGAALVAKEDAVPVLIDDALGFTDPERLAKMGEVFDTIGADGQVIVLTCSPTRYGGVKGAHRIDLDAIQ

>BL;Rv1303, H37Rv2.tab 1459766:1460248 forward MW:16863
VTTPAQDAPLVFPSVAFRPVRLFFINVGLAAVAMLVAGVFGHLTVGMFLGLGLLLGLLNALLVRRSAESITAKEHPLKRS	(SEQ ID NO:465)
NALNSASRLAIITILGLIIAYIFRPAGLGVVFGLAFFQVLLVATTALPVLKKLRTATEEPVATYSSNGQTGGSEGRSASD
D

>BL;Rv1312, H37Rv2.tab 1467688:1468128 forward MW:16594
MSAPMIGMVVLVVVLGLAVLALSYRLWKLRQGGTAGIMRDIPAVGGHGWRHGVIRYRGGEAAFYRLSSLRLWPDRRLSRR	(SEQ ID NO:466)
GVEIISRRAPRGDEFDIMTDEIVVVELCDSTQDRRVGYEIALDRGALTAFLSWLESRPSPRARRRSM

>BL;Rv1324, H37Rv2.tab 1487161:1488072 forward MW:32138
VTRPRPPLGPAMAGAVDLSGIKQRAQQNAAASTDADRALSTPSGVTEITEANFEDEVIVRSDEVPVVVLLWSPRSEVCVD	(SEQ ID NO:467)
LLDTLSGLAAAAKGKWSLASVNVDVAPRVAQIFGVQAVPTVVALAAGQPISSFQGLQPADQLSRWVDSLLSATAGKLKGA
ASSEESTEVDPAVAQARQQLEDGDFVAARKSYQAILDANPGSVEAKAAIRQIEFLIRATAQRPDAVSVADSLSDDIDAAF
AAADVQVLNQDVSAAFERLIALVRRTSGEERTRvRTRLIELFELFDPADPEVVAGRRNLANALY

>BL;Rv1332, H37Rv2.tab 1500926:1501579 forward MW:24054
MPPVCGRRCSRTGEIRGYSGSIVRRWKRVETRDGPRFRSSLAPHEAALLKNLAGAMIGLLDDRDSSSPSDELEEITGIKT	(SEQ ID NO:468)
GHAQRPGDPTLRRLLPDFYRPDDLDDDDPTAVDGSESFNAALRSLHEPEIIDAKRVAAQQLLDTVPDNGGRLELTESDAN
AWIAAVNDLRLALGVMLEIGPRGPERLPGNHPLAAHFNVYQWLTVLQEYLVLVLMGSR

>BL;Rv1342c, H37Rv2.tab 1508187:1508546 reverse MW:13382
MTAPETPAAQHAEPAIAVERIRTALLGYRIMAWTTGLWLIALCYEIVVRYVVKVDNPPTWIGVVNGWVYFTYLLLTLNLA	(SEQ ID NO:469)
VKVRWPLGKTAGVLLAGTIPLLGIVVEHFQTKEIKARFGL

>BL;Rv1343c, H37Rv2.tab 1508546:1508923 reverse MW:14241
VSTTRRRRPALIALVIIATCGCLALGWWQWTRFQSTSGTFQNLGYALQWPLFAWFCVYAYRNFVRYEETPPQPPTGGAAA	(SEQ ID NO:470)
EIPAGLLPERPKPAQQPPDDPVLREYNAYLAELAKDDARKQNRTTA

>BL;Rv1390, H37Rv2.tab 1565093:1565422 forward MW:11810
VSISQSDASLAAVPAVDQFDPSSGASGGYDTPLGITNPPIDELLDRvSSKYALVIYAAKRARQINDYYNQLGEGILEYVG	(SEQ ID NO:471)
PLVEPGLQEKPLSIALREIHADLLEHTEGE

>BL;Rv1417, H37Rv2.tab 1592150:1592611 forward MW:16351
VTAAPNDWDVVLRPHWTPLFAYAAAFLIAVAHVAGGLLLKVGSSGVVFQTADQVAMGALGLVLAGAVLLFARPRLRVGSA	(SEQ ID NO:472)
GLSVRNLLGDRIVGWSEVIGVSFPGGSRWARIDLADDEYIPVMAIQAVDKDRAVAANDTVRSLLARYRPDLCAR

>DL;Rv1476, H37Rv2.tab 1666204:1666761 forward MW:19601
MTGPYFPQTIPFLPSYIPQDVDMTAVKAEVAALGVSAPPAATPGLLEVVQHARDEGIDLKIVLLDHNPPNDTPLRDIATV	(SEQ ID NO:473)
VGADYSDATVLVLSPNYVGSYSTQYPRvTLEAGEDHSKTGNPVQSAQNFVHELSTPEFPWSALTIVLLIGVLAAAVGARL
MQLRGRRSATSTDAAPGAGDDLNQGV

>BL;Rv1590, H37Rv2.tab 1791334:1791570 forward MW:8602
MVEIVAGKQRAPVAAGVYNVYTGELADTATPTAARMGLEPPRFCAQCGRRMVVQVRPDGWWARCSRHGQVDSADLATQR	(SEQ ID NO:474)

>BL;Rv1591, H37Rv2.tab 1791570:1792232 forward MW:23151
VTEPPGFGGPSEPSGAPRTSRTRAVLFVMLGLSATGVLVGGLWAWIAPPIHAVVAITRAGERVHEYLGSESQNFPIAPFM	(SEQ ID NO:475)
LLGLLSVLAVVASALMWQWREHRGPQMVAGLSIOLTTAAAIAAGVGALVVRLRYGALDFDTVPLSRGDHALTYVTQAPPV
FFARRPLQIALTLMWPAGIASLVYALLAAGTARDDLGGYPAVDPSSNARTEALETPQAPVS

>BL;Rv1610, H37Rv2.tab 1809443:1810147 forward MW:24586
VAANAGSVRPNRRARPMIGIAQLLLVVAAGALWMAARLPWVVIGSFDELGPPKEVTLTGASWSTALLPLALLMLAAAVAA	(SEQ ID NO:476)
LAVRGWPLRALAVLLAAASFAVGYLGISLWVVPDVAARGADLAHVPVVTLVGSARHYWGAVAAVLAAVCALLAAVFLMSS
AAIRGSAGEDMARYAAPRARRSIARRQHSNAAGRAAPQDDGPDMGPRMSERMIWEALDEGRDPTDREQESDTEGR

>BL;Rv1635c, H37Rv2.tab 1840575:1842242 reverse MW:60035
MNASRPGAPPHAGLPSRRTAGDQDHRADPKVTRIMSASTLEQPAAAHVDELVARMRGRLLDPLAIAVLAAVISGAWASRP	(SEQ ID NO:477)
SLWFDEGATISASASRTLPELWSLLGHIDAVHGLYYLLMHGWFAIFPPTELWSRLPSCLAIGAAAAGVVVFAKQFSGRTT
AVCAGAVFAILPRVTWAGIEARSSALSVAAAVWLTVLLVAAVRCNTQRRWLLYALVLMLSILVSINLALLVPAYATMVPL
LASGKSRKSPVIWWTVVTAAALGAMTPFILFAMGQVWQVGWIAGLNRNIILDVIHRQYFDHSVPFAILAGLIVAAGIAAH
LAGARGPGGDTHRLVLVSAAWIVVPTAVVLIYSATVEPIYYPRYLILTAPAAAVILAVCVVTIARKPWLIAGVVFLLAAA
AFPNYFFTQRGPYAKEGWDYSQVADVISAHAKPGDCLLVDNTAGWRPGPIRALLATRPAAFRSLIDVERGTYGPKVGTLW
DGHVAVWLTTAKIDKCPTLWTIANRDKSLPDHQVGEMLSPGTGFGRTPVYRFPSYLGFRIVERWQFHYSQVVKSTR

>BL;Rv1647, H37Rv2.tab 1856774:1857721 forward MW:33939
LAGSARTTYPCHVEVGPQDSESGAPDETATAMASPVPRQRSALRWLRTVNRSPGLVSFIHRARRLLPGDPEFGDPLSTAG	(SEQ ID NO:478)
EGGPRAAARAADRLLRDRDAASREVGLSVLQVWQALTEAVSRRPANPEVTLVFTDLVGFSTWSLHAGDDATLTLLRQVAR
AVESPLLDAGGHIVKRLGDGIMAVFRNPTVALRAVLVAQDAVKSLEVQGYTPRMRIGIHTGRPQRLAADWLGVDVNIAAR
VMERATKGGIMISQPTLDLIPQSELDALGVVARRVRKPVFASKPTGIPPDLAIYRIKTVSESTAADNFDEMSPDAQ

>BL;Rv1693, H37Rv2.tab 1917756:1917929 forward MW:6094
MTIDPDQIRAEIDALLASLPDPADAENGPSLAELEGIARRLSEAHEVLLAALESAEKG	(SEQ ID NO:479)

>BL;Rv1697, H37Rv2.tab 1921542:1922720 forward MW:42423
MRMSALLSRNTSRPGLIGIARVDRNIDRLLRRvCPGDIVVLDVLDLDRITADALVEAEIAAVVNASSSVSGRYPNLGPEV	(SEQ ID NO:480)
LVTNGVTLIDETGPEIFKKVKDGAKVRLYEGGVYAGDRRLIRGTERTDHDIADLMREAKSGLVAHLEAFAGNTIEFIRSE
SPLLIDGIGIPDVDVDLRRRHVVIVADEPSGPDDLKSLKPFIKEYQPVLVGVGTGADVLRKAGYRPQLIVGDPDQISTEV
LKCGAQVVLPADADGHAPGLERIQDLGVGANTFPAAGSATDLALLLADHHGAALLVTAGHAANIETFFDRTRvQSNPSTF
LTRLRVGEKLVDAKAVATLYRNHISGGAIALLALTMLIAIIVALWVSRTDGVVLHWIIDYWNRFSLWVQHLVS

>BL;Rv1698, H37Rv2.tab 1922745:1923686 forward MW:32391
MISLRQHAVSLAAVFLALAMGVVLGSGFFSDTLLSSLRSEKRDLYTQIDRLTDQRDALREKLSAADNFDIQVGSRIVHDA	(SEQ ID NO:481)
LVGKSVVIFRTPDAHDDDIAAVSKIVGQAGGAVTATVSLTQEFVEANSAEKLRSVVNSSILPAGSQLSTKLVDQGSQAGD
LLGIALLSNADPAAPTVEQAQRDTVLAALRETGFITYQPRDRIGTANATVVVTGGALSTDAGNQGVSVARFAAALAPRGS
GTLLAGRDGSANRPAAVAVTRADADMAAEISTVDDIDAEPGRITVILALHDLINGGNVGHYGTGHGAMSVTVSQ

>BL;Rv1754c, H37Rv2.tab 1984982:1986670 reverse MW:60608
MYRYQVRVQQRRSEMNRWVATRSRRHTYQWITDHKSPRDHYRHISELRTSIATSSPGRCDMSPIPRIVSVSLAWAAAIGL	(SEQ ID NO:482)
MVPIGLAPPAMAAPCSGDAANAPPPPSAIVTDPGATALGPVRPGHGPIPTGRKPRGANDRAPLPKLGPLISALLNPGARN
AAPLQQQALVPRANPGPNPAPNPPATGPQPPNATQLTPNFAPAPDPAPAAAPDPGATLAGATTSLAEWVTGPDSPNKTLE
RFGISGTDLGIPWDNGDPANRQVLMIFGDTFGYCAVDGHQWRYNTLFRSQDRDLGNGVHVTSGDASNRYSGSPVRQPGFS
KQLINSIKWARDETGIIPTAGIAVGKTQYVNFMSIRNWGRDGEWTTNYSGIAVSKDNGQTWGVFPGTIRASGPDSGGKAR
FVPGNENFQMGAYLKSNDGYLYSFGTPPGRGGSAYLARvPQRFVPDLTKYQYWNGDSNSWVPNKPDAATPVIPGPVGEMS
VQYNTYLKQYLALYTNGMNDVVARTAPAPQGPWSAEQMLVSSWQMPGGIYAPMMHPWSTGKDVYFNLSLWSAYNVNLMHT
VLP

>BL;Rv1782, H37Rv2.tab 2017740:2019257 forward MW:53689
VAEESRGQRGSGYGLGLSTRTQVTGYQFLARRTANALTRWRVRMEIEPGRRQTLAVVASVSAALVICLGALLWSFISPSG	(SEQ ID NO:483)
QLNESPIIADRDSGALYVRVGDRLYPALNLASARLITGRPDNPHLVRSSQIATMPRGPLVGIPGAPSSFSPKSPPASSWL
VCDTVATSSSIGSLQGVTVTVIDGTPDLTGHRQILSGSDAVVLRYGGDAWVIREGRRSRIEPTNRAVLLPLGLTPEQVSQ
ARPMSRALFDALPVGPELLVPEVPNAGGPATFPGAPGPIGTVIVTPQISGPQQYSLVLGDGVQTLPPLVAQILQNAGSAG
NTKPLTVEPSTLAKMPVVNRLDLSAYPDNPLEVVDIREHPSTCWWWERTAGENRARVRVVSGPTIPVAATEMNKVVSLVK
ADTSGRQADQVYFGPDHANFVAVTGNNPGAQTSESLWWVTDAGARFGVEDSKEARDALGLTLTPSLAPWVALRLLPQGPT
LSRADALVEHDTLPMDMTPAELVVPK

>BL;Rv1794, H37Rv2.tab 2031066:2031965 forward MW:32399
MDQQSTRTDITVNVDGFWMLQALLDIRHVAPELRCRPYVSTDSNDWLNEHPGMAVMREQGIVVNDAVNEQVAARMKVLAA	(SEQ ID NO:484)
PDLEVVALLSRGKLLYGVIDDENQPPGSRDIPDNEFRVVLARRGQHWVSAVRvGNDITVDDVTVSDSASIAALVMDGLES
IHHADPAAINAVNVPMEEMLEATKSWQESGFNVPSGGDLRRMGISAATVAALGQALSDPAAEVAVYARQYRDDAKGPSAS
VLSLKDGSGGRIALYQQARTAGSGEAWLAICPATPQLVQVGVKTVLDTLPYGEWKTHSRV

>DL;Rv1797, H37Rv2.tab 2035483:2036700 forward MW:44178
MKAQRSFGLALSWPRVTAVFLVDVLILAVASHCPDSWQADHHVAWWVGVGVAAVVTLLSVVSYHGITVISGLATWVRDWS	(SEQ ID NO:485)
ADPGTTLGAGCTPAIDHQRRFGRDTVGVREYNGRLVSVIEVTCGESGPSGRHWHRKSPVPMLPVVAVADGLRQFDIHLDG
IDIVSVLVRGGVDAAKASASLQEWEPQGWKSEERAGDRTVADRRRTWLVLRMNPQRNVAAVACRDSLASTLVAATERLVQ
DLDGQSCAARPVTADELTEVDSAVLADLEPTWSRPGWRHLKHFNGYATSFWVTPSDITSETLDELCLPDSPEVGTTVVTV
RLTTRVGSPALSAWVRYHSDTRLPKEVAAGLNRLTGRQLAAVRASLPAPTHRPLLVIPSRNLRDHDELVLPVGQELEHAT
SSFVGQ

>BL;Rv1828, H37Rv2.tab 2073081:2073821 forward MW:26411
VSAPDSPALAGMSIGAVLDLLRPDFPDVTISKIRFLEAEGLVTPRRASSGYRRFTAYDCARLRFILTAQRDHYLPLKVIR	(SEQ ID NO:486)
AQLDAQPDGELPPFGSPYVLPRLVPVAGDSAGGVGSDTASVSLTGIRLSREDLLERSEVADELLTALLKAGVITTGPGGF
FDEHAVVILQCARALAEYGVEPRHLRAFRSAADRQSDLIAQIAGPLVKAGKAGARDRADDLAREVAALAITLHTSLIKSA
VRDVLHR

>BL;Rv1830, H37Rv2.tab 2074841:2075515 forward MW:23988
VTQLVTRARSARGSTLGEQPRQDQLDFADHTGTAGDGNDGAAAASGPVQPGLFPDDSVPDELVGYRGPSACQIAGITYRQ	(SEQ ID NO:487)
LDYWARTSLVVPSIRSAAGSGSQRLYSFKDILVLKIVKRLLDTGISLHNIRVAVDHLRQRGVQDLANITLFSDGTTVYEC
TSAEEVVDLLQGGQGVFGIAVSGAMRELTGVIADFNGERADGGESIAAPEDELASRRKHRDRKIG

>BL;Rv1836c, H37Rv2.tab 2082606:2084636 reverse MW:69677
MGRHSKPDPEDSVDDLSDGNAAEQQNWEDISGSYDYPGVDQPDDGPLSSEGHYSAVGGYSASGSEDYPDIPPRPDWEPTG	(SEQ ID NO:488)
AEPIAAAPPPLFRFGHRGPGDWQAGHRSADGRRGVSIGVIVALVAVVVMVAGVILWRFFGDALSNRSHTAAARCVGGKDT
VAVIADPSIADQVKESADSYNASAGPVGDRCVAVAVTSAGSDAVINGFIGKWPTELGGQPGLWIPSSSISAARLTGAAGS
QAISDSRSLVISPVLLAVRPELQQALANQNWAALPGLQTNPNSLSGLDLPAWGSLRLANPSSGNGDAAYLAGEAVAAASA
PAGAPATAGIGAVRTLMGARPKLADDSLTAANDTLLKPGDVATAPVHAVVTTEQQLFQRGQSLSDAENTLGSWLPPGPAA
VADYPTVLLSGAWLSQEQTSAASAFARYLHKPEQLAKLARAGFRvSDVKPPSSPVTSFPALPSTLSVGDDSMRATLADTM
VTASAGVAATIMLDQSMPNDEGGNSRLSNVVAALENRIKAMPPSSVVGLWTFDGREGRTEVPAGPLADPVNGQPRPAALT
AALGKQYSSGGGAVSFTTLRLIYQEMLANYRVGQANSVLVITAGPHTDQTLDGPGLQDFIRKSADPAKPIAVNIIDFGAD
PDRATWEAVAQLSGGSYQNLETSASPDLATAVNIFLS

>BL;Rv1845c, H37Rv2.tab 2095221:2096168 reverse MW:32704
VSALAFTILAVLLAGPTPALLARATWPLRAPRAANVLWQAIALAAVLSSFSAGIAIASRLLMPGPDGRPTTSFVGAAGRL	(SEQ ID NO:489)
GWPLWAAYITVFALTVLVGARLAVAVVRVATATRRRRAHHRMVVDLVGVGHNGALAQPCARARDLRVLDVAQPLAYCLPG
VRSRVVVSEGTLTALADAEVAAILTHERAHLRARHDLVLEAFTAVHAAFPRLVRSANALGAVQLLVELLADDAAVRAAGR
TPLARALVACASGRAPSGALAVGGPSTVLRVRRLSGRGNSAVLSAAAYLAAAAVLVVPTVALAVPWLTQLQRLFIA

>BL;Rv1846c, H37Rv2.tab 2096186:2096599 reverse MW:15211
MAKLTRLGDLERAVMDHLWSRTEPQTVRQVHEALSARRDLAYTTVMTVLQRLAKKNLVLQIRDDRAHRYAPVHGRDELVA	(SEQ ID NO:490)
GLMVDALAQAEDSGSRQAALVHFVERVGADEADALRRALAELEAGHGNRPPAGAATET

>BL;Rv1861, H37Rv2.tab 2109165:2109467 forward MW:10330
MDITATTEFSAMNLDGKTGIGWLGYIVIGGIAGWLASKIVKGGGSGILMNVVIGVVGAFGAGLVLNALGVDVNHGGYWFT	(SEQ ID NO:491)
FFVALGGAVVLLWIVCMVRKT

>BL;Rv1871c, H37Rv2.tab 2121498:2121884 reverse MW:14663
LNAAMNLKREFVNRVQRFVVNPIGRQLPMTMLETIGRKTGQPRRTAVGGRVVDNQFWMVSEHGEHSDYVYNIKANPAVRV	(SEQ ID NO:492)
RIGGRWRSGTAYLLPDDDPRQRLRGLPRLNSAGVRANGTDLLTIRVDLD

>BL;Rv1883c, H37Rv2.tab 2133234:2133692 reverse MW:17280
MCLDQVMEGSATVHMAAPPDKIWTLIADVRNTGRFSPETFEAEWLDGATGPALGARFRGHVRRNGIGPVYWTVCEPGREF	(SEQ ID NO:493)
GFAVLLGDRPVNNWHYRLTPTADGTEVTESFRLPPSVLTTVYYRVFGGWLRQRRNIRDMTKTLQRIKDLVEAG

>BL;Rv1891, H37Rv2.tab 2139741:2140145 forward MW:14108
MIRELVTTAAITGAAIGGAPVAGADPQRYDGDVPGMNYDASLGAPCSSWERFIFGRGPSGQAEACHFPPPNQFPPAETGY	(SEQ ID NO:494)
WVISYPLYGVQQVGAPCPKPQAAAQSPDGLPMLCLGARGWQPGWFTGAGFFPPEP

>BL;Rv1893, H37Rv2.tab 2140486:2140701 forward MW:7467
MSFNPKDAVDAVRDIAANAVEKASDIVENAGHIIRGDIAGGASGIVKDSIDIATHAVDRTKEVFTGKTDDEG	(SEQ ID NO:495)

>BL;Rv1906c, H37Rv2.tab 2152428:2152895 reverse MW:15536
MRLKPAPSPAAAFAVAGLILAGWAGSVGLAGADPEPAPTPKTAIDSDGTYAVGIDIAPGTYSSAGPVGDGTCYWKRMGNP	(SEQ ID NO:496)
DGALIDNALSKKPQVVTIEPTDKAFKTHGCQPWQNTGSEGAAPAGVPGPEAGAQLQNQLGILNGLLGPTGGRVPQP

>BL;Rv1919c, H37Rv2.tab 2171064:2171525 reverse MW:16803
MSGRKFSFEVTKTSSAPAATLFRLVTDGGNWATWAKPIVAQSSWARRGDPAPGGIGAIRKLGMWPVFVQEETVEYEQDRR	(SEQ ID NO:497)
HVYKLVGARTPVQDYFGEVVLTPNASGGTDLRWSGSFTEKVRGTGPVMRAALGGAVRFFAGQLVKAAEREAVRR

>BL;Rv1976c, H37Rv2.tab 2218847:2219251 reverse MW:14997
VRWIVDGMNVIGSRPDGWWRDRHRANVMLVERLEGWAITKARGDDVTVVFERPPSTAIPSSVVEVAHAPKAAANSADDEI	(SEQ ID NO:498)
VRLVRSGAQPQEIRVVTSDKALTDRVRDLGAAVYPAERFRDLIDPRGSNAARRTQ

>BL;Rv2050, H37Rv2.tab 2307821:2308153 forward MW:12971
MADRvLRGSRLGAVSYETDRNHDLAPRQIARYRTDNGEEFEVPFADDAEIPGTWLCRNGMEGTLIEGDLPEPKKVKPPRT	(SEQ ID NO:499)
HWDMLLERRSIEELEELLKERLELIRSRRRG

>BL;Rv2054, H37Rv2.tab 2313125:2313835 forward MW:25183
MTTIEIDAPAGPIDALLGLPPGQGPWPGVVVVHDAVGYVPDNKLISERIARAGYVVLTPNMYARGGRARCITRVFRELLT	(SEQ ID NO:500)
KRGRALDDILAARDHLLANPECSGRVGIVGFCMGGQFALVLSPRGFGATAPFYGTPLPRHLSETLNGACPIVASFGTRDP
LGIGAANRLRKVTAAKNIPADIKSYPGAGHSFANKLPGQPLVRIAGFGYNEAATEDAWRRVFEFFGQHLRAGSPGEP

>BL;Rv2061c, H37Rv2.tab 2316684:2317085 reverse MW:14782
VTPTFSDLAEAQYLLLTTFTKDGRPKPVPIWAALDTDRGDRLLVITEKKSWKVKRIRNTPRVTLATCTLRGRPTSEAVEA	(SEQ ID NO:501)
TAAILDESQTGAVYDAIVKRYGIQGKLFTFVSKLRGGMRNNIGLELKVAESETG

>BL;Rv2091c, H37Rv2.tab 2348561:2349292 reverse MW:26019
MSGPQGSDPRQPWQPPGQGADHSSDPTVAAGYPWQQQPTQEATWQAPAYTPQYQQPADPAYPQQYPQPTPGYAQPEQFGA	(SEQ ID NO:502)
QPTQLGVPGQYGQYQQPGQYGQPGQYGQPGQYAPPGQYPGQYGPYGQSGQGSKRSVAVIGGVIAVMAVLFIGAVLILGFW
APGFFVTTKLDVIKAQAGVQQVLTDETTGYGAKNVKDVKCNNGSDPTVKKGATFECTVSIDGTSKRVTVTFQDNKGTYEV
GRPQ

>BL;Rv2111c, H37Rv2.tab 2370601:2370792 reverse MW:6944
MAQEQTKRGGGGGDDDDIAGSTAAGQERREKLTEETDDLLDEIDDVLEENAEDFVRAYVQKGGQ	(SEQ ID NO:503)

>BL;Rv2125, H372V2.tab 2386293:2387168 forward MW:31808
VTPSEGNAPLPELHNTVVVAAFEGWNDAGDAAGDAVAHLAASWQALPIVEIDDEAYYDYQVNRPVIRQVDGVTRELQWPA	(SEQ ID NO:504)
MRISHCRPPGSDRDVVLMCGVEPNMRWRTFCDELLAVIDKLNVDTVVILGALLADTPHTRPVPVSGAAYSAASARQFGLQ
ETRYEGPTGIAGVFQSACVGAGIPAVTFWAAVPHYVSHPPNPKATIALLRRvEDVLDVEVPLADLPAQAEAWEREITETI
AEDHELAEYVQTLEQHGDAAVDMNEALGNIDGDALAAEFERYLRRRRPGFGR

>BL;Rv2133c, H37Rv2.tab 2393854:2394639 reverse MW:28284
VLADGELTVLGRIRSASNATFLCESTLGLRSLHCVYKPVSGERPLWDFPDGTLAGRELSAYLVSTQLGWNLVPHTIIRDG	(SEQ ID NO:505)
PAGIGMLQLWVQQPGDAVDSDPLPGPDLVDLFPAHRPRPGYLPVLRAYDYAGDEVVLMHADDIRLRRMAVFDVLINNADR
KGGHILCGIDGQVYGVDHGLCLHVENKLRTVLWGWAGKPIDDQILQAVAGLADALGGPLAEALAGRIAAAEIGALRRRAQ
SLLDQPVMPGPNGHRPIPWPAF

>BL;Rv2134c, H37Rv2.tab 2394653:2395237 reverse MW:21217
MARAIHVFRTPDRFVAGTVGQPGNRTFYLQAVHDSRvVSVVLEKQQVAVLAERIGALLFEVNRRFGTPVPPEPTEIDDLS	(SEQ ID NO:506)
PLIMPVDAEFRVGTMGLGWDSEAQSVVVELLAVTDAEFDASVVLDDTEEGPDAVRVFLTPESARQFATRSYRVISAGRPP
CPLCDEPLDPEGHICARTNGYRRDVLLGSGDDPAG

>BL;Rv2137c, H37Rv2.tab 2396905:2397315 reverse MW:14965
MRNMKSTSHESESGKLLSISSCRPREMVLQRYSLGMTVTADRHLADKREEFAVEDISTGIFASGYGQVGDGRSFSFHIEH	(SEQ ID NO:507)
RSLVVEIYRPRvAGPVPQAEDVVAMAVRGLVDIDLTDERSLAAAVRDSVASAAPVSR

>BL;Rv2144c, H37Rv2.tab 2404168:2404521 reverse MW:12027
MLIIALVLALIGLLALVFAVVTSNQLVAWVCIGASVLGVALLIVDALRERQQGGADEADGAGETGVAEEADVDYPEEAPE	(SEQ ID NO:508)
ESQAVDAGVIGSEEPSEEASEATEESAVSADRSDDSAK

>BL;Rv2146c, H37Rv2.tab 2405669:2405956 reverse MW:10804
LVVFFQILGFALFIFWLLLIARvVVEFIRSFSRDWRPTGVTVVILEIIMSITDPPVKVLRRLIPQLTIGAVRFDLSIMVL	(SEQ ID NO:509)
LLVAFIGMQLAFGAAA

>BL;Rv2147c, H37Rv2.tab 2406121:2406843 reverse MW:27629
VNSHCSHTFITDNRSPRARRGHAMSTLHKVKAYFGMAPMEDYDDEYYDDRAPSRGYARPRFDDDYGRYDGRDYDDARSDS	(SEQ ID NO:510)
RGDLRGEPADYPPPGYRGGYADEPRFRPREFDRAEMTRPRFGSWLRNSTRGALANDPRRMAMMFEDGHPLSKITTLRPKD
YSEARTIGERFRDGSPVIMDLVSMDNADAKRLVDFAAGLAFALRGSFDKVATKVFLLSPADVDVSPEERRRIAETGFYAY
Q

>BL;Rv2164c, H37Rv2.tab 2427087:2428238 reverse MW:39647
MRAKREAPKSRSSDRRRRADSPAAATRRTTTNSAPSRRIRSRAGKTSAPGRQARVSRPGPQTSPMLSPFDRPAPAKNTSQ	(SEQ ID NO:511)
AKARAKARKAKAPKLVRPTPMERLAARLTSIDLRPRTLANKVPFVVLVIGSLGVGLGLTLWLSTDAAERSYQLSNARERT
RMLQQHKEALERDVREAASAPALAEAARRQGMIPTRDTAHLVQDPDGNWVVVGTPKPADGVPPPPLNTKLPEDPPPPPKP
AAVPLEVPVRVTPGPDDPAPPARSGPEVLVRTPDGTATLGGATHLPTQAGPQLPGPVPIPGAPGPMPAPPLGAVPSPAPA
ENPVPLQVGAAPPACLPGPAPVAATPGLSGGSQPMVAPPAPVPANGEQFGPVTAPVPTAPGAPR

>BL;Rv2169c, H37Rv2.tab 2431568:2431969 reverse MW:14571
MPLSDHEQRMLDQIESALYAEDPKFASSVRGGGFRAPTARRRLQGAALFIIGLGMLVSGVAFKETMIGSFPILSVFGFVV	(SEQ ID NO:512)
MFGGVVYAITGPRLSGRMDRGGSAAGASRQRRTKGAGGSFTSRMEDRFRRRFDE

>BL;Rv2170, H37Rv2.tab 2432235:2432852 forward MW:22926
LAIFLIDLPPSDMERRLGDALTVYVDAMRYPRGTETLRAPMWLEHIRRRGWQAVAAVEVTAAEQAEAADTTALPSAAELS	(SEQ ID NO:513)
NAPMLGVAYGYPGAPGQWWQQQVVLGLQRSGFPRLAIARLMTSYFELTELHILPRAQGRGLGEALARRLLAGRDEDNVLL
STPETNGEDNRAWRLYRRLGFTDIIRGYHFAGDPRAFAILGRTLPL

>BL;Rv2172c, H37Rv2.tab 2433634:2434536 reverse MW:33007
VTLNTIALELVPPNLEGGKERAIEDARKVVQYSAASGLDGRIRHVMMPGMIAEDDDRPIPMQPKLDVLDFWSIIKPELAG	(SEQ ID NO:514)
VHGLCTQVTAFMDEPSLHRRLVDLSDAGMEGIVFVGVPRTMQDGEGSGVAPTDALSLYRQLVANRGVIVIPTRDGEQGRL
NFKCSRGATYGMTQLLYSDAIVGFLREFARTTEHRPEILLSFGFVPKVETRIGLINWLIQDPGNAAVADEQAFVQKLAGS
EPARRRRLMVDLYKRVLDGVADLGFPLSIHLEATYGVSAAAFETFAEMLAYWSPAEPGKPD

>BL;Rv2175c, H37Rv2.tab 2437449:2437886 reverse MW:15743
MPGRAPGSTLARVGSIPAGDDVLDPDEPTYDLPRvAELLGVPVSKVAQQLREGHLVAVRRAGGVVIPQVFFTNSGQVVKS	(SEQ ID NO:515)
LPGLLTILHDGGYRDTEIMRWLFTPDPSLTITRDGSRDAVSNARPVDALHAHQAREVVRRAQAMAY

>BL;Rv2179c, H37Rv2.tab 2441814:2442317 reverse MW:19488
VRYFYDTEFIEDGNTIELISIGVVAEDGREYYAVSTEFDPERAGSWVRTHVLPKLPPPASQLWRSRQQIRLDLEEFLRID	(SEQ ID NO:516)
GTDSIELWAWVGAYDHVALCQLWGPMTALPPTVPRFTRELRQLWEDRGCPRMPPRPRDVHDALVDARDQLRRFRLITSTD
DAGRGAAR

>BL;Rv2183c, H37Rv2.tab 2445418:2445810 reverse MW:13322
VSGAHTDVRPELRKLAQAILDGIDPAVRvAAAMASGGGPGTGKCQQVWCPLCALAALVTGEQHPLLTVIADHSLALLEVI	(SEQ ID NO:517)
RAIVDDIDRSAKPPPEGPPGGGQTGASGGENTNGEGSMKSHYQAIPVTIEE

>BL;Rv2185c, H37Rv2.tab 2447069:2447500 reverse MW:16292
VADKTTQTIYIDADPGEVMKAIADIEAYPQWISEYKEVEILEADDEGYPKRARMLMDAAIFKDTLIMSYEWPEDRQSLSW	(SEQ ID NO:518)
TLESSSLLKSLEGTYRLAPKGSGTEVTYELAVDLAVPMIGMLKRKAERRLIDGALKDLKKRVEG

>BL;Rv2186c, H37Rv2.tab 2447608:2447994 reverse MW:14573
MNSIQIADETYVAADAARvSAAVADRCSWRRWWPDLRLQVTEDRADKGIRWTVTGALTGTMEIWLEPSMDGVLLHYFLHA	(SEQ ID NO:519)
EPTGVAAWQLARMNLARMTHHRRVAGKKMAFEVKTVLERSRPIGVSPVT

>BL;Rv2197C, N37Rv2.tab 2461507:2462148 reverse MW:22480
MVSRYSAYRRGPDVISPDVIDRILVGACAAVWLVFTGVSVAAAVALMDLGRGFHEMAGNPHTTWVLYAVIVVSALVIVGA	(SEQ ID NO:520)
IPVLLRARRMAEAEPATRPTGASVRGGRSIGSGHPAKRAVAESAPVQHADAFEVAAEWSSEAVDRIWLRGTVVLTSAIGI
ALIAVAAATYLMAVGHDGPSWISYGLAGVVTAGMPVIEWLYARQLRRVVAPQSS

>BL;Rv2199c, H37Rv2.tab 2463236:2463652 reverse MW:14865
MHIEARLFEFVAAFFVVTAVLYGVLTSMFATGGVEWAGTTALALTGGMALIVATFFRFVARRLDSRPEDYEGAEISDGAG	(SEQ ID NO:521)
ELGFFSPHSWWPIMVALSGSVAAVGIALWLPWLIAAGVAFILASAAGLVFEYYVGPEKH

>BL;Rv2203, H37Rv2.tab 2468231:2468920 forward MW:24371
MPGPHSPNPGVGTNGPAPYPEPSSHEPQALDYPHDLGAAEPAFAPGPADDAALPPAAYPGVPPQVSYPKRRHKRLLIGIV	(SEQ ID NO:522)
VALALVSAMTAAIIYGVRTNGANTAGTFSEGPAKTAIQGYLNALENRDVDTIVRNALCGIHDGVRDKRSDQALAKLSSDA
FRKQFSQVEVTSIDKIVYWSQYQAQVLFTMQVTPAAGGPPRGQVQGIAQLLFQRGQVLVCSYVLRTAGSY

>BL;Rv2206, H37Rv2.tab 2470958:2471329 forward MW:13988
MMAGEEAYLLPRDRGPVRRYVRDVVDSRRNLLGLFMPSALTLLFVMFAVPQVQFYLSPAMLILLALMTIDAIILGRKVGR	(SEQ ID NO:523)
LVDTKFPSNTESRWRLGLYAAGRASQIRRLRAPRPQVERGGDVG

>BL;Rv2219, H37Rv2.tab 2486235:2486984 forward MW:26864
MAKPRNAAESKAAKAQANAARKAAARQRRAQLWQAFTLQRKEDKRLLPYMIGAFLLIVGASVGVGVWAGGFTMFTMIPLG	(SEQ ID NO:524)
VLLGALVAFVIFGRRAQRTVYRKAEGQTGAAAWALDNLRGKWRVTPGVAATGNLDAVHRVIGRPGVIFVGEGSAARVKPL
LAQEKKRTARLVGDVPIYDIIVGNGDGEVPLAKLERHLTRLPANITVKQMDTVESRLAALGSRAGAGVMPKGPLPTTAKM
RSVQRTVRRK

>BL;Rv2229c, H37Rv2.tab 2502738:2503472 reverse MW:26851
MKAGVAQQRSLLELAKLDAELTRIAHRATHLPQRAAYQQVQAEHNAANDRMAALRIAAEDLDGQVSRFESEIDAVRKRGD	(SEQ ID NO:525)
RDRSLLTSGATDAKQLADLQHELDSLQRRQASLEDALLEVLERREELQAQQTAESRALQALRADLAAAQQALDEALAEID
QARHQHSSQRDMLTATLDPELAGLYERQRAGGGPGAGRLQGHRCGACRIEIGRGELAQISAAAEDEVVRCPECGAILLRL
EGFEE

>BL;Rv2235, H37Rv2.tab 2507637:2508449 forward MW:29762
MPRLAFLLRPGWLALALVVVAFTYLCFTVLAPWQLGKNAKTSRENQQIRYSLDTPPVPLKTLLPQQDSSAPDAQWRRVTA	(SEQ ID NO:526)
TGQYLPDVQVLARLRvVEGDQAFEVLAPFVVDGGPTVLVDRGYVRPQVGSHVPPIPRLPVQTVTITARLRDSEPSVAGKD
PFVRDGFQQVYSINTGQVAALTGVQLAGSYLQLIEDQPGGLGVLGVPHLDPGPFLSYGIQWISFGILAPIGLGYFAYAEI
RARRREKAGSPPPDKPMTVEQKLADRYGRRR

>BL;Rv2239c, H37Rv2.tab 2511179:2511652 reverse MW:16962
MPIATVCTWPAETEGGSTVVAADHASNYARKLGIQRDQLIQEWGWDEDTDDDIRAAIEEACGGELLDEDTDEVIDVVLLW	(SEQ ID NO:527)
WRDGDGDLVDTLMDAIGPLAEDGVIWVVTPKTGQPGHVLPAEIAEAAPTAGLMPTSSVNLGNWSASRLVQPKSRAGKR

>BL;Rv2242, H37Rv2.tab 2515304:2516545 forward MW:44606
VNDNQLAPVARPRSPLELLDTVPDSLLRRLKQYSGRLATEAVSAMQERLPFFADLEASQRASVALVVQTAVVNFVEWMHD	(SEQ ID NO:528)
PHSDVGYTAQAFELVPQDLTRRIALRQTVDMVRVTMEFFEEVVPLLARSEEQLTALTVGILKYSRDLAFTAATAYADAAE
ARGTWDSRMEASVVDAVVRGDTGPELLSRAAALNWDTTAPATVLVGTPAPGPNGSNSDGDSERASQDVRDTAARHGRAAL
TDVHGTWLVAIVSGQLSPTEKFLKDLLAAFADAPVVIGPTAPMLTAAHRSASEAISGMNAVAGWRGAPRPVLARELLPER
ALMGDASAIVALHTDVMRPLADAGPTLIETLDAYLDCGGAIEACARKLFVHPNTVRYRLKRITDFTGRDPTQPRDAYVLR
VAATVGQLNYPTPH

>BL;Rv2256c, H37Rv2.tab 2529344:2529874 reverse MW:18896
VEPKEQQMRASNQFADVTSGVVYIHASPAAVCPHVEWALSSTLQAKANLVWTPQPALPPQLRAVTNWVGPVGTGARLANA	(SEQ ID NO:529)
LRSWSVLRFEVTEDPSPGVDGQRFSHTPQLGLWSGAMSANGDIMVGEMRLRAMMAQGADTLAAELDSVLGTAWDQALEVY
RDGGDAGEVTWLSRGVG

>BL;Rv2257c, H37Rv2.tab 2530007:2530822 reverse MW:28385
MTALEVLGGWPVPAAAAAVIGPAGVLATHGDTARvFALASVTKPLVARAAQVAVEEGVVNLDTPAGPPGSTVRHLLAHTS	(SEQ ID NO:530)
GLAMHSDQALARPGTRRMYSNYGFTVLAESVQRESGIEFGRYLTEAVCEPLGMVTTRLDGGPAAAGFGATSTVADLAVFA
GDLLRPSTVSAQMHADATTVQFPGLDGVLPGYGVQRPNDWGLGFEIENSKSPHWTGECNSTRTFGHFGQSGGFIWVDPKA
DLALVVLTARDFGDWALDLWPAISDAVLAEYT

>BL;Rv2342, H37Rv2.tab 2620272:2620526 forward MW:9187
LIGYVAVLGLGYVLGAKAGRRRYEQIASTYRALTGSPVARSMIEGGRRKIANRISPDAGFVTLAEIDNQTAVVQRGVERQ	(SEQ ID NO:531)
PKTAR

>BL;Rv2347c, H37Rv2.tab 2626226:2626519 reverse MW:10977
MATRFMTDPHAMRDMAGRFEVHAQTVEDEARRMWASAQNISGAGWSGMAEATSLDTMAQMNQAFRNIVNMLHGVRDGLVR	(SEQ ID NO:532)
DANNYEQQEQASQQILSS

>BL;Rv2365c, H37Rv2.tab 2646750:2647088 reverse MW:11130
MMRRPITLAEQLDAEDAKLVVLARAAMARAEAGAGAAVRDVDGRTYAAAPVALSALELTGLQAAVAAAVSSGATGLQAAV	(SEQ ID NO:533)
LVAGSVDDPGIAAVRELAPTAAIIVTDRAGNPL

>BL;Rv2376c, H37Rv2.tab 2655612:2656115 reverse MW:16635
MKMVKSIAAGLTAAAAIGAAAAGVTSIMAGGPVVYQMQPVVFGAPLPLDPASAPDVPTAAQLTSLLNSLADPNVSFANKG	(SEQ ID NO:534)
SLVEGGIGGTEARIADHKLKKAAEHGDLPLSFSVTNIQPAAAGSATADVSVSGPKLSSPVTQNVTFVNQGGWMLSRASAN
ELLQAAGN

>BL;Rv2413c, H37Rv2.tab 2710354:2711301 reverse MW:33113
LHLVLGDEELLVERAVADVLRSARQRAGTADVPVSRMRAGDVGAYELAELLSPSLFAEERIVVLGAAAEAGKDAAAVIES	(SEQ ID NO:535)
AAADLPAGTVLVVVHSGGGRAKSLANQLRSMGAQVHPCARITKVSERADFIRSEFASLRvKVDDETVTALLDAVGSDVRE
LASACSQLVADTGGAVDAAAVRRYHSGKAEVRGFDIADKAVAGDVAGAAEALRWAMMRGEPLVVLADALAEAVHTIGRVG
PQSGDPYRLAAQLGMPPWRvQKAQKQARRWSRDTVATAMRLVAELNANVKGAVADADYALESAVRQVAELVADRGR

>BL;Rv2446c, H37Rv2.tab 2745770:2746138 reverse MW:13311
MTDRSREPADPWKGFSAVMAATLILEAIVVLLAIPVVDAVGGGLRPASLGYLVGLAVLLILLTGLQRRPWAIWVNLGAQP	(SEQ ID NO:536)
VLVAGFAVYPGVCFIGVLFAALWVLIAYLRAEVRRRRDYRVSQ

>BL;Rv2466c, H37Rv2.tab 2768264:2768884 reverse MW:23035
MLEKAPQKSVADFWFDPLCPWCWITSRWILEVAKVRDIEVNFHVMSLAILNENRDDLPEQYREGMARAWGPVRVAIAAEQ	(SEQ ID NO:537)
AHGAKVLDPLYTAMGNRIHNQGNHELDEVITQSLADAGLPAELAKAATSDAYDNALRKSHHAGMDAVGEDVGTPTIHVNG
VAFFGPVLSKIPRGEEAGKLWDASVTFASYPHFFELKRTRTEPPQFD

>BL;Rv2468c, H37Rv2.tab 2771647:2772147 reverse MW:17288
MTHRSSRLEVGPVARGDVATIEHAELPPGWVLTTSGRISGVTEPGELSVHYPFPIADLVALDDALTYSSRACQVRFAIYL	(SEQ ID NO:538)
GDLGRDTAARAREILGKVPTPDNAVLLAVSPNQCAIEVVYGSQVRGRGAESAAPLGVAAASSAFEQGELVDGLISAIRVL
SAGIAPG

>BL;Rv2476c, H37Rv2.tab 2777391:2782262 reverse MW:176902
MTIDPGAKQDVEAWTTFTASADIPDWISKAYIDSYRGPRDDSSEATKAAEASWLPASLLTPAMLGAHYRLGRHRAAGESC	(SEQ ID NO:539)
VAVYRADDPAGFGPALQVVAEHGGMLMDSVTVLLHRLGIAYAAILTPVFDVHRSPTGELLRIEPKAEGTSPHLGEAWMHV
ALSPAVDHKGLAEVERLLPKVLADVQRVATDATALIATLSELAGEVESNAGGRFSAPDRQDVGELLRWLGDGNFLLLGYQ
RCRVADGMVYGEGSSGMGVLRGRTGSRPRLTDDDKLLVLAQARVGSYLRYGAYPYAIAVREYVDGSVVEHRFVGLFSVAA
MNADVLEIPTISRRVREALAMAESDPSHPGQLLLDVIQTVPRPELFTLSAQRLLTMARAVVDLGSQRQALLFLRADRLQY
FVSCLVYMPRDRYTTAVRMQFEDILVREFGGTRLEFTARVSESPWALMHFMVRLPEVGVAGEGAAAPPVDVSEANRIRIQ
GLLTEAARTWADRLIGAAAAAGSVGQADAMHYAAAFSEAYKQAVTPADAIGDIAVITELTDDSVKLVFSERDEQGVAQLT
WFLGGRTASLSQLLPMLQSMGVVVLEERPFSVTRPDGLPVWIYQFKISPHPTIPLAPTVAERAATANRFAEAVTAIWHGR
VEIDRFNELVMRAGLTWQQVVLLRAYAKYLRQAGFPYSQSYIESVLNEHPATVRSLVDLFEALFVPVPSGSASNRDAQAA
AAAVAADIDALVSLDTDRILRAFASLVQATLRTNYFVTRQGSARCRDVLALKLNAQLIDELPLPRPRYEIFVYSPRVEGV
HLRFGPVARGGLRWSDRRDDFRTEILGLVKAQAVKNAVIVPVGAKGGFVVKRPPLPTGDPAADRDATRAEGVACYQLFIS
GLLDVTDNVDHATASVNPPPEVVRRDGDDAYLVVAADKGTATFSDIANDVAKSYGFWLGDAFASGGSVGYDHKAMGITAR
GAWEAVKRHFREIGIDTQTQDFTVVGIGDMSGDVFGNGMLLSKHIRLIAAFDHRHIFLDPNPDAAVSWAERRRMFELPRS
SWSDYDRSLISEGGGVYSREQKAIPLSAQVRAVLGIDGSVDGGAAEMAPPNLIRAILRAPVDLLFNGGIGTYIKAESESD
ADVGDRANDPVRVNANQVRAKVIGEGGNLGVTALGRVEFDLSGGRINTDALDNSAGVDCSDHEVNIKILIDSLVSAGTVK
ADERTQLLESMTDEVAQLVLADNEDQNDLMGTSRANAASLLPVHAMQIKYLVAERGVNRELEALPSEKEIARRSEAGIGL
TSPELATLMAHVKLGLKEEVLATELPDQDVFASRLPRYFPTALRERFTPEIRSHQLRREIVTTMLINDLVDTAGITYAFR
IAEDVGVTPIDAVRTYVATDAIFGVGHIWRRIRAANLPIALSDRLTLDTRRLIDRAGRWLLNYRPQPLAVGAEINRFAAM
VKALTPRMSEWLRGDDKAIVEKTAAEFASQGVPEDLAYRVSTGLYRYSLLDIIDIADIADIDAAEVADTYFALMDRLGTD
GLLTAVSQLPRHDRWHSLARLAIRDDIYGALRSLCFDVLAVGEPGESSEQKIAEWEHLSASRVARARRTLDDIRASGQKD
LATLSVAARQIRRMTRTSGRGISG

>BL;Rv2484c, H37Rv2.tab 2791022:2792494 reverse MW:52309
MAESGESPRLSDELGPVDYLMHRGEANPRTRSGIMALELLDGTPDWDRFRTRFENASRRVLRLRQKVVVPTLPTAAPRWV	(SEQ ID NO:540)
VDPDFNLDFHVRRVRVSGPATLREVLDLAEVILQSPLDISRPLWTATLVEGMADGRAAMLLHVSHAVTDGVGGVEMFAQI
YDLERDPPPRSTPPQPIPEDLSPNDLMRRGINHLPIAVVGGVLDALSGAVSMAGRAVLEPVSTVSGILGYARSGIRVLNR
AAEPSPLLRRRSLTTRTEAIDIRLADLHKAAKAGGGSINDAYLAGLCGALRRYHEALGVPISTLPMAVPVNLRAEGDAAG
GNQFTGVNLAAPVGTIDPVARMKKIRAQMTQRRDEPAMNIIGSIAPVLSVLPTAVLEGITGSVIGSDVQASNVPVYPGDT
YLAGAKILRQYGIGPLPGVAMMVVLISRGGWCTVTVRYDRASVRNDELFAQCLQAGFDEILALAGGPAPRVLPASFDTQG
AGSVPRSVSGS

>BL;Rv2507, H37Rv2.tab 2822438:2823256 forward MW:28520
MNDPRRPQRFGPPLSGYGPTGPQVPPNPPTADPAYADQSPYASTYGGYVSPPWSPGGPPPRPPQWPPGPHEASPTQQLPQ	(SEQ ID NO:541)
YWQYDQPPPGGFPPDGLTPPPPQGPRTPRWLWFAAGSAVLLVVALVIALVIANGSVKKQTAIEPLPPMPGPSPTRPTTTT
PTPPSPSAAPAPTTTTGTPSETVAGAMQTVVYDVTGEGRAISITYMDSGNVIQTEFNVALPWRKEVSLSKSSLHPASVTI
VNIGHNVTCSVTVAGVQVRQRTGAGLTICDAPS

>BL;Rv2520c, H37Rv2.tab 2837391:2837615 reverse MW:8341
VVDRDPNTIKQEIDQTRDQLAATIDSLAERANPRRLADDAKTRVIAFLRKPIVTVSLVGIGSVVVVVVIHKIRNR	(SEQ ID NO:542)

>BL;Rv2525c, H37Rv2.tab 2849855:2850574 reverse MW:25369
MSVSRRDVLKFAAATPGVLGLGVVASSLRAAPASAGSLGTLLDYAAGVIPASQIRAAGAVGAIRYVSDRRPGGAWMLGKP	(SEQ ID NO:543)
IQLSEARDLSGNGLKIVSCYQYGKGSTADWLGGASAGVQHARRGSELHAAAGGPTSAPIYASIDDNPSYEQYKNQIVPYL
RSWESVIGHQRTGVYANSKTIDWAVNDGLGSYFWQHNWGSPKGYTHPAAHLHQVEIDKRKVGGVGVDVNQILKPQFGQWA

>BL;Rv2536, H37Rv2.tab 2860452:2861141 forward MW:24626
MTNWMLRGLAFAAAMVVLRLFQGALINAWQMLSGLISLVLLLLFAIGGVVWGVMDGRADAKASPDPDRRQDLAMTWLLAG	(SEQ ID NO:544)
LVAGALSGAVAWLISLFYKAIYTGGPINELTTFAAFTALIVFLVGIVGVAVGRWLVDRQLAKAPVRHHGLAAEHERAADT
DVFSAVRADDSPTGEMQVAQPEAQTAAVATVEREAPTEVIRTTESDTPTEVIRTDTEADQTKPGDEPKKD

>BL;Rv2588C, H37Rv2.tab 2915849:2916193 reverse MW:12966
MESFVLFLPFLLIMGGFMYFASRRQRRAMQATIDLHDSLQPGERVHTTSGLEATIVAIADDTIDLEIAPGVVTTWMKLAI	(SEQ ID NO:545)
RDRILPDDDIDEELNEDLDKDVDDVAGERRVTNDS

>BL;Rv2609c, H37Rv2.tab 2936813:2937865 reverse MW:38096
MTWLVLAGAVLLVVLVAFGAWGYQTANRLNRLNVRYDLSWQSLDSALARRAVVARAVAIDAYGGAPQGSRLAALADAAEG	(SEQ ID NO:546)
APRHARENAENELSAALANVNPASLPAALIAELADAEARVLLARRFHNDAVRDTLALGERRLVRLLRLGGTAVLPTYFEI
VERPHALVNGDQGASGRRTSARVVLLDDSGAVLLLCGSDPANPAFRDGAAPKWWFTVGGQVRPGERLAQAAARELAEETG
LRVAPADMIGPIWRRDEVFEFNGSLIDSEEFYLVHRTRRFEPAVQGRTELERRYIRDARWCDANDIAQLVAAGERWPLQ
LGELLPAANRLVDVALDNGAARDAGVPQPIR

>BL;Rv2673, H37Rv2.tab 2989290:2990588 forward MW:48883
VYGALVTAADSIRTGLGASLLAGFRPRTGAPSTATILRSALWPAAVLSVLHRSIVLTTNGNITDDFKPVYRAVLNFRRGW	(SEQ ID NO:547)
DIYNEHFDYVDPHYLYPPGGTLLMAPFGYLPFAPSRYLFISINTAAILVAAYLLLRMFNFTLTSVAAPALILAMFATETV
TNTLVFTNINGCILLLEVLFLRWLLDGRASRQWCGGLAIGLTLVLKPLLGPLLLLPLLNRQWRALVAAVVVPVVVNVAAL
PLVSDPMSFFTRTLPYILGTRDYFNSSILGNGVYFGLPTWLILFLRILFTAITFGALWLLYRYYRTGDPLFWFTTSSGVL
LLWSWLVMSLAQGYYSMMLFPFLMTVVLPNSVIRNWPAWLGVYGFMTLDRWLLFNWMRWGRALEYLKITYGWSLLLIVTF
TVLYFRYLDAKADNRLDGGIDPAWLTPEREGQR

>BL;Rv2680, H37Rv2.tab 2996104:2996733 forward MW:22555
LTSAGDDAERSDEEERRLTSAEPALFREAVAANNAVTVRPEIELGPIRPPQRLAPYSYALGAEIKHPELDVIPERSEGDA	(SEQ ID NO:548)
FGRLIMLYDPDGSDAWDGTIRLVAYVQADLDSSEAVDPLLPEVAWSWLVDALTARTDQVRALGGTVTATTSVRYGDISGP
PRAHQLELRASWTATTPDLGAHVQAFCDVLEHAAGLPPAGVTDLGSRSRA

>BL;Rv2683, H37Rv2.tab 3000111:3000605 forward MW:17729
MKVNIDPTAPTFATYRRDMRAEQMAEDYPVVSIDSDALDAARMLAEHRLPGLLVTAGAGKQYAVLPASQVVRFIVPRYVQ	(SEQ ID NO:549)
DDPLLAGVLNESTADRCAERLSGKKVRDVLPDHLVEVPPANADDTIIEVAAVMARLRSPLLAVVKDGSLLGVVTASRLLA
AALKT

>BL;Rv2695, H37Rv2.tab 3011915:3012619 forward MW:24154
MAVDLDGVTTVLLPGTGSDNDYVRRAFSAPLRRAGAVLVTPVPHPGRLIDGYRAALDDAARDGPVVVGGVSLGAAVAAAW	(SEQ ID NO:550)
ALEHPDRAVAVLAALPAWTGEPELAPAAQAARYTAARLRCDGLAATTTRMRASSPVWLAEELTRSWRVQWPELPDAMEEA
AAYVAPSRAELARLVAPLAVAAAVDDPIHPLQVAADWVSVAPHAALRTVTLDEIGADAAALGSACLAALAEVSGA

>BL;Rv2696c, H37Rv2.tab 3012831:3013607 reverse MW:27216
MAFGRRTGKDGGKRKAGHAPVQPADEHVRPEDTVVASAAAASGVEDQEELQGPFDIDDFDDPSVAVLARLDLGSVLIPMP	(SEQ ID NO:551)
AAGQVQVELTESGVPSAVWVITPNGRYSIAAYAAPKTGGLWREVAGELADSLRKDSAKVSIKDGPWGREVIGIAAGVVRF
IGVDGYRWNIRCVVNGPQETVDALTEEAREALADTVVRRGDTPLPVRTPLPVHLPEPMAAQLREAAAAQADTQRQAAAGV
ARRGAQGSAMQQLRSTTGG

>BL;Rv2698, H37Rv2.tab 3014172:3014654 forward MW:17530
VSGTRLAPHSVRYRERLWVPWWWWPLAFALAALIAFEVNLGVAALPDWVPFATLFTVAAGTLLWLGRVEIRVTAGSADGA	(SEQ ID NO:552)
GVKLWAGPAHLPVAVIARSAEIPATAKSAALGRQLDPAAYVLHRAWVGPMVLVVLDDPNDPTPYWLVSCRHPERVLSALR
S

>BL;Rv2699c, H37Rv2.tab 3014665:3014964 reverse MW:10915
MPTDYDAPRRTETDDVSEDSLEELKARRNEAASAVVDVDESESAESFELPGADLSGEELSVRVVPKQADEFTCSSCFLVQ	(SEQ ID NO:553)
HRSRLASEKNGVMICTDCAA

>BL;Rv2700, H37Rv2.tab 3015202:3015849 forward MW:22627
VVAQITEGTAFDKHGRPFRRRNPRPAIVVVAFLVVVTCVMWTLALTRPPDVREAAVCNPPPQPAGSAPTNLGEQVSRTDM	(SEQ ID NO:554)
TDVAPAKLSDTKVHVLNASGRGGQAADIAGALQDLGFAQPTAANDPIYAGTRLDCQGQIRFGTAGQATAAALWLVAPCTE
LYHDSRADDSVDLALGTDFTTLAHNDDIDAVLANLRPGATEPSDPALLAKIHANSC

>BL;Rv2708c, H37Rv2.tab 3021550:3021795 reverse MW:8962
MSGMQTQTIERTDADERVDDGTGSDTPKYFHYVKKDKIAESAVMGSHVVALCGEVFPVTRAPKPGSPVCPDCKRIYDTLK	(SEQ ID NO:555)
KG

>BL;Rv2709, H37Rv2.tab 3021838:3022281 forward MW:16810
MWDSRVNKHGLRLGFNGQFDDFDDFDDKGRPVLITAAAPSYEVEHRTRVRKYLTLMAFRVPALILAAIAYGAWHNGLISL	(SEQ ID NO:556)
LIVAASVPLPWMAVLIANDRPPRRADEPRRFDVARRRIPLFPTAERPALEPRRQPAERSAPRGFADHG

>BL;Rv2714, H37Rv2.tab 3027064:3028035 forward MW:35520
MARDQGADEAREYEPGQPGMYELEFPAPQLSSSDGRGPVLVHALEGFSDAGHAIRLAAAHLKAALDTELVASFAIDELLD	(SEQ ID NO:557)
YRSRRPLMTFKTDHFTHSDDPELSLYALRDSIGTPFLLLAGLEPDLKWERFITAVRLLAERLGVRQTIGLGTVPMAVPHT
RPITMTAHSNNRELISDFQPSISEIQVPGSASNLLEYRMAQHGHEVVGFTVHVPHYLTQTDYPAAAQALLEQVAKTGSLQ
LPLAVLAEAAAEVQAKIDEQVQASAEVAQVVAALERQYDAFIDAQENRSLLTRDEDLPSGDELGAEFERFLAQQAEKKSD
DDPT

>BL;Rv2715c, H37Rv2.tab 3031042:3031536 reverse MW:17324
MTPVRPPHTPDPLNLRGPLDGPRWRRAEPAQSRRPGRSRPGGAPLRYHRTGVGMSRTGHGSRPVPPATTVGLALLAAAIT	(SEQ ID NO:558)
LWLGLVAQFGQMITGGSADGSADSTGRvPDRLAVVRvETGESLYDVAVRvAPNAPTRQVADRIRELNGLQTPALAVGQTL
IAPVG

>BL;Rv2722, H37Rv2.tab 3034634:3034879 forward MW:9077
MPCLARQPVDLPPWAGPRCGPYCPRARITLLQRTTIAKSNRKYYENGYPADVKLMPGHAAVVSNRAAARAGFALPCRKRQ	(SEQ ID NO:559)
PD

>BL;Rv2728c, H37Rv2.tab 3040768:3041460 reverse MW:23455
VLSAIGIVPSAPVLVPELAGAAAAELADLGAAVIAAASLLPKSWIAVGTGRADDVVRPTDVGTFAGFGADVRVGLAPQDG	(SEQ ID NO:560)
DGVAVPVELPLCALLTAWVRGQARPEARAQVHVYASDHGSDAAVARGRQLRADIDREPDPIGVLVVADGLNTLTPRAPGG
YDPDGAGMQRALDDALASGDLAVLTRLPAQVLGRvAFQVLAGLAEPGPRSAKEFYRGAPHGVGYFAGVWQP

>BL;Rv2732c, H37Rv2.tab 3044377:3044988 reverse MW:21989
MMSHEHDAGDLDALRAEIEAAERRvAREIEPGARALVVAILVFVLLGSFILFHTGSVRGWDVLFSSHGAGRAAVALPSRV	(SEQ ID NO:561)
FAWLALVFGVGFSMLALLTRRWALAWVALAGSANASGTGLLAVWSRQTVAAGHPGPGIGLIVAWITAIVLTFXWAQVVWS
RTIVQLAAEERRRRVVAQQQCKTLLDHVQTDSEAGTTPDRGTDR

>BL;Rv2738c, H37Rv2.tab 3051808:3052011 reverse MW:7551
MLAGVRLTEFHERVALHFGAAYGSSVLLDHVLTGFDGRSAAQAIEDGVEPRDVWRALCADFDVPHDRW	(SEQ ID NO:562)

>BL;Rv2740, H37Rv2.tab 3053232:3053678 forward MW:16593
MAELTETSPETPETTEAIRAVEAFLNALQNEDFDTVDAALGDDLVYENVGFSRIRGGRRTATLLRRMQGRVGFEVKIHRI	(SEQ ID NO:563)
GADGAAVLTERTDALIIGPLRvQFWVCGVFEVDDGRITLWRDYFDVYDMFKGLLRGLVALVVPSLKATL

>BL;Rv2771c, H37Rv2.tab 3080583:3081032 reverse MW:16000
VRRLLIVHHTPSPHMQEMFEAVVSGATDPEIEGVEVVRRPALTVSPIEMLEADGYLLGTPANLGYISGALKHAFDVCYYL	(SEQ ID NO:564)
CLDTTRGRSFGAYIHGNEGTEGAERAVDAITTGLGWVQAAETVVVMGKPSKADIEACWNLGATVAAQLMG

>BL;Rv2772c, H37Rv2.tab 3081121:3081591 reverse MW:17326
MTRRTLYVQLIIAFMCVAMVAYLVMLGRvAVAMIGSGRAAAAGLGLALLILPVIGLWANIATLRAGFAYQRLARLIAEDG	(SEQ ID NO:565)
LDIDASALPRRASGRIQRDAADALFAAVRTELEDDADDWRRWYRLARAYDYAGDRRRAREANKTALQLEGRARPGAR

>BL;Rv2795c, H37Rv2.tab 3103939:3104910 reverse MW:37568
VTWKGSGQETVGAEPTLWAISDLHTGHLGNKPVAESLYPSSPDDWLIVAGDVAERTDEIRWSLDLLRRRFAKVIWVPGNH	(SEQ ID NO:566)
ELWTTNRDPMQIFGRARYDYLVNMCDEMGVVTPEHPFPVWTERGGPATIVPMFLLYDYSFLPEGANSKAEGVAIAKERNV
VATDEFLLSPEPYPTRDAWCHERVAATRARLEQLDWMQPTVLVNHFPLLRQPCDALFYPEFSLWCGTTKTADWHTRYNAV
CSVYGHLHIPRTTWYDGVRFEEVSVGYPREWRRRKPYSWLRQVLPDPQYAPGYLNDFGGHFVITPEMRTQAAQFRERLRQ
RQSR

>BL;Rv2840c, H37Rv2.tab 3147961:3148257 reverse MW:10601
VRTCVGCRKRGLAVELLRvVAVSTGNGNYAVIVDTATSLPGRGAWLHPLRQCAQQAIRRAFARALRIAGSPDTSAVVEY	(SEQ ID NO:567)
LESLGELEPPGNRTGSNRT

>BL;2V2843, H37Rv2.tab 3150170:3150712 forward MW:17735
VLPAAPVINRLTNRPISRRGVLAGGAALAALGVVSACGESAPKAPAVEELRSPLDQARHDGALAAAAATAIGIPPQVAAA	(SEQ ID NO:568)
LTVVATQRTSHARALATEIARAAGKLVSATSETSSSSPSPTDPAAPPPAVSDVIDSLRTSAGEASRLVATTSGYRAGLLA
SIAASCTASYTVALVPSGPSI

>BL;Rv2844, H37Rv2.tab 3150712:3151197 forward MW:16940
MTSSEPAHGATPKRSPSEGSADNAALCDALAVEHATIYGYGIVSALSPPGVNFLVADALKQHRHRRDDVIVMLSARGVTA	(SEQ ID NO:569)
PIAAAGYQLPMQVSSAANAARLAVRMENDGATAWRAVVEHAETADDRvFASTALTESAVMATRWNRvLGAWPITAAFPGG
DE

>BL;Rv2876, H37Rv2.tab 3187662:3187973 forward MW:11805
MFGQWEFDVSPTGGIAVASTEVEHFAGSQHEVDTAEVPSAAWGWSRIDHRTWHIVGLCIFGFLLAMLRGNHVGHVEDWFL	(SEQ ID NO:570)
ITFAAVVLFVLARDLWGRRRGWIR

>BL;Rv2898c, H37Rv2.tab 3207944:3208327 reverse MW:14223
MTTLKTMTRVQLGAMGEALAVDYLTSMGLRILNRNWRCRYGELDVIACDAATRTVVFVEVKTRTGDGYGGLAHAVTERKV	(SEQ ID NO:571)
RRLRRLAGLWLADQEERWAAVRIDVIGVRVGPKNSGRTPELTHLQGIG

>BL;Rv2901C, H37Rv2.tab 3211805:3212107 reverse MW:12225
MSAEDLEKYETEMELSLYREYKDIVGQFSYVVETERRFYLANSVEMVPRNTDGEVYFELRLADAWVWDMYRPARFVKQVR	(SEQ ID NO:572)
VVTFKDVNIEEVEKPELRLPE

>BL;Rv2917, H37Rv2.tab 3226362:3228239 forward MW:68334
VRVTRLVDAESTRCDVGPAPKSVANLHFTAATSRFRLGRERANSVRSDGGWGVLQPVSATFNPPLRGWQRRALVQYLGTQ	(SEQ ID NO:573)
PRDFLAVATPGSGKTSFALRIAAELLRYHTVEQVTVVVPTEHLKVQWAHAAAAHGLSLDPKFANSNPQTSPEYHGVMVTY
AQVASHPTLHRVRTEARKTLVVFDEIHNGGDAKTWGDAIREAFGDATRRLALTGTPFRSDDSPIPFVSYQPDADGVLRSQ
ADHTYGYAEALADGVVRPVVFLAYSGQARWRDSAGEEYEARLGEPLSAEQTARAWRTALDPEGEWMPAVITAADRRLRQL
RAHVPDAGGMIIASDRTTARAYARLLTTMTAEEPTVVLSDDPGSSARITEFAQGTSRWLVAVRMVSEGVDVPRLSVGVYA
TNASTPLFFAQAIGRFVRSRRPGETASIFVPSVPNLLQLASALEVQRNHVLGRPHRESAHDPLDGDPATRTQTERGGAER
GFTALGADAELDQVIFDGSSFGTATPTGSDEEADYLGIPGLLDAEQMRALLHRRQDEQLRKRAQLQKGATQPATSGASAS
VHGQLRDLRRELHTLVSIAHHRTGKPHGWIHDERRRRCGGPPIAAATRAQIKARIDALRQLNSERS

>BL;Rv2926c, H37Rv2.tab 3240550:3241170 reverse MW:22378
VDLGGVRRRISLMARQHGPTAQRHVASPMTVDIARLGRRPGAMFELHDTVHSPARIGLELIAIDQGALLDLDLRVESVSE	(SEQ ID NO:574)
GVLVTGTVAAPTVGECARCLSPVRGRVQVALTELFAYPDSATDETTEEDEVGRVVDETIDLEQPIIDAVGLELPFSPVCR
PDCPGLCPQCGVPLASEPGHRHEQIDPRWAKLVEMLGPESDTLRGER

>BL;Rv2949c, H37Rv2.tab 3299973:3300569 reverse MW:22587
MTECFLSDQEIRKLNRDLRILIAANGTLTRVLNIVADDEVIVQIVKQRIHOVSPKLSEFEQLGQVGVGRVLQRYIILKGR	(SEQ ID NO:575)
NSEHLFVAAESLIAIDRLPAAIITRLTQTNDPLGEVMAASHIETFKEEAKVWVGDLPGWLALHGYQNSRKRAVARRYRVI
SGGQPIMVVTEHFLRSVFRDAPHEEPDRWQFSNAITLAR

>BL;Rv2968c, H37Rv2.tab 3323073:3323702 reverse MW:23100
VVAARPAERSGDPAAVRVPVPSAWWVLIGGVIGLFASMTLTVEKVRILLDPIYVPSCNVNPIVSCGSVMTTPQASLLGFP	(SEQ ID NO:576)
NPLLGIAGFTVVVVTGVLAVAKVPLPRWYWIGLAVGILVGVAFVHWLIPQSLYRIGALCPYCMVVWAVIATLLVVVASIV
FGPMRENRGSQERvGARLLYQWRWSLATLWFTTVFLLIMVRFWDYWSTLI

>BL;Rv2980, H37Rv2.tab 3335959:3336501 forward MW:18752
VTGESDGPPRAVLIAAAALAAAVIGVILVVAANRQPPERPVVIPAVPAPQATGPGCKALLAALPQRLGEYPRAPVAEPTT	(SEQ ID NO:577)
AGATAWRTGPNSTPVILRCGLDRPAEFVVGSAIQVVDRVQWFQVAAQNPDEPGRSTWYTVDRPVYVALTLPSGSGPTAIQ
ELSDVIDHTIPAVPIOPAPAR

>BL;Rv3005c, H37Rv2.tab 3363695:3364531 reverse MW:28827
VTSSNDSHWQRPDDSPGPMPGRPVSASLVDPEDDLTPARYAGDFGSGTTTVIPPYDAASSGVGNSGYSLIEAAEPLPYVQ	(SEQ ID NO:578)
PQPGRQVPAGSAGIDMDDDERVRAAGRRGTQNLGLLILRVGLGAVLIAHGLQKLFGWWDGQGLAGFQNSLSDIGYQHAEI
LAYVSAGGEIVAGVLLVLGLFTPLAAAGALAFLINGLLAGISAQHSRPVAYFLQDGHEYQITLVVMAVAVILSGPGRYGL
DAARGWAHRPFIGSFVALLGGIAAGIAVWVLLNGANPLA

>BL;Rv3013, H37Rv2.tab 3371814:3372467 forward MW:22967
VRSYLLRIELADRPGSLGSLAVALGSVGADILSLDVVERGNGYAIDDLVVELPPGAMPDTLITAAEALNGVRVDSVRPHT	(SEQ ID NO:579)
GLLEAHRELELLDHVAAAEGATARLQVLVNEAPRVLRVSWCTVLRSSGGELHRLAGSPGAPETRANSAPWLPIERAAALD
GGADWVPQAWRDMDTTMVAAPLGDTHTAVVLGRPGPEFRPSEVARLGYLAGIVATMLR

>BL;Rv3015c, H37Rv2.tab 3374653:3375663 reverse MW:34212
VSVFATATGIGSWPGTAAREAAQVVVGELAGALAYLTELPARGVGADMLGRAGGLLVDVAIDTVPRGYRIAARPGAVTRR	(SEQ ID NO:580)
AASLLDEDMDALEEAWETAGLRGCGRAVKVQAPGPVTLVAGLELANGHRAITDPGAVRDLAASLAEGVAAHRAALARRLD
TPVVVQFDEPSLPAALGGRLTGVTALSPVAPLDETVAEALLDTCIAAVDADVALHSCSPDLPWDLLQRSRISAVSVDAST
LQAADLDAVAAFVESGRTVVLGLVPVTAPERAPSMEEVAAAAVAVTDRLGVPRSALRDRLGVSPACGLANATGQWARTAV
GLARDVAEAFARDPEAI

>BL;Rv3035, H37Rv2.tab 3395378:3396457 forward MW:37305
LAAGPALSARGYLALNGQTPAGCSLMEWQNDNNGRQRWCVRLVQGGGFAGPLFDGFDNLYVGQPGAIISFPPTQWTRWRQ	(SEQ ID NO:581)
PVIGMPSTPRFLGHGRLLVSTHLGQLLVFDTRRGMVVGSPVDLVDGIDPTDATRGLADCAPARPGCPVAAAPAFSSVNGT
VVVSVWQPGEPAAKLVGLKYHAEQLVREWTSDAVSAGVLASPVLSADGSTVYVNGRDHRLWALNAADGKAKWSAPLGFLA
QTPPALTPHGLIVSGGGPDTALAAFRDAGDHAEGAWRRDDVTALSTASLAGTGVGYTVISGPNHDGTPGLSLLVFDPANG
HTVNSYPLPGATGYPVGVSVGNDRRvVTATSDGQVYSFAP

>BL;Rv3038c, H37Rv2.tab 3398427:3399407 reverse MW:36049
MTRSSNIPADATPNPHATAEQVAAARHDSKLAQVLYHDWEAENYDEKWSISYDQRCVDYARGRFDAIVPDEVIAQLPYDR	(SEQ ID NO:582)
ALELGCGTGFFLLNLIQAGVARRGSVTDLSPGMVKVATRNGQALGLDIDGRvADAEGIPYDDDAFDLVVGHAVLHHIPDV
ELSLREVVRVLKPGGRFVFAGEPTTVGDGYARTLSTLTWRVVTNATKLPGLRGWRRPQGELDESSRAAALEALVDLHTFT
PQDLQRIAHNAGAVEVQTATEEFTAANLGWPLRTFECTVPPGRLGWGWARFAFTSWKTLGWVDANVWRHVVPKGWFYNVM
ITGVKPS

>BL;Rv3195, H37Rv2.tab 3564363:3565778 forward MW:49325
VSTGEVMGDLPFGFSSGDDPPEDPSGRDKRGKDGADSGSGANPLGAFGIGGEFNMADLGQIFTRLGEMFGGVGTAMAAGK	(SEQ ID NO:583)
TSGPVNYDLARQVASSSIGFIAPIPAATNSAIADAVHLADTWLDGATSLPAGATKAVGWSPTDWVDNTLATWKRLCDPMA
QQISTVWASSLPEEAKSMAGPLLSIMSQMGGIAFGSQLGQALGRLSREVLTSTDIGLPLGPKGVAAILPGAVESFAAGLE
QPRSEILTFLATREAAHHRLFSHVPWLASQLLGAVEAYAMGMKIDMTGIEELARDINPTSLADPAAMEQLLSQGVFEPKA
TPAQTQALERLETLLALIEGWVQTVVTAALGERIPGEAALSETLRRRRASGGPAEQTFATLVGLELRPRKLREAGALWER
LTRAVGMDARDAVWQHPDLLPATDDLDDPAAFIDRvIGGDTSGIDEAIAELERDQQARGADDSGHDGGPVDN

>BL;Rv3205c, H37Rv2.tab 3581629:3582504 reverse MW:31352
MGSTRLTGVNVEPPPEHVLVAFGLAGAQPILLGAGWEGGWRCGEVVLSMVADNARAAWSARvRETLFVDGVRLARPVRST	(SEQ ID NO:584)
DGRYVVSGWRADTFVAGAPEPRHDEVVSAAVRLHEATGKLERPRFLTQGPAAPWAEIDVFVAADRAGWEERPLQSVPPGV
PTAPPAADPQRSIDLINQLAGLRKPTKSPNQLVUGDLYGTVLFAGTAPPGITDITPYWRPASWAAGVAVVDALSWGAADD
GLIERWNALPEWPQMLLRALMFRLAVYALHPRSTAEAFPGLAHTAALVRLVL

>BL;2V3207c, H37Rv2.tab 3583803:3584657 reverse MW:31034
VSTYGWRAYALPVLMVLTTVVVYQTVTGTSTPRPAAAQTVRDSPAIGVVGTAILDAPPRGLAVFDANLPAGTLPDGGPFT	(SEQ ID NO:585)
EAGDKTWRvVPGTTPQVGQGTVKVFRYTVEIENGLDPTMYGGDNAFAQMVDQTLTNPKGWTHNPQFAFVRIDSGKPDFRI
SLVSPTTVRGGCGYEFRLETSCYNPSFGGMDRQSRVFINEARWVRGAVPFEGDVGSYRQYVINHEVGHAIGYLRHEPCDQ
QGGLAPVMMQQTFSTSNDDAAKFDPDFVKADGKTCRFNPWPYPIP

>BL;Rv3208c, H37Rv2.tab 3585679:3585948 reverse MW:9400
VEVKIGITDSPRELVFSSAQTPSEVEELVSNALRDDSGLLTLTDERGRRFLIHTARIAYVEIGVADARRvGFGVGVDAAA	(SEQ ID NO:586)
GSAGKVATSG

>BL;Rv3209, H37Rv2.tab 3586273:3586830 forward MW:19118
VALGAVATAVIINSGDSTSTKAIVGAPAPRTVISTSPRPTAPTSTSPHPSPSTLRPQLPPETVTTVAPPGTGPTTVPTRT	(SEQ ID NO:587)
PTAAPPQTAVPPPAPLNPRTVVYRvTGTKQLFDLVNVVYTDARGFPVTDFNVSLPWTKMVVLNPGVQTESVVATSLYSRL
NCSIVNTGAQTVVASTNNAIIATCTR

>BL;Rv3212, H37Rv2.tab 3589393:3590613 forward MW:42506
MVKPERRTKTDIAAAATIAVVVAVAASLIWWTSDARATISRPAAVAVPTPAPAREVPTSLKQLWTAASPATRVPVVVGGT	(SEQ ID NO:588)
VATGDGRQVDGRDPATGESLWSYARDTDLCGVTWVYHYAVAVYRYDRGCGQVSTIDGSTGRRGAARSGYADPRVRLPSDG
TTVLSAGDTRLELWRSDMVRMLAYGEIDARVKPSNRGLQSGCTLESAAASSAAVSVLEACTNQADLRLVLLRPGKEDDEP
IQRIVPEPGVRPGSGARVLVVSQNNTAVYLPARSGAQPRVDVIDETGATVSSTLLAKPPSTSAVASRTGNLVTWWTGDAL
LVFDAGNLTQRYTIAAGETTAPVGPGVMMAGQLLVPVTGGIGVYDPVSGANNRYIPVTRPPSTSAVIPAVSGSRVIEQRG
DTLVALG

>BL;Rv3217C, H37Rv2.tab 3593806:3594234 reverse MW:14260
VPVRAPAAVRGAGLIVAVQGGAALVVAAALLVRGLAGADQHIVNGLGTAGWFVLVGGAVLAAGCRLAVGKLWGRGLAVFA	(SEQ ID NO:589)
QLLLLPVAWYLIVGSHQPAIGIPVGIIALGVLVLLFSPPSIRWAAGRDQRGAASAANRGPDSR

>BL;Rv3242C, H37Rv2.tab 3621572:3622210 reverse MW:22481
VLDLVLPLECGGCGAPATRWCAACAAELSVAAGEPHVVSPRVDPQVPVFALGRYAGVRRQAILAMKEHGRRDLVAPLACA	(SEQ ID NO:590)
LIVGVDHLLSWGMLENPLTMVPAPTRRWAARRRGGDPVSRMARIAGATLGRHHDVTVVPALRMRALARDSVGLGASARER
NITGRVLLRGQRPRNEVVLVDDIITTGATARESVRVLQAAGVRVGAVLAVAAA

>BL;Rv3256c, H37Rv2.tab 3636277:3637314 reverse MW:35277
VNVARAIDLEDTEGLIAADRGALLRAASMAGAQVRAIAAAADEGELDLLRGSDRPRSVIWVTGRGTAETAGTILASTLGA	(SEQ ID NO:591)
GAAEPIVLASAAPPWVGPLDVLIVAGDDPGDPALVGAAAIGVRRGARVVVVAPYEGPLRDSTAGRVAVLEPRLRVPDEFG
LSRYLAAGLAALQTVDPKLRIDLASLADELDAEALRNSAGREVFTNPAKALAARVSGCQLALAGDNAATLALARHGSSVM
LRIANQVVAATRLSDAVVALRAGTPPDALFHDEEIDGPAPQRLRvLALALAGERTVVAARVAGLDDAYLVAAEDVPELLD
APVGSGGAVLAVRLEMAAVYLRLVRG

>BL;2V3258c, H37Rv2.tab 3638813:3639301 reverse MW:16810
MRVSGASAALVHDSLSVVNVPRRCCRPGCPHYAVATLTFVYSDSTAVIGPLATAREPHSWDLCVGHAGRITAPRGWELVR	(SEQ ID NO:592)
HAGPLPSHPDEDDLVALADAVREGGPSAGRRHHPGGNGAPLHGFDDFPAAATGAPTGGGVLAPPEPGAGRRRGHLRVLPD
PAD

>BL;Rv3259, H37Rv2.tab 3639424:3639840 forward MW:15649
MRGPLLPPTVPGWRSRAERFDMAVLEAYEPIERRWQERVSQLDIAVDEIPRIAAKDPESVQWPPEVIADGPIALARLIPA	(SEQ ID NO:593)
GVDVRGNATRARIVLFRKPIERRAKDTEELGELLHEILVAQVAIYLDVDPSVIDPTIDD

>BL;Rv3269, H37Rv2.tab 3650233:3650511 forward MW:9750
MAIQVFLAKATTTVITGLAGVTAYEILKKAAAKAPLRQTAVSAAALGLRGTRKAEEAAESARLKVADVMAEARERIGEES	(SEQ ID NO:594)
PTPAISDLHDHDH

>BL;Rv3277, H37Rv2.tab 3659877:3660692 forward MW:30079
MNEVTAGVRELATAIMVSRHLTGVLAGHGSQTVTYHFASILCSSVHSLVVSFADATIARLPGVVQPYAQRHHELIKFAIV	(SEQ ID NO:595)
GGTTFIIDTAIFYTLKLTVLEPKPVTAKVIAGIVAVIASYVLNREWSFRDRGGRERHHEALLFFAFSGVGVLLSMAPLWF
SSYILQLRVPTVSLTMENIADFISAYIIGNLLQMAFRFWAFRRWVFPDEFARNPDKALESALTAGGIAEVFEDVLEGGFE
DGNVTLLRAWRNRANRFAQLGDSSEPRvSKTS

>BL;Rv3278C, H37Rv2.tab 3660653:3661168 reverse MW:19820
MSYPENVLAAGEQVVLHRHPHWNRLIWPVVVLVLLTGLAAFGSGFVNSTPWQQIAKNVIHAVIWGIWLVIVGWLTLWPFL	(SEQ ID NO:596)
SWLTTHPVVTNRRvMFRHGVLTRSGIDIPLARINSVEFRDRIFERIFRTGTLIIESASQDPLEFYNIPRLREVHALLYHE
VFDTLGSDESPS

>BL;Rv3281, H37Rv2.tab 3663688:3664218 forward MW:19013
MGTCPCESSERNEPVSRVSGTNEVSDGNETNNPAEVSDGNETNNPAEVSDGNETNNPAPVSRVSGTNEVSDGNETNNPAP	(SEQ ID NO:597)
VSRvSGTNEVSDGNETNNPAPVTEKPLHPHEPHIEILRGQPTDQELAALIAVLGSISGSTPPAQPEPTRWGLPVDQLRYP
VFSWQRITLQEMTHMRR

>BL;Rv3311, H37Rv2tab 3698120:3699379 forward MW:45732
MVADLVPIRLSLSAGDRYTLWAPRWRDAGDEWEAFLGKDDDLYGFESVSDLVAFVRTDTENDLVDHPAWQDLTGAHAHNL	(SEQ ID NO:598)
NPAEDNQFDLVVVEELLAEKPTAESVAALAASLAIVSAIGSVCELAAVSKFFNGNPILGTVSGGLEHFTGKAGNKRWNSI
AEVIGRSWDDVLAAIDEIISTPEVDAELSEKVAEELAEEPEGAEEVAAEVEATQDTQEAAESDDEEADAPGDSVVLGGDR
DFWLQVGIDPIQIMTGTATFYTLRCYLDDRPIFLGRNGRISVFGSERALARYLADEHDHDLSDLSTYDDIRTAATDGSLA
VAVTDDNVYVLSGLVDDFADGPDAVDREQLDLAVELLRDIGDYSEDSAVDKALETTRPLGQLVAYVLDPHSVGKPTAPYA
AAVREWEKLERFVESRLRRE

>BL;Rv33S4, H37Rv2.tab 3769110:3769496 forward MW:12987
MNLRRHQTLTLRLLAASAGILSAAAFAAPAQANPVDDAFIAALNNAGVNYGDPVDAKALGQSVCPILAEPGGSFNTAVAS	(SEQ ID NO:599)
VVARAQGMSQDMAQTFTSIAISMYCPSVMADVASGNLPALPDMPGLPGS

>BL;Rv3368c, H37Rv2.tab 3780337:3780978 reverse MW:23733
MTLNLSVDEVLTTTRSVRKRLDFDKPVPRDVLMECLELALQAPTGSNSQGWQWVFVEDAAKKKAIADVYLANARGYLSGP	(SEQ ID NO:600)
APEYPDGDTRGERMGRVRDSATYLAEHMHRAPVLLIPCLKGREDESAVGGVSFWASLFPAVWSFCLALRSRGLGSCWTTL
IILLDNGEHKVADVLGIPYDEYSQGGLLPIAYTQGIDFRPAKRLPAESVTHWNGW

>BL;Rv3412, H37Rv2.tab 3831725:3832132 forward MW:15269
VRDHLPPGLPPDPFADDPCDPSAALEAVEPGQPLDQQERMAVEADLADLAVYEALLAHKGIRGLVVCCDECQQDHYHDWD	(SEQ ID NO:601)
MLRSNLLQLLIDGTVRPHEPAYDPEPDSYVTWDYCRGYADASLNEAAPDADRFRRR

>BL;Rv3415c, H37Rv2.tab 3833696:3834520 reverse MW:28627
VNETPHAPVVEQVLVAAAFGNQPGSWPLPTAITPHHLWLRAVAAGGQGRYAHAYGDLSVLRRLVPAGPLASLAHSTQGSL	(SEQ ID NO:602)
LRQLGWHTLARGWDGRALALAGADREAGADALIGLAADALGVGRFAAAGALLDRADPLVVSPLVADRLAVRRRWVAAELA
MATGDGATAVRHAEEAVELTQAMAVASARHRvKSDVVLAAALCSAGAVARARAVGEEALDATARFGLLPLRWALACLLID
IGTVTFSAQQLRELTKIRNICAGQVRRAGGCWRTA

>BL;Rv3438, H37Rv2.tab 3857396:3858235 forward MW:29209
VPRIRKLVAALHRRGPHRVLRGDLAFAGLPGVVYTPEAGLHLPGVAFGHDWLTGTSRYSGLLEHLASWGIVAAAPDSERG	(SEQ ID NO:603)
LAPSVLNLAFDLGVALDIVAGVRLGPGKISVHPAKLGLVGHGFGGSAAVFAAAGLTGTHVKSVAAIFPTVTNPAAEQPAA
TLDVPGLILTAPGDPKTLTSNALGLSRAWDKATLRIVSKARAGGLVEGRRLTKVLGLPGPHRRTQRSVRALLTGYLLYTL
GGDKTYRRFADPDLQLPKTDPIDPEAPPITPGEKIVTLLK

>BL;Rv3587c, H37Rv2.tab 4028971:4029762 reverse MW:27067
VLDLEPRGPLPTEIYWRRRGLALGIAVVVVGIAVAIVIAFVDSSAGAKPVSADKPASAQSHPGSPAPQAPQPAGQTEGNA	(SEQ ID NO:604)
AAAPPQGQNPETPTPTAAVQPPPVLKEGDDCPDSTLAVKGLTNAPQYYVGDQPKFTMVVTNIGLVSCKRDVGAAVLAAYV
YSLDNKRLWSNLDCAPSNETLVKTFSPGEQVTTAVTWTGMGSAPRCPLPRPAIGPGTYNLVVQLGNLRSLPVPFILNQPP
PPPGPVPAPGPAQAPPPESPAQGG

>BL;Rv3603c, H37Rv2.tab 4045210:4046118 reverse MW:31104
MERFDGLRPARLKVGIISAGRVGTALGVALQRADHVVVACSAISHASRRRAQRRLPDTPVLPPLDVAASAELLLLAVTDS	(SEQ ID NO:605)
ELAGLVSGLAATSAVRPQTIVAHTSGANGIGILAPLAQQGCIPLAIHPAMTFTGSDEDISRLPDTCFGITAADDVGYAIG
QSLVLEMGGEPFCVREDARILYHAALAHASNHIVTVLADALEALRAALSGGELLGQQTVDDQPGGIVERIVGPLARAALE
NTLQRGQAALTGPVARGDAAAVADHLAALADVDAALAQAYRINALRTAQRAHAPADVVEVLTA

>BL;Rv3604c, H37Rv2.tab 4046306:4047691 reverse MW:49862
VPRAASAMAEPAMGVGRRRCWPGGRPGMRGCLRGEFGRTAYPAKPCGNRRTGATRGLTSPGYSQAMTVLSRGARVRRGGR	(SEQ ID NO:606)
RPGWVLLTALLVLAIGASSALVFTDRVELLKLAVLLALWAAVAGAFVSVLYRRQSDVDQARVRDLKLVYDLQLDREISAR
REYELTLESQLRRELASELRAPAADEVAALRAELAALRTSLEILFDADLEHRPALGTVEKEARAARALDGESPPADWVSS
DRVMAVRGGDGASRTDEASIIDVPEVGVPPVSGGPRHYEAPPPPQPEPLFEPRHRPPPLPPQQERPVWQPVTSHGQWLPA
ETPGSQWASVEPETTPAAPPPGRRRRARHASPADQAYNPPAYVELAAQYGESGRRSRHSAEHRDHDIGGSGAGTGERPPS
PPMAPPPPAEPTRRHRTADTPPDDSGGLHARDPLTGGQSVADLMARLQVESTGGGRRRRRGE

>BL;Rv3605c, H37Rv2.tab 4047708:4048181 reverse MW:16789
MGPTRKRDLTAAVVGAAAVGYLLVAVLYRWFPPITVWTGLSLLAVAVAEALWARYVRVKISDGEIGDGPGWLHPLVVARS	(SEQ ID NO:607)
LMVAKASAWVGALVTGWWIGVLAYFLPRRSWLRAAAEDTTGTVVAAGSALALVVAALWLQHCCKSPQDPTEHADGAES

>BL;Rv3614c, H37Rv2.tab 4054145:4054696 reverse MW:19802
VDLPGNDFDSNDFDAVDLWGADGAEGWTADPIIGVGSAATPDTGPDLDNAHGQAETDTEQEIALFTVTNPPRTVSVSTLM	(SEQ ID NO:608)
DGRIDHVELSARvAWMSESQLASEILVIADLARQKAQSAQYAFILDRMSQQVDADEHRvALLRKTVGETWGLPSPEEAAA
AEAEVFATRYSDDCPAPDDESDPW

>BL;Rv3615c, H37Rv2.tab 4054815:4055123 reverse MW:10795
MTENLTVQPERLGVLASHHDNAAVDASSGVEAAAGLGESVAITHGPYCSQFNDTLNVYLTAHNALGSSLHTAGVDLAKSL	(SEQ ID NO:609)
RIAAKIYSEADEAWRKAIDGLFT

>BL;Rv3616c, H372V2.tab 4055200:4056375 reverse MW:39888
MSRAFIIDPTISAIDGLYDLLGIGIPNQGGILYSSLEYFEKALEELAAAFPGDGWLGSAADKYAGKNRNHVNFFQELADL	(SEQ ID NO:610)
DRQLISLIHDQANAVQTTRDILEGAKKGLEFVRPVAVDLTYIPVVGHALSAAFQAPFCAGAMAVVGGALAYLVVKTLINA
TQLLKLLAKLAELVAAAIADIISDVADIIKGTLGEVWEFITNALNGLKELWDKLTGWVTGLFSRGWSNLESFFAGVPGLT
GATSGLSQVTGLFGAAGLSASSGLAHADSLASSASLPALAGIGGGSGFGGLPSLAWVHAASTRQALRPRADGPVGAAAEQ
VGGQSQLVSAQGSQGMGGPVGMGGMHPSSGASKGTTTKKYSEGAAAGTEDAERAPVEADAGGGQKVLVRNVV

>BL;Rv3619c, H37Rv2.tab 4059987:4060268 reverse MW:9832
MTINYQFGDVDAHGAMIRAQAGSLEAEHQAIISDVLTASDFWGGAGSAACQGFITQLGRNFQVIYEQANAHGQKVQAAGN	(SEQ ID NO:611)
NMAQTDSAVGSSWA

>BL;Rv3632, H37Rv2.tab 4071236:4071577 forward MW:13068
MNWIQVLLIASIIGLLFYLLRSRRSARSRAWVKVGYVLFVLAGIYAVLRPDDTTVVANWFGVRRGTDLMLYALVIVIAFSFT	(SEQ ID NO:612)
TLSTYMRFKDLELRYARIARALALEGAQAPEQCR

>BL;Rv3647c, H37Rv2.tab 4087613:4088188 reverse MW:20314
VSQLSFFAAESVPPAVADLSGVLAGPGQIVLVGCGARLSVVVAESWRASALAEMIQEAGLVPEVARTDENTPLVRTAVDP	(SEQ ID NO:613)
LLCGIAAEWTRGAVKTVPPRWLPGPRELRAWTLAAGSPEADRYLLGLDPHAPDTHS PLASALMRvGIAPTLIGTRGTRPA
LRISGRRRLSRLVENVGEPPDGAEAWVQWPRT

>BL;Rv3662c, H37Rv2.tab 4101268:4102035 reverse MW:26338
VTVDPLAPLMELPGVAAASDRVRDALSRvHRHRANLRGWPVAAAEASLRAARASSVLDGGPARLHDAGAPTSGKPALSDP	(SEQ ID NO:614)
VFAGALRVGQALEGGAGPVVGVWRRAPLQALARLHMLAAADQVDDDRLGRPRSDADVGPRLELLALVVTHPTLASAPVVA
AVAHGELLTLRPFGCADGVVARAVSRLVTIATGLDPHGLGVPEVIWMRQPAEYHDAARRFAGGTPDGVAGWLLLCCGAML
DGAREALSIAESLSPG

>BL;Rv3668c, H37Rv2.tab 4109786:4110481 reverse MW:23102
LQTAHRRFAAAFAAVLLAVVCLPANTAAADDKLPLGGGAGIVVNGDTMCTLTTIGHDKNGDLIGFTSAHCGGPGAQIAAE	(SEQ ID NO:615)
GAENAGPVGIMVAGNDGLDYAVIKFDPAKVTPVAVFNGFAINGIGPDPSFGQIACKQGRTTGNSCGVTWGPGESPGTLVM
QVCGGPGDSGAPVTVDNLLVGMIHGAFSDNLPSCITKYIPLHTPAVVMSINADLADINAKNRPGAGFVPVPA

>BL;Rv3669, H37Rv2.tab 4110827:4111342 forward MW:18887
VSKIDRKNGVPSTLTTIPLADPHAGPAEPSIGDLIKDATTQMSTLVRAEVELARAEITRDVKKGLTGSVFFISSLVVGFY	(SEQ ID NO:616)
STFFFFFFVAELLDTWIWRWVAFLLVFAIMVVVTAVLALLGFLKVRRIRGPRQTIASVKETRTALTPGHDKTPVTPKPVT
SDRATPVDPSGW

>BL;Rv3680, H37Rv2.tab 4119795:4120952 forward MW:41405
MSVTPKTLDMGAILADTSNRVVVCCGAGGVGKTTTAAALALRAAEYGRTVVVLTIDPAKRLAQALGINDLGNTPQRVPLA	(SEQ ID NO:617)
PEVPGELHAMMLDMRRTFDEMVMQYSGPERAQSILDNQFYQTVATSLAGTQEYMAMEKLGQLLSQDRWDLIVVDTPPSRN
ALDFLDAPKRLGSFMDSRLWRLLLAPGRGIGRLITGVMGLAMKALSTVLGSQMLADAAAFVQSLDATFGGFREKADRTYA
LLKRRGTQFVVVSAAEPDALREASFFVDRLSQESMPLAGLVFNRTHPMLCALPIERAIDAAETLDAETTDSDATSLAAAV
LRIHAERGQTAKREIRLLSRFTGANPTVPVVGVPSLPFDVSDLEALRALADQLTTVGNDAGRAAGR

>BL;Rv37OSc, H37Rv2.tab 4148321:4148962 reverse MW:22359
MRIAAAVVSIGLAVIAGFAVPVADAHPSEPGVVSYAVLGKGSVGNIVGAPMGWEAVFTRPFQAFWVELPACNNWVDIGLP	(SEQ ID NO:618)
EVYDDPDLASFNGATTQTSATDQTHLVKQAVGVFASNDAADRAFHRvVDRTVGCSGQTTAIHLDDGTTQVWSFAGGPSTG
TDEAWTKQEAGTDRRCFVQTRLRENVLLQAKVCQSGNAGPAVNVLAGAMQNTLG

>BL;Rv3716c, H37Rv2.tab 4160515:4160913 reverse MW:13357
MQPGGDMSALLAQAQQMQQKLLEAQQQLANSEVHGQAGGGLVKVVVKGSGEVIGVTIDPKVVDPDDIETLQDLIVGAMRD	(SEQ ID NO:619)
ASQQVTKMAQERLGALAGANRPPAPPAAPPGAPGMPGMPGMPGAPGAPPVPGI

>BL;Rv3718c, H37Rv2.tab 4161818:4162258 reverse MW:15661
MGQVSAASTILINAEPTATLDALADYETVRPKILSPHYSEYQVLEGGKGRGTVAKWRLQATQSRVRDVQVNVDVAGHTVI	(SEQ ID NO:620)
EKDMNSSMVTNWTVAPAGPGSSVTVKTTWTGAGGVKGFFEKTFAPLGLKKIQAEVLSNLKTELEGDA

>BL;Rv3723, H37Rv2.tab 4168536:4169297 forward MW:27367
MGRKVAVLWHASFSIGAGVLYFYFVLPRWPELMGDTGHSLGTGLRIATGALVGLAALPVVFTLLRTRKPELGTPQLALSM	(SEQ ID NO:621)
RIWSIMAHVLAGALIVGTAISEVWLSLDAAGQWLFGIYGAAAAIAVLGFFGFYLSFVAELPPPPPKPLKPKKPKQRRLRR
KKTAKGDEAEPEAAEEAENTELAAQEDEEAVEAPPESIESPGGEPESATREAPAAETATAEEPRGGLRNRRPTGKTSHRR
RRTRSGVQVAKVDE

>BL;Rv3753c, H37Rv2.tab 4199724:4200221 reverse MW:17917
MQRPAADTPDGFGVAVVREEGRWRCSPMGPKALTSLRAAETELRELRSAGAVFGLLDVDDEFFVIVRPAPSGTRLLLSDA	(SEQ ID NO:622)
TAALDYDIAAEVLDNLDAEIDPEDLEDADPFEEGDLGLLSDIGLPEAVLGVILDETDLYADEQLGRIAREMGFADQLSAV
IDRLGR

>BL;Rv3760, H37Rv2.tab 4205538:4205837 forward MW:10533
VPGSVPGKAPEEPPVKFTRAAAVWSALIVGFLILILLLIFIAQNTASAQFAFFGWRWSLPLGVAILLAAVGGGLITVFAG	(SEQ ID NO:623)
TARILQLRRAAKKTHAAALR

>BL;Rv3779, H37Rv2.tab 4224985:4226982 forward MW:71763
VGLWFGTLIALILLIAPGAMVARIAQLRWPVAIAVGPALTYGVVALAIIPYGALGIPWNGWTALAALAVTCAVATGLQLL	(SEQ ID NO:624)
LARFRDLDAEALAVSRWPAVTVAAGVLLGALLIGWAAYRGIPHWQSIPSTWDAVWHANTVRFILDTGQASSTHMGELRNV
ETHAPLYYPSVFHGLVAVFCQLTGAAPTTGYTLSSLAASVWLFPVSAAVLTWRAVRSHPGALWSASCASAEWRAAGAAGT
AAALSASFTAVPYVEFDTAAMPNLAAYGIAVPTMVLITSTLRHRDRIPVAVLALVGVFSLHITGGIVVALLVSAWWLFEA
LRHPVRSRLADLLTLAGVAAMAGLVMLPQFLSVRQQEDIIAGHAFPTYLSKKRGLFDAVFQHSRHLNDFPVQYALIVLAA
IGGLILLVKKIWWPLAVWLLLIVMNVDAGTPLGGPIGGVAGALGEFFYHDPRRIAAATTLLLMLMAGVALFATVNLLVAA
AKRLTDRFRPQPVSVWASATATLLIGATLVSAWHYFPRHRFLFGDKYDSVMIDQKDLDANAYLASLPGARDTLIGNANTD
GTAWMYAVAGLHPLWTHYDYPLQQGPGYHRFIFWAYGRNGESDPRvLEAIQVLRIRYILTSTPTVRGFAVPDGLVSLETS
RSWAKIYDNGEARIYEWRGTAAATHS

>BL;Rv3780, H37Rv2.tab 4226989:4227522 forward MW:19484
VRKRMVIGLSTGSDDDDVEVIGGVDPRLIAVQENDSDESSLTDLVEQPAKVMRIGTMIKQLLEEVRAAPLDEASRNRLRD	(SEQ ID NO:625)
IHATSIRELEDGLAPELREELDRLTLPFNEDAVPSDAELRIAQAQLVGWLEGLFHGIQTALFAQQMAARAQLQQMRQGAL
PPGVGKSGQHGHGTGQYL

>BL;Rv3792, H37Rv2.tab 4237932:4239860 forward MW:69516
MPSRRKSPQFGHEMGAFTSARAREVLVALGQLAAAVVVAVGVAVVSLLAIARVEWPAFPSSNQLHALTTVGQVGCLAGLV	(SEQ ID NO:626)
GIGWLWRHGRFRRLARLGGLVLVSAFTVVTLGMPLGATKLYLFGISVDQQFRTEYLTRLTDTAALRDMTYIGLPPFYPPG
WFWIGGRAAALTGTPAWEMFKPWAITSMAIAVAVALVLWWRMIRFEYALLVTVATAAVMLAYSSPEPYAAMITVLLPPML
VLTWSGLGARDRQGWAAVVGAGVFLGFAATWYTLLVAYGAFTVVLMALLLAGSRLQSGIKAAVDPLCRLAVVGAIAAAIG
STTWLPYLLRAARDPVSDTGSAQHYLPADGAALTFPMLQFSLLGAICLLGTLWLVMRARSSAPAGALAIGVLAVYLWSLL
SMLATLARTTLLSFRLQPTLSVLLVAAGAFGFVEAVQALGKRGRGVIPMAAAIGLAGAIAFSQDIPDVLRPDLTIAYTDT
DGYGQRGDRRPPGSEKYYPAIDAAIRRVTGKRRDRTVVLTADYSFLSYYPYWGFQGLTPHYANPLAQFDKRATQIDSWSG
LSTADEFIAALDKLPWQPPTVFLMRHGAHNSYTLRLAQDVYPNQPNVRRYTVDLRTALFADPRFVVEDIGPFVLAIRKPQ
ESA

>BL;Rv38O2c, H37Rv2.tab 4263358:4264365 reverse MW:35448
MAKNSRRKRHRILAWIAAGAMASVVALVIVAVVIMLRGAESPPSAVPPGVLPPGPTPAHPHKPRPAFQDASCPDVQMISV	(SEQ ID NO:627)
PGTWESSPQQNPLNPVQFPKALLLKVTGPIAQQFAPARVQTYTVAYTAQFHNPLTTDNQMSYNDSRAEGTRAMVAAMTDM
NNRCPLTSYVLIGFSQGAVIAGDVASDIGNGRGPVDEDLVLGVTLIADGRRQQGVGNQVPPSPRGEGAEITLHEVPVLSG
LGLTMTGPRPGGFGALDGRTNEICAQGDLICAAPAQAFSPANLPTTLNTLAGGAGQPVHAMYATPEFWNSDGEPATEWTL
NWAHQLIENAPHPKHR

>BL;Rv3805c, H37Rv2.tab 4266956:4268836 reverse MW:68710
MVRVSLWLSVTAVAVLFGWGSWQRRWIADDGLIVLRTVRNLLAGNGPVFNQGERVEANTSTAWTYLLYVGGWVGGPMRLE	(SEQ ID NO:628)
YVALALAMVLSLLGMVLLMLGTGRLYAPSLRGRRAIMLPAGALVYIAVPPARDFATSGLESGLVLAYLGLLWWMMVCWSQ
PLRARPDSQMFLGALAFVAGCSVLVRPEFALIGGLALIMMLIAARTWRRRVLIVLAGGFLPVAYQIFRMGYYGLLVPSTA
LAKDAAGDKWSQGMIYVSNFNRPYALWVPLVLSVPLGLLLMTARRRPSFLRPVLAPDYGRvARAVQSPPAVVAFIVGSGV
LQALYWIRQGGDFMHGRvLLAPLFCLLAPVGVIPILLPDGKDFSRETGRWLVGALSGLWLGIAGWSLWAANSPGMGDDAT
RVTYSGIVDERRFYAQATGHAHPLTAADYLDYPRMAAVLTALNNTPEGALLLPSGNYNQWDLVPMIRPSSGTAPGGKPAP
KPQHAVFFTNMGMLGMNVGLDVRVIDQIGLVNPLAAHTERLKHARIGHDKNLFPDWVIADGPWVKWYPGIPGYIDQQWVT
QAEAALQCPATRAVLNSVRAPITLHRFLSNVLHSYEFTRYRIDRVPRYELVRCGLDVPDGPGPPPRE

>BL;Rv3807c, H37Rv2.tab 4269843:4270337 reverse MW:17218
MVAVQSALVDRPGMLATARGLSHFGEHCIGWLILALLGAIALPRRRREWLVAGAGAFVAHAIAVLIKRLVRRQRPDHPAI	(SEQ ID NO:629)
AVNVDTPSQLSFPSAHATSTTAAALLMGRATGLPLPVVLVPPMALSRILLGVHYPSDVAVGVALGATVGAIVDSVGGGRQ
RARKR

>BL;Rv3808c, H37Rv2.tab 4270369:4272279 reverse MW:71507
MSELAASLLSRVILPRPGEPLDVRKLYLEESTTNARRAHAPTRTSLQIGAESEVSFATYFNAFPASYWRRWTTCKSVVLR	(SEQ ID NO:630)
VQVTGAGRVDVYRTKATGARIFVEGHDFTGTEDQPAAVETEVVLQPFEDGGWVWFDITTDTAVTLHSGGWYATSPAPGTA
NIAVOIPTFNRPADCVNALRELTADPLVDQVIGAVIVPDQGERKVRDHPDFPAAAARLGSRLSIHDQPNLGGSGGYSRVM
YEALKNTDCQQILFMDDDIRLEPDSILRvLAMHRFAKAPMLVGGQMLNLQEPSHLNIMGEVVDRSIFMWTAAPHAEYDHD
FAEYPLNDNNSRSKLLHRRIDVDYNGWWTCMIPRQVAEELGQPLPLFIKWDDADYGLRAAEHGYPTVTLPGAAIWHMAWS
DKDDAIDWQAYFHLRNRLVVAAMHWDGPKAQVIGLVRSHLKATLKHLACLEYSTVAIQNKAIDDFLAGPEHIFSILESAL
PQVHRIRKSYPDAVVLPAASELPPPLHKNKAMKPPVNPLVIGYRLARGIMHNLTAANPQHHRRPEFNVPTQDARWFLLCT
VDGATVTTADGCGVVYRQRDRAKNFALLWQSLRRQRQLLKRFEEMRRIYRDALPTLSSKQKWETALLPAANQEPEHG

>BL;Rv3821, H37Rv2.tab 4285973:4286683 forward MW:24627
MWSTVLVLALSVICEPVRIGLVVLMLNRRRPLLHLLTFLCGGYTMAGGVANVTLVVLGATPLAGHFSVAEVQIGTGLIAL	(SEQ ID NO:631)
LIAFALTTNVIGKHVRRATHARVGDDGGRVLRESVPPSGAHKLAVRARCFLQGDSLYVAGVSGLGAALPSANYMGAMAAI
LASGATPATQALAVVTFNVVAFTVAEVPLVSYLAAPRKTRAFMAALQSWLRSRSRRDAALLVAAGGCLMLTLGLSNL

>BL;Rv3835, H37Rv2.tab 4309047:4310393 forward MW:47043
MLDAPEQDPVDPGDPASPPHGEAEQPLPGPRWPRALRASATRRALLLTALGGLLIAGLVTAIPAVGRAPERLAGYIASNP	(SEQ ID NO:632)
VPSTGAKINASFNRVASGDCLMWPDGTPESAAIVSCADEHRFEVAESIDMRTFPGMEYGQNAAPPSPARIQQISEEQCEA
AVRRYLGTKFDPNSKFTISMLWPGDRAWRQAGERRMLCGLQSPGPNNQQLAFKGKVADIDQSKVWPAGTCLGIDATTNQP
IDVPVDCAAPHAMEVSGTVNLAERFPDALPSEPEQDGFIKDACTRMTDAYLAPLKLRTTTLTLIYPTLTLPSWSAGSRVV
ACSIGATLGNGGWATLVNSAKGALLINGQPPVPPPDIPEERLNLPPIPLQLPTPRPAPPAQQLPSTPPGTQHLPAQQPVV
TPTRPPESHAPASAAPAETQPPPPDAGAPPATQSPEATPPGPAEPAPAG

>BL;Rv3843c, H37Rv2.tab 4315571:4316596 reverse MW:37353
VIQVCSQCGTGWNVRERQRvWCPRCRGMLLAPLADMPAEARWRTPARPQVPTASDTRRTPPRLPPGFRWIAVRPGAAPPP	(SEQ ID NO:633)
RHGPRLRGPTPRYAGIPRWGLTDHVDQAPVPASAKAGPSPAAVRTTLLVSLLVFSIAVVVFVVRYVLLVINRNTLLNSVV
ASASVWLGVLVSLAAIAAAGTTIVLLVRWLVARRAAAFMHQGLPERRSARELWAGCLLPMVNLLWAPLYVIELALVEDRY
TRLRRPIVVWWIVWIVSNAISMFAFATSWVTDAQGIANNTTMMVLAYLCAAAAVAAAARVFEGFEQKPVERPAHRWVVVN
TDGRSAPASSVAVELDGQEPAA

>BL;Rv3847, H37Rv2.tab 4321538:4322068 forward MW:18278
MGTGSGGPIGVSPFHSRGALKGFVISGRWPDSTKEWAQLLMVAVRvASLPGLLSTTTVFGAREELPDEPEPGTVGLVLAE	(SEQ ID NO:634)
GTVFGESAIQPGYFADHQPPALLMLHPPSETTPSLPECTGAASGCVLLPGLPYLGLEHRAAWVEAEADGTITSMVSRVGV
DPISHPDTAILAMLLAA

>BL;2V3849, H37Rv2.tab 4323499:4323894 forward MW:14708
MSTTFAARLNRLFDTVYPPGRGPHTSAEVIAALKAEGITMSAPYLSQLRSGNRTNPSGATMAALANFERIKAAYFTDDEY	(SEQ ID NO:635)
YEKLDKELQWLCTMRDDGVRRIAQRAHGLPSAAQQKVLDRIDELRRAEGIDA

>BL;Rv3850, M37Rv2.tab 4324015:4324668 forward MW:23811
MGLFGKRKSRATRRAEARAIKARAKLEAKLSAKNEARRIKAAQRAESKALKAQLKARRDSDRAALKVAEAELKVAREGKL	(SEQ ID NO:636)
LSPTRIRRLLTVSRLLAPILTPVIYRAANAARGLIDQRRADQLGVPLAQIGRFSGHGARLSARvGGAERSLRMVQEKKPK
DVETKQFVSAVTNRLTDLSAIWAAAEHMPAKRRRTAHSAISSQLDGIEADLMARLGLT

>BL;Rv3867, H37Rv2.tab 4342770:4343318 forward MW:19945
MVDPPGNDDDHGDLDALDFSAAHTNEASPLDALDDYAPVQTDDAEGDLDALHALTERDEEPELELFTVTNPQGSVSVSTL	(SEQ ID NO:637)
MDGRIQHVELTDKATSMSEAQLADEIFVIADLARQKARASQYTFMVENIGELTDEDAEGSALLREFVGMTLNLPTPEEAA
AAEAEVFATRYDVDYTSRYKADD

>BL;Rv3869, H37Rv2.tab 4345039:4346478 forward MW:51093
MGLRLTTKVQVSGWRFLLRRLEHAIVRRDTRMFDDPLQFYsRSIALGIVVAVLILAGAALLAYFKPQGKLGGTSLFTDRA	(SEQ ID NO:638)
TNQLYVLLSGQLHPVYNLTSARLVLGNPANPATVKSSELSKLPMGQTVGIPGAPYATPVSAGSTSIWTLCDTVARADSTS
PVVQTAVIANPLEIDASIDPLQSHEAVLVSYQGETWIVTTKGRHAIDLTDRALTSSMGIPVTARPTPISEGMFNALPDMG
PWQLPPIPAAGAPNSLGLPDDLVIGSVFQIHTDKGPQYYVVLPDGIAQVNATTAAALRATQAHGLVAPPAMVPSLVVRIA
ERvYPSPLPDEPLKIVSRPQDPALCWSWQRSAGDQSPQSTVLSGRHLPISPSAMNMGIKQIHGTATVYLDGGKFVALQSP
DPRYTESMYYIDPQGVRYGVPNAETAKSLGLSSPQNAPWEIVRLLVDGPVLSKDAALLEHDTLPADPSPRKVPAGASGAP

>DL;Rv3874, H37Rv2.tab 4352274:4352573 forward MW:10793
MAEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQAAVVRFQEAANKQKQELDEISTNIRQAG	(SEQ ID NO:639)
VQYSRADEEQQQALSSQMGF

>BL;Rv3876, H37Rv2.tab 4353010:4355007 forward MW:70645
MAADYDKLFRPHEGMEAPDDMAAQPFFDPSASFPPAPASANLPKPNGQTPPPTSDDLSERFVSAPPPPPPPPPPPPPTPM	(SEQ ID NO:640)
PIAAGEPPSPEPAASKPPTPPMPIAGPEPAPPKPPTPPMPIAGPEPAPPKPPTPPMPIAGPAPTPTESQLAPPRPPTPQT
PTGAPQQPESPAPHVPSHGPHQPRRTAPAPPWAKMPIGEPPPAPSRPSASPAEPPTRPAPQHSRRARRGHRYRTDTERNV
GKVATGPSIQARLRAEEASGAQLAPGTEPSPAPLGQPRSYLAPPTRPAPTEPPPSPSPQRNSGRRAERRVHPDLAAQNAA
AQPDSITAATTGGRRRKRAAPDLDATQKSLRPAAKGPKVKKVKPQKPKATKPPKVVSQRGWRHWVHALTRINLGLSPDEK
YELDLHARVRRNPRGSYQIAVVGLKGGAGKTTLTAALGSTLAQVRADRILALDADPGAGNLADRVGRQSGATIADVLAEK
ELSHYNDIRAHTSVNAVNLEVLPAPEYSSAQRALSDADWHFIADPASRFYNLVLADCGAGFFDPLTRGVLSTVSGVVVVA
SVSIDGAQQASVALDWLRNNGYQDLASRACVVINHIMPGEPNVAVKDLVRHFEQQVQPGRVVVMPWDRHIAAGTEISLDL
LDPIYKRKVLELAAALSDDFERAGRR

>BL;Rv3877, H37Rv2.tab 4355007:4356539 forward MW:53981
LSAPAVAAGPTAAGATAARPATTRVTILTGRRMTDLVLPAAVPMETYIDDTVAVLSEVLEDTPADVLGGFDFTAQGVWAF	(SEQ ID NO:641)
ARPGSPPLKLDQSLDDAGVVDGSLLTLVSVSRTERYRPLVEDVIDAIAVLDESPEFDRTALNRFVGAAIPLLTAPVIGMA
MRAWWETGRSLWWPLAIGILGIAVLVGSFVANRFYQSGHLAECLLVTTYLLIATAAALAVPLPRGVNSLGAPQVAGAATA
VLFLTLMTRGGPRKRHELASFAVITAIAVIAAAAAFGYGYQDWVPAGGIAFGLFIVTNAAKLTVAVARIALPPIPVPGET
VDNEELLDPVATPEATSEETPTWQAIIASVPASAVRLTERSKLAKQLLIGYVTSGTLILAAGAIAVVVRGHFFVHSLVVA
GLITTVCGFRSRLYAERWCAWALLAATVAIPTGLTAKLIIWYPHYAWLLLSVYLTVALVALVVVGSMAHVRRvSPVVKRT
LELIDGAMIAAIIPMLLWITGVYDTVRNIRF

>BL;Rv3880c, H37Rv2.tab 4360202:4360546 reverse MW:12167
VSMDELDPHVARALTLAARFQSALDGTLNQMNNGSFRATDEAETVEVTINGHQWLTGLRIEDGLLKKLGAEAVAQRVNEA	(SEQ ID NO:642)
LHNAQAASAYNDAAGEQLTAALSAMSRANNEGMA

>BL;Rv3882c, H37Rv2.tab 4362035:4363420 reverse MW:50397
MRNPLGLRFSTGHALLASALAPPCIIAFLETRYWWAGIALASLGVIVATVTFYGRRITGWVAAVYAWLRRRRRPPDSSSE	(SEQ ID NO:643)
PVVGATVKPGDHVAVRWQGEFLVAVIELIPRPFTPTVIVDGQAHTDDMLDTGLVEELLSVHCPDLEADIVSAGYRVGNTA
APDVVSLYQQVIGTDPAPANRRTWIVLRADPERTRKSAQRRDEGVAGLARYLVASATRIADRLASHGVDAVCGRSFDDYD
HATDIGFVREKWSMIKGRDAYTAAYAAPGGPDVWWSARADHTITRVRVAPGMAPQSTVLLTTADKPKTPRGFARLFGGQR
PALQGQHLVANRHCQLPIGSAGVLVGETVNRCPVYMPFDDVDIALNLGDAQTFTQFVVRAAAAGAMVTVGPQFEEFARLI
GAHIGQEVKVAWPNATTYLGPHPGIDRVILRHNVIGTPRHRQLPIRRvSPPEESRYQMALPK

>BL;Rv3909, H37Rv2.tab 4394192:4396597 forward MW:83878
VTALQLGWAALARVTSAIGVVAGLGMALTVPSAAPHHALAGEPSPTPFVQVRIDQVTPDVVTTSSEPHVTVSGTVTNTGDR	(SEQ ID NO:644)
PVRDVMVRLEHAAAVTSSTALRTSLDGGTDQYQPAADFLTVAPELDRGQEAGFTLSAPLRSLTRPSLAVNQPGIYPVLLVN
VNGTPDYGAPARLDNARFLLPVVGVPPDQATDFGSAVAPETTAPVWITMLWPLADRPRLAPGAPGGTVPVRLVDDDLANS
VNGTPDYGAPARLDNARFLLPVVGVPPDQATDFGSAVAPETTAPVWITMLWPLADRPRLAPGAPGGTVPVRLVDDDLANS
LANGGRLDILLSAAEFATNREVDPDGAVGRALCLAIDPDLLITVNAMTGGYVVSDSPDGAAQLPGTPTHPGTGQAAASSW
LDRLRTLVHRTCVTPLPFAQADLDALQRVNDPRLSAIATISPADIVDRILDVSSTRGATVLPDGPLTGRAINLLSTHGNT
VAVAAADFSPEEQQGSSQIGSALLPATAPRRLSPRVVAAPFDPAVGAALAAAGTNPTVPTYLDPSLFVRIAHESITARRQ
DALGAMLWRSLEPNAAPRTQILVPPASWSLASDDAQVILTALATAIRSGLAVPRPLPAVIADAAARTEPPEPPGAYSAAR
GRFNDDITTQIGGQVARLWKLTSALTIDDRTGLTGVQYTAPLREDMLRALSQSLPPDTRNGLAQQRLAVVGKTIDDLFGA
VTIVNPGGSYTLATEHSPLPLALHNGLAVPIRVRLQVDAPPGMTVADVGQIELPPGYLPLRVPIEVNFTQRVAVDVSLRT
PDGVALGEPVRLSVHSNAYGKVLFAITLSAAAVLVTLAGRRLWHRFRGQPDRADLDRPDLPTGKHAPQRRAVASRDDEKH
RV

[0236]

Claims

What is claimed is:

1. A method for identification and the selection of essential genes for the survival or the virulence of mycobacterium species which comprises:

c. Optionally, testing the polypolynucleotide selected in step b) for its capacity of virulence or involved in the survival of a mycobacterium species said testing being based on the activation or inactivation of said polypolynucleotide in a bacterial host or said testing being based on the activity of the product of expression of said polynucleotide in vivo or in vitro.

2. A method according to claim 1, wherein the first genomic sequence of mycobacterium belongs to Mycobacterium tuberculosis.

3. A method according to claim 1, wherein the second genomic sequence of mycobacterium belongs to Mycobacterium leprae.

4. A method according to any one of claims 1 to 3, wherein the complete genomic sequence of said mycobacterium species is analysed.

5. A method for the identification and the selection in silico of essential genes for the survival or the virulence of mycobacterium species according to any one of claims 1 to 4.

6. Purified polynucleotide molecule obtained by the method according to any one of claims 1 to 5.

7. A purified polynucleotide molecule of claim 6 which encodes essential proteins or fragments of proteins of Mycobacteium species.

8. A purified polynucleotide molecule of a formula selected from the group consisting of polynucleotidic sequences, which encode for polypeptides and regulatory sequences essential for the virulence and/or the survival of mycobacterium which are, in one hand, specific to Mycobacterium tuberculosis and, in the other hand, specific to Mycobacterium leprae, that is to say, said polynucleotidic sequences are not found in publicly accessible banks of non-Mycobacterium tuberculosis and non-Mycobacterium leprae genome.

9. A purified polynucleotide molecule according to claim 8 obtained by the method according to any one of claims 1 to 5.

10. A purified polynucleotide molecule that hybridizes to either strand of a denratured, double-stranded DNA comprising the purified polynucleotide sequence according to claims 6 to 9 under conditions of moderate stringency in 50% formamide and 6× SSC at 42° C. with washing conditions of 60° C., 0.5×SSC, 0.1% of SDS.

11. The purified polynucleotide molecule as claimed in claim 10, wherein said purified polynucleotide molecule is derived by mutagenesis.

12. A purified polynucleotide molecule degenerate from the purified polynucleotide molecule according to any one of claims 6 to 9 as a result of the genetic code.

13. A purified polynucleotide according to any one of claims 6 to 9 which encodes M. tuberculosis or M. leprae marker polypeptide.

14. A purified polynucleotide molecule according to any one of claims 6 to 9 which encodes an allelic variant of M. tuberculosis or M. leprae marker polypeptide according to claim 13.

15. A purified polynucleotide molecule according to any one of claims 6 to 9 which encodes a similar sequence of M. tuberculosis or M. leprae marker polypeptide DNA according to claim 13.

16. A purified polypeptide encoded by a polynucleotide molecule according to claim 8.

17. A purified polypeptide of a formula selected from the group consisting of SEQ ID NO: X to SEQ ID NO: Y.

18. A purified polypeptide according to claim 17 encoded by a polynucleotide molecule according to claims 6 or 9.

19. A purified polypeptide according to claim 16 in non-glycosylated form.

20. A purified polypeptide according to claim 16 in glycosylated form.

21. A purified polypeptide according to claim 17 in non-glycosylated form.

22. A purified polypeptide according to claim 17 in glycosylated form.

23. A purified polypeptide according to claim 18 in non-glycosylated form.

24. A purified polypeptide according to claim 18 in non-glycosylated form.

25. Process of screening of active molecules comprising:

a. Preparation of at least one purified polynucleotidic molecule or fragment thereof according to claims 6 to 9 in an acceptable medium,

b. Contacting the purified polynucleotide sequence or a fragment thereof corresponding to said essential gene of interest with an active molecule to be tested, and

c. Selecting the active molecule by inhibition or activation of the activity of the purified polynucleotide compared to the standard activity of the essential gene in absence of said active molecule.

26. Process of screening of an active molecule comprising:

a. Preparation of at least one purified polypeptide according to claims 16 to 24 or fragment thereof to be used as a target in an acceptable medium,

b. Contacting said purified polypeptide or fragment thereof obtained in step a) with an active molecule to be tested, and

c. Selecting the active molecule by inhibition or activation of the activity of the purified polypeptide obtainable after expression of the essential gene selected according to claim 1 and compared to the standard activity of said polypeptide.

27. A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001 at the C.N.C.M. under the accession number I-2625.

28. A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001 at the C.N.C.M. under the accession number I-2626.

29. A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001 at the C.N.C.M. under the accession number I-2627.

30. A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001 at the C.N.C.M. under the accession number I-2628.

31. A recombinant BAC containing a fragment of M. tuberculosis genome deposited on Feb. 20, 2001 at the C.N.C.M. under the accession number I-2629.

32. A recombinant cosmid containing a fragment of M. leprae genome deposited on Feb. 21, 2001 at the C.N.C.M. under the accession number I-2632.

33. A recombinant cosmid containing a fragment of M. leprae genome deposited on Feb. 21, 2001 at the C.N.C.M. under the accession number I-2633.

34. A recombinant purified vector that directs the expression of a polynucleotide molecule selected from the group consisting of purified polynucleotide molecule selected according to claims 1 or 6, 7, 8, 9, 13, 14 and 15.

35. A recombinant purified vector that directs the expression of a purified polynucleotide molecule according to claims 10 or 11.

36. A recombinant purified vector that directs the expression of a purified polynucleotide molecule according to claim 12.

37. A recombinant purified vector containing a part of the polynucleotide insert of claims 27 to 32 or claims 33 to 35 which is a plasmid.

38. A host cell transfected or transduced with the vector of claim 34.

39. A host cell transfected or transduced with the vector of claim 35.

40. A host cell transfected or transduced with the vector of claim 36.

41. A host cell transfected or transduced with the plasmid of claim 37.

42. A method for the production of mycobacterium purified marker polypeptide comprising culturing a host cell of claim 38 under conditions promoting expression, and recovering the polypeptide from the culture medium.

43. A method for the production of mycobacterium purified marker polypeptide comprising culturing a host cell of claim 39 under conditions promoting expression, and recovering the polypeptide from the culture medium.

44. A method for the production of mycobacterium purified marker polypeptide comprising culturing a host cell of claim 40 under conditions promoting expression, and recovering the polypeptide from the culture medium.

45. A method for the production of mycobacterium purified marker polypeptide comprising culturing a host cell of claim 41 under conditions promoting expression, and recovering the polypeptide from the culture medium.

46. The method according to any one of claims 42 to 45, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, and mammalian cells.

47. An immunological complex comprising a Mycobacterium purified marker polypeptide produced by a method according to any one of claims 42 to 45 and an antibody that specifically recognizes said polypeptide.

48. A composition comprising at least a mycobacterium purified polypeptide marker produced by a method according to any one of claims 42 to 45.

49. A method for detecting infection by mycobacteria, said method comprises:

a. Providing a composition according to claim 48 with a biological sample suspected to be infected with a mycobacterium,

b. Assaying for the presence of said mycobacterium, and

c. Optionally, detecting the presence of mycobacteria in said biological sample if infected.

50. The method of claim 49, which in step b) the assay is performed by electrophoresis or by immunoassay with antibodies that are immunologically reactive with M. tuberculosis and/or M. leprae.

51. An in vitro diagnostic method for the detection of the presence or the absence of antibodies which bind to an antigen or fragment of antigen comprising a mycobacterium purified polypeptide molecule according to any one of claims 16 to 24, wherein the method comprises contacting the antigen or fragment of antigen with a biological fluid for a time and under conditions sufficient for the antigen and antibodies in the biological fluid to form an immunological complex, detecting the formation of the complex, and optionally measuring the formation of the immunologicalcomplex.

52. The method as claimed in claim 51, wherein the formation of the immunological complex is detected by immunoassay method based on western blot technique, ELISA, indirect immuno-fluorescense assay, or immunoprecipitation assay.

53. An in vitro diagnostic method for the detection of the presence or the absence of antibodies which bind to an antigen or fragment of antigen comprising a mycobacterium purified polypeptide molecule obtained by a method according to any one of claims 42 to 45, wherein the method comprises contacting the antigen or fragment of antigen with a biological fluid for a time and under conditions sufficient for the antigen and antibodies in the biological fluid to form an immunological complex, detecting the formation of the complex, and optionally measuring the formation of the immunological complex.

54. The method as claimed in claim 53, wherein the formation of the immunological complex is detected by immunoassay method based on western blot technique, ELISA, indirect immuno-fluorescence assay, or immunoprecipitation assay.

55. A kit for the in vitro diagnostics of mycobacterium infections comprising:

a. A mycobacterium purified polypeptide molecule according to any one of claims 16 to 24 or mixture thereof,

b. Antibodies capable of forming an immunological complex with said polypeptides, and

c. Acceptable medium to permit the detection of the formation of the complex thereof.

56. A kit as claimed in claim 55 useful for the detection of M. tuberculosis infections.

57. A kit as claimed in claim 55 useful for the detection of M. leprae infections.

58. An immunogenic composition comprising at least a purified polypeptide according to any one of claims 16 to 24 in an amount sufficient to induce an immunogenic or protective response in vivo, and a pharmaceutically acceptable carrier therefor.

59. A polynucleotidic probe comprising a purified polynucleotide molecule or fragment thereof according to any one of claims 6 to 15.

60. A polynucleotidic probe which is complementary to the full length sequence of a purified nucleic acid that hybridizes under conditions of moderate stringency in 50% formamide and 6× SSC at 42° C. with washing conditions of 60° C., 0.5×SSC, 0.1% SDS with a nucleic acid encoding a purified polypeptide according to any one of claims 6 to 24.

61. A method for the detection of the presence or the absence of mycobacteria in a sample comprising:

a. contacting a sample suspected to contain genetic material of mycobacteria with at least one probe according to claims 59 or 60,

b. Detecting the hybridization under conditions of moderate stringency in 50% formamide and 6× SSC at 42° C. with washing conditions of 60° C., 0.5×SSC, 0.1% SDS.

62. A method for the detection of the presence or the absence of mycobacteria according to claim 61, wherein said method is specific for the detection of M. tuberculosis infections.

63. A method for the detection of the presence or the absence of mycobacteria according to claim 61, wherein said method is specific for the detection of M. leprae infections.

64. A method for the detection of the presence or the absence of mycobacteria according to any one of claims 61 to 63, wherein the sample contains nucleic acids of at least one microorganism other than the mycobacteria.

65. A method of selection according to claim 1, wherein the comparison of the genetic informations of different types of organisms, wherein the method comprises:

a. Providing a database including sequence libraries for a plurality of types of organism, said libraries having multiple genomic sequences,

b. Providing one or more probe sequences according to claims 59 or 60,

c. Determining homologous matches between one or more of said probe sequences and one or more sequences of said sequences in said genomic libraries; and

d. Displaying the results of said determination.

66. A method according to claims 1 to 4, wherein the genomic sequence of a first mycobacterium species is the recombinant BAC deposited at the C.N.C.M. according to claim 27.

67. A method according to claims 1 to 4, wherein the genomic sequence of a first mycobacterium species is the recombinant BAC deposited at the C.N.C.M. according to claim 28.

68. A method according to claims 1 to 4, wherein the genomic sequence of a first mycobaterium species is the recombinant BAC deposited at the C.N.C.M. according to claim 29.

69. A method according to claims 1 to 4, wherein the genomic sequence of a first mycobacterium species is the recombinant BAC deposited at the C.N.C.M. according to claim 30.

70. A method according to claims 1 to 4, wherein the genomic sequence of a first mycobacterium species is the recombinant BAC deposited at the C.N.C.M. according to claim 31.

71. A method according to claims 1 to 4, wherein the genomic sequence of the second mycobacterium species is the recombinant BAC deposited at the C.N.C.M. according to claim 32.

72. A method according to claims 1 to 4, wherein the genomic sequence of the second mycobacterium species is the recombinant BAC deposited at the C.N.C.M. according to claim 33.

73. An in vitro diagnostic method for the detection of the presence or the absence of essential nucleotidic sequences for the survival or the virulence in mycobacterium by hybridization or amplification of said specific sequence comprising:

a. Providing a composition comprising a probe according to claims 59 or 60 with a sequence library of interest to be tested in an acceptable medium and in sufficient time to obtain an hybridization and/or an amplification of said sequence,

b. Purifying the sequence which hybridizes with said probe; and

c. Optionally, quantifying said sequence.

74. A method according to claim 1, wherein the first genomic sequence of mycobacterium belongs to Mycobacterium microti.